0001558370-25-00068910-Q BIO-TECHNE Corp 20250206202502061630291630311631031 0 0001558370-25-000689 10-Q 82 20241231 20250206 20250206 BIO-TECHNE Corp 0000842023 2836 411427402 MN 0630 10-Q 34 000-17272 25597849 614 MCKINLEY PL N E MINNEAPOLIS MN 55413 6123798854 614 MCKINLEY PLACE NE MINNEAPOLIS MN 55413 TECHNE CORP /MN/ 19920703 10-Q 1 tech-20241231x10q.htm 10-Q BIO-TECHNE Corp_December 31, 20240000842023--06-302025Q2falsehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpenseBIO-TECHNE Corphttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpensehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrent0000842023us-gaap:RetainedEarningsMember2024-12-310000842023us-gaap:AdditionalPaidInCapitalMember2024-12-310000842023us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-12-310000842023us-gaap:RetainedEarningsMember2024-09-300000842023us-gaap:AdditionalPaidInCapitalMember2024-09-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-3000008420232024-09-300000842023us-gaap:RetainedEarningsMember2024-06-300000842023us-gaap:AdditionalPaidInCapitalMember2024-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300000842023us-gaap:RetainedEarningsMember2023-12-310000842023us-gaap:AdditionalPaidInCapitalMember2023-12-310000842023us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000842023us-gaap:RetainedEarningsMember2023-09-300000842023us-gaap:AdditionalPaidInCapitalMember2023-09-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-3000008420232023-09-300000842023us-gaap:RetainedEarningsMember2023-06-300000842023us-gaap:AdditionalPaidInCapitalMember2023-06-300000842023us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300000842023tech:EmployeeStockPurchasePlan2014Member2014-10-300000842023us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-12-310000842023us-gaap:RestrictedStockMember2024-07-012024-12-310000842023us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-12-310000842023us-gaap:RestrictedStockMember2023-07-012023-12-310000842023tech:LunaphoreTechnologiesSaMember2024-07-012024-12-310000842023us-gaap:ServiceMember2024-10-012024-12-310000842023us-gaap:RoyaltyMember2024-10-012024-12-310000842023us-gaap:IntersegmentEliminationMember2024-10-012024-12-310000842023tech:RestOfWorldMember2024-10-012024-12-310000842023tech:ProductAndServicesMember2024-10-012024-12-310000842023tech:OtherRevenuesFromBusinessHeldForSaleMember2024-10-012024-12-310000842023tech:InstrumentsMember2024-10-012024-12-310000842023tech:EMEAExcludingUKMember2024-10-012024-12-310000842023tech:ConsumablesMember2024-10-012024-12-310000842023tech:APACExcludingGreaterChinaMember2024-10-012024-12-310000842023country:US2024-10-012024-12-310000842023country:GB2024-10-012024-12-310000842023country:CN2024-10-012024-12-310000842023us-gaap:ServiceMember2024-07-012024-12-310000842023us-gaap:RoyaltyMember2024-07-012024-12-310000842023us-gaap:IntersegmentEliminationMember2024-07-012024-12-310000842023tech:RestOfWorldMember2024-07-012024-12-310000842023tech:ProductAndServicesMember2024-07-012024-12-310000842023tech:OtherRevenuesFromBusinessHeldForSaleMember2024-07-012024-12-310000842023tech:InstrumentsMember2024-07-012024-12-310000842023tech:EMEAExcludingUKMember2024-07-012024-12-310000842023tech:ConsumablesMember2024-07-012024-12-310000842023tech:APACExcludingGreaterChinaMember2024-07-012024-12-310000842023country:US2024-07-012024-12-310000842023country:GB2024-07-012024-12-310000842023country:CN2024-07-012024-12-310000842023us-gaap:ServiceMember2023-10-012023-12-310000842023us-gaap:RoyaltyMember2023-10-012023-12-310000842023us-gaap:IntersegmentEliminationMember2023-10-012023-12-310000842023tech:RestOfWorldMember2023-10-012023-12-310000842023tech:ProductAndServicesMember2023-10-012023-12-310000842023tech:InstrumentsMember2023-10-012023-12-310000842023tech:EMEAExcludingUKMember2023-10-012023-12-310000842023tech:ConsumablesMember2023-10-012023-12-310000842023tech:APACExcludingGreaterChinaMember2023-10-012023-12-310000842023country:US2023-10-012023-12-310000842023country:GB2023-10-012023-12-310000842023country:CN2023-10-012023-12-310000842023us-gaap:ServiceMember2023-07-012023-12-310000842023us-gaap:RoyaltyMember2023-07-012023-12-310000842023us-gaap:IntersegmentEliminationMember2023-07-012023-12-310000842023tech:RestOfWorldMember2023-07-012023-12-310000842023tech:ProductAndServicesMember2023-07-012023-12-310000842023tech:InstrumentsMember2023-07-012023-12-310000842023tech:EMEAExcludingUKMember2023-07-012023-12-310000842023tech:ConsumablesMember2023-07-012023-12-310000842023tech:APACExcludingGreaterChinaMember2023-07-012023-12-310000842023country:US2023-07-012023-12-310000842023country:GB2023-07-012023-12-310000842023country:CN2023-07-012023-12-310000842023tech:ImpairmentOfAssetsHeldForSaleMembertech:FiscalYear2024RestructuringActionsMember2023-07-012024-06-300000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMember2024-12-310000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2024-12-310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2024-12-310000842023tech:FiscalYear2025RestructuringActionsMember2024-12-310000842023tech:FiscalYear2024RestructuringActionsMember2024-12-310000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMember2024-09-300000842023tech:FiscalYear2025RestructuringActionsMember2024-09-300000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2024-06-300000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2024-06-300000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2024-06-300000842023tech:FiscalYear2024RestructuringActionsMember2024-06-300000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2023-06-300000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2023-10-012023-12-310000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2023-07-012023-09-300000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2025RestructuringActionsMember2024-07-012024-09-300000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2024-07-012024-09-300000842023tech:FiscalYear2024RestructuringActionsMember2024-07-012024-09-300000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2024-04-012024-06-300000842023tech:ImpairmentOfAssetsHeldForSaleMembertech:FiscalYear2024RestructuringActionsMember2024-04-012024-06-300000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2024-04-012024-06-300000842023tech:FiscalYear2024RestructuringActionsMember2024-04-012024-06-300000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2024-01-012024-03-310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2024-01-012024-03-310000842023tech:FiscalYear2024RestructuringActionsMember2024-01-012024-03-310000842023us-gaap:CommonStockMember2024-10-012024-12-310000842023us-gaap:CommonStockMember2024-07-012024-09-300000842023us-gaap:CommonStockMember2023-10-012023-12-310000842023us-gaap:CommonStockMember2023-07-012023-09-300000842023us-gaap:MachineryAndEquipmentMember2024-12-310000842023us-gaap:LandMember2024-12-310000842023us-gaap:ConstructionInProgressMember2024-12-310000842023us-gaap:BuildingAndBuildingImprovementsMember2024-12-310000842023us-gaap:MachineryAndEquipmentMember2024-06-300000842023us-gaap:LandMember2024-06-300000842023us-gaap:ConstructionInProgressMember2024-06-300000842023us-gaap:BuildingAndBuildingImprovementsMember2024-06-300000842023tech:SpearBioMember2024-07-012024-07-310000842023tech:WilsonWolfCorporationMember2023-03-312023-03-310000842023tech:WilsonWolfCorporationMember2021-12-012021-12-310000842023tech:LunaphoreTechnologiesSaMember2023-07-012024-06-300000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMember2024-07-012024-09-300000842023tech:FiscalYear2025RestructuringActionsMember2024-07-012024-09-300000842023us-gaap:EmployeeSeveranceMembertech:ProteinSciencesMember2023-07-012024-06-300000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2023-07-012024-06-300000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2023-07-012024-06-300000842023tech:FiscalYear2024RestructuringActionsMember2023-07-012024-06-300000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2024-10-012024-12-310000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndSpatialBiologyMember2024-10-012024-12-310000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2024-07-012024-12-310000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndSpatialBiologyMember2024-07-012024-12-310000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2023-10-012023-12-310000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndSpatialBiologyMember2023-10-012023-12-310000842023us-gaap:OperatingSegmentsMembertech:ProteinSciencesMember2023-07-012023-12-310000842023us-gaap:OperatingSegmentsMembertech:DiagnosticsAndSpatialBiologyMember2023-07-012023-12-310000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-10-012024-12-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-10-012024-12-310000842023us-gaap:DesignatedAsHedgingInstrumentMember2024-10-012024-12-310000842023us-gaap:AccumulatedTranslationAdjustmentMember2024-10-012024-12-310000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-10-012024-12-310000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-12-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-12-310000842023us-gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-12-310000842023us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-12-310000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-012024-12-310000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-10-012023-12-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-10-012023-12-310000842023us-gaap:DesignatedAsHedgingInstrumentMember2023-10-012023-12-310000842023us-gaap:AccumulatedTranslationAdjustmentMember2023-10-012023-12-310000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-10-012023-12-310000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-12-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-12-310000842023us-gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-12-310000842023us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-12-310000842023us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012023-12-310000842023tech:SpearBioMemberus-gaap:OtherNoncurrentAssetsMember2024-12-310000842023tech:AmendedCreditAgreementMember2024-12-310000842023us-gaap:RevolvingCreditFacilityMembertech:AmendedCreditAgreementMember2022-08-312022-08-310000842023srt:MaximumMember2024-12-310000842023tech:ExchangedTradedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023tech:ExchangedTradedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023tech:WilsonWolfCorporationMember2024-07-012024-12-310000842023tech:ProteinSciencesMember2024-07-012024-12-310000842023tech:DiagnosticsAndSpatialBiologyMember2024-07-012024-12-310000842023tech:DiagnosticsAndSpatialBiologyMember2024-12-310000842023tech:ProteinSciencesMember2024-06-300000842023tech:DiagnosticsAndSpatialBiologyMember2024-06-300000842023srt:MinimumMembertech:LunaphoreTechnologiesSaMemberus-gaap:TradeNamesMember2024-12-310000842023srt:MaximumMembertech:LunaphoreTechnologiesSaMemberus-gaap:TradeNamesMember2024-12-310000842023tech:LunaphoreTechnologiesSaMemberus-gaap:DevelopedTechnologyRightsMember2024-12-310000842023tech:LunaphoreTechnologiesSaMemberus-gaap:CustomerRelationshipsMember2024-12-310000842023us-gaap:TradeNamesMember2024-12-310000842023us-gaap:PatentsMember2024-12-310000842023us-gaap:OtherIntangibleAssetsMember2024-12-310000842023us-gaap:DevelopedTechnologyRightsMember2024-12-310000842023us-gaap:CustomerRelationshipsMember2024-12-310000842023us-gaap:TradeNamesMember2024-06-300000842023us-gaap:PatentsMember2024-06-300000842023us-gaap:OtherIntangibleAssetsMember2024-06-300000842023us-gaap:DevelopedTechnologyRightsMember2024-06-300000842023us-gaap:CustomerRelationshipsMember2024-06-300000842023tech:WilsonWolfCorporationMember2023-03-310000842023us-gaap:RetainedEarningsMember2024-10-012024-12-310000842023us-gaap:RetainedEarningsMember2024-07-012024-09-300000842023us-gaap:RetainedEarningsMember2023-10-012023-12-310000842023us-gaap:RetainedEarningsMember2023-07-012023-09-300000842023tech:CurrentAssetsHeldForSaleMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2024-12-310000842023tech:ProteinSciencesMember2024-12-310000842023tech:ProteinSciencesMember2023-12-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-08-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-03-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-05-310000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000842023us-gaap:OtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-

gaap:FairValueMeasurementsRecurringMember2024-12-310000842023us-gaap:OtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-
gaap:FairValueMeasurementsRecurringMember2024-12-310000842023us-gaap:OtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:OtherCurrentAssetsMemberus-gaap:CashFlowHedgingMemberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-12-310000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-12-310000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-06-300000842023tech:ForwardStartingSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-06-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-12-310000842023us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-12-310000842023us-gaap:CommonStockMember2024-12-310000842023us-gaap:CommonStockMember2024-09-
300000842023us-gaap:CommonStockMember2024-06-300000842023us-gaap:CommonStockMember2023-12-310000842023us-gaap:CommonStockMember2023-09-300000842023us-
gaap:CommonStockMember2023-06-3000008420232023-12-3100008420232023-06-300000842023tech:LunaphoreTechnologiesSaMemberus-gaap:TradeNamesMember2024-06-
300000842023tech:LunaphoreTechnologiesSaMemberus-gaap:DevelopedTechnologyRightsMember2024-06-300000842023tech:LunaphoreTechnologiesSaMemberus-
gaap:CustomerRelationshipsMember2024-06-300000842023us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-
300000842023tech:LunaphoreTechnologiesSaMember2023-07-072023-07-070000842023us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-
310000842023us-gaap:FairValueMeasurementsRecurringMember2024-12-310000842023us-gaap:OtherNoncurrentAssetsMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:OtherNoncurrentAssetsMemberus-
gaap:NetInvestmentHedgingMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-
gaap:FairValueMeasurementsRecurringMember2024-06-300000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-07-012024-06-300000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMember2024-10-012024-12-310000842023us-gaap:CostOfSalesMember2024-10-012024-12-
310000842023tech:EmployeeStockPurchasePlan2014Member2024-10-012024-12-310000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-12-
310000842023us-gaap:CostOfSalesMember2024-07-012024-12-310000842023tech:EmployeeStockPurchasePlan2014Member2024-07-012024-12-310000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMember2023-10-012023-12-310000842023us-gaap:CostOfSalesMember2023-10-012023-12-
310000842023tech:EmployeeStockPurchasePlan2014Member2023-10-012023-12-310000842023us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-12-
310000842023us-gaap:CostOfSalesMember2023-07-012023-12-310000842023tech:EmployeeStockPurchasePlan2014Member2023-07-012023-12-310000842023us-
gaap:AdditionalPaidInCapitalMember2024-10-012024-12-310000842023us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000842023us-
gaap:AdditionalPaidInCapitalMember2023-10-012023-12-310000842023us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-3000008420232024-08-012024-08-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMemberus-gaap:CorporateMember2024-10-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMembertech:ProteinSciencesMember2024-10-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMembertech:DiagnosticsAndSpatialBiologyMember2024-10-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2024-10-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2025RestructuringActionsMemberus-gaap:CorporateMember2024-10-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2025RestructuringActionsMembertech:ProteinSciencesMember2024-10-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2024-10-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2024-10-012024-12-310000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMembertech:FiscalYear2025RestructuringActionsMember2024-10-012024-12-310000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMembertech:FiscalYear2024RestructuringActionsMember2024-10-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMember2024-10-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2024-10-012024-12-310000842023us-
gaap:CostOfSalesMembertech:FiscalYear2025RestructuringActionsMember2024-10-012024-12-310000842023tech:FiscalYear2025RestructuringActionsMemberus-
gaap:CorporateMember2024-10-012024-12-310000842023tech:FiscalYear2025RestructuringActionsMembertech:ProteinSciencesMember2024-10-012024-12-
310000842023tech:FiscalYear2025RestructuringActionsMembertech:DiagnosticsAndSpatialBiologyMember2024-10-012024-12-
310000842023tech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2024-10-012024-12-
310000842023tech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2024-10-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2025RestructuringActionsMember2024-10-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2024-10-012024-12-310000842023tech:FiscalYear2025RestructuringActionsMember2024-
10-012024-12-310000842023tech:FiscalYear2024RestructuringActionsMember2024-10-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMemberus-gaap:CorporateMember2024-07-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMembertech:ProteinSciencesMember2024-07-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMembertech:DiagnosticsAndSpatialBiologyMember2024-07-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2024-07-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2024-07-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2025RestructuringActionsMemberus-gaap:CorporateMember2024-07-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2025RestructuringActionsMembertech:ProteinSciencesMember2024-07-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2024-07-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2024-07-012024-12-310000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMembertech:FiscalYear2025RestructuringActionsMember2024-07-012024-12-310000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMembertech:FiscalYear2024RestructuringActionsMember2024-07-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2025RestructuringActionsMember2024-07-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2024-07-012024-12-310000842023us-
gaap:CostOfSalesMembertech:FiscalYear2025RestructuringActionsMember2024-07-012024-12-310000842023tech:FiscalYear2025RestructuringActionsMemberus-
gaap:CorporateMember2024-07-012024-12-310000842023tech:FiscalYear2025RestructuringActionsMembertech:ProteinSciencesMember2024-07-012024-12-
310000842023tech:FiscalYear2025RestructuringActionsMembertech:DiagnosticsAndSpatialBiologyMember2024-07-012024-12-
310000842023tech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2024-07-012024-12-
310000842023tech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2024-07-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2025RestructuringActionsMember2024-07-012024-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2024-07-012024-12-310000842023tech:FiscalYear2025RestructuringActionsMember2024-
07-012024-12-310000842023tech:FiscalYear2024RestructuringActionsMember2024-07-012024-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2023-10-012023-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-10-012023-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMembertech:DiagnosticsAndSpatialBiologyMember2023-10-012023-12-
310000842023tech:ImpairmentOfAssetsHeldForSaleMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-10-012023-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2023-10-012023-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-10-012023-12-310000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMembertech:FiscalYear2024RestructuringActionsMember2023-10-012023-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2023-10-012023-12-310000842023us-
gaap:CostOfSalesMembertech:FiscalYear2024RestructuringActionsMember2023-10-012023-12-
310000842023tech:ImpairmentOfAssetsHeldForSaleMembertech:FiscalYear2024RestructuringActionsMember2023-10-012023-12-
310000842023tech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2023-10-012023-12-
310000842023tech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-10-012023-12-
310000842023tech:FiscalYear2024RestructuringActionsMembertech:DiagnosticsAndSpatialBiologyMember2023-10-012023-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2023-10-012023-12-310000842023tech:FiscalYear2024RestructuringActionsMember2023-
10-012023-12-310000842023us-gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2023-07-012023-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-07-012023-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMembertech:DiagnosticsAndSpatialBiologyMember2023-07-012023-12-
310000842023tech:ImpairmentOfAssetsHeldForSaleMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-07-012023-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2023-07-012023-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-07-012023-12-310000842023us-
gaap:SellingGeneralAndAdministrativeExpensesMembertech:FiscalYear2024RestructuringActionsMember2023-07-012023-12-310000842023us-
gaap:EmployeeSeveranceMembertech:FiscalYear2024RestructuringActionsMember2023-07-012023-12-310000842023us-
gaap:CostOfSalesMembertech:FiscalYear2024RestructuringActionsMember2023-07-012023-12-
310000842023tech:ImpairmentOfAssetsHeldForSaleMembertech:FiscalYear2024RestructuringActionsMember2023-07-012023-12-
310000842023tech:FiscalYear2024RestructuringActionsMemberus-gaap:CorporateMember2023-07-012023-12-
310000842023tech:FiscalYear2024RestructuringActionsMembertech:ProteinSciencesMember2023-07-012023-12-
310000842023tech:FiscalYear2024RestructuringActionsMembertech:DiagnosticsAndSpatialBiologyMember2023-07-012023-12-
310000842023tech:AssetRelatedAndOtherMembertech:FiscalYear2024RestructuringActionsMember2023-07-012023-12-310000842023tech:FiscalYear2024RestructuringActionsMember2023-
07-012023-12-310000842023tech:ProteinSciencesMember2023-07-012024-06-300000842023tech:ProteinSciencesMember2022-07-012023-06-300000842023us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-012024-12-310000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-3000008420232024-07-
012024-09-300000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-310000842023us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-
012023-09-3000008420232023-07-012023-09-300000842023us-gaap:RevolvingCreditFacilityMembertech:AmendedCreditAgreementMember2022-08-310000842023us-
gaap:OtherNoncurrentAssetsMember2024-12-310000842023us-gaap:OtherNoncurrentAssetsMember2024-06-3000008420232023-10-012023-12-
310000842023tech:WilsonWolfCorporationMember2024-12-310000842023tech:WilsonWolfCorporationMembertech:FirstPartOfForwardContractMember2024-12-
310000842023tech:WilsonWolfCorporationMembertech:SecondPartOfForwardContractMember2024-12-310000842023us-gaap:CurrencySwapMemberus-
gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-07-310000842023us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-07-310000842023tech:LunaphoreTechnologiesSaMember2024-06-3000008420232024-12-3100008420232024-06-
3000008420232023-07-012023-12-310000842023us-gaap:OperatingSegmentsMember2024-10-012024-12-310000842023us-gaap:OperatingSegmentsMember2024-07-012024-12-
310000842023us-gaap:OperatingSegmentsMember2023-10-012023-12-310000842023us-gaap:OperatingSegmentsMember2023-07-012023-12-3100008420232024-10-012024-12-
3100008420232025-02-0300008420232024-07-012024-12-31xbrli:sharesiso4217:USDtech:itemxbrli:pureiso4217:USDxbrli:sharestech:segmentTable of Contentsâ€‹â€‹â€‹UNITED
STATESSECURITIES AND EXCHANGE COMMISSIONWashington, DC 20549FORM 10-Qâ€‹â˜’QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934For the quarterly period ended December 31, 2024, orâ˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the
transition period from Â toâ€‹Commission file number 0-17272BIO-TECHNE CORPORATION(Exact name of registrant as specified in its
charter)Minnesota41-1427402(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)Â Â 614 McKinley Place N.E.Minneapolis, MN 55413(612) 379-
8854(Address of principal executive offices) (Zip Code)(Registrant's telephone number, including area code)Securities registered pursuant to Section 12(b) of the Exchange Act:â€‹Title of each
classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $0.01 par valueTECHThe NASDAQ Stock Market LLCâ€‹Indicate by check mark whether the registrant
(1)Â has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2)Â has been subject to such filing requirements for the past 90 days.Â Â Â Â YesÂ Â â˜’Â Â Â Â NoÂ Â Â â˜â€‹Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such
shorter period that the registrant was required to submit such files).Â Â Â Â YesÂ Â â˜’Â Â Â Â NoÂ Â Â â˜â€‹Indicate by check mark whether the registrant is a large accelerated filer, an

accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.â€‹LargeÂ acceleratedÂ filerâ˜‘AcceleratedÂ filerâ˜Â Â Â Â Non-accelerated filerâ˜SmallerÂ reportingÂ companyâ˜Â Â Â Â Â Â Emerging growth companyâ˜â€‹If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜â€‹Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b- 2).Â Â Â Â â˜Â Â YesÂ Â Â Â â˜Â Â Noâ€‹At February 3, 2025, 158,087,683 shares of the Company's Common Stock (par value $0.01) were outstanding.â€‹â€‹â€‹â€‹ Table of Contentsâ€‹TABLE OF CONTENTSâ€‹â€‹ PagePART I. FINANCIAL INFORMATIONÂ ItemÂ 1.Condensed Consolidated Financial Statements (Unaudited)1Â ItemÂ 2.Management's Discussion and Analysis of Financial Condition and Results of Operations27Â ItemÂ 3.Quantitative and Qualitative Disclosures about Market Risk36Â ItemÂ 4.Controls and Procedures37Â PART II: OTHER INFORMATIONÂ ItemÂ 1.Legal Proceedings37Â Â ItemÂ 1A.Risk Factors37Â Â ItemÂ 2.Unregistered Sales of Equity Securities and Use of Proceeds38Â Â Item 3.Defaults Upon Senior Securities38Â Â Item 4.Mine Safety Disclosures38Â Â Item 5.Other Information38Â Â ItemÂ 6.Exhibits39Â Â â€‹SIGNATURES42â€‹â€‹â€‹â€‹â€‹ Table of ContentsPART I. FINANCIAL INFORMATIONITEMÂ 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTSCONDENSED CONSOLIDATED STATEMENTS OF EARNINGSAND COMPREHENSIVE INCOMEBio-Techne Corporation and Subsidiaries(in thousands, except per share data)(unaudited)â€‹â€‹â€‹â€‹â€‹

Condensed Consolidated Statements of Earnings as follows (in thousands): â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Quarter Ended â€‹Six Months Endedâ€‹â€‹DecemberÂ 31,Â â€‹DecemberÂ 31,Â â€‹â€‹â€‹2024â€‹â€‹2023â€‹â€‹2024â€‹â€‹2023Cost of salesâ€‹$ â€”â€‹ $ 1,174â€‹ $ â€”â€‹ $ 1,174Selling, general and administrative(1)â€‹â€‹ 323â€‹â€‹ 10,250â€‹â€‹ 1,076â€‹â€‹ 10,250Totalâ€‹ $ 323â€‹ $ 11,424â€‹ $ 1,076â€‹ $ 11,424(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. â€‹Restructuring and restructuring-related costs by segment are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

9,669â€‹Â 6,397Other assetsâ€‹$ 274,990â€‹$ 264,265â€‹â€‹Note 4. Acquisitions:We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our Consolidated Statements of Earnings and Comprehensive Income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.There were no acquisitions in the first half of fiscal 2025.â€‹13 Table of ContentsFiscal year 2024Â AcquisitionsLunaphore Technologies SA.On July 7, 2023, the Company acquired all of the ownership interests of Lunaphore Technologies SA (â€œLunaphoreâ€) for $169.7 million, in a cash-free, debt-free acquisition. Lunaphore is a leading developer of fully automated spatial biology solutions. The Lunaphore acquisition adds spatial biology instruments to Bio-Techneâ€™s portfolio to accelerate our leadership position in translational and clinical research markets. The transaction was accounted for in accordance with ASCÂ 805,Â Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Companyâ€™s product portfolio and the expected revenue growth from increased market penetration. The goodwill isÂ notÂ deductible for income tax purposes. The business became part of the Diagnostics and Spatial Biology operating segment in the first quarter of fiscal yearÂ 2024.Â The allocation of purchase price consideration related to Lunaphore was completed in the fourth quarter of fiscal 2024. The fair values of the assets acquired and liabilities assumed as of June 30, 2024 are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹Final allocation at June 30, 2024Current assets$ 12,155Equipment and other long-term assetsÂ 1,470GoodwillÂ 104,650Intangible assets:â€‹â€‹Developed technologiesÂ 60,300TradenamesÂ 4,900Customer relationshipsÂ 1,200Total assets acquiredÂ 184,675â€‹â€‹â€‹LiabilitiesÂ 7,096Deferred income taxes, netÂ 7,872Net assets acquired$ 169,707â€‹â€‹â€‹Cash paid Â 169,707â€‹â€‹14 Table of ContentsTangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology and customer relationships was based on managementâ€™s forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The purchase price allocated to trade names was based on management's forecasted cash inflows and outflows and using a relief from royalty method. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is 8 years.Â The amount recorded for trade names is being amortized with the expense reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for trade names ranges from 4 years to 8 years.Â The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the calculation of acquired net operating losses.â€‹NoteÂ 5. Fair Value Measurements:The Companyâ€™s financial instruments include cash and cash equivalents, available-for-sale investments, derivative instruments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt.Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.â€‹15 Table of ContentsThe following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands).â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â TotalÂ Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹carryingÂ â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹valueÂ asÂ ofâ€‹Fair/ Sheet Locationâ€‹DecemberÂ 31,Â â€‹InputsÂ ConsideredÂ asâ€‹â€‹â€‹2024â€‹LevelÂ 1â€‹LevelÂ 2â€‹LevelÂ 3â€‹â€‹Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Assetsâ€‹Â â€‹Â Â Â â€‹Â Â Â â€‹Â Â Â â€‹Â designated as hedging instruments - cash flow hedgesOther current assetsâ€‹$ 6,063â€‹$ â€”â€‹$ 6,063â€‹$ â€”Derivatives designated as hedging instruments - cash flow hedgesOther assetsâ€‹â€‹ 528â€‹â€‹ â€”â€‹â€‹ 528â€‹â€‹ â€”Derivatives designated as hedging instruments - net investment hedgeOther assetsâ€‹â€‹ 2,699â€‹â€‹ â€”â€‹â€‹ 2,699â€‹â€‹ â€”Total assetsâ€‹$ 9,290â€‹$ â€”â€‹$ 9,290â€‹$ â€”â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

â€‹Â 0 â€‹Â (4,768)â€‹Â â€‹â€‹Â (4,767)Cash dividendsÂ â€‹â€‹â€‹â€‹â€‹Â â€‹â€‹Â (12,654)â€‹Â â€‹â€‹Â (12,654)Stock-based compensation expenseÂ â€‹â€‹Â â€‹â€‹Â 9,981â€‹Â â€‹â€‹Â â€‹â€‹Â 9,981Common stock issued to employee stock purchase planÂ 33â€‹â€‹1 â€‹Â 2,093â€‹Â â€‹â€‹Â â€‹â€‹Â 2,094Employee stock purchase plan expenseâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ 112â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ 112Balances at SeptemberÂ 30,Â 2023Â 158,355â€‹$ 1,584â€‹$ 746,606â€‹$ 1,327,572â€‹$ (78,016)â€‹$ 1,997,746Net earningsÂ â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹ 27,465â€‹â€‹â€‹â€‹Â 27,465Other comprehensive income (loss)â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

portfolio as well as improving biopharma end market conditions and continued uptake of our cell and gene therapy workflow solutions in our Protein Sciences segment. Gross MarginsConsolidated gross margins for the quarter and six months ended December 31, 2024 were 65.3% and 64.3%, respectively, compared to 64.8% and 65.8% for the same prior year periods. Under purchase accounting, inventory is valued at fair value less expected selling and marketing costs, resulting in reduced margins in future periods as the inventory is sold. Excluding the impact of costs recognized upon the sale of acquired inventory, amortization of intangibles, stock-based compensation expense, restructuring and restructuring-related expenses, and the impact of a business held-for-sale, adjusted gross margins for the quarter and six months ended December 31, 2024 were 70.5% and 70.0%, respectively, compared to 69.7% and 70.5% for the quarter and six months ended December 31, 2023, respectively. Fluctuations in consolidated gross margin and adjusted gross margin, as a percentage of sales, have primarily resulted from changes in product mix. We expect that, in the future, gross margins will continue to be impacted by the mix of our portfolio growing at different rates as well as future acquisitions.â€‹28 Table of ContentsA reconciliation of the reported consolidated gross margin percentages, adjusted for acquired inventory sold, intangible amortization, stock compensation expense, restructuring and restructuring-related charges, and the impact of a business held-for-sale included in cost of sales, is as follows (in thousands):â€‹â€‹â€‹

basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to the transition to a new CEO, goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition. The Companyâ€™s non-GAAP adjusted net earnings, in total and on a per share basis, also excludes gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.The Company periodically reassesses the components of our non-GAAP adjustments for changes in how we evaluate our performance, changes in how we make financial and operational decisions, and considers the use of these measures by our competitors and peers to ensure the adjustments are still relevant and meaningful.Readers are encouraged to review the reconciliations of the adjusted financial measures used in management's discussion and analysis of the financial condition of the Company to their most directly comparable GAAP financial measures provided within the Company's consolidated financial statements.â€‹35 Table of ContentsFORWARD LOOKING INFORMATION AND CAUTIONARY STATEMENTSThis quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those regarding the Company's expectations as to the effect of changes to accounting policies, the amount of capital expenditures for the remainder of the fiscal year, the source of funding for capital expenditure requirements, the sufficiency of currently available funds for meeting the Company's needs, the impact of fluctuations in foreign currency exchange rates, and expectations regarding gross margin fluctuations, increasing research and development expenses, increasing selling, general and administrative expenses and income tax rates. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: integration of newly acquired businesses, the introduction and acceptance of new products, general national and international economic, political, regulatory, and otherÂ conditions, increased competition, the reliance on internal manufacturing and related operations, supply chain challenges, the impact of currency exchange rate fluctuations, the recruitment and retention of qualified personnel, the impact of governmental regulation, maintenance of intellectual property rights, credit risk and fluctuation in the market value of the Company's investment portfolio, and unseen delays and expenses related to facility construction and improvements. For additional information concerning such factors, see the Company's Annual Report on Form 10-K for fiscal 2024Â as filed with the Securities and Exchange Commission and Part II. Item 1A below.â€‹ITEMÂ 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKThe Companyâ€™s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the Companyâ€™s Annual Report on Form 10-K for the year ended June 30, 2024.â€‹â€‹36 Table of ContentsITEMÂ 4. CONTROLS AND PROCEDURES(a) Evaluation of disclosure controls and procedures.The Company maintains disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). The Company's management has evaluated, with the participation of its Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered in this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2024, our disclosure controls and procedures were effective.(b) Changes in internal controls over financial reporting.There were no changes in the Company's internal control over financial reporting during the second quarter of fiscal 2025 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.PART II. OTHER INFORMATIONITEMÂ 1. LEGAL PROCEEDINGSAs of February 6, 2025, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.â€‹ITEMÂ 1A. RISK FACTORSDuring the quarter and six months ended December 31, 2024, there have been noÂ material changes from the risk factors found in Part I, Item 1A, "Risk Factors," of the Company's Annual Report on Form 10-K for the year ended June 30, 2024.â€‹37 Table of Contentsâ€‹ITEMÂ 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSThe Companyâ€™s repurchase plan approved by the Board on February 2, 2022, granted management the discretion to mitigate the dilutive effect of stock option exercises. The plan authorizes the Company to purchase up to $400 million in stock. The table below sets forth certain information regarding our purchases of common stock in open market transactions during fiscal year 2025. â€‹â€‹â€‹

recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent function):â€‹a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andâ€‹b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.â€‹Date: February 6, 2025â€‹/s/ James HippelJames HippelExecutive Vice President, Chief Financial Officer EX-32.1 4 tech-20241231xex32d1.htm EX-32.1 Exhibit 32.1â€‹CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report of Bio-Techne Corporation (the â€œCompanyâ€) on Form 10-Q for the quarter ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Kim Kelderman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:â€‹(1)The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; andâ€‹(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹Â /s/ Kim KeldermanÂ Kim KeldermanÂ President and Chief Executive OfficerFebruary 6, 2025â€‹ EX-32.2 5 tech-20241231xex32d2.htm EX-32.2 Exhibit 32.2â€‹CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002â€‹In connection with the Quarterly Report of Bio-Techne Corporation (the â€œCompanyâ€) on Form 10-Q for the quarter ended December 31, 2024Â as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, James Hippel, Executive Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:â€‹(1)The Report fully complies with the requirements of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; andâ€‹(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹Â /s/ James HippelÂ James HippelÂ Executive Vice President, Chief Financial OfficerFebruary 6, 2025â€‹ EX-101.SCH 6 tech-20241231.xsd EX-101.SCH 995200100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Selected Balance Sheet Data - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - Selected Balance Sheet Data - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 99940304 - Disclosure - Selected Balance Sheet Data - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940306 - Disclosure - Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940308 - Disclosure - Selected Balance Sheet Data - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940402 - Disclosure - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 99940502 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Leases - Balance Sheet Classification (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - Leases - Fair Value of the Lease Liability by Payment Date (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) link:presentationLink link:calculationLink link:definitionLink 99941102 - Disclosure - Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 995200205 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Selected Balance Sheet Data link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Acquisitions link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Debt and Other Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Share-based Compensation link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Other Income / (Expense) link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995211401 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930103 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Selected Balance Sheet Data (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Other Income / (Expense) (Tables) link:presentationLink link:calculationLink link:definitionLink 99931303 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 99940102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Selected Balance Sheet Data - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940305 - Disclosure - Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940307 - Disclosure - Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Acquisitions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940503 - Disclosure - Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 99940504 - Disclosure - Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - Leases - Cash Paid (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Share-based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Segment Information - Financial Information Relating to Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 tech-20241231_cal.xml EX-101.CAL EX-101.DEF 8 tech-20241231_def.xml EX-101.DEF EX-101.LAB 9 tech-20241231_lab.xml EX-101.LAB Document Information [Table] Document Information [Line Items] Document Type Document Quarterly Report Document Period End Date Document Transition Report Securities Act File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME Statement [Table] Statement [Line Items] Revenue from Contract with Customer, Excluding Assessed Tax Net sales Revenues, net Cost of Goods and Services Sold Cost of sales Gross Profit Gross margin Operating expenses: Selling, General and Administrative Expense Corporate general, selling, and administrative expenses Selling, general and administrative Research and Development Expense (Excluding Acquired in Process Cost) Research and development Operating Expenses Total operating expenses Operating Income (Loss) Operating income Nonoperating Income (Expense) Other income (expense) Total other income (expense), net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Earnings before income taxes Income Tax Expense (Benefit) Income taxes Income Tax Expense (Benefit), Total Net earnings Other comprehensive income (loss): Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Foreign currency translation income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income Earnings Per Share [Abstract] Earnings per share: Earnings Per Share, Basic Basic (in dollars per share) Earnings per share - basic Earnings Per Share, Diluted Diluted (in dollars per share) Earnings per share - diluted Weighted average common shares outstanding: Weighted Average Number of Shares Outstanding, Basic Basic (in shares) Weighted-average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Weighted-average common shares outstanding - diluted (in shares) CONDENSED CONSOLIDATED BALANCE SHEETS Assets [Abstract] ASSETS Current assets: Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Short-Term Investments Short-term available-for-sale investments Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, less allowance for doubtful accounts of $4,904 and $4,386, respectively Inventory, Net Inventories Disposal Group, Including Discontinued Operation, Assets, Current Current assets held-for-sale Other Assets, Current Other current assets Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Operating Lease, Right-of-Use Asset Operating lease right of use assets Right-of-use assets Goodwill Ending balance Beginning balance Goodwill Intangible Assets, Net (Excluding Goodwill) Ending balance Beginning balance Intangible assets, net Total intangible assets, net Other Assets, Noncurrent Other assets Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts Payable, Current Trade accounts payable Employee-related Liabilities, Current Salaries, wages and related accruals Accrued Liabilities, Current Accrued expenses Contract with Customer, Liability, Current Contract liabilities Accrued Income Taxes, Current Income taxes payable Operating Lease, Liability, Current Current operating lease liabilities Operating lease liabilities - current Other Liabilities, Current Other current liabilities Liabilities, Current Total current liabilities Deferred Income Tax Liabilities, Net Deferred income taxes Deferred tax liabilities Long-Term Debt and Lease Obligation Long-term debt obligations Operating Lease, Liability, Noncurrent Noncurrent operating lease liabilities Operating lease liabilities Other Liabilities, Noncurrent Other long-term liabilities Equity [Abstract] Bio-Techne's Shareholders' equity: Represents the value of undesignated capital stock as of the balance sheet date. Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding Common Stock, Value, Issued Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,915,999 and 158,216,258 respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Retained earnings Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Equity, Attributable to Parent Balance Balance Total Bio-Techne's shareholders' equity Liabilities and Equity Total liabilities and shareholders' equity Accounts Receivable, Allowance for Credit Loss, Current Accounts receivable, allowance for doubtful accounts Represents the no par value for undesignated capital stock. Undesignated capital stock, no par (in dollars per share) Undesignated capital stock, no par (in dollars per share) Represents the shares authorized for undesignated capital stock. Undesignated capital stock, shares authorized (in shares) Undesignated capital stock, shares authorized (in shares) Represents the shares issued for undesignated capital stock. Undesignated capital stock, shares issued (in shares) Undesignated capital stock, shares issued (in shares) Represents the shares outstanding for undesignated capital stock. Undesignated capital stock, shares outstanding (in shares) Undesignated capital stock, shares outstanding (in shares) Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized (in shares) Common Stock, Shares, Issued Common stock, shares issued (in shares) Common Stock, Shares, Outstanding Balances (in shares) Balances (in shares) Common stock, shares outstanding (in shares) CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net earnings Net earnings Adjustments to reconcile net earnings to net cash provided by operating activities: Depreciation, Depletion and Amortization Depreciation and amortization The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting. Costs recognized on sale of acquired inventory Costs recognized on sale of acquired inventory Costs recognized on sale of acquired inventory Deferred Income Taxes and Tax Credits Deferred income taxes Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Fair value adjustment to contingent consideration payable Fair value adjustment to contingent consideration payable The amount of fair value adjustment made on available for sale securities during the period. Fair value adjustment on available-for-sale investments Fair value adjustment on available-for-sale investments Equity Method Investment, Realized Gain (Loss) on Disposal (Gain) Loss on equity method investment The value of asset impairment restructuring charge. Asset impairment restructuring Asset impairment restructuring The amount of noncash portion of lease expense during the period. Leases, net Leases, net Impairment of Long-Lived Assets to be Disposed of Impairment charges related to the disposal group Impairment of assets held-for-sale Other Operating Activities, Cash Flow Statement Other operating activity Change in operating assets and operating liabilities, net of acquisition: Increase (Decrease) in Accounts and Other Receivables Trade accounts and other receivables, net Increase (Decrease) in Inventories Inventories Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Trade accounts payable, accrued expenses, contract liabilities, and other Increase (Decrease) in Employee Related Liabilities Salaries, wages and related accruals Increase (Decrease) in Income Taxes Payable Income taxes payable Net Cash Provided by (Used in) Operating Activities Net cash provided by (used in) operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Proceeds from Sale of Debt Securities, Available-for-Sale Proceeds from sale of available-for-sale investments Payments to Acquire Debt Securities, Available-for-Sale Purchases of available-for-sale investments Payments to Acquire Property, Plant, and Equipment Additions to property and equipment Payments to Acquire Businesses, Net of Cash Acquired Acquisitions, net of cash acquired Cash paid, net of cash acquired Proceeds from Equity Method Investment, Distribution, Return of Capital Distributions from (Investments in) Wilson Wolf Payments to Acquire Investments Investment in Spear Bio Payments in Investment Proceeds from Sale, Property, Held-for-Sale Proceeds from sale of assets held-for-sale Net Cash Provided by (Used in) Investing Activities Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Payments of Ordinary Dividends, Common Stock Cash dividends Proceeds from Stock Options Exercised Proceeds from stock option exercises Payments for Repurchase of Common Stock Re-purchases of common stock Proceeds from Long-Term Lines of Credit Borrowings under line-of-credit agreement Repayments of Lines of Credit Repayments of long-term debt Payment, Tax Withholding, Share-Based

Payment Arrangement Taxes paid on RSUs and net share settlements Net Cash Provided by (Used in) Financing Activities Net cash provided by (used in) financing activities Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate changes on cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Supplemental disclosure of cash flow information: Income Taxes Paid Cash paid for income taxes Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Basis of Presentation and Summary of Significant Accounting Policies Disclosure Text Block [Abstract] Notes to Financial Statements Business Description and Accounting Policies [Text Block] Basis of Presentation and Summary of Significant Accounting Policies Revenue Recognition Revenue from Contract with Customer [Text Block] Revenue Recognition Selected Balance Sheet Data Supplemental Balance Sheet Disclosures [Text Block] Supplemental Balance Sheet and Cash Flow Information Acquisitions Business Combination Disclosure [Text Block] Acquisitions Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurements Debt and Other Financing Arrangements Debt Disclosure [Text Block] Debt and Other Financing Arrangements Leases Lessee, Operating Leases [Text Block] Leases Comprehensive Income (Loss) Note [Text Block] Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information Earnings Per Share [Text Block] Earnings Per Share Share-based Compensation Share-Based Payment Arrangement [Text Block] Share-based Compensation Other income (expense). Other Income and Other Expense Disclosure [Text Block] Other Income / (Expense) Income Taxes Income Tax Disclosure [Text Block] Income Taxes Segment Information Segment Reporting Disclosure [Text Block] Segment Information Subsequent Events Subsequent Events [Text Block] Subsequent Events Policy Text Block [Abstract] Investment, Policy [Policy Text Block] Investments Disclosure of accounting policy for restructuring actions. Restructuring Actions [Policy Text Block] Restructuring actions Legal Costs, Policy [Policy Text Block] Legal Matters New Accounting Pronouncements, Policy [Policy Text Block] Recently Adopted Accounting Pronouncements and Relevant New Standards Issued Not Yet Adopted Segments [Axis] Segments [Domain] Consist of the remaining portion of the Biotechnology segment and the Protein Platforms operating segment. Protein Sciences [Member] Protein Sciences Table Text Block [Abstract] Notes Tables Restructuring and Related Costs [Table Text Block] Schedule of restructuring charges Disaggregation of Revenue [Table Text Block] Schedules of disaggregated revenue Schedule of Inventory, Current [Table Text Block] Schedule of inventories Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of changes in carrying amount of net intangible assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of estimated future amortization expense for intangible assets Schedule of Goodwill [Table Text Block] Schedule of changes to the carrying amount of goodwill Schedule of Other Assets, Noncurrent [Table Text Block] Schedule of other assets Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Represents information pertaining to Lunaphore Technologies SA. Lunaphore Technologies SA [Member] Lunaphore Technologies SA. Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of the aggregate purchase price of the acquisitions that was allocated to the assets acquired and liabilities assumed Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of information by level for financial assets and liabilities that are measured at fair value on a recurring basis Schedule of Derivative Instruments [Table Text Block] Schedule of contractual amounts of the outstanding instruments Derivative Instruments, Gain (Loss) [Table Text Block] Schedule of pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses The tabular disclosure for asset and liabilities of operating leases of the lessee. Lessee, Operating Lease, Asset and Liabilities [Table Text Block] Schedule of table that summarizes the balance sheet classification of the Company's operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company's operating leases The tabular disclosure of cash flow information of operating leases of the lessee. Lessee, Operating Lease, Cash Flow Information [Table Text Block] Schedule of the table that summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of the fair value of the lease liability by payment date for the operating leases by fiscal year Schedule of Stockholders Equity [Table Text Block] Schedule of the Consolidated Changes in Equity Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of changes in Accumulated Other Comprehensive Income (Loss) Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of the calculation of basic and diluted earnings per share Schedule of Other Nonoperating Income (Expense) [Table Text Block] Schedule of the components of other income (expense) Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of financial information by reportable segment Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Selling, General and Administrative Expenses [Member] Selling, General and Administrative Expenses Investment, Name [Axis] Investment, Name [Domain] Represents Wilson Wolf Corporation. Wilson Wolf Corporation [Member] Wilson Wolf Corporation Represents Spear Bio. Spear Bio [Member] Spear Bio Scenario [Axis] Scenario [Domain] Represents the first part of the forward contract. First Part of Forward Contract [Member] First Part of Forward Contract Represents the second part of the forward contract. Second Part of Forward Contract [Member] Second Part of Forward Contract Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Domain] Represents information pertaining to current assets held for sale. Current Assets, Held For Sale [Member] Current Assets, Held For Sale Other Noncurrent Assets [Member] Other Noncurrent Assets Other assets Restructuring Plan [Axis] Restructuring Plan [Domain] Represents information pertaining to fiscal year 2024 restructuring actions. Fiscal Year 2024 Restructuring Actions [Member] Fiscal Year 2024 Restructuring Actions Number of Operating Segments Number of Operating Segments Long-Term Investments Long-term investments Represents the milestone of annual revenue in forward contract. Forward Contract Milestone Annual Revenue Required Forward Contract, Milestone, Annual Revenue Required Represents the milestone of annual EBITDA in forward contract. Forward Contract Milestone Annual EBITDA Forward Contract, Milestone, Annual EBITDA Equity Method Investment, Ownership Percentage Investment percentage Represents the multiple for total expected payments of forward contract in milestone. Forward Contract Milestone Multiple For Total Expected Payments Forward Contract, Milestone, Multiple for Total Expected Payments Represents the additional investment. Forward Contract Additional Investment Forward Contract, Additional Investment Income (Loss) from Equity Method Investments Gain (loss) on equity method investment Equity Method Investment, Aggregate Cost Investment amount Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Positions eliminated during the period as a percentage Disposal Group, Including Discontinued Operation, Goodwill, Current Goodwill attributable to disposal group held for sale Asset Impairment Charges Asset Impairment Charges Disposal Group, Including Discontinued Operation, Inventory, Current Inventory, sold as part of disposal group Financing Receivable, after Allowance for Credit Loss Promissory note related to sale of inventory of disposal group Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Property, plant and equipment attributable to disposal group held for sale Amount of pre-tax restructuring charges. Pre-tax Restructuring Charges Pre-tax restructuring charges Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Number of expired vested stock options (in shares) Total value of options that expired during period. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expired Options in Period, Value Total net pre-tax value of options that expired Legal Fees Litigation charges Estimated Litigation Liability Accrued litigation Restructuring Type [Axis] Type of Restructuring [Domain] Employee Severance [Member] Employee severance Represents information pertaining to asset related and other costs of restructuring pursuant to a plan. Asset Related And Other [Member] Asset-related and other Represents information pertaining to impairment of assets held for sale pursuant to restructuring plan. Impairment Of Assets, Held For Sale [Member] Impairment of assets held-for-sale Cost of Sales [Member] Cost of Sales Corporate Segment [Member] Corporate Consist of the ACD operating segment and the Diagnostics and Spatial Biology operating segment. Diagnostics and Spatial Biology [Member] Diagnostics and Spatial Biology Represents information pertaining to fiscal year 2025 restructuring actions. Fiscal Year 2025 Restructuring Actions [Member] Fiscal Year 2025 Restructuring Actions Amount of expenses associated with exit or disposal activities pursuant to an authorized plan for the current period, net of adjustments. Restructuring costs, net of adjustments Restructuring costs, net of adjustments Restructuring Reserve, Noncurrent Accrued restructuring actions balances Accrued restructuring actions balances Restructuring Charges Restructuring and restructuring-related costs Restructuring costs Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Payments for Restructuring Cash payments Restructuring Reserve, Settled without Cash Non-cash adjustments Restructuring Reserve, Accrual Adjustment Adjustments Contract with Customer, Liability Contract with Customer, Liability, Total Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Product and Service [Axis] Product and Service [Domain] Represents the information pertaining to consumables products. Consumables [Member] Consumables Represents the information pertaining to instruments which typically consist of longer-lived assets. Instruments [Member] Instruments Service [Member] Services Represents the product and services provided by the company. Product and Services [Member] Product and Services Royalty [Member] Royalty revenues Geographical [Axis] Geographical [Domain] UNITED STATES United States Regions of Europe, Middle East and Africa, excluding the United Kingdom. EMEA, excluding UK [Member] EMEA, excluding United Kingdom UNITED KINGDOM United Kingdom Represents the APAC, excluding Greater China. APAC, excluding Greater China [Member] APAC, excluding Greater China CHINA Greater China Rest of the geographical locations in the world. Rest of World [Member] Rest of World Non-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. Inventory Finished Goods Net Of Reserves Non Current Inventory, Finished Goods, Net of Reserves, Non-current Inventory, Raw Materials, Net of Reserves Raw materials Inventory, Finished Goods, Net of Reserves Finished goods Amount of inventory, net of reserves, including both current and non-current portions. Inventory Net Current And Non Current Inventories, net Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Land [Member] Land Building and Building Improvements [Member] Building and improvements Machinery and Equipment [Member] Machinery and equipment Construction in Progress [Member] Construction in progress Property, Plant and Equipment, Gross Property and equipment, cost Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Accumulated depreciation and amortization Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed Technology Rights [Member] Developed technology Trade Names [Member] Tradenames Customer Relationships [Member] Customer relationships Patents [Member] Patents Other Intangible Assets [Member] Other intangibles Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum Minimum [Member] Minimum Finite-Lived Intangible Assets, Gross Definite-lived intangibles assets Finite-Lived Intangible Assets, Accumulated Amortization Accumulated amortization Finite-Lived Intangible Assets, Net Definite-lived intangibles assets, net Finite-Lived Intangible Asset, Useful Life Finite-Lived Intangible Asset, Useful Life (Year) Amount of other additions lacking physical substance with a definite life. Finite lived Intangible Assets Other Additions Other additions Amortization of Intangible Assets Amortization expense Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss) Currency translation Impairment of Intangible Assets, Finite-Lived Restructuring Impairment Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Remainder 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four 2029 Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finite-Lived Intangible Asset, Expected Amortization, After Year Four Thereafter Goodwill, Foreign Currency Translation Gain (Loss) Currency translation Equity Method Investments Equity method investment in Wilson Wolf Derivative Asset Derivative Instruments Derivative Asset, Statement of Financial Position [Extensible Enumeration] Inventory, Noncurrent Long-term inventory Equity Securities without Readily Determinable Fair Value, Amount Investment in Spear Bio Amount of noncurrent assets classified as other. Assets classified as noncurrent other Other Business Combination, Consideration Transferred Net assets acquired Acquisition amount Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Current assets Amount of equipment and other long-term assets acquired at the acquisition date. tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets Equipment and other long-term assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Intangible assets Amount of assets acquired, including goodwill, at the acquisition date. tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill Total assets acquired Amount of liabilities excluding deferred income taxes assumed at the acquisition date. tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Deferred income taxes, net Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Net assets acquired Payments to Acquire Businesses, Gross Cash paid Derivative Instrument [Axis] Derivative Contract [Domain] Represents forward starting swap. Forward Starting Swap [Member] Forward starting swaps Currency Swap [Member] Cross-currency swap Hedging Relationship [Axis] Hedging Relationship [Domain] Cash Flow Hedging [Member] Cash flow hedges Net Investment Hedging [Member] Net investment hedge Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities Other long-term liabilities Hedging Designation [Axis] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Designated as hedging instruments Investments, Fair Value Disclosure Investments, Fair Value Disclosure, Total Investments, Fair Value Disclosure Derivative, Notional Amount Derivative, Notional Amount Number of interim settlement dates for the derivative instruments. Derivative Number Of Interim Settlement Dates Number of interim settlement dates Nominal or face amount of derivatives at maturity. Derivative Notional Amount At Maturity Notional amount at maturity Business Combination, Contingent Consideration, Liability Contingent consideration Amount of decrease in notional amount of derivatives. Derivative, Decrease in Notional Amount Decrease in notional amount at each interim date Asset Class [Axis] Asset Class [Domain] Represents exchanged traded securities. Exchanged Traded Securities [Member] Exchanged traded investment grade bond funds Measurement Frequency [Axis] Measurement Frequency [Domain] Fair Value, Recurring [Member] Fair Value, Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Other Current Assets [Member] Other current assets Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Derivative instruments - assets Assets, Fair Value Disclosure Liabilities, Fair Value Disclosure Total liabilities Derivative [Table] Derivative [Line Items] Derivative, Fair Value, Net Fair value of derivative instruments Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Line Items] (Gain) Loss Recognized in AOCI OCI, before Reclassifications, before Tax, Attributable to Parent (Gain) Loss Recognized in Accumulated Other Comprehensive Loss Amounts before reclassifications Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Amounts reclassified out (Gain) Loss Reclassified into Income Credit Facility [Axis] Credit Facility [Domain] Revolving Credit Facility [Member] Revolving Credit Facility Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents the information pertaining to amended credit agreement. Amended Credit Agreement [Member] Amended Credit Agreement Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity The element representing the additional borrowing capacity under a line of credit. Line Of Credit Facility Additional Borrowing Capacity Line of Credit Facility, Additional Borrowing Capacity Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Line of Credit, Current Line of Credit, Current Variable Lease, Cost Variable Lease, Cost Operating Lease, Cost Fixed Lease, Cost Lessee, Operating Lease, Renewal Term Lessee, Operating Lease, Renewal Term (Year) Operating Lease, Liability Total operating lease liabilities Total lease obligations Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Discount Rate, Percent Operating Lease, Payments Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Remainder 2025 Lessee, Operating Lease, Liability, to be Paid, Year One 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four 2029 Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee Operating Lease Liability To Be Paid After Year Four Thereafter Lessee, Operating Lease, Liability, to be Paid Total Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Amounts representing interest Equity Components [Axis] Equity Component [Domain] AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Common Stock, Dividends, Per Share, Declared Common Stock, dividends, per share, declared (in dollars per share) Stock Repurchased During Period, Shares Share repurchases (in shares) Stock Repurchased During Period, Shares (in

shares) Interest Expense, Nonoperating Interest expense Interest expense Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit), Total Common Stock [Member] Common Stock Additional Paid-in Capital [Member] Additional Paid-in Capital Retained Earnings [Member] Retained Earnings Amount after tax, before reclassification of translation adjustments of other comprehensive income (loss). Other Comprehensive Income (Loss), before Translation Reclassification, Net of Tax Other comprehensive income (loss) before reclassification Stock Repurchased During Period, Value Share repurchases Stock Issued During Period, Value, Stock Options Exercised Common stock issued for exercise of options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Common stock issued for exercise of options (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Common stock issued for restricted stock awards Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Common stock issued for restricted stock awards (in shares) Dividends, Common Stock, Cash Cash dividends APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation expense Stock Issued During Period, Value, Employee Stock Purchase Plan Common stock issued to employee stock purchase plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued to employee stock purchase plan (in shares) APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition Employee stock purchase plan expense AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Unrealized Gains (Losses) on Debt Securities Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Foreign Currency Translation Adjustments Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract] Other comprehensive income (loss), before tax: Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent Total other comprehensive income (loss), before tax Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent Tax (expense) benefit Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total other comprehensive income (loss), net of tax Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share, amount (in shares) Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Income allocated to participating securities Net Income (Loss) Available to Common Stockholders, Basic Income available to common shareholders Net Income (Loss) Available to Common Stockholders, Diluted Income available to common shareholders Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Dilutive effect of stock options and restricted stock units (in shares) Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) Restricted Stock [Member] Restricted Stock Plan Name [Axis] Plan Name [Domain] Information pertaining to the 2014 Employee Stock Purchase Plan. Employee Stock Purchase Plan 2014 [Member] Employee Stock Purchase Plan 2014 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Granted, shares (in shares) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Granted, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average fair values (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted, shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted, weighted average exercise price (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Common stock issued for exercise of options intrinsic values Share-Based Payment Arrangement, Expense Stock based compensation, inclusive of employer taxes Stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost, period for recognition (Year) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Number of shares authorized (in shares) Investment Income, Net Interest income Gain (Loss) on Investments Gain (loss) on investment(1) Amount of income (expense) related to nonoperating activities, classified as other. Other Nonoperating income and expense Other non-operating income (expense), net Effective Income Tax Rate Reconciliation, Percent Effective income tax rate reconciliation, percent, total Represents the income tax expense (benefit) related to discrete tax items. Income Tax Expense Benefit Discrete Tax Items Income tax expense (benefit), discrete tax items Share-Based Payment Arrangement, Expense, Tax Benefit Share-based compensation excess tax benefit Represents information related to other net immaterial discrete income tax expense (benefit). Income Tax Expense Benefit Other Immaterial Discrete Tax Items Net Income tax expense (benefit), other immaterial discrete tax items, net Schedule of Revenues from External Customers and Long-Lived Assets [Table] Consolidation Items [Axis] Consolidation Items [Domain] Operating Segments [Member] Operating Segments Intersegment Eliminations [Member] Intersegment Eliminations Represents the information pertaining to other revenues relating to the business that has met the held-for-sale criteria. Other Revenues from Business Held for Sale [Member] Other Revenues from Business Held for Sale Revenues from External Customers and Long-Lived Assets [Line Items] Represents the amount of amortization of acquired intangible assets. Amortization Of Acquired Intangible Assets Amortization of intangibles Business Combination, Acquisition Related Costs Acquisition related expenses and other Gain (Loss) from Litigation Settlement Certain litigation charges Income (Loss) from Individually Significant Component Disposed of or Held-for-Sale, Excluding Discontinued Operations, before Income Tax Impairment of assets held-for-sale Amount of impact on income from business held for sale. Impact of Business Held for Sale Impact of business held-for-sale(1) EX-101.PRE 10 tech-20241231_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1 Document And Entity Information - shares 6 Months Ended Dec. 31, 2024 Feb. 03, 2025 Document Information [Line Items] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Dec. 31, 2024 Â Document Transition Report false Â Securities Act File Number 0-17272 Â Entity Registrant Name BIO-TECHNE Corp Â Entity Incorporation, State or Country Code MN Â Entity Tax Identification Number 41-1427402 Â Entity Address, Address Line One 614 McKinley Place N.E. Â Entity Address, City or Town Minneapolis Â Entity Address, State or Province MN Â Entity Address, Postal Zip Code 55413 Â City Area Code 612 Â Local Phone Number 379-8854 Â Title of 12(b) Security Common Stock, $0.01 par value Â Trading Symbol TECH Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 158,087,683 Entity Central Index Key 0000842023 Â Current Fiscal Year End Date --06-30 Â Document Fiscal Year Focus 2025 Â Document Fiscal Period Focus Q2 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1 CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME Â Â Â Â Â Net sales $ 297,031 $ 272,598 $ 586,489 $ 549,533 Cost of sales 103,145 96,011 209,586 187,755 Gross margin 193,886 176,587 376,903 361,778 Operating expenses: Â Â Â Â Â Selling, general and administrative 121,451 115,667 240,612 220,998 Research and development 25,016 22,916 48,885 46,914 Total operating expenses 146,467 138,583 289,497 267,912 Operating income 47,419 38,004 87,406 93,866 Other income (expense) (4,543) (4,617) (4,359) (10,921) Earnings before income taxes 42,876 33,387 83,047 82,945 Income taxes 7,986 5,922 14,557 4,486 Net earnings 34,890 27,465 68,490 78,459 Other comprehensive income (loss): Â Â Â Â Â Foreign currency translation income (loss) (25,518) 18,025 (4,262) 6,423 Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 (45) (3,670) (3,072) (4,020) Other comprehensive income (loss) (25,563) 14,355 (7,334) 2,403 Comprehensive income $ 9,327 $ 41,820 $ 61,156 $ 80,862 Earnings per share: Â Â Â Â Â Basic (in dollars per share) $ 0.22 $ 0.17 $ 0.43 $ 0.5 Diluted (in dollars per share) $ 0.22 $ 0.17 $ 0.42 $ 0.49 Weighted average common shares outstanding: Â Â Â Â Â Basic (in shares) 158,431 157,533 158,481 157,826 Diluted (in shares) 160,626 160,060 161,353 161,001 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 Current assets: Â Â Cash and cash equivalents $ 177,549 $ 151,791 Short-term available-for-sale investments 0 1,072 Accounts receivable, less allowance for doubtful accounts of $4,904 and $4,386, respectively 217,940 241,394 Inventories 188,373 179,731 Current assets held-for-sale 1,047 9,773 Other current assets 49,731 33,658 Total current assets 634,640 617,419 Property and equipment, net 249,753 251,154 Right-of-use assets 85,383 91,285 Goodwill 964,607 972,663 Intangible assets, net 461,051 507,081 Other assets 274,990 264,265 Total assets 2,670,424 2,703,867 Current liabilities: Â Â Trade accounts payable 33,120 37,968 Salaries, wages and related accruals 53,594 49,818 Accrued expenses 27,543 24,886 Contract liabilities 27,715 27,930 Income taxes payable 3,141 3,706 Operating lease liabilities - current 13,511 12,920 Other current liabilities 2,632 2,151 Total current liabilities 161,256 159,379 Deferred income taxes 37,723 55,863 Long-term debt obligations 300,000 319,000 Operating lease liabilities 81,616 87,618 Other long-term liabilities 11,337 13,157 Bio-Techne's Shareholders' equity: Â Â Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0 Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,915,999 and 158,216,258 respectively 1,579 1,582 Additional paid-in capital 875,864 820,337 Retained earnings 1,286,699 1,325,247 Accumulated other comprehensive loss (85,650) (78,316) Total Bio-Techne's shareholders' equity 2,078,492 2,068,850 Total liabilities and shareholders' equity $ 2,670,424 $ 2,703,867 X - DefinitionRepresents the value of undesignated capital stock as of the balance sheet date. + ReferencesNo definition available. + Details Name: tech_UndesignatedCapitalStockValue Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of long-term debt and lease obligation, classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 15 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Accounts receivable, allowance for doubtful accounts $ 5,632 $ 4,386 Undesignated capital stock, no par (in dollars per share) $ 0 $ 0 Undesignated capital stock, shares authorized (in shares) 5,000,000 5,000,000 Undesignated capital stock, shares issued (in shares) 0 0 Undesignated capital stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.01 $ 0.01 Common stock, shares authorized (in shares)

400,000,000 400,000,000 Common stock, shares issued (in shares) 157,915,999 158,216,258 Common stock, shares outstanding (in shares) 157,915,999 158,216,258 X - DefinitionRepresents the no par value for undesignated capital stock. + ReferencesNo definition available. + Details Name: tech_UndesignatedCapitalStockNoParValue Namespace Prefix: tech_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRepresents the shares authorized for undesignated capital stock. + ReferencesNo definition available. + Details Name: tech_UndesignatedCapitalStockSharesAuthorized Namespace Prefix: tech_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents the shares issued for undesignated capital stock. + ReferencesNo definition available. + Details Name: tech_UndesignatedCapitalStockSharesIssued Namespace Prefix: tech_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents the shares outstanding for undesignated capital stock. + ReferencesNo definition available. + Details Name: tech_UndesignatedCapitalStockSharesOutstanding Namespace Prefix: tech_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Net earnings $ 68,490 $ 78,459 Adjustments to reconcile net earnings to net cash provided by operating activities: Â Â Depreciation and amortization 55,221 56,343 Costs recognized on sale of acquired inventory 373 364 Deferred income taxes (13,417) (22,314) Stock-based compensation expense 24,892 22,846 Fair value adjustment to contingent consideration payable 0 (3,500) Fair value adjustment on available-for-sale investments 0 (283) (Gain) Loss on equity method investment (420) 4,295 Asset impairment restructuring 9,841 0 Leases, net 492 1,196 Impairment of assets held-for-sale 0 6,038 Other operating activity 305 256 Change in operating assets and operating liabilities, net of acquisition: Â Â Trade accounts and other receivables, net 20,940 20,333 Inventories (11,713) (9,577) Prepaid expenses (405) (3,149) Trade accounts payable, accrued expenses, contract liabilities, and other (29) 5,382 Salaries, wages and related accruals 3,882 (4,305) Income taxes payable (10,217) (9,885) Net cash provided by (used in) operating activities 148,235 142,499 CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Proceeds from sale of available-for-sale investments 1,085 23,759 Purchases of available-for-sale investments 0 (5,526) Additions to property and equipment (15,993) (28,456) Acquisitions, net of cash acquired 0 (169,707) Distributions from (Investments in) Wilson Wolf 1,403 2,149 Investment in Spear Bio (15,000) 0 Proceeds from sale of assets held-for-sale 1,789 0 Net cash provided by (used in) investing activities (26,716) (177,781) CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Cash dividends (25,424) (25,213) Proceeds from stock option exercises 30,641 19,670 Re-purchases of common stock (75,628) (80,042) Borrowings under line-of-credit agreement 0 225,000 Repayments of long-term debt (19,000) (128,000) Taxes paid on RSUs and net share settlements (5,997) (21,302) Net cash provided by (used in) financing activities (95,408) (9,887) Effect of exchange rate changes on cash and cash equivalents (353) (5,270) Net change in cash and cash equivalents 25,758 (50,439) Cash and cash equivalents at beginning of period 151,791 180,571 Cash and cash equivalents at end of period 177,549 130,132 Supplemental disclosure of cash flow information: Â Â Cash paid for income taxes 37,593 37,645 Cash paid for interest $ 9,831 $ 8,586 X - DefinitionThe value of asset impairment restructuring charge. + ReferencesNo definition available. + Details Name: tech_AssetImpairmentRestructuringCharge Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of fair value adjustment made on available for sale securities during the period. + ReferencesNo definition available. + Details Name: tech_FairValueAdjustmentOnAvailableForSaleSecurities Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: tech_FairValueAdjustmentToContingentConsiderationPayable Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting. + ReferencesNo definition available. + Details Name: tech_FairValueWriteUpOfAcquiredInventory Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of noncash portion of lease expense during the period. + ReferencesNo definition available. + Details Name: tech_NoncashPortionOfLeaseExpense Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) and income tax credits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_DeferredIncomeTaxesAndTaxCredits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of an equity method investment. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15 + Details Name: us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-

gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details Name: us-gaap_PaymentsToAcquireEquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 21D -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D + Details Name: us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfPropertyHeldForSale Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99

-Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1 Basis of Presentation and Summary of Significant Accounting Policies 6 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Basis of Presentation and Summary of Significant Accounting Policies Note 1. Basis of Presentation and Summary of Significant Accounting Policies:The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature.Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended JuneÂ 30, 2024, included in the Company's Annual Report on Form 10-KÂ for fiscal 2024. A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-KÂ for fiscal 2024. The Company follows these policies in preparation of the interim unaudited Condensed Consolidated Financial Statements.The Company manages its business under two operating segments, Protein Sciences and Diagnostics and Spatial Biology (formerly Diagnostics and Genomics). The name change is intended to better reflect the focus and scope of our offerings. The manner in which we operate our business and review discrete financial information did not change. Segment information presented herein reflects the updated name of the operating segment. The operating segments the Company operated under were consistent with the Company's operating segments disclosed in the Company's Annual Report on Form 10-K for fiscal 2024.Investments:Â In July 2024, the Company paid $15 million to enter into an investment in Spear Bio. This investment is accounted for under the cost-method as we own less than 20% of the outstanding stock and we concluded that we do not have significant influence. Under the cost-method, the fair value is not estimated if there are no identified events or changes in circumstances. No such events or changes in circumstances were identified in the period ended December 31, 2024. The Companyâ€™s total investment of $15 million is included within Other assets on the Condensed Consolidated Balance Sheet.In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf.Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. â€‹â€‹The investment in Wilson Wolf is accounted for as an equity method investment under ASC 323. The Company initially records its equity method investments at the amount of the Companyâ€™s investment and adjusts each period for the Companyâ€™s share of the investeeâ€™s income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. For the quarter ended December 31, 2024, the gain on the investment in Wilson Wolf was not material. In the six months ended December 31, 2024, there was $0.4 million of gain recorded on the Companyâ€™s Consolidated Statement of Earnings and Comprehensive Income related to the investment. The Companyâ€™s total investment of $241 million is included within Other assets on the Consolidated Balance Sheet.Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets,Â leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action. Fiscal Year 2025 Restructuring Actions:In the first quarter of fiscal 2025, the Company announced enterprise-wide restructuring focused on recovering operating margins and optimizing our manufacturing footprint. The Company is expecting to incur costs related to these actions through fiscal 2026, which will be recorded when specified criteria are met. The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):â€‹â€‹â€‹

2024â€‹$ 177â€‹$ 92â€‹$ â€”â€‹$ 269(1) Relates to impacted employeesâ€™ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. (2) Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives.(3) Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024.Protein Sciences RealignmentIn December 2022, the Company informed employees it would undertake certain actions to strategically reallocate operations resources to high growth areas of the business. Additional actions were taken in June 2023 primarily related to the sales organization. The actions impacted a limited number of employees and were completed in the fourth quarter of fiscal 2024. As a result of the realignment, a pre-tax charge of $1.7 million related to employee severance was recorded in the Selling, general and administrative line of operating income within our Protein Sciences segment during the year ended June 30, 2023. Adjustments in fiscal year 2024 related to the refinement of employee severance payouts. Additional pre-tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, were as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Employeeâ€‹â€‹severanceAccrued restructuring actions balance as of June 30, 2023â€‹$ 897Fiscal year 2024 cash paymentsâ€‹â€‹ (1,118)First quarter fiscal year 2024 adjustments(1)â€‹â€‹ 89Second quarter fiscal year 2024 adjustments(1)â€‹â€‹ 132 Accrued restructuring actions balance as of June 30, 2024â€‹$ â€”(1) Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. â€‹Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Companyâ€™s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Companyâ€™s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.â€‹The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income.â€‹In August 2024, 794,400 shares of outstanding vested stock options related to former employees expired which have now been excluded from the Companyâ€™s dilutive EPS calculation for the period ended December 31, 2024. The expiration date of these options is currently under dispute. The total net pre-tax value of these options on the expiration date was approximately $32 million. As of December 31, 2024, the matter is under review and the Company is unable to estimate any future exposure related to this matter at this time.â€‹The Company recognized $1.4 million and $1.7 million of certain litigation charges during the quarter and six months ended December 31, 2024. There was no comparable activity during the quarter and six months ended December 31, 2023. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Companyâ€™s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in Other current liabilities and Other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for the legal matters included within our litigation charges line, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Companyâ€™s consolidated earnings, financial position, and/or cash flows.Recently Adopted Accounting PronouncementsThere were no accounting pronouncements adopted in the quarter ended December 31, 2024. Refer to the Form 10-K for accounting pronouncements adopted prior to June 30, 2024.â€‹Relevant New Standards Issued Not Yet Adoptedâ€‹In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.â€‹In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.â€‹In November 2024, the FASB issued ASU 2024-03, Income Statement â€”Reporting Comprehensive Incomeâ€”Expense Disaggregation Disclosures (Subtopic 220-40), which requires incremental disclosures on purchases of inventory, employee compensation, depreciation, intangible asset amortization, and other expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2027 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. â€‹Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our unaudited condensed consolidated financial statements. X - DefinitionThe entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue Recognition 6 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Revenue Recognition Note 2. Revenue Recognition:Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controls, and hematology instrument controls that are typically single-use products recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consistÂ of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed hasÂ noÂ alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time.We recognize royalty revenues in the period the sales occur usingÂ thirdÂ party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount thatÂ approximates the value to the customer and the performance completed to date.The CompanyÂ elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Companyâ€™s unfulfilled performance obligations for contracts with an original length greater than one year were not material as of December 31, 2024.Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contractâ€™s transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contractsâ€™ inception.â€‹Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both.Contract assets include revenues recognized in advance of billings. Contract assets are included within Other current assets in the accompanying balance sheet as the amount of time expected to lapse until the Company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of December 31, 2024Â are not material.Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of December 31, 2024Â and June 30, 2024Â were approximately $30.4Â million and $30.2Â million, respectively. Contract liabilities as of June 30, 2024 subsequently recognized as revenue during the quarterÂ andÂ sixÂ month periodÂ ended December 31, 2024Â were approximately $8.0Â million and $19.9 million, respectively. Contract liabilities as of June 30, 2023 subsequently recognized as revenue during the quarter and six months ended December 31, 2023 were approximately $7.1 million and $18.8 million, respectively. Contract liabilities in excess of one year are included in Other long-term liabilities on the Consolidated Balance Sheet.Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material.Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. WeÂ elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized.The following tables present our disaggregated revenue for the periods presented.Revenue by type is as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a qualitative goodwill impairmentÂ assessment for all of its reporting units during the fourth quarter of fiscal 2024. No indicators of impairment were identified as part of our assessment.â€‹Other Assets: â€‹Other assets consist of (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â DecemberÂ 31,Â â€‹June 30,â€‹Â Â Â Â 2024â€‹2024â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Equity method investment in Wilson Wolfâ€‹ 241,354â€‹$ 242,337Derivative instrumentsâ€‹â€‹ 3,227â€‹â€‹ 9,813Long-term inventoryâ€‹â€‹ 5,740â€‹â€‹ 5,718Investment in Spear Bioâ€‹â€‹ 15,000â€‹â€‹ â€”Otherâ€‹Â 9,669â€‹Â 6,397Other assetsâ€‹$ 274,990â€‹$ 264,265â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1 Acquisitions 6 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Acquisitions Note 4. Acquisitions:We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our Consolidated Statements of Earnings and Comprehensive Income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred.There were no acquisitions in the first half of fiscal 2025.â€‹Fiscal year 2024Â AcquisitionsLunaphore Technologies SA.On July 7, 2023, the Company acquired all of the ownership interests of Lunaphore Technologies SA (â€œLunaphoreâ€) for $169.7 million, in a cash-free, debt-free acquisition. Lunaphore is a leading developer of fully automated spatial biology solutions. The Lunaphore acquisition adds spatial biology instruments to Bio-Techneâ€™s portfolio to accelerate our leadership position in translational and clinical research markets. The transaction was accounted for in accordance with ASCÂ 805,Â Business Combinations. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Companyâ€™s product portfolio and the expected revenue growth from increased market penetration. The goodwill isÂ notÂ deductible for income tax purposes. The business became part of the Diagnostics and Spatial Biology operating segment in the first quarter of fiscal yearÂ 2024.Â The allocation of purchase price consideration related to Lunaphore was completed in the fourth quarter of fiscal 2024. The fair values of the assets acquired and liabilities assumed as of June 30, 2024 are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Final allocation at June 30, 2024Current assets$ 12,155Equipment and other long-term assetsÂ 1,470GoodwillÂ 104,650Intangible assets:â€‹â€‹Developed technologiesÂ 60,300TradenamesÂ 4,900Customer relationshipsÂ 1,200Total assets acquiredÂ 184,675â€‹â€‹Liabilities assumedÂ 7,096Deferred income taxes, netÂ 7,872Net assets acquired$ 169,707â€‹â€‹Cash paid Â 169,707â€‹â€‹Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology and customer relationships was based on managementâ€™s forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The purchase price allocated to trade names was based on management's forecasted cash inflows and outflows and using a relief from royalty method. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for developed technology is 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is 8 years.Â The amount recorded for trade names is being amortized with the expense reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for trade names ranges from 4 years to 8 years.Â The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the calculation of acquired net operating losses. X - DefinitionThe entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContent + Details Name: us-gaap_BusinessCombinationDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1 Fair Value Measurements 6 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Fair Value Measurements NoteÂ 5. Fair Value Measurements:The Companyâ€™s financial instruments include cash and cash equivalents, available-for-sale investments, derivative instruments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt.Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances.The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation.â€‹The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands).â€‹Â Â Â Â TotalÂ Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1 Leases 6 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Leases Note 7. Leases:As a lessee, the Company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is Bio-Techneâ€™s incremental borrowing rate or, if available, the rate implicit in the lease.Â Bio-Techne determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During the six months ended December 31, 2024, the Company recognized $2.6Â million in variable lease expense and $8.7Â million relating to fixed lease expenseÂ in the Condensed Consolidated Statements of Earnings and Comprehensive Income.The following table summarizes the balance sheet classification of the Companyâ€™s operating leases and amounts of right-of-use assets and lease liabilitiesÂ and the weighted average remaining lease term and weighted average discount rate for the Companyâ€™s operating leases (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹Â Â Â AsÂ ofâ€‹â€‹â€‹â€‹â€‹DecemberÂ 31,Â â€‹â€‹BalanceÂ SheetÂ Classificationâ€‹2024Operating leases:Â â€‹Â Â Â â€‹Â Â â€‹Operating lease right-of-use assetsÂ â€‹Right-of-use assetâ€‹$ 85,383â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Current operating lease liabilitiesÂ â€‹Operating lease liabilities - currentâ€‹$ 13,511Noncurrent operating lease liabilitiesÂ â€‹Operating lease liabilitiesâ€‹Â 81,616Total operating lease liabilitiesâ€‹â€‹â€‹â€‹â€‹$ 95,127â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted average remaining lease term (in years):â€‹Â â€‹â€‹Â 8.09â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted average discount rate (%):â€‹Â â€‹â€‹Â 4.26â€‹The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for new operating lease liabilities for the six months ended December 31, 2024 (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six months ended â€‹â€‹DecemberÂ 31,Â â€‹Â Â Â Â 2024Cash amounts paid on operating lease liabilitiesâ€‹$ 8,068â€‹â€‹â€‹â€‹Right-of-use assets obtained in exchange for lease liabilitiesâ€‹$ 1,321â€‹The following table summarizes the fair value of the lease liability byÂ payment dateÂ for the Companyâ€™s operating leases by fiscal year (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹â€‹â€‹â€‹â€‹DecemberÂ 31,Â â€‹â€‹2024Remainder 2025â€‹$ 8,3992026â€‹Â 16,5682027â€‹Â 13,7322028â€‹Â 13,5692029â€‹Â 13,115Thereafterâ€‹Â 48,159Totalâ€‹$ 113,542Less: Amounts representing interestâ€‹Â 18,415Total lease obligationsâ€‹$ 95,127â€‹Certain leases include one or more options to renew, with terms that extend the lease term up to five years. Bio-Techne includes the option to renew the lease as part of the right-of-use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, Bio-Techne is not reasonably certain to exercise such options. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1 Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information 6 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information Note 8.Â Supplemental Equity and Accumulated Other Comprehensive Income (Loss):â€‹Supplemental Equityâ€‹The Company has declared cash dividends per share of $0.08 and $0.16 in the three and sixÂ months ended December 31, 2024 and 2023, respectively.â€‹Consolidated Changes in Equity (amounts in thousands):â€‹Â Â Â Â Bio-Techne ShareholdersÂ Â Â Â Â Â Â Â â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Months Ended Dec. 31, 2024 Notes to Financial Statements Â Share-based Compensation Note 10. Share-based Compensation:During theÂ six months ended December 31, 2024 and 2023, the Company grantedÂ 0.8 million and 0.9 million stock options at weighted average grant prices of $74.65Â and $81.49 and weighted average fair values of $25.43Â and $27.83, respectively. During the six months ended December 31, 2024 and 2023, the Company granted 0.5 million and 0.3 millionÂ restricted stock units at a weighted average fair value of $74.96Â and $79.26, respectively. During the six months ended December 31, 2024Â and 2023, the Company granted 11,696 and 27,196Â shares of restricted common stock shares at a weighted average fair value of $68.37Â and $56.98.Stock options for 0.8 million and 1.2 million shares of common stock with total intrinsic values of $28.3 million and $61.6 million were exercised during the six months ended December 31, 2024 and 2023, respectively.â€‹Stock-based compensation expense, inclusive of payroll taxes,Â of $14.5Â million and $12.4Â million was included in selling, general and administrative expenses for the quarter ended December 31, 2024Â and 2023, respectively. Stock-based compensation expenses, inclusive of payroll taxes,Â of $24.8 million and $23.5Â million was included in selling, general, and administrative expenses for the six months ended December 31, 2024Â and 2023, respectively. Additionally, the Company recognized $0.4Â million and $0.7Â million of stock-based compensation costs in cost of goods sold in the quarter and six months ended December 31, 2024,Â respectively, compared toÂ $0.3Â million and $0.5Â million in cost of goods sold in the comparative prior year periods. As of December 31, 2024, there was $62.6 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized isÂ 2.1Â years.In fiscal 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 800,000 shares were allocated to the ESPP. The Company recorded expense of $0.4 million for the quarter ended December 31, 2024 and $0.3 million for the quarter ended December 31, 2023. The Company recorded expense of $0.4Â million and $0.5Â million for the six monthsÂ ended December 31, 2024 and 2023, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1 Other Income / (Expense) 6 Months Ended Dec. 31, 2024 Notes to Financial Statements Â Other Income / (Expense) Note 11. Other Income / (Expense):â€‹The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands):â€‹â€‹â€‹

Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ 34,890 $ 27,465 $ 68,490 $ 78,459 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1 Insider Trading Arrangements 3 Months Ended Dec. 31, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1 Basis of Presentation and Summary of Significant Accounting Policies (Policies) 6 Months Ended Dec. 31, 2024 Policy Text Block [Abstract] Â Investments Investments:Â In July 2024, the Company paid $15 million to enter into an investment in Spear Bio. This investment is accounted for under the cost-method as we own less than 20% of the outstanding stock and we concluded that we do not have significant influence. Under the cost-method, the fair value is not estimated if there are no identified events or changes in circumstances. No such events or changes in circumstances were identified in the period ended December 31, 2024. The Companyâ€™s total investment of $15 million is included within Other assets on the Condensed Consolidated Balance Sheet.In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf.Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. â€‹â€‹The investment in Wilson Wolf is accounted for as an equity method investment under ASC 323. The Company initially records its equity method investments at the amount of the Companyâ€™s investment and adjusts each period for the Companyâ€™s share of the investeeâ€™s income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. For the quarter ended December 31, 2024, the gain on the investment in Wilson Wolf was not material. In the six months ended December 31, 2024, there was $0.4 million of gain recorded on the Companyâ€™s Consolidated Statement of Earnings and Comprehensive Income related to the investment. The Companyâ€™s total investment of $241 million is included within Other assets on the Consolidated Balance Sheet. Restructuring actions Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets,Â leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action. Fiscal Year 2025 Restructuring Actions:In the first quarter of fiscal 2025, the Company announced enterprise-wide restructuring focused on recovering operating margins and optimizing our manufacturing footprint. The Company is expecting to incur costs related to these actions through fiscal 2026, which will be recorded when specified criteria are met. The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Quarter Ended â€‹Six Months Ended â€‹â€‹DecemberÂ 31,Â â€‹DecemberÂ 31,Â â€‹â€‹2024â€‹2024Cost of salesâ€‹$ 2,691â€‹$ 7,589Selling, general and administrative(1)â€‹â€‹ 273â€‹â€‹ 5,644Totalâ€‹$ 2,964â€‹$ 13,233(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs.Restructuring and restructuring-related costs by segment are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended December 31, 2024â€‹â€‹â€‹â€‹Employeeâ€‹â€‹Asset-related â€‹â€‹â€‹â€‹â€‹â€‹â€‹severanceâ€‹â€‹and otherâ€‹â€‹TotalProtein Sciencesâ€‹$ 39â€‹$ 2,755â€‹$ 2,794Diagnostics and Spatial Biologyâ€‹â€‹ (19)â€‹â€‹ â€”â€‹â€‹ (19)Corporateâ€‹â€‹ 185â€‹â€‹ 4â€‹â€‹ 189Totalâ€‹$ 205â€‹$ 2,759â€‹$ 2,964â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Six months ended December 31, 2024â€‹â€‹â€‹â€‹Employeeâ€‹â€‹Asset-related â€‹â€‹â€‹â€‹â€‹â€‹â€‹severanceâ€‹â€‹and otherâ€‹â€‹TotalProtein Sciencesâ€‹$ 2,313â€‹$ 10,172â€‹$ 12,485Diagnostics and Spatial Biologyâ€‹â€‹ 425â€‹â€‹ â€”â€‹â€‹ 425Corporateâ€‹â€‹ 319â€‹â€‹ 4â€‹â€‹ 323Totalâ€‹$ 3,057â€‹$ 10,176â€‹$ 13,233â€‹â€‹The following table summarizes the changes in the Companyâ€™s accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Employeeâ€‹Assetâ€‹â€‹â€‹Â Â Â Â severance(1)Â Â Â Â impairment and other(2)Â Â Â Â TotalExpense incurred in the first quarter of 2025â€‹$ 2,852â€‹$ 7,417â€‹$ 10,269Cash paymentsâ€‹â€‹ (189)â€‹â€‹ â€”â€‹â€‹ (189)Non-cash adjustmentsâ€‹â€‹ â€”â€‹â€‹ (7,417)â€‹â€‹ (7,417)Accrued restructuring actions balance as of September 30, 2024â€‹$ 2,663â€‹$ â€”â€‹$ 2,663Expense incurred in the second quarter of 2025â€‹â€‹ 205â€‹â€‹ 2,759â€‹â€‹ 2,964Cash paymentsâ€‹â€‹ (1,211)â€‹â€‹ (335)â€‹â€‹ (1,546)Non-cash adjustmentsâ€‹â€‹ â€”â€‹â€‹ (2,424)â€‹â€‹ (2,424)Accrued restructuring actions balance as of December 31, 2024â€‹$ 1,657â€‹$ â€”â€‹$ 1,657(1) Relates to impacted employeesâ€™ final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites. (2) Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites.Fiscal Year 2024 Restructuring Actions:In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the second quarter of fiscal 2025 as we incurred charges relating to our business held-for-sale and consulting fees related to optimizing efficiency. The Company is expecting to incur costs related to these actions through the end of fiscal 2025, which will be recorded when specified criteria are met.As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of an impairment test performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. There were no impairment charges related to the disposal group during the first half of fiscal 2025. During the quarter ended December 31, 2024, the Company entered into an agreement with a buyer to purchase the remaining inventory for approximately $8 million. As part of the arrangement, the

Company and the buyer entered into a promissory note that will mature in February 2027 and agrees that the buyer shall pay in quarterly installments. As of December 31, 2024, the fair value of the note receivable was approximately $6 million and is included within Other current assets and Other assets on the Condensed Consolidated Balance Sheet. As of December 31, 2024, the assets remaining within the disposal group primarily include the land and building of $1.0 million, which is net of expected selling costs. These assets are actively marketed at a fair value based on market conditions such that the held-for-sale criterion are still met. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance sheet as of December 31, 2024 and June 30, 2024. â€‹The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Condensed Consolidated Statements of Earnings as follows (in thousands): â€‹Quarter Ended â€‹Six Months Endedâ€‹â€‹DecemberÂ 31,Â â€‹DecemberÂ 31,Â â€‹â€‹â€‹2024â€‹â€‹2023â€‹â€‹2024â€‹â€‹2023Cost of salesâ€‹$ â€”â€‹$ 1,174â€‹$ â€”â€‹$ 1,174Selling, general and administrative(1)â€‹â€‹ 323â€‹â€‹ 10,250â€‹â€‹ 1,076â€‹â€‹ 10,250Totalâ€‹$ 323â€‹$ 11,424â€‹$ 1,076â€‹$ 11,424(1) Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. â€‹Restructuring and restructuring-related costs by segment are as follows (in thousands):â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

â€‹â€‹â€‹DecemberÂ 31,Â â€‹DecemberÂ 31,Â â€‹â€‹Â Â Â Â 2024Â Â Â Â 2023â€‹2024Â Â Â Â 2023â€‹Consumablesâ€‹$ 230,715â€‹$ 211,126â€‹$ 461,560â€‹$ 435,673â€‹Instrumentsâ€‹Â 30,868â€‹Â 29,825â€‹Â 57,074â€‹Â 54,685â€‹Servicesâ€‹Â 27,350â€‹Â 24,129â€‹Â 54,707â€‹Â 45,583â€‹Total product and services revenue, netâ€‹$ 288,933â€‹$ 265,080â€‹$ 573,341â€‹$ 535,941â€‹Royalty revenuesâ€‹Â 8,098â€‹Â 7,518â€‹Â 13,148â€‹Â 13,592â€‹Total revenues, netâ€‹$ 297,031â€‹$ 272,598â€‹$ 586,489â€‹$ 549,533â€‹â€‹â€‹Revenue by geography is as follows (in thousands):â€‹â€‹â€‹

Incomeâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â â€‹Quarter Ended â€‹Six Months Ended â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹DecemberÂ 31,Â â€‹DecemberÂ 31,Â â€‹Location of (Gain) Loss â€‹Â Â Â Â â€‹2024Â Â Â Â 2023â€‹2024â€‹2023â€‹in Income StatementCash flow hedgesâ€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â

0.43â€‹$ 0.50â€‹ â€‹â€‹â€‹

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LegalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LitigationReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-5Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_NotesReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details Name: us-gaap_PaymentsToAcquireEquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s). + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=tech_ProteinSciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=tech_FiscalYear2024RestructuringActionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=tech_CurrentAssetsHeldForSaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tech_WilsonWolfCorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=tech_FirstPartOfForwardContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=tech_SecondPartOfForwardContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tech_SpearBioMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1 Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended 12 Months Ended Dec. 31, 2024 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2024 Dec. 31, 2023 Jun. 30, 2024 Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments $ 323 Â Â Â Â $ 11,424 Â $ 1,076 $ 11,424 Â Accrued restructuring actions balances Â $ 952 Â Â Â Â 952 Â Â Restructuring costs 323 753 $ 21,072 $ 1,273 11,424 Â Â Â Â Cash payments Â Â Â Â Â Â Â (1,759) Â $ (7,682) Non-cash adjustments Â Â Â Â Â Â Â Â (25,354) Adjustments Â Â Â Â Â Â Â Â Â 219 Accrued restructuring actions balances 269 Â 952 Â Â Â 269 Â 952 Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 2,964 Â Â Â Â Â 13,233 Â Â Accrued restructuring actions balances 2,663 Â Â Â Â Â Â Â Â Restructuring costs 2,964 10,269 Â Â Â Â Â Â Â Â Cash payments (1,546) (189) Â Â Â Â Â Â Â Â Non-cash adjustments (2,424) (7,417) Â Â Â Â Â Â Â Â Accrued restructuring actions balances 1,657 2,663 Â Â Â Â 1,657 Â Â Corporate | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 346 Â Â Â 1,225 Â 1,045 1,225 Â Corporate | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 189 Â Â Â Â Â 323 Â Â Diagnostics and Spatial Biology | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments Â Â Â Â 739 Â Â 739 Â Diagnostics and Spatial Biology | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments (19) Â Â Â Â Â 425 Â Â Protein Sciences | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments (23) Â Â Â 9,460 Â 31 9,460 Â Protein Sciences | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 2,794 Â Â Â Â Â 12,485 Â Â Cost of Sales | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments Â Â Â Â 1,174 Â Â 1,174 Â Cost of Sales | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 2,691 Â Â Â Â Â 7,589 Â Â Selling, General and Administrative Expenses | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 323 Â Â Â 10,250 Â 1,076 10,250 Â Selling, General and Administrative Expenses | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 273 Â Â Â Â Â 5,644 Â Â Employee severance | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments (33) Â Â Â 4,882 Â (22) 4,882 Â Accrued restructuring actions balances Â 761 Â Â Â Â 761 Â Â Restructuring costs $ (33) Â $ 409 $ 133 $ 4,882 Â Â Â Â Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of Goods and Services Sold, Selling, General and Administrative Expense Â Cost of Goods and Services Sold, Selling, General and Administrative Expense Cost of Goods and Services Sold, Selling, General and Administrative Expense Cost of Goods and Services Sold, Selling, General and Administrative Expense Â Â Â Â Cash payments Â Â Â Â Â Â Â (551) Â (4,882) Adjustments Â Â Â Â Â Â Â Â Â 219 Accrued restructuring actions balances $ 177 Â $ 761 Â Â Â 177 Â 761 Employee severance | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 205 Â Â Â Â Â 3,057 Â Â Accrued restructuring actions balances 2,663 Â Â Â Â Â Â Â Â Restructuring costs $ 205 $ 2,852 Â Â Â Â Â Â Â Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of Goods and Services Sold, Selling, General and Administrative Expense Cost of Goods and Services Sold, Selling, General and Administrative Expense Â Â Â Â Â Â Cash payments $ (1,211) $ (189) Â Â Â Â Â Â Â Accrued restructuring actions balances 1,657 2,663 Â Â Â Â 1,657 Â Â Employee severance | Corporate | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments Â Â Â Â $ 1,193 Â (3) 1,193 Â Employee severance | Corporate | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 185 Â Â Â Â Â 319 Â Â Employee severance | Diagnostics and Spatial Biology | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments Â Â Â Â 739 Â Â 739 Â Employee severance | Diagnostics and Spatial Biology | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments (19) Â Â Â Â Â 425 Â Â Employee severance | Protein Sciences Â Â Â Â Â Â Â Â Accrued restructuring actions balances Â 0 Â Â Â $ 897 0 897 897 Cash payments Â Â Â Â Â Â Â (1,118) Adjustments Â Â Â Â 132 $ 89 Â Â Â Accrued restructuring actions balances Â 0 Â Â Â Â Â 0 Employee severance | Protein Sciences | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Restructuring costs, net of adjustments (33) Â Â Â 2,950 Â (19) 2,950 Â Employee severance | Protein Sciences | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Restructuring costs, net of adjustments 39 Â Â Â Â Â 2,313 Â Â Asset-related and other | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 356 Â Â Â 504 Â 1,098 504 Â Accrued restructuring actions balances Â 190 Â Â Â Â 190 Â Â Restructuring costs $ 356 $ 753 $ 4,737 $ 1,140 $ 504 Â Â Â Â Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of Goods and Services Sold, Selling, General and Administrative Expense Cost of Goods and Services Sold, Selling, General and Administrative Expense Cost of Goods and Services Sold, Selling, General and Administrative Expense Cost of Goods and Services Sold, Selling, General and Administrative Expense Â Â Â Â Cash payments Â Â Â Â Â Â Â (1,208) Â (2,800) Non-cash adjustments Â Â Â Â Â Â Â Â (3,391) Accrued restructuring actions balances $ 92 Â $ 190 Â Â Â 92 Â 190 Asset-related and other | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 2,759 Â Â Â Â Â 10,176 Â Â Restructuring costs $ 2,759 $ 7,417 Â Â Â Â Â Â Â Â Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of Goods and Services Sold, Selling, General and Administrative Expense Cost of Goods and Services Sold, Selling, General and Administrative Expense Â Â Â Â Â Â Cash payments $ (335) Â Â Â Â Â Â Â Non-cash adjustments (2,424) $ (7,417) Â Â Â Â Â Â Asset-related and other | Corporate | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 346 Â Â Â $ 32 Â 1,048 32 Â Asset-related and other | Corporate | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 4 Â Â Â Â Â 4 Â Â Asset-related and other | Protein Sciences | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments 10 Â Â Â 472 Â 50 472 Â Asset-related and other | Protein Sciences | Fiscal Year 2025 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments $ 2,755 Â Â Â Â Â $ 10,172 Â Â Impairment of assets held-for-sale | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments Â Â Â Â 6,038 Â Â 6,038 Â Restructuring costs Â Â $ 15,926 Â $ 6,038 Â Â Â Â Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Â Â Cost of Goods and Services Sold, Selling, General and Administrative Expense Â Cost of Goods and Services Sold, Selling, General and Administrative Expense Â Â Â Â Non-cash adjustments Â Â Â Â Â Â Â Â Â $ (21,963) Impairment of assets held-for-sale | Protein Sciences | Fiscal Year 2024 Restructuring Actions Â Â Â Â Â Â Â Â Restructuring costs, net of adjustments Â Â Â Â $ 6,038 Â Â $ 6,038 Â X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan for the current period, net of adjustments. + ReferencesNo definition available. + Details Name: tech_RestructuringCostsNetOfAdjustments Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes restructuring charges. + ReferencesReference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveAccrualAdjustment1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset. +

ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of decrease in the reserve for full or partial settlement through consideration other than cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveSettledWithoutCash2 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_RestructuringPlanAxis=tech_FiscalYear2024RestructuringActionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=tech_FiscalYear2025RestructuringActionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=tech_DiagnosticsAndSpatialBiologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=tech_ProteinSciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=tech_AssetRelatedAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringCostAndReserveAxis=tech_ImpairmentOfAssetsHeldForSaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue Recognition - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Jun. 30, 2024 Revenue Recognition Â Â Â Â Â Contract with Customer, Liability, Total $ 30.4 Â $ 30.4 Â $ 30.2 Contract with Customer, Liability, Revenue Recognized $ 8.0 $ 7.1 $ 19.9 $ 18.8 Â X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1 Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Revenues, net $ 297,031 $ 272,598 $ 586,489 $ 549,533 United States Â Â Â Â Â Revenues, net 159,906 147,793 324,921 306,898 EMEA, excluding United Kingdom Â Â Â Â Â Revenues, net 70,392 62,538 129,455 117,334 United Kingdom Â Â Â Â Â Revenues, net 13,243 10,675 27,187 23,126 APAC, excluding Greater China Â Â Â Â Â Revenues, net 19,010 19,042 37,131 36,392 Greater China Â Â Â Â Â Revenues, net 24,754 24,459 49,074 49,944 Rest of World Â Â Â Â Â Revenues, net 9,726 8,091 18,721 15,839 Consumables Â Â Â Â Â Revenues, net 230,715 211,126 461,560 435,673 Instruments Â Â Â Â Â Revenues, net 30,868 29,825 57,074 54,685 Services Â Â Â Â Â Revenues, net 27,350 24,129 54,707 45,583 Product and Services Â Â Â Â Â Revenues, net 288,933 265,080 573,341 535,941 Royalty revenues Â Â Â Â Â Revenues, net $ 8,098 $ 7,518 $ 13,148 $ 13,592 X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=tech_EMEAExcludingUKMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_GB Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=tech_APACExcludingGreaterChinaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CN Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=tech_RestOfWorldMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=tech_ConsumablesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=tech_InstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=tech_ProductAndServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1 Selected Balance Sheet Data - Narrative (Details) - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 Other Noncurrent Assets Â Â Inventory, Finished Goods, Net of Reserves, Non-current $ 5,740 $ 5,718 X - DefinitionNon-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesNo definition available. + Details Name: tech_InventoryFinishedGoodsNetOfReservesNonCurrent Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1 Selected Balance Sheet Data - Inventories (Details) - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 Selected Balance Sheet Data Â Â Raw materials $ 83,960 $ 79,377 Finished goods 110,153 106,072 Inventories, net $ 194,113 $ 185,449 X - DefinitionAmount of inventory, net of reserves, including both current and non-current portions. + ReferencesNo definition available. + Details Name: tech_InventoryNetCurrentAndNonCurrent Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockSupplementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryFinishedGoodsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.BB) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryRawMaterialsNetOfReserves Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 50 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1 Selected Balance Sheet Data - Property and Equipment (Details) - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 Property and equipment, cost $ 520,066 $ 507,710 Accumulated depreciation and amortization (270,313) (256,556) Property and equipment, net 249,753 251,154 Land Â Â Property and equipment, cost 8,104 8,150 Building and improvements Â Â Property and equipment, cost 249,193 243,863 Machinery and equipment Â Â Property and equipment, cost 235,984 215,948 Construction in progress Â Â Property and equipment, cost $ 26,785 $ 39,749 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1 Selected Balance Sheet Data - Intangible Assets (Details) - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 Definite-lived intangibles assets $ 1,048,916 $ 1,054,860 Accumulated amortization (587,865) (547,779) Definite-lived intangibles assets, net 461,051 Â Total intangible assets, net 461,051 507,081 Developed technology Â Â Definite-lived intangibles assets 675,072 675,674 Tradenames Â Â Definite-lived intangibles assets 151,066 151,561 Customer relationships Â Â Definite-lived intangibles assets 210,881 211,276 Patents Â Â Definite-lived intangibles assets 4,736 4,343 Other intangibles Â Â Definite-lived intangibles assets $ 7,161 $ 12,006 X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1 Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details) $ in Thousands 6 Months Ended Dec. 31, 2024 USD ($) Selected Balance Sheet Data Â Beginning balance $ 507,081 Other additions 249 Amortization expense (38,911) Currency translation (318) Restructuring Impairment (7,050) Ending balance $ 461,051 X - DefinitionAmount of other additions lacking physical substance with a definite life. + ReferencesNo definition available. + Details Name: tech_FinitelivedIntangibleAssetsOtherAdditions Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockSupplementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 53 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1 Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details) $ in Thousands Dec. 31, 2024 USD ($) Selected Balance Sheet Data Â Remainder 2025 $ 37,819 2026 72,318 2027 62,182 2028 58,478 2029 45,912 Thereafter 184,342 Definite-lived intangibles assets, net $ 461,051 X - DefinitionAmount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: tech_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockSupplementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 54 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1 Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details) $ in Thousands 6 Months Ended Dec. 31, 2024 USD ($) Beginning balance $ 972,663 Currency translation (8,056) Ending balance 964,607 Protein Sciences Â Beginning balance 423,449 Currency translation (3,642) Ending balance 419,807 Diagnostics and Spatial Biology Â Beginning balance 549,214 Currency translation (4,414) Ending balance $ 544,800 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=tech_ProteinSciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=tech_DiagnosticsAndSpatialBiologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1 Selected Balance Sheet Data - Other Assets (Details) - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 Selected Balance Sheet Data Â Â Equity method investment in Wilson Wolf

$ 241,354 $ 242,337 Derivative Instruments $ 3,227 $ 9,813 Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other assets Other assets Long-term inventory $ 5,740 $ 5,718 Investment in Spear Bio 15,000 Â Other 9,669 6,397 Other assets $ 274,990 $ 264,265 X - DefinitionAmount of noncurrent assets classified as other. + ReferencesNo definition available. + Details Name: tech_AssetsClassifiedAsNoncurrentOther Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes derivative asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 30: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockSupplementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInventories not expected to be converted to cash, sold or exchanged within the normal operating cycle. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 56 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1 Acquisitions - Narrative (Details) - USD ($) $ in Thousands 6 Months Ended Jul. 07, 2023 Dec. 31, 2024 Dec. 31, 2023 Cash paid, net of cash acquired Â $ 0 $ 169,707 Lunaphore Technologies SA. Â Â Â Acquisition amount $ 169,700 Â Â Â Lunaphore Technologies SA. | Developed technology Â Â Â Finite-Lived Intangible Asset, Useful Life (Year) Â 14 years Â Lunaphore Technologies SA. | Customer relationships Â Â Â Finite-Lived Intangible Asset, Useful Life (Year) Â 8 years Â Lunaphore Technologies SA. | Minimum | Tradenames Â Â Â Finite-Lived Intangible Asset, Useful Life (Year) Â 4 years Â Lunaphore Technologies SA. | Maximum | Tradenames Â Â Â Finite-Lived Intangible Asset, Useful Life (Year) Â 8 years Â X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=tech_LunaphoreTechnologiesSaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1 Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) - USD ($) $ in Thousands 12 Months Ended Jul. 07, 2023 Jun. 30, 2024 Dec. 31, 2024 Goodwill Â $ 972,663 $ 964,607 Lunaphore Technologies SA. Â Â Â Current assets Â 12,155 Â Equipment and other long-term assets Â 1,470 Â Goodwill Â 104,650 Â Total assets acquired Â 184,675 Â Liabilities Â 7,096 Â Deferred income taxes, net Â 7,872 Â Net assets acquired Â 169,707 Â Cash paid Â 169,707 Â Net assets acquired $ 169,700 Â Â Â Lunaphore Technologies SA. | Developed technology Â Â Â Intangible assets Â 60,300 Â Lunaphore Technologies SA. | Tradenames Â Â Â Intangible assets Â 4,900 Â Lunaphore Technologies SA. | Customer relationships Â Â Â Intangible assets Â $ 1,200 Â X - DefinitionAmount of assets acquired, including goodwill, at the acquisition date. + ReferencesNo definition available. + Details Name: tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equipment and other long-term assets acquired at the acquisition date. + ReferencesNo definition available. + Details Name: tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities excluding deferred income taxes assumed at the acquisition date. + ReferencesNo definition available. + Details Name: tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of identifiable intangible assets recognized as of the acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 55 -Paragraph 37 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -

Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1 + Details Name: us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=tech_LunaphoreTechnologiesSaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1 Fair Value Measurements - Narrative (Details) $ in Thousands 1 Months Ended 3 Months Ended 6 Months Ended Jul. 31, 2023 USD ($) item Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Dec. 31, 2024 USD ($) Dec. 31, 2023 USD ($) Aug. 31, 2024 USD ($) Mar. 31, 2023 USD ($) May 31, 2021 USD ($) Income Tax Expense (Benefit), Total Â $ 7,986 $ 5,922 $ 14,557 $ 4,486 Â Â Â Forward starting swaps | Cash flow hedges | Designated as hedging instruments Â Â Â Â Â Â Â Derivative, Notional Amount Â Â Â Â Â $ 100,000 $ 100,000 $ 200,000 Cross-currency swap | Net investment hedge | Designated as hedging instruments Â Â Â Â Â Â Â Derivative, Notional Amount $ 150,000 Â Â Â Â Â Â Â Number of interim settlement dates | item 3 Â Â Â Â Â Â Â Notional amount at maturity $ 110,000 Â Â Â Â Â Â Â Decrease in notional amount at each interim date $ 10,000 Â Â Â Â Â Â Â X - DefinitionAmount of decrease in notional amount of derivatives. + ReferencesNo definition available. + Details Name: tech_DerivativeDecreaseInNotionalAmount Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNominal or face amount of derivatives at maturity. + ReferencesNo definition available. + Details Name: tech_DerivativeNotionalAmountAtMaturity Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of interim settlement dates for the derivative instruments. + ReferencesNo definition available. + Details Name: tech_DerivativeNumberOfInterimSettlementDates Namespace Prefix: tech_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=tech_ForwardStartingSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1 Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 Assets, Fair Value Disclosure $ 9,290 $ 11,690 Total liabilities Â 2,051 Other current assets | Cash flow hedges Â Â Derivative instruments - assets 6,063 805 Other assets | Cash flow hedges Â Â Derivative instruments - assets 528 Â Other assets | Net investment hedge Â Â Derivative instruments - assets 2,699 Â Assets, Fair Value Disclosure Â 9,813 Other long-term liabilities Â Â Contingent consideration Â 2,051 Level 1 Â Â Assets, Fair Value Disclosure Â 1,072 Level 2 Â Â Assets, Fair Value Disclosure 9,290 10,618 Total liabilities Â 2,051 Level 2 | Other current assets | Cash flow hedges Â Â Derivative instruments - assets 6,063 805 Level 2 | Other assets | Cash flow hedges Â Â Derivative instruments - assets 528 Â Level 2 | Other assets | Net investment hedge Â Â Derivative instruments - assets $ 2,699 Â Assets, Fair Value Disclosure Â 9,813 Level 2 | Other long-term liabilities Â Â Contingent consideration Â 2,051 Exchanged traded investment grade bond funds Â Â Investments, Fair Value Disclosure Â 1,072 Exchanged traded investment grade bond funds | Level 1 Â Â Investments, Fair Value Disclosure Â $ 1,072 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 8 -SubTopic 20 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column F)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20 + Details Name: us-gaap_DerivativeLiabilityFairValueGrossAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=tech_ExchangedTradedSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1 Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details) - Designated as hedging instruments - USD ($) $ in Millions Dec. 31, 2024 Jun. 30, 2024 Cash flow hedges | Forward starting swaps Â Â Derivative [Line Items] Â Â Fair value of derivative instruments $ 300 $ 300 Net investment hedge | Cross-currency swap Â Â Derivative [Line Items] Â Â Fair value of derivative instruments $ 140 $ 150 X - DefinitionFair value of the assets less the liabilities of a derivative or group of derivatives. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeFairValueOfDerivativeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=tech_ForwardStartingSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1 Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details) - Designated as hedging instruments - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 (Gain) Loss Recognized in AOCI Â Â Â Â Â (Gain) Loss Recognized in Accumulated Other Comprehensive Loss $ (6,001) $ 13,214 $ 4,174 $ 15,199 (Gain) Loss Reclassified into Income (2,815) (3,457) (6,196) (6,694) Cash flow hedges | Forward starting swaps Â Â Â Â Â (Gain) Loss Recognized in AOCI Â Â Â Â Â (Gain) Loss Recognized in Accumulated Other Comprehensive Loss 1,689 5,669 6,699 7,956 (Gain) Loss Reclassified into Income (2,155) (2,620) (4,754) (5,159) Net investment hedge | Cross-currency swap Â Â Â Â Â (Gain) Loss Recognized in AOCI Â Â Â Â Â (Gain) Loss Recognized in Accumulated Other Comprehensive Loss (7,690) 7,545 (2,525) 7,243 (Gain) Loss Reclassified into Income $ (660) $ (837) $ (1,442) $ (1,535) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E + Details Name: us-gaap_DerivativeInstrumentsGainLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=tech_ForwardStartingSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1 Debt and Other Financing Arrangements - Narrative (Details) - USD ($) $ in Thousands 6 Months Ended Aug. 31, 2022 Dec. 31, 2024 Dec. 31, 2023 Borrowings under line-of-credit agreement Â $ 0 $ 225,000 Amended Credit Agreement Â Â Â Line of Credit, Current Â $ 300,000 Â Revolving Credit Facility | Amended Credit Agreement Â Â Â Line of Credit Facility, Maximum Borrowing Capacity $ 1,000,000 Â Â Line of Credit Facility, Additional Borrowing Capacity $ 400,000 Â Â Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.10% Â Â X - DefinitionThe element representing the additional borrowing capacity under a line of credit. + ReferencesNo definition available. + Details Name: tech_LineOfCreditFacilityAdditionalBorrowingCapacity Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_LinesOfCreditCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLongTermLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=tech_AmendedCreditAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1 Leases - Narrative (Details) $ in Millions 6 Months Ended Dec. 31, 2024 USD ($) Variable Lease, Cost $ 2.6 Fixed Lease, Cost $ 8.7 Maximum Â Lessee, Operating Lease, Renewal Term (Year) 5 years X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_VariableLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1 Leases - Balance Sheet Classification (Details) - USD ($) $ in Thousands Dec. 31, 2024 Jun. 30, 2024 Leases Â Â Operating lease right of use assets $ 85,383 $ 91,285 Current operating lease liabilities 13,511 12,920 Noncurrent operating lease liabilities 81,616 $ 87,618 Total operating lease liabilities $ 95,127 Â Operating Lease, Weighted Average Remaining Lease Term 8 years 1 month 2 days Â Operating Lease, Weighted Average Discount Rate, Percent 4.26% Â X - ReferencesNo definition available. + Details Name: us-gaap_LesseeOperatingLeaseDescriptionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 65 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1 Leases - Cash Paid (Details) $ in Thousands 6 Months Ended Dec. 31, 2024 USD ($) Leases Â Operating Lease, Payments $ 8,068 Right-of-Use Asset Obtained in Exchange for Operating Lease Liability $ 1,321 X - ReferencesNo definition available. + Details Name: us-gaap_LesseeOperatingLeaseDescriptionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 66 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1 Leases - Fair Value of the Lease Liability by Payment Date (Details) $ in Thousands Dec. 31, 2024 USD ($) Leases Â Remainder 2025 $ 8,399 2026 16,568 2027 13,732 2028 13,569 2029 13,115 Thereafter 48,159 Total 113,542 Less: Amounts representing interest 18,415 Total lease obligations $ 95,127 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: tech_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LesseeOperatingLeaseDescriptionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-

gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 67 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1 Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Jun. 30, 2024 Common Stock, dividends, per share, declared (in dollars per share) $ 0.08 $ 0.08 $ 0.16 $ 0.16 Â Deferred tax liabilities $ 37,723 Â $ 37,723 Â $ 55,863 Interest expense $ 2,148 $ 4,329 4,324 $ 9,222 Â Accumulated Other Comprehensive Income (Loss) Â Â Â Â Â Deferred Income Tax Expense (Benefit), Total Â Â $ 1,600 $ 2,700 Â X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1 Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2024 Dec. 31, 2023 Balance $ 2,138,650 $ 2,068,850 $ 1,997,746 $ 1,966,516 $ 2,068,850 $ 1,966,516 Balances (in shares) Â 158,216,258 Â Â 158,216,258 Â Net earnings 34,890 $ 33,600 27,465 50,993 $ 68,490 $ 78,459 Other comprehensive income (loss) before reclassification (25,563) 18,229 14,355 (11,952) Â Â Share repurchases (75,628) Â (80,042) Â Â Â Common stock issued for exercise of options 5,164 20,892 3,841 (2,577) Â Â Common stock issued for exercise of options (in shares) Â Â Â Â 800,000 1,200,000 Common stock issued for restricted stock awards (993) (2,644) 0 (4,767) Â Â Cash dividends (12,736) (12,688) (12,559) (12,654) Â Â Stock-based compensation expense 14,335 10,146 12,413 9,981 Â Â Common stock issued to employee stock purchase plan Â 2,227 Â 2,094 Â Â Employee stock purchase plan expense 373 38 340 112 Â Â Balance $ 2,078,492 2,138,650 1,963,559 1,997,746 $ 2,078,492 $ 1,963,559 Balances (in shares) 157,915,999 Â Â Â 157,915,999 Â Common Stock Â Â Â Â Â Â Balance $ 1,589 $ 1,582 $ 1,584 $ 1,576 $ 1,582 $ 1,576 Balances (in shares) 158,878,000 158,216,000 158,355,000 157,642,000 158,216,000 157,642,000 Share repurchases $ (11) Â $ (14) Â Â Â Share repurchases (in shares) (1,118,000) Â (1,397,000) Â Â Â Common stock issued for exercise of options $ 1 $ 6 $ 1 $ 6 Â Â Common stock issued for exercise of options (in shares) 132,000 577,000 157,000 633,000 Â Â Common stock issued for restricted stock awards $ 0 $ 1 $ 0 $ 1 Â Â Common stock issued for restricted stock awards (in shares) 24,000 50,000 27,000 47,000 Â Â Common stock issued to employee stock purchase plan Â $ 0 Â $ 1 Â Â Common stock issued to employee stock purchase plan (in shares) Â 35,000 Â 33,000 Â Â Balance $ 1,579 $ 1,589 $ 1,571 $ 1,584 $ 1,579 $ 1,571 Balances (in shares) 157,916,000 158,878,000 157,142,000 158,355,000 157,916,000 157,142,000 Additional Paid-in Capital Â Â Â Â Â Â Balance $ 855,973 $ 820,337 $ 746,606 $ 721,543 $ 820,337 $ 721,543 Common stock issued for exercise of options 5,183 23,224 4,914 12,877 Â Â Common stock issued for restricted stock awards 0 1 0 0 Â Â Stock-based compensation expense 14,335 10,146 12,413 9,981 Â Â Common stock issued to employee stock purchase plan Â 2,227 Â 2,093 Â Â Employee stock purchase plan expense 373 38 340 112 Â Â Balance 875,864 855,973 764,273 746,606 875,864 764,273 Retained Earnings Â Â Â Â Â Â Balance 1,341,175 1,325,247 1,327,572 1,309,461 1,325,247 1,309,461 Net earnings 34,890 33,600 27,465 50,993 Â Â Share repurchases (75,617) Â (80,028) Â Â Â Common stock issued for exercise of options (20) (2,338) (1,074) (15,460) Â Â Common stock issued for restricted stock awards (993) (2,646) Â (4,768) Â Â Cash dividends (12,736) (12,688) (12,559) (12,654) Â Â Balance 1,286,699 1,341,175 1,261,376 1,327,572 1,286,699 1,261,376 Accumulated Other Comprehensive Income (Loss) Â Â Â Â Â Â Balance (60,087) (78,316) (78,016) (66,064) (78,316) (66,064) Other comprehensive income (loss) before reclassification (25,563) 18,229 14,355 (11,952) Â Â Balance $ (85,650) $ (60,087) $ (63,661) $ (78,016) $ (85,650) $ (63,661) X - DefinitionAmount after tax, before reclassification of translation adjustments of other comprehensive income (loss). + ReferencesNo definition available. + Details Name: tech_OtherComprehensiveIncomeLossBeforeTranslationReclassificationNetOfTax Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_DividendsCommonStockCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation. + ReferencesNo definition available. + Details Name: us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit. + ReferencesNo definition available. + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased and retired during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1 Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Balance $ 2,138,650 $ 1,997,746 $ 2,068,850 $ 1,966,516 Other comprehensive income (loss), before tax: Â Â Â Â Balance 2,078,492 1,963,559 2,078,492 1,963,559 Unrealized Gains (Losses) on Debt Securities Â Â Â Â Balance 5,075 12,512 8,102 12,862 Other comprehensive income (loss), before tax: Â Â Â Â Amounts before reclassifications (1,689) (5,669) (6,699) (7,956) Amounts reclassified out 2,155 2,620 4,754 5,159 Total other comprehensive income (loss), before tax 466 (3,049) (1,945) (2,797) Tax (expense) benefit (511) (621) (1,127) (1,223) Total other comprehensive income (loss), net of tax (45) (3,670) (3,072) (4,020) Balance 5,030 8,842 5,030 8,842 Foreign Currency Translation Adjustments Â Â Â Â Balance (65,162) (90,528) (86,418) (78,926) Other comprehensive income (loss), before tax: Â Â Â Â Amounts before reclassifications (26,021) 17,387 (5,362) 5,252 Amounts reclassified out 660 837 1,442 1,535 Total other comprehensive income (loss), before tax (25,361) 18,224 (3,920) 6,787 Tax (expense) benefit (157) (199) (342) (364) Total other comprehensive income (loss), net of tax (25,518) 18,025 (4,262) 6,423 Balance (90,680) (72,503) (90,680) (72,503) Accumulated Other Comprehensive Income (Loss) Â Â Â Â Balance (60,087) (78,016) (78,316) (66,064) Other comprehensive income (loss), before tax: Â Â Â Â Amounts before reclassifications (27,710) 11,718 (12,061) (2,704) Amounts reclassified out 2,815 3,457 6,196 6,694 Total other comprehensive income (loss), before tax (24,895) 15,175 (5,865) 3,990 Tax (expense) benefit (668) (820) (1,469) (1,587) Total other comprehensive income (loss), net of tax (25,563) 14,355 (7,334) 2,403 Balance $ (85,650) $ (63,661) $ (85,650) $ (63,661) X - DefinitionAmount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -

URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A + Details Name: us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1 Earnings Per Share - Narrative (Details) - shares shares in Millions 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Earnings Per Share [Abstract] Â Â Â Â Antidilutive securities excluded from computation of earnings per share, amount (in shares) 4.1 6.2 3.6 4.1 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 71 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1 Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2024 Dec. 31, 2023 Earnings Per Share [Abstract] Â Â Â Â Â Â Net earnings $ 34,890 $ 33,600 $ 27,465 $ 50,993 $ 68,490 $ 78,459 Net earnings 34,890 Â 27,465 Â 68,490 78,459 Income allocated to participating securities (3) Â (3) Â (12) (13) Income available to common shareholders $ 34,887 Â $ 27,462 Â $ 68,478 $ 78,446 Weighted-average shares outstanding - basic (in shares) 158,431 Â 157,533 Â 158,481 157,826 Earnings per share - basic $ 0.22 Â $ 0.17 Â $ 0.43 $ 0.5 Income available to common shareholders $ 34,887 Â $ 27,462 Â $ 68,478 $ 78,446 Dilutive effect of stock options and restricted stock units (in shares) 2,195 Â 2,527 Â 2,872 3,175 Weighted-average common shares outstanding - diluted (in shares) 160,626 Â 160,060 Â 161,353 161,001 Earnings per share - diluted $ 0.22 Â $ 0.17 Â $ 0.42 $ 0.49 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 65 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 66 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 72 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1 Share-based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Oct. 30, 2014 Granted, shares (in shares) Â Â 800,000 900,000 Â Granted, weighted average exercise price (in dollars per share) Â Â $ 74.65 $ 81.49 Â Weighted average fair values (in dollars per share) Â Â $ 25.43 $ 27.83 Â Common stock issued for exercise of options (in shares) Â Â 800,000 1,200,000 Â Common stock issued for exercise of options intrinsic values Â Â $ 28,300 $ 61,600 Â Unrecognized compensation cost $ 62,600 Â $ 62,600 Â Â Unrecognized compensation cost, period for recognition (Year) Â Â 2 years 1 month 6 days Â Â Employee Stock Purchase Plan 2014 Â Â Â Â Â Â Stock-based compensation expense 400 $ 300 $ 400 500 Â Number of shares authorized (in shares) Â Â Â Â 800,000 Selling, General and Administrative Expenses Â Â Â Â Â Stock-based compensation expense 14,500 12,400 24,800 23,500 Â Cost of Sales Â Â Â Â Â Stock-based compensation expense $ 400 $ 300 $ 700 $ 500 Â Restricted Stock Units (RSUs) Â Â Â Â Â Granted, shares (in shares) Â Â 500,000 300,000 Â Granted, weighted average exercise price (in dollars per share) Â Â $ 74.96 $ 79.26 Â Restricted Stock Â Â Â Â Â Granted, shares (in shares) Â Â 11,696 27,196 Â Granted, weighted average exercise price (in dollars per share) Â Â $ 68.37 $ 56.98 Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=tech_EmployeeStockPurchasePlan2014Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1 Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Other income (expense). Â Â Â Â Interest expense $ (2,148) $ (4,329) $ (4,324) $ (9,222) Interest income 1,348 816 2,274 1,706 Gain (loss) on investment(1) Â Â Â 283 Gain (loss) on equity method investment 46 (1,914) 420 (4,204) Other non-operating income (expense), net (3,789) 810 (2,729) 516 Total other income (expense), net $ (4,543) $ (4,617) $ (4,359) $ (10,921) X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesNo definition available. + Details Name: tech_OtherNonoperatingIncomeAndExpense Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized and unrealized gain (loss) on investment. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(a)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 74 R63.htm IDEA: XBRL DOCUMENT v3.25.0.1 Income Taxes (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Income Taxes Â Â Â Â Â Effective income tax rate reconciliation, percent, total 18.60% 17.70% 17.50% 5.40% Income tax expense (benefit), discrete tax items $ (2.2) $ (2.8) $ (5.2) $ (16.3) Share-based compensation excess tax benefit 1.0 1.3 4.3 11.7 Income tax expense (benefit), other immaterial discrete tax items, net $ (1.2) $ (1.5) $ (0.9) $ (4.6) X - DefinitionRepresents the income tax expense (benefit) related to discrete tax items. + ReferencesNo definition available. + Details Name: tech_IncomeTaxExpenseBenefitDiscreteTaxItems Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents information related to other net immaterial discrete income tax expense (benefit). + ReferencesNo definition available. + Details Name: tech_IncomeTaxExpenseBenefitOtherImmaterialDiscreteTaxItemsNet Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of tax benefit for recognition of expense of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 75 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1 Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Dec. 31, 2024 Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2023 Jun. 30, 2024 Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net $ 297,031 $ 272,598 $ 586,489 $ 549,533 Â Operating income 47,419 38,004 87,406 93,866 Â Costs recognized on sale of acquired inventory Â Â (373) (364) Â Certain litigation charges (1,386) Â (1,678) Â Â Intangible assets, net 461,051 Â 461,051 Â $ 507,081 Corporate general, selling, and administrative expenses (121,451) (115,667) (240,612) (220,998) Â Consumables Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net 230,715 211,126 461,560 435,673 Â Instruments Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net 30,868 29,825 57,074 54,685 Â Services Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net 27,350 24,129 54,707 45,583 Â Product and Services Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net 288,933 265,080 573,341 535,941 Â Royalty revenues Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net 8,098 7,518 13,148 13,592 Â Other Revenues from Business Held for Sale Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net 1,849 Â 4,152 Â Â Operating Segments Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Operating income 90,352 84,142 175,170 173,029 Â Costs recognized on sale of acquired inventory (185) (183) (373) (364) Â Amortization of intangibles (18,559) (19,769) (38,300) (39,620) Â Acquisition related expenses and other (2,010) 525 (3,523) 1,114 Â Impairment of assets held-for-sale Â (6,038) Â (6,038) Â Stock based compensation, inclusive of employer taxes (15,238) (12,958) (25,875) (24,453) Â Restructuring and restructuring-related costs (3,287) (5,518) (14,309) (5,607) Â Corporate general, selling, and administrative expenses (1,641) (2,197) (3,227) (4,195) Â Impact of business held-for-sale(1) (627) Â (479) Â Â Operating Segments | Protein Sciences Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net 211,551 197,670 416,086 402,325 Â Operating income 87,112 79,586 167,653 167,947 Â Operating Segments | Diagnostics and Spatial Biology Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net 84,135 75,408 167,327 148,204 Â Operating income 3,240 4,556 7,517 5,082 Â Intersegment Eliminations Â Â Â Â Â Revenues from External Customers and Long-Lived Assets [Line Items] Â Â Â Â Â Revenues, net $ (504) $ (480) $ (1,076) $ (996) Â X - DefinitionRepresents the amount of amortization of acquired intangible assets. + ReferencesNo definition available. + Details Name: tech_AmortizationOfAcquiredIntangibleAssets Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting. + ReferencesNo definition available. + Details Name: tech_FairValueWriteUpOfAcquiredInventory Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of impact on income from business held for sale. + ReferencesNo definition available. + Details Name: tech_ImpactOfBusinessHeldForSale Namespace Prefix: tech_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThis element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23 + Details Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_GainLossRelatedToLitigationSettlement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax of income (loss) from an individually significant component disposed of or held-for-sale including the portion attributable to the noncontrolling interest. Excludes discontinued operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A + Details Name: us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=tech_ConsumablesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=tech_InstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ServiceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=tech_ProductAndServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_RoyaltyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=tech_OtherRevenuesFromBusinessHeldForSaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=tech_ProteinSciencesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-

gaap_StatementBusinessSegmentsAxis=tech_DiagnosticsAndSpatialBiologyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ö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

E;@^F1L$.5QO=$HA^AX%] M 2!:0R8&R%FTP[HF,=GP+2QUE$P='<]BXUHL/D@762: MBC*RIN.I(VCA Q-!8$37&$7QT7*X*GIG&[H5(J/^Y*ZB-?Z^0'=5?/@:>T:@ MLN[$^5NB"KV?
5QM/+PL(G!.BNXMVR]I/^XH4KZ'?Q&^AER.2LY'B8E/WF &4 M-<$Y?GOHZ?G.W;MZ^3N,WE*3),KTMLP]HBEE.(O-7KRXVW@+//JZ85H1C:4K MVD5=CGM1G[FL@Z5,B2QTFLE-/KS
\&]@"*FM[QQXA8ZQ.I/2W[!\QO8[2&+W M>F1[HCNZ/Y#;>(9E/_KJA_LC%+5/GO5MS__J^Y^1B/QKMG[V(R@I??_VX/8S M$GYTLOOV9(F/_)&9]&52-_<]FX%K5]-%.C.=9M/9,IF9+Z?
98CE)9_)%MEP- MLM.7*=T#>Y5EB\ESJ+A) M=Z\FJWXX7V2+1:#<)TTLTQ%2TA;:@0VHTTU/5AGD\W@F%6VF ZC:9Y-YV?#Q69VSY1.X%:&_>;#4/%5I MMIIA_SI5I50E>&-
_O3_VG^_9=Y]^WY]BUY]JW? MO]62R,^_WTXSIGC_'UP>OT6CQ0=0FFTPG9\YH'4.R0G<\Z6WZ;(D M.&RUF*?#^6+(J1 RD88;N9S(#_4^,_:J $UFVR5L/'E\]#"=(V'R7"1K?,- M^U5T?="?
G*N7_L2X2OYC0EM0^7_2J&E#FQ'^;NIG^S_K;L)_5,/R\$_?.VXJ M6=-M;H>MD_%J,0HWP6[@=./_L<+]%SV(_[D7:)@-+<#SG=:N&] !_5^8U_\! M4$L#!!0 (,N#1EH*^03X@ < <7 8
>&PO=V]R:W-H965T&ULU5AK;^.V$OTKA%L4":#&>DM.DP!)VFVWZ/8&\?;N9T:B;:*2 MJ"6I>--?WT/*EJC826_;Q0+WBV6.R:AS)D'=;$5\G>U84R33W75J,O91NOV M?
#Y7Q8;55)V)EC5XLQ*RIAI#N9ZK5C):VD5U-0]]/YW7E#>SJPLKNY-7%Z+3 M%6_8G22]JVLJGVY8);:7LV"V%]SS]48;P?SJHJ5KMF3ZM_9.8C0?M)2\9HWB
MHB&2K2YGU\Y36SFVPG_Y6RKG/_$G.1!B- -X&UY.?,-(%:Q0AL-%()'=LNJ MRB@"C(\[G;-A2[/0_;_7_L:>'6=YH(K=BNH#+_7F)9J3HE!;U;C$0U+SIG_33S@[.@MQ_84&X6Q!:W/U&%N7W
M5-.K"RFV1)K9T&;^V*/:U0#'&^.4I99XR[%.7RVM?5A);FA%FX*I:!6"T74Q MU]C 3)L7.V4WO;+P!64I>2<:O5'DAZ9DY73'], &=.$>W4WXJL+O67%&HL C MH1_&K^B+AM-&5E_T@KY?A6:*:$'>\
:GY;0B2TTU \NT.G;>7EU\7)T)F'/5 MTH)=SA 1BLE'-KOZYJL@];][!6P\@(U?TWZU[-JVLM <^H>VI3DEJH>8.@ M(F^;/CC!\F-G>'T78Q(2G9%7B"'.'1X!0TC.U&1 "H'P5)J(%3GA#=$;T2F M4Z?
GY)NO\M"/OOML3W"!U0],6C[LA3]W#=#[WL%L0YC^%X7M>T"W#S-)%BC M!NG7)(^\1>H[@FSA15DY<(4I&3X'1X%02^%R31/93S_"8>Q8 MVB,-
O#%N$BQB+P@B5Y(G7APO!HG9Z-G>?*?OR?CKZ\3+8M]2R?P-8;"$&(:G[MA*2Z!\4^=MC S#3O7H9#C.R,W$E4/JF?[%E^^-CQUH3B^53.]O+_ITCXQ2!W M".P%?
CP=)R.?;SI>E;Q9*WM>7K=2//;YGX_@=+4 G)I^; M[!IE'B+_#!BPP#R.!_&QG5:=GU9AZT!:0TV.H!2+\N381@MP/0Q,(X[T(,' MU8@I"7W/3]-Q[&>(D=$LUT71U5UEV5,R9'\4D[[-
@%):"ZGY'[U@B_B6T:>P;>V>)&_MA$L!AI9AY[B]K1K/E#QMR2.LV#2B$NLGQ[QIEDSRTE+UM":C20, MX!.706:../ "[-1W1VHYP9A[&51ZHRB M>"1(G\CYX/EQ>5>8%#J0@]-
#+.U99H7YH]FV%)%\ZZ_?,&=9Y?IQ[BR!U)4F, M)' \8([*1Y)G6)$X\9$"+IL,4K>"],+'0!Y'B!Q:O8/'(D)7]^QYN"$#33U M+:$I"@65\@G)SB#L&AL21O/AR5%Y[ )$*Q<(5=/O'BF#GR&TCH;*WPJ"&
[;F M36-.]; KK<8]ZW-R)\U.J!.4 MRZ-9_@0[)OXI^"\E:XHGHB5M5#4EPZ@^R$_-=>(X_>.-GT$[J\C9;U;\P6#XU_G?4[7#.RX*"LDS^7 M+6AEKF=\6C-Z.T\Z8-?J831IU1&'*.EAX,Y9@
@IFJA7P^0D\M(X/#W >Q)[M<1 ?D>?P-OJ-0V]><19I[*7.G \(NT=:=0B[*3N,D$W(ML;L]K$0G]89\[*@T/,4,ABZ1K+@]8+@G1J5UR .?36\9,5]5TD.\VL2F*8\FC M+8$"I04J)"FX1)%1FRED
%9:QV(UJLA5=92I8R0N#D9)6*&4C?\Q4_37D5D#0 M/!GRFENUJ58&9<4UM7>=\2!CBC/90RG[UW"?XBT.Q %-LM8D'UBB:\RX[-/C M<0OL#F_\
<49^%7NX0MJLY.RW17P3CH9#\Q4W"!5IH<7,@E('SMFS%F#?!$ZE M7ZX/_-_ZOL_7YYEK&[KIFN$PI;UA*FTMB/-]X)5"*T0UXO7],+T'[9^2%3N;>/Q%2N*S_,MQDQ\ON\YG]K?R(%$7A[>0
MR]9$"3+/P6SZR.T:U34>I%BVS*"\<46>PM%FXB")$(PG2X M:AW[ZC5W/DZBW5W;3["&;2@;_7?*03I\Y;WN/VZ.T_M/Q_^H1"NC2,566_J? M9&PO=V]R:W-H965T&ULS5C989(D$1#0@P &A9_?J>
M"U 495M.TH=.7R02O/MR[B5/EL9^=840GMV62KO37N%]=30XM8NAJZS@66 JU7"<)/O#DDO=.SL)9Y_LV8FIO9):?++,U67)[>I" M*+,\[8UZZV//G51\(:Z$_Z/Z9'$W;*5DLA3:2:.9%?EI[WQT=#$E
M^D#PIQ1+U[EFY,G]@Q[+1,YKY3^;Y6^B\6>/Y*5&N?#+EI%VDO18 M6CMORH89%I12QW]^V\2APW"PBV'<,(R#W5%1L/(5]_SLQ)HELT0-:7017 W< M,$YJ2LJ5MW@JP>?/SM-
OM722(N1.AAX2Z7R8-MP7D7N\@WN??3#:%XZ]UIG(MMOF'L*0U9[PVYV+\J,!7(AVPR:C/QLEX^HB\2>O>),B;[)#WT7CAF#?LC=1< MIY(K=N6Y%R@K_Z"_4=ST87'4(4>NXJDX[:$%G+ WHG?
V])?1?G+\B+'3UMCI M8]*_FXO'NN8+ M[AE7M@W HT5VIJ[47&@!.,&!:01>=203R2 MC.=UB?.Y@+34+=3\FZ@\R[FT[(:K\N8X4G_7L Q>!7%!#SV%)>CJ0 SXLTUP
M<"B\%%#"N5YU"4&J=5;.$?ZZ0%:SS,-K%@.]4P9Z3C>/DN*4()[Z/C M%Z&.GXSV#PN.SB2_0&&3-I.*%05#6X,5A9964J M4,)HA:QI.DA7(3ZP=!.#)7$)W(@8J@"G+Q&0B/SJ ,;.]G:%YW\G,K)\
<[L.F7!!4$6811B:4;!A# M*U4&;4!+9D:/2JZQ%U,^GX5'1#?13:SE.UW3E$OLE.Q^HE:Q:1]."?73 UI; MP 6"L >22?T0ZSS4/&ARFJ_N8F#G[,2TU/&O0.#)248$.NAUZP!,!/-F=;4
MWK%_.V')UU%=>YE]WVE/]<=B >YPZ-F_< 61DB*/$]F:%5=^U;C08%E)]\PF MP30W'HR_I#4AR"R!OV$Y"2L6^=X,7WK+H=>5"&HTRRD4"[2JHX'00AUVBXSH
MLQU;Q@\M&:WY9PFB9CC[DPFH8Y3FM'EW/C0 O7.VH-,K:_*G=Y+_S?[?U M!^L [,I^MQ!_.NG_TW!T?<(JL,!?Z(BF&BC?6W$A_,WN0W.+D"MX'=Z@PI;2
M,#3!;"8SEC<9=Z.\]C4M4]C[TO"89W\A/7'%"11\NB['$@&>YP;OELT-*6@_&9W] M U!+ P04 " #+@T9:L0+\Y%0+ ^+ &0 'AL+W=O\>V?!>+I:6&DZOGJSX0GP0]N/JG<;7
M:44EEJG(C%09TV+^M/=L^/CYF/[[#K]+L3:-=T:2S)3Z1!^OXJ>] 3DA%9 MHL#QN!'7(DF($-CX7-#L55/2P.9[2?VEDQVRS+@1URKYMXSM\FGOO,=B,>=Y M8M^K]3]$(<^$Z$4J,>Z7K7W?
T:#'HMQ8E1:#P4$J,__DMX4>&@/.]PT(BP&A MX]M/Y+A\P2V_>J+5FFGJ#6KTXD1UH\&Y8&\$ M-[D6T+@U3TXMB%.7TZ@@]-P3"O<0FK(W*K-
+P_Z>Q2)NCS\%4Q5G8J)!TY>,J,]]'Y55AAF%7LI,YY%DB?L@^5VO[R>W+B; M' 7+8[/BD7C:0S08H6]$[^KGGX;3P>4!9L<5L^-#U+_%+(<)D=1LPOIL#\7' M[+>E8-:4BF1FK<]
<5[U&2QX)%W"P9SV+_(C[G\H8G MU"-@_(;+A,\2<0*\.#%HQJ@;86SJ_X^%1F<*Q"9EC(LBE=,<6D0'/4"AT;CB M&]\2P<5DML 8>C42Y+@+;C5+Y,*]$C&PEJAL<6*%3C'ES!;BWSCQI:&PA9YB
MQN0)^G-]>N06(Y$G,9J+@\D,D"1!&;31WP GE09'TOUA-<_,7&C&62+Y M3";2;B 9]54:W"4;WX5[#]0NQB8OP#K3R"TXMK*2$+U$!*\J+EC)ZWMPV)X M:!\V M/&0C"NP75B%
(-.H1.)R,=0MI30A(Z6&P:]@X%5#HJY ?=@QM.#WMB\ MTL(V34"*3.47X16"D<2,FI%?D^1+DJ1:H-!NUSS;[3S;0(GP#C>U4ZZ33AG; M07DF/+_K)?13N5&?O=WE05>O77KT!B2V(#K)ZF<7M?
%J2Q&>QTQ5!H&V.7BS MW'G'7*L41&*!%3 F8QB5ZTB8/OO8(6V#+2AC&T-1YNG+NR?@,;Z-C M: ZO4/J^I,A7D(-ZS. :&.47;+?RE=HD6M0CDCK*4[*]DX80((*?+9267XIX
MFC(;;$VGU"6X3JW4&JFZT%L+/! %?NQF'34M]S@&,,5MI M"16XB'7;@(\6QH<1&1T,51IH:%V*BFY8TBWQL4V;*!0D3,)U-YW=V8,.$C4S M=Z%7BN&4Z_)FRA:3>'PL6#Y2T+.F;EE[SN-
Z:,/5B9%N)PR8D(Y4+ &<%KCG M<*C*G4:U:MJ@A1G[23M^\1=\H78(3R$6!$N6'-#$4+,TS-5,2R]48:MX:(M8K&:PP?A2W:I8I6H!6FKH4XKHF4F/SQJF).3KW)"JTRTW--1;P0U*S&7?+$I
M52UVRC<>MZM%5&B"F<;RB%4F DP[$Y(VUDL9+4EP[=:L!$R2' 5:.&.2=A0M M/K&(L"4W5827+'@%(M9*C"GT4VJ[M3B;W,U7X'2IVQH0ZFCTL"[:0?M''B^< M'* -
HM*C3Y_1KF(PNG11.U<)+."PC/2#15VK&[AV"Z^P;GB,("Z_"D.5GQ80 MX>S6X)4 D!;S7+MU")@$91XY/:G<@)HYKGG\T<_?E(6D#T4]XEIO2 D/+8;7 MO-_1E&U[-
J#LHVER])PGM"JQ#RXC?:TB[Q+EWT@*1H#$%!B4#:^\I!R7>P(M_;YN'VN4350?Y<+0_@ZWOD??S?S/O(O?M?N+:C=-6UJ*16Z]]$L1+TBMS>W[
M20,"Z7\,>NL@FT*#XI:W9W_$IL%@.FI\N_P@O+Q#CWOBC'?K8Q*>=^JDR=M= M^GXKEYFP3;QVK![F- RF%Q=WYO5P;X\->R9ZQ"Z"\&)PT%A?Z_&_]OP_V!X& MVW_FV/>,!M\(M Y@2V M ?
5[^F?!-1K;,K<=H9*15 G4C]EI&5'PV,H26GK M2P]'JQR-"!L&@[/PP/=NC-XS@.Z!]O)Y/IC<&9P.]7T8N+\(SH>CO7QU__L5 MD!P. ;@Q8:!-/A^0$3?:_GZ\86]ZY\C[G$]^MG206!->\8WGL\P%2UZ1?
D%!-\(3K&DXE(-+4 U'@U56E'5V MBLP;,S19\^B2.D8G"2;@'1#5;*R4-HM?=^2 M1MQ&2YX!8P+*"\U*1'"+R_DA1P[HS)>4O3JMSS!%0%RXZJVD5;&G'B,CC:.^\HW234ISSB,+S&1
MN(7_PNFHF10,;\'50"W-)\(\A3R9U$Y.W%3"W\QVJ%/A 50_K*5!$I_/L)Y+ MKC?]KB2=N?.-S/IZ;S-V2BT4YJAG4]@F4&5Y&W(H[4YEDE A]/CQ@V-H9[98 M[6I>-1BK1_@XI&U0*U-T'R^[HXTPI]I!;
5NC5"CP6#KZ[K#_$=A3>O7+GC> MEG$X'NRV3>HV8HZ(DF%A2,MOR^..PFH++K.B](@)V""TS5[/N6C**2AR+$GB; MA]>B.&27RG30*N$4]&C7J!(9.P_M.H.K@,@7;XF*D;*5(*/VQ9U-]%N
M>!FQ-=7)N"F\=[Ō$_#.=M?GT2]0TC%VVXB\]R)2BPP+@SNG =3E:9XX!?E5 MF")*BR6=@6-Q<4.VR?TKAR^BJSMVK5H_0''-\]AO"Y'.QE8D.(VW6AH?H^TH MN/L.YJ\^]T1HQT8PF)Y?
X#D)IM.+1ONTE8(_8F?!Q63:&8G?3Z@NG-CK76>T MP:TQY"R8C'?W[4=A, DGQSOM9T$X'NW)BQ^QHVDPP#EH%PW&@8!\.S MYO=P$@SWE#3^FY];,5R@H=\@*"PLD4IWD?
I;GW\QLN]EL>QLK H%P/VF)OX, M4I0?@+]";=6"\.-0Y,%0!W$WG"#NW-LT'#1CZ6@4R8ZV\1;)BW\#J X ^_*T?WA9P-VN-E-"MR] MDZ2X 1#_D9?5J>*$D*
[WQ7GB+F\4&=)=]B!%D!X1]^'@\MG;ZU?N=7AY3,/= M=:/SH+A80^>1B&7/+K=6RUGN4XI"N.W4L9"_[@;8KIRE%%*MBHL_IO\U_>V4 MFG95]S'3@B=N%^8WL$>>U#%MA7?&?
T5_4$BMB/ZALH$_>N^^:G6]_XK5GLK& MOCM4=(Z]=8_*N=YP>%E<_"C*U&4RIT%/6[\C]39[J-M;%6/HEN7 M-6;(_XM[04Y5=>4THVI+^4?I'GTL'ZVJP+WQ5UTJ\!E/K/DZ*_,;NBEWHN8G
MD1:QI!/CJ+YML%6E:(AI.N7,]59I1)JZ]D$$B\M IBK(%N?QU-GTNRX,GC;N M=*9"+]S-58PG0?SUSJJUNAS[S-\)K;O[F[5ON%Z06R=BCJ&#_MFDQ[2_K>H
MK%JY&Z(S9:U*W>M2\%AHZH#_YPK>7'S0!-65X:O_ %!+ P04 " #+@T9: MS;XSD?<# P"0 &0 'AL+W=O:9V1Q(;+KDFN9+5K^\9[FJKN+;0 M%C L7F;.G+EP9J<[Y[^.DI]+8,,LV,5:7_7[(-
URJT',56]RLG"]5Q-:O M^Z'RK(JD5)K^:#"XZ)=*VVP^36=W?CYU=33:\IVG4)>E\OLK-FXWRX;9X>!> MKS=1#OKS::76_,#QU^K.8]?O4 I=L@W:6?*\FF6+X>751.23P&^:=^%H3>+)
MTKFOLOFIF&4#(<2&\R@("C];OF9C! @'T'EO,K#,IBL?K \QL\ MKHNXF64?,RIXI6H3[]WN,[?^O!>\W)F0_M.ND1U#.*]#=&6K# :EMLVO>FKC
M<*3PC:'$\D9%-9]ZMR,OTD"317(U:8.\ MC*1L0;=QPYX^::MLKNV:%MXKNV;$/X9I*4*/3S%O:J@1V] GM!7YR-FT _MVH*+;_7[H-CQ'!UX7HU. MYPWJ/Q\)Q&@]'D!-ZX\WN<\,:OX/WL(@>*[N"Q
M,O0057S=WP9N\C*1F" Y6S^_7?#B\$/)\A..K*34^C_/TFG M824&=-&C?P5_2;>6%O4:)7G(P^B>&8*N^VND ZT:_^ M,=P:7*E<&QWWY%9T-J2E-@8-X9QV&YUO*!<2#-:0QO,N$B.TBP*]$$-
AG$T& M [R]I(7NM?P#'45*)V*%6HYZ$^7&HY5['(&2"+K3RFL.YN&#J0G!670HK!%K' M"#LJ?ZQU^&\\EZR\Y!-Y1=H5_F@+8VIIF#Q>2Y.0O/9>I'S0P0UL5M(3>F0
M.F9!B)O@.]1!*7V!'AA*N+C=LK?2.(^][A[ ].;A]M/]6ZI,'5(VJLKH/-G% M[%AKVUC^Q[&8+%BJ"S6'V'I7)LO125@-PQQ&C7#7[J6@UE6A8D-8T6.M/*#,
M7KS0H35I;V,_E/0F9N2@W)M4S(KY].P::&?%R#8M<$"Z'#0X$(0)0ZO%#<& M3U,!SU_?AT08M2!'" _&PO=V]R:W-H965T-3E1ILO-
@=P[+Z0RE[U#HT&K)14%*"NT8@:RJ]ZK^.)F0NO]@G\$;&SG/R-+EEI_H<&[M]*HW)$ @(7&D@>-C#0N0DA0AC*^USEZ()0EV_S?:WWK;T98EM[#0\K-(77[5
MF_=8"AFOI+O5FS^@MF=*^A(MK?]EF[!V/.RQI+).%[4P(BB$"D]^7_NA(S!_ M2F!4"XP\[K"11_F:.WY]:?2&&5J-VNB/-]5+(SBA*'AWSN!;@7+N^D] D^SE MP*$NFADDM=Q-D!L](3=C[[5RN65O5
KIOOP ,;1 1@V0F]%!A:\AZ;-Q'+'1 M<#0YH& _<&C;V^L9/Z/N@'5CF-'LK%%>)X)+=.>X $\H]:F]0-WE<'=7&A2UY M E<]3'X+9@V]Z^?/XMGPY0&PDQ;LY)#V U$X+$=&LK,^"_(7[)5EG$FP%B!B
M+@>VT$?)U1;G: '36282L!&3?(F_7*682ZK*L#8J(]2*X3\AA1.TAENVP6JA MYQIRD4B:3'0IP-2R&KGW.!C<(Z?@ MDZJ266RTP@%'FYWUJ*3@R]H(
MQ@WL@*2,.S2@0*R)SP.68D+XHDX)"VWH@XMOUEQ6"#"K]RKYUB?.X\C([%38 M1%=!^]XR4!)-3,N\B@ M(H-A62$M]]GKD'FTT(I[5@1: :(5AJ0 Q1(]WA##?E9W(GLRZL^0'Z4DJD='
MK!&PWW$_XPCNR;Q_UBXU($-.8; R<8^:]@5]GRXTXE'D#/QGM124.6F'483@/?:'05DLND:]PVI_)B<3, M%EBUW!]BM4=K!{2)\Z# @)>D+,]LB=+Q=NZ5S!U/#?^.*.2P83'TQD=14?\ MKOK:Z'^S
MPMY='MHNC\2C^ M/ZF2<6%V/=BNWVK4;]ERVS1EH8L[^IQ!P0QS'F "NR7'SL'#PX?QEM/ TN MP>%T+TCC\W.:W%59/(NF&#B$1S\^[<=.9ES[MS<3PE[^/M/4.:
MV17R/(JGYS5+=J)&6B8CO%U8NEO4B6:@;F7)IT*A'K [,H_GT80V\:I"S/12 MBI4_"[LI\8!.%V HKYH@U:2 *4VM+Q8(]O&Z##]P4\,S C817I5=[OF2D@9[M>
[AW4/F&KK_N'&OO>9]Q17@UWHJ)^K'3Y=)M_5XK--QP&>WYR#*E MW:,FZ!UH6^&UH=ZE_]B=>-#Y2E& 6?E0,39<*<('BW:V_=SS*GSEV"T/WXK> M<[,2BBXB&8H.^V?37HA),W"Z]-
\\EMHY7?B_.7"L,5] [S.--^=Z0!NT"\&N M_P-02P,$% @ RX-&6O%9;.#Q"0 >38 !D !X;"]W;W)K&UL[5MM2N*+^HJ905NI]E
MN3H=3:MJ_F8\5O%4SH0Z+N8RAS>3HIR)"A[+F[&:EU(DIM,L&U/7Y>.92//1 MV8EI^UB>G12+*DMS^;%$:C&;B?+A0F;%W>F(C)8-G]*;::4;QF>IC<$_T[EG>K<(SV3ZZ+XHA\^)*S-
WF,NU4/*RR/Z3)M7T M=!2.4"(G8I%5GXJ[?\AF/K[F%Q>9,O_174/KCE"\4%4Q:SJ#!+,TKZ_BOEF' MT3K0I@,UC]N)?J0Q\5, M(BYR.,45NJJ@I71
MJZ9L\ZW9>79VVLS>J+F(Y>D(%E3)\E:.SG[^B7#WEPW">BMAO4WEM MFL@\46@.@ZDIO$'%!+URC]W02 1WA*,T1R - _)52FF:5WJ-9K9M2ZR8"S9*S M:^"QU"Y#!C<,
T*IN308DST(O]\:/(DU>@S8LGS_)"EQK9UI]6]DVAMF==E_.C;JUO,0\ MK3KS>B?*/,UO6OK:%&M+;(VMT"TN1 9@"+Q%A?ZY $5@;F,3Q \Q!7M:TK]"
M!/LA[3S#%3,6]"@8]3'UNFU.$&)&^%&GB6*7ASCT7?O'!"SRL;C[7AG#W'6W MO:YW->ZM>]J#RT.I&H&%H]'CQT9/E-&35*D%: / ,Y+WLHQ39;"LF&L55<@/ MVA5L=P#PB<+&+!\="JL?
KA<;=B>,Z-IQ0:&J,HVUK=7OQ)TH 5S]X4H2RQV, MSCV^?G3SWCL"Y>Q!]U/7U"' +]PPVQ6!,<37.L9+S&[#5AL/" NM[[<;&W$Q M\?C.DC7DMF6&8$/.YEGQ)ZH?C%?E#%X-HGF8':(^0-
N[>)3V.Q@9REJZG>; M1MMU_FOM*'RV90"++N!.(NZH1!.U*-.E'G.?1]' 6LCSH>P23P.VT. M=[$;!GW4(2S$_%"H,YB;!^:V'H4>D7T]--IJ68#8/F?# 5;N=JF@*_?V1M<. M?@]-?GV+$T66';)3'0AQ;0
;L V(/R!\-A(/]L\#CS?$S#V[ORQ(!D-U>@]/ M+DP.\Q7B!SAZ')L%/90$FPFYUZ.@(<<\ZE(YH:\!\5%L!@&;%PVMYUN.?BO9 MS(L9LOUZV]B@/%MK[)>_ ^'4<^/1HV[....6NGU*XZ>(JPD^HXQ(?
EWN!{(:F MU&C]R.N\KC<,I-M-;;VMX^& ;\HQ]/O@L#F-[VW):33!LSUIA*-P&/ULIGY2 M1C-4W'98<"T;%/OQ55-[+^NL"7F^E],\-N8TS.0TS.]F)SJGZ?KFP //[/;] M.:,!*'L7L70EQ>U74L 2HP!#]Y?):4
$CV\/N!JR;R>GT9&>/Y2[:;;F,RRR M9"(.V6"= ^(04DZZ 3YZA-Z> H.;(-I+:\>A(7## .FYP8[S(3AT+/;_<:4 M9BC8+BG-KE?W0\]:WX]V2V@,X>$3&HH]\O2$H>G^L@F-]_2MZ_+8E-#4X1D9 MA&?
=P"O@']:/RCZ4@]WV@CB',\PY>1R>,;U_ [%V/,'2IU)ZMXMF M,@'.QV9FHK,(U\L]*F7=H-V]B*?M]'>;O8;7^OU)D,+!ZN2.QS^:X M;\LQG[/F?.[=/FV?
*\>O9F^63^^;#=\9DGYKJW39=KE4EEV9O&V58;4Z'3W; MUOU#1X'..SK9R[#TGH(J# NXV"@KO*K$?<<(?7! _?*L+I_1HUY34['=JE\8 M74MM2GJ,PVG4>7.&V_
N]=FS4NDDC47M@2U>E8<6]^%02!&II1#J0)P4$%AO MED.U8X#F%8MJT(-B8@EC.!]",B12Q& _VJ-AG 8?>A2,./6*>ERMG^$ M/@,GI_$U1^-8R; 9"M < 0DL=^
MM0+4W65]% \H.G^IZ]7VGWS@,$#PV#OUT-X#02&F+@])0DYI+ #!&3?%0*: M4S6+^>J8B=J,7?_^B>P1!GHX\"VX@SUO6+_DF$3\,# (F;,U@F(XLAV0._K$ M='JEAV\A)MP*A3\B
MPA>%0K8."O79%W]^Y34**ZQU];!0\-R>& MR,\"-^"&Z; 03;'GLKWBP3X /B4F[']H*K# 6!>.87ORHD+SLM!' ?6AQ+*D MVJVDFNIEFM_H\N5\' M4A^6$L=M;[?N92\6 1 _ B!H ,N]D+>J
-#DON256CF%UO6YYZFL@)*JF:BA RW72|%0LE6R))).7.4[4$FENEDGNA[Z=>25GEK)>6=RW72]%HSBJXED0U94GEPR5P ML5\Y@=,S/K-
=H0W#6R]KNH,;T'_6UQ(I;T#)60F58J(B$K8KYTUP?AF;_7;# M7PSV:K0FQI.-$+>&^)"O'-\8!!PR;1 H?N[@+7!N@-",KQVF,QQI%,?K'OV] M]1U]V5
%;P7_PG)=K)R%0W+8TH;KSV+_&W3^) 8O$US97[)O]T:^0()&:5%V MRFA!R:KV2^^[.(P4%L\IA)U":.UN#[)67E%-UTLI]D2:W8AF%M95JXW&L<\J6F6, M59PZE]-
&)KM0:495!):]8A;JB4;A/N03N,ZCU2$Y+T6"L7Y^3ER\6H1]= M_/3O[PV5&NVQ.3IP;]C])'F?5<>4A'*#^B8M3S+[K\E=\Q.=X+Q[&DDC"H*+ M-NP_+UR?\/]_N-
>>^0N)8G=QYN,BG+MQFHPDZ<*-K62.B^1LD'RH,E'BA6." M9=1D"SZ[&D//,E9C3F'**<@:R32#PT&NHM?'UT$X)D:2_I@[RKA-83P&.Z7F
MK(UC(7@.\K$KB_F(85T*'[DT7XP8QK4X'1A?[%\\Y+_2.Y!8L=J3%,%:IS0F MOG%N/IG?^?SO]N.E^9Z\5FC,!VBV7'5!EL=+);(FI3 M=92M-FB*EBPS,6^%3<7T(0*A&YPE(RH)YR-
J,3]$(G*#>?*\U^,P'W>^KWN# M.ZGOIB-W#.VG_H@\W"B))K3O'\+Q[<3_D?<\E<:'U.V_IN#G_R#BMK1C;FX$ MZK?] M9WWN08+GP7 P1."&1?L*QHM^]V$G;X9'
SR(PI(+44&4"N;'L IMK: MC=T]X$QPBZ^X1@O 8ADA1HB)?&9]]!;|'TN&MN;2F,;QQ\.GK5F]/?869B3 MK13ED[9F3Q6)9P$VU)S;V0"]3V?A0/?'?^V:!K"]P:3'"84)CJU7.Q$,W&&>
M>M..$8?M[3#VD&PO M=V]R:W-H965T3>-XV&W1PTXD[MFZGI1*X-9P)FBNAU65*UO00N-^=!$NP.;MFJ,/:@.YU4= 5S,']4,X6[;F,E
M9R4(S:0@"I;GP45R=MFW\D[@3P8;W5H3RV0AY9W=W.3G06P! 8?,6 L4_^[A M"CBWAA#&]]IFT+BTBNWUSOH7QQVY+*B&*\G_8KDISH-Q0')8TC4WMW+S*]1\
M!M9>)KEVOV3C97MQ0+*U-K*LE1%!R83_IP]U"%H*XT,*::V0.MS>D4/YF1HZ MG2BY(M6 MIO5EBZ]I2?2 I2'Y*H4I-+D6.>3[^EU$U4!+=] NTZ,&/T,6D5X2DC1.^T?L
M]1JJ/6>O=\#>;]*)D:2+TQ0D3'*R=Q0 UAB1K_$UYOKOVS.=LN9KF@&YP&V M@P9U#\'TXX=D&'\Z K;?@.T?L_ZNO!RW9&F3)([((9-GY/-:,;$BI@"BV0,I M?1[!YI%@%J!
<@&HR0:C([:(7.@5KB8HM62DJ#,K'T1CKE'/7@*9X"W0BK%,DR57)+.J!\-!\Y09YQ$_5.W?*:VI$R1 M>\K7M58ZB/HJKY6.HC%"Q0Q5X"8 WT;_>'!$*]9H]>#7*Q8I[[6C#CF--C
M)';,3X>>P^@T2H?_)XULW04)KC4MEA<,%L<,EF631IKB3=Q&8ZCWLAS M&0RCTS$6XUXIX,OE6>$D4?I8. V:/0@;9@IL:(.=S 2"Q%=%ME<&XU8NG/=A M$@V;DPTH(/
F.V)_)_&=#]M'S\,$[CWB=/L.ZVK-5MZ-"N(43(&5]K5+-8 M[I5DG-BZ /HT*%/^D\JY.D4?\1/=7>A,7',"3X9D/\(5F!P"1PIT)S?&

]KJ@S2>B_+U]CIU^FE_2<)[Z2]%N'7Z(5OXO<#B;S(C \OSF6,ZQ:H(A7@.M<8)M=J+Z!! M96POF\;.,&UU'4JO12N$SZ*"/#@U'KB0XN0>!U S0.N)$;:?)JRR/.(5$2^
M(;UGD\L3(Q*W9%.PK&BBL ^2:5=M6OUT >VRP(=IE+A(88AN!%DRG6%+IG$R MV*\E!$47G.$'7.[.+YD\^099(:R(JJ3R+E&Q3Z[+BLLM0#T\9VN5%5A89,:I M(#]?SV>S7\
(:LPT[K2J%-'*RV+9=_J3]."TPR: P>X+\GAGIDA>'SI/O+6\) MJ>2@V4IXGC80?.LG[\WMG%@73+LAOK(Q$W:$P@ZH3T>U UHA4(S'.([#.(YW M4]V-8>PRF>VR;M%:.CY%
[;93MO3K+G=3I-U_[QEJ>QWQ-L7>.^$\Z[,?'THO M?5AV6Q__):B5N^)H3-1:&'\':$Z;6]2%OSP\BOLKV%>J5O@2)1R6J{J;! 0 MY:\U?F-DY:X2"VGP8N*6!=X$05D!?
+Z4^+%9;ZR#YFXY_0=02P,$% @ MRX-&6ER3+69) P *0D !D !X;"]W)K&UL MQ59=:=+TWCST-FW2>Y\56!M-07(E.4[^_5T!
MP3C^F,E3'VS0:L_16>U*RV2M]"]3(%IXJDIIIEYA[?(B"$Q68,7-F5JBI)FY MTA6W--2+P"PU\KP&567 PG 45%Q(;S:I;=Z-E$K6PJ)MQK,JJJX?K[$4JVG M7N2]&'Z(16&=(9A-
EGR!=VA_+F\UC8*.)1<52B.4!(WSJ?F]Q\OD0:E?;G"33[W0"<(2,^L8.#T>\0+TA&1C-\MI]I_6#>^<>A!MC)652V8 M%%1"-D_^U.Y##Y > K
6P&K=S4*URL_<\ME$JS5HYTUL[J4.M4:3."%=4NZL MIEE!.#O[9@O4<",S52$$,+A^HG0;/)T$EMB=3Y"U3)<-$SO -(*O2MK"P+7,
M,=_&!Z2JD\9>I%VRHX2?,3N#./*!A2PYPA=WH<8U7WR [Q]ET8!5\$5(+C/! M2[BSW"*5F#7[XFWHDOUT[K13G.Y,*&*#J#0Y07X+!)I=*NFV!-0<5(T1#6: +8(,0!-TI)PW
ME\]"+C9[Z7#77$LR&N RARMRTEBXD_R(+P*XII^!N2KI7C PJ"G5RA#]"3] MZ>?W%=>6MJ NZIW9._&T5?4[#E3#6#T0WM7QFR9=T;N_>_(_E1(D-!;;A'0N M{)A)3_N6Q(_9^8XEV;*<^XRQC:5;H,W\:W&1'R?ICC6-1KMA^&R<[,&/ MPXWO7]0[8% J8TZ!+FHA'VGINI+V925B^[/U%CM+XT.KX^^5L,]0(55C?DQ+ MLAOL(/+/H][&=]XLW/5-
?!;V?)O3*97\0 U7<^N.U.MSYX/$C9!![(_37F+3 M:,\JS!_WDS_LI>A>6;H"#YSPK6H9)O$KRR@:OZZHX7:-1:%_SJ*=O=AW-0:] M]E6A7M1-VM!-M)*VZ62=M?
L.^-2TOXU[\Q'QE>N%D 9*G!,T/!L//=!-8VX& M5BWK9OB@++76^K6@;QG4SH'FYXJNRW;@%NB^CF;_ U!+ P04 " #+@T9: M:=]=M8T# 8"@ &0 'AL+W=OND5QM170:#3 BNF?
5FCH)E/"6RV<[4ZM%K(Q)1=XIT W5<74PS66,\WA;&& M8+6HV0;OT7RL[Q2-@IXEXQ4*S:4 A?G2>Q5=78_M>K?@$\>M'GR#C60MY1<[M>)LMO=
*PA)38QD8_7W#&RQ+2T0ROG:<7N_2 H??>_;7+G:*9"_G.CY+>(NI#TDT M@CB,QV?XDCZ\Q/$E)_C^D08U& FON6 BY:R$>\,,4EN9)^-MZ<9/T]D=8YN-P!OUQJV T5I =KE8
BA,94B@Z\-4P85R!QRKE/*'M5E M HRF;(%@RS1$"T63G8])ZF_CCRUYOSI4VH/D.JK8A3R@^5.>[M[*0%$QLKQ#$=Y^I1:O8YL90#AVAW %#_8K6FV7T/4_#$IVB*FO"7X8G+<*9(

MK8#UP_>,6%4N*_ZPP!1<*C>"_^O<&0I>T+&^1H$Y-YIF2U<"4O*8R&;L(O9C M.F3*TIV7)/!B,C!DC:+"_48.CEOB("6/9;9"YH="HJF?_+&2Y+C\]P7I^,N> MZIE319<-
+KQF;P(O+#0WWC@;RND_Z_))&[Y"@=D3_[M.7^CG\W%[>^7=[!OH&#[WI-D5L#ILB_(>--U!N:/CO@O]%WO#4UOV9+_ M\FD[ZYS?R7$9IW]4QN.L/G4K!
(/;ND*U<6\2305OA&DO[M[:/WM>M;?]]^7M MF^D=4QLN-)28$S3T9Q,/5/L.:0=&UN[N7TM#+PGW6=#3#95=0/.YI%NC&U@' M_6-P]1]02P,$% @ RX-&6ID X]3-!0 *A !D !X;"]W;W)K&ULQ5A9;]LX$/XKA%MT$X"))>I.DP!)NL7FH6VVWN.9 MEFF;J$2Z)!7'_?4[I [3B>WTH<"^6#QF/LX]I"_74GW32\8,>]HKH:]&2V-6 M%^.Q+I>LIOI1W;&J MLD
@QO<.D.NDRI9G>R^I?/S/)JE(_0C,UI4YFOL(68&*#[D7K8+#4Y=@ L-T>EQW(M;0M"#H"DZ),49JG1[V+&9KO\8Q!HD(KT4MV2HX ?6'F.HA C$I#X"WXT:!DY MO.@
WF=IF$9&HH]<4%%R6J&)H899U?4^?5NX>#^<390+O:(ENQI!)FBF'MGH M^MV;, W>'Q$V'H2-CZ'_K$N.@UB-41B=HSUH%^BO)4-WLEY1L?E-0S@)R#]' MQ1YIU5!K+-WQ0?
HKX!(+! ,'(4KF$F&&(*NVVUR4LH8=!D0,E4P9* FH7%*U M:&U?2@UP8+1@ F JMTAG$.9<&,POB[R!![@QJCF<9HI> (MQJ)5M4%4:PEN-"#$FILE,J 0!WU*=*MZ9E<"R
II="RXC-'KYNIYC-. M%;=2:+0&(>R7EM\;KGE7*TK9"*>68I5C P6X> 2+2+7!B-82COCAS&E/])C/ M>@XN#!4+/JV8%9>95F<)HJJ]+VFY\X]#PH\" :D%>OFO6"#"L7J*?
#9*G5TT98P^Q/M M6?D,7=>EPZ^SPXNXZ3?>(A*&.$E"&(5%AM,L\;B,,,5!GMI10'!$DE=CK>?- M8QQ&R3#-$AP'^3 -TPS0LNT\SC$)8O3%I4$7:N@D/'VA2(CSN-BK9DA>J@U"
M).0@];T %_<5K=\\28)X>^Q)G ?>+,1!EGKSHH#9G5]'1.\[W\)@UR"R%B89 MP4F1>WM)GN(X+^PH+G 21;_,Y:]]OSRKT:\'VY$@RC,0'QUH5I["^$
M$*GA3@Z$680#4H";M;"%JY0+P7^T?BCTRE7WKAEX,9,G?@3ED3>+LIU9 M"%W\ZR';/E#4&^ L]1>B*>!'[I1@5,""S=>0WO>8[06/ 1'(0>
M3D(2#Q,GQ9,@A!B(T5W7XRLX8]&JT;?[YP$%^13EZV@Q M7+5!,..;ZY)5LS/H2V?.63]]%!2^Z,A1A^@G1I;?NHL0!)^UJ[.!;ONNMI<7 MD(W5JTINP,Z&/NTX-L'$/_8D)+A(_
62X#SS(XK$.$["U^9;>&E:90-?=>Z M_97A0E&Z./9\2/+,@TL@LW8$B"&0BAV"-,ALU5/0Q@&QOZ;A[<7MR(5MQY=Q MZ.N!H?
^<[@A&_#ED:@%ZWP_WN2E84S#]W,/[NL9)ZD.]ZLLX*PY3[Y3[((4F MSG JM@<6(/S+!DAU;Y,VXF1*_<:A!LBO"W=< F/>;8L M >S/)93^;F(/&/X>N/X/4$L#!!0 (,N#1EJA+APN!@(
*X$ 9 M>&PO=V]R:W-H965T*9'VKT$U&1->P 6\#OS<:X*!HI%9>@+-># M&-CG]&:^6J<^/R3\X-#9LS'QE>RT?O'!MRJGL3<$ DKT!.9>1[@%(3S(V7@= MF'3]8*?-;=5QCJN?
*\4@L;GJ3K MQN^P[D@O2!(!D$2?/<;!9=W#%F1&=T1X[,=S0]" MJ4'MS''E?\H6C5OE3H?%MMU9>&U!(;D_NJ?-(G18OQB5 V+=(Y(+B"5YU IK M2^Y5!=7?
^LC9&3TE]T_K9!)X!>6,+.:?2!(GZ01O,=:X"+S%!=Z31K $-7G@ MBJF2,T&VR!#D17I[7/H^SK?)RC:LA)RZ/K!@CD"+CQ_FR_C+A-ET-)M.T?_O MATPC?+UDGL[(/ZP5>=(*9N_9C,[.D
1S")UB2:E;A?UQ&F?'9KSIS^"?]+Z3 M'YDY<&6)@+V3QK//5Y28OCOZ '433N1.HSO?85B["P6,3W#K>^TJ& *_P7A% M%;\!4$L#!!0 (,N#1EJ0OI PA (+\' 9 >&PO=V]R:W-H965T
M6TJ61:--I2&.J8&R?37)M M+!([LYT6_OUL)\T*A*IB?$E\YWN>QW>V[J(-%_F?)14F4-L4*RTH R2RH++#OND-<$LJ<.+*^A8@C7JN",E@().NR M).)Q"@7?3!S/V3JNZ2I7QH'CJ"(KN
%U6RV$MG#'DM$2F*2<(0'+B7/AC>>A MB;U /09W=XDZ/CH!!TARM#/G->2L$Q&6&EMPX#35F?:Z/BOZ 3HBC.52S1G M&60]^&0_?K@'CW7.7>+^-O&IOYV>'PH"^=_U.?OUG]
M23&"[A4$EB]XRROHN^R&+NRG,[UM+"N2PL31S4N"6(,3?_S@#=TO?95^3[+D M/SQ#STD+EG*2T#*W[F4)WWWT% ,+849">LX"$?G;H37 MNP5^&>6?A&PO=V]R:W-
H965TNJY,2ZBPG/ :F'Z2B<&4M &>RL_.5Z8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0 M*D/ ^G: .Z#4@+3&GY[I#%N:Q-/QD?[-UJYKV6,)=YS^)IDJ8^>3@S+(<4/5 MCK??
H:]G9G@II])>4=O%AI\=E#92\:I/U@858=T=O_3G<)>+<3@CXAL-[= M1M;R'BN<1(*W2)AH83,#6ZK-UG*$F9?R(1^2G2>2C;Z>#,0Z$G@C+ "K83 MK !]
[$I&KM([F#@W[6GKCA9W+S06Y^U:D]@=!?$;[@-LY\SVTQN"VN/KAQOW'N M13_WI#]4(K;!25*><-4URJ&U:'1KKK^\C>\Z](/6!2$240AUZG>9*%?I^@Z
M7S=1O+;=9L^5[EUV6.J?!0@3H)_GG*OCQ&PP_'Z2-U!+ P04 " #+@T9: M\;RQ$U 4 \4@ &0 'AL+W=OO4C+ M(E:)?)^)O-QN@^SA6L;IWLY8TL_K%[G^';104E M4EN9Y"I-
1"97+T^N1L^OYS2>!_R7DG>Y\[>@G2S3]!-]>1>]/!D20C*684$0 M GS._:R#'+Y.HU_4E&Q>7ER>2(BN0K* MN/B0WOV[-/N9$KPPC7/^7]R9L<,3$99YD6[-9&"P58G^#.X-
'1XSP3<3?,9; M+\!8?A\4P:L767HG,AH-:/0';Y5G SF5$%-NB@R_*LPK7ET'N.0)?^A/ M#L ;5Q:[,!SQ'GB\MP?Q4=X7XCI.PT_BOZ^6>9%!GOZG;[L:VJ0?&NG8\WP7
MA/+ER8XHGMW*DU=__M-H-OSN *Z3"M?)(>BOWB6W,B^@,T7>A]JC)XMWB0 = MY78I,Z(CJ%ELI'B=;G=!\B!V@8K$J3^%0,8QR4N1"DS#6)7@ST 4=^GY+L@* M
:MQ%V21",%CHIBXVZAP VW^N538?@,J9FZ#3Q+"!S"J4$$LTKM$9OE&[?#$ M(@>8,4R)C,02F)19N(%2DI2NRC@6!+AX(#PDX!?X0_RDXAPX_I3&*ZR5[=),
M"_F9\\,SH58BE%D!,P8$DA*+9_)6)B5 9_:)#+($@I^+I<3&9+4*J!/8=N8MDGC*!4=/Y0'Q?9G9O/Y= 'S]* M,ACBAP 28 >.FW(:28R#T<2P8H.EW(UL@HCHSN,-,D60K8D3?T\.0F7IAY
& M4:2(K=CGJ3_V764(0I9O,5H,%O]&E'96'L"<)]'4Q#_.#D@WQ$TF-5,T-KG$ MD.CPW#M@()((2/@3R%P8Q^&2@:.'_9?[SLM8Y@'F)(0 MRB*A[T""I#*Z#8CT&-
]!U2,+X.YG"Y>:"X5_9BGP%]M.DQ[,3WU_=D3\1^.^ M$5KR!N+=RF5JO1(9 M8XR_8.C_?Q7.92N@#DE,PM@N8JD ML8M8HL(KM+XR6P-1C=-(LTM_9!RLG8T!9@DK&Z MW9
!1LB/YM_E[M)LOZ-_(0@#5+!!["0LE,:Z;VJ^(6-NX&HX4CJ PW3+LA"G M><[(W4+LB= G&P*C)Q"7*&6);$A%ZLLW3*HOAU)R9ZC2[=_TFXI.X Q-R^2&#A\@X3O-NDS&/
W:U=Q@0IRKI8JT@&XY9, BI_YD M5)N!W'AMP+Q3Q0;H_YVV!Y7(R?;T\>DZB-F$W5#$/$0,DZKD'%Z,.K[.RX MDQ(+=NI\5NH-'@^"Z8]K>V&+MRJ'+Q+_A&
23Z>B.>Q*#WMNA4+[2"M^%.?I M^32UZ9AA4Z$,(:C$P2C"B5R>XSA%G'-76*4X6&D1(7&YE?P4YUPR@!QP96N5 M:$%(=_!(ZA<>4&9.+*8!I056:0D \57>[^C82=J8$I,Q-
4S)CC1E*)<551 2 MIN5ZX^QNYIEHF=WX4M:R?0?!%#E6P*$,7\-,L2+5L>3'37O/VMT[3\XM)HB? M$?;D;$"T@8,YTH=!6HJTK5I8';(<>5.+P!U6/YT*WYLM1L[WN3>]
M7(@;1.X@CB?6$N<:<%E[&$2H9/BUN3X;/>NN.Q]WGDV]V60B/K*-<===S";. M]]'8\\=C!OKAL?+ 9XBZ0,&;4$G,=V5FO&@P$7>B$* MXWDI!Y[@I.[AH1\:*'X ?
0D,0ORQWMXMNA]2^4-WVU.*)L ;HA3#A5U*L^/ ML)U(I0-@3<)O[0\Z:LCJ]PCU(B>HL'655:<[K5UG_C,C9&\0MB6YU!%;5F^[M$X-RW.JJV^74U:ZY-QFU1-2?+?2Y"@=S3?
&N_;\UDK6FT3^FR7E(4/4YM1_P M7A",9G=)^_RJ5]QMP&K%- N&[PMC18/^H)QL[&XVG/TY$WGD]8GO&,FFQ-$[1ROLB8WMNSECTM)+RO]0KFXCX^@3OO6"7EV_T>D3VK?
K:_$X MI=$J\,\6.W.',Z:B6M MTC32:7H$)J&;7FHA9W+H)JFW@A<3MT%<2DJQJYS)0K\3ESD_G;B^KJ!\/92% MBOBD1="?OC4BHVRNM@9N+M$!J850Y[3\P;#:DPF"=
2DHZIZ:W:W'B?PVFF% MQQR/*>_TE#2$S=4^D.W2$?]_E !AO10+.B44Z;\D[>ZP+>%[:%9'"9N BB$- M83]0OMJ32+6:QU:1*41E&8C &H=A+8Q:A)?
E@^2:654);19M*/V(N=F#SK4W M"P*7EFMMK8*V910)TTIM@QWQ=[UN$SVJ-VX5M RK4:"HBVXLW5BQY(*I>'N7 M64E!5P?8@[3GG(]N :=@XXQ5S$PR=
LIB^(6>.8&G:+ML[UH=L> _JWA/SM'WB]]MG M;!_[^FP^]@;.CF4 MUN!.!L9OY)9&=#II(#ULYF/T !?#_Z_)Z-_]\U@2_*!T]LJO_?S,K.:[AJ5Z
M[#:^Z6+V\W,2K+U>H\.4AEI\H^4.)'W/QN-GSM?1T/G2-2UG?F.T[RVF[H1) M(UT\\X;C2^?[PIO,AD_'K>1^-K/Y^-NJN=S8.S/6N^;-9YTC>=3QL+.+[HZ M.O8?#73D^?
ZT8ZA;$C&>NF:Y*Q)-NS[Q+B]=&9@.72/?EHB6%_B]?AZN'_UA MAO\PP\VB*ZG-89USVP3^,,*/,<)GXVZHBYAS0^.X[0J*#H=/J'W/O1G!^;)BZ]@;+_KJ
MN]C*8M;C8L[\OZ-;0@#5+!![*

M1@8Y*ZHG?:S]<(R"7ROXEG>UD&7YB6HZ'DJQ(-)((YIYL:9:;23'"K,I=UKB M+$,]/?X,:)(B)_=TRD%]'+H:0TB(A-!=E MH961EB9.S4NI@" 4ZK2A/.Z)1QIEFM:+ 7-K0!41X0>@:8C";=FR6(!IE; MZ2>2"5.Q69D@)2!80YXANV^#VEUXGQE/!7I MZ?_NQ<.43UB!@J)4"*H^7A CV0TNW^QY93USK#3F.>13D#;7=R>OZRV[LULV MV=ZRE9 I$.2/':L/F[DCN7<+5[*W3^::J?>D'W:"?O##[IJ44@)NZLZ^;07/ M(>Z;,J?8)RJD-44OZ(2>1[Z*(GZE558R?:\3>1&Y%YKRHT //=^30=CQ_/,?
M]N.WHQ++),,2J&Q+A/Y9=_#Z=+:S]2G%@*],$]J:2MATU;"XJL*5HK#K26F M*B-SRA);55;UC14Q+[&;$UM @.3HQA*]:N,H;=UU4[_\=1@QU;@G%20\QADM
M9E4E*_#@U@*XKR&T&W]$0W@[JW?*R4NM;FJ\8H\OK\Y78,Y7VU73%L#7JO)W MNTL=5; MA8GQY\J-UJ^FL1Y1&["6=KI1_UEN3\MQBV_;EO,Z@>^U9%C49%CT
MGS(LI4R2!\K+9F2;Q9),E^B9I0VF9+.+/^G:*)ABQ<#J:LK5OOAOIW9$_+^< M[;-GCFWV;WX$:3U$V-B\MA[X
M9JR_.19&5G>P.>9Y(4SO!TXQ9:S+NK]CA<.ZHZY$8H&I>>3SZ#PT'}59X\$ M>\THK$]9@3B@UHW=ZW=Z9A$+5>V9F'(VL^>BS3BO6NN^0';VYCD5&N^Q M]C4#BGMA!'
^%7@WJS_, LU?$>-_ 5!+ P04 " #+@T9:OT.F_]H("- M,P &0 'AL+W=O@6V26:2[+;=.VWOSB:]_4Q B>GRX@).LO?7]PBP#4;&=F)OLS/[Q8"0 MCHZDDS@M3D?
3LIR]F4R*8*H2OWB=S50*;VZS//%+ M>,SO)L4L5WY8-4KB";5M.4G*!V=G51E'_*SDVQ>QE&J/N2HF">)GW^^4''V
M<#HBHT7!Q^AN6NJ"R=G)S+]35ZK\8_8AAZ?)4DH8)2HMHBQ%N;H]'9V3-Q=" MUZ\J_"]2#T7K'NF1W&39)_WP/CP=V5HA%:N@U!)\N-RK2Q7'6A"H\7CIR1RA4M_X\+C]F#
[^H9CR5@D$6%]4O M>FCJVB,4S(LR2YK&H$$2I?75?VSF89<&M&E *[WKCBHMW_JE?W:29P\HU[5! MFKZIAEJU!S\M,0G0?!/)G'
M?JE"]-]RJG)TF26P[%.]'O<*O4^#+%'(BK.B&,-3;1YZGJUK_R96Q?AD4H)^ MNI=)T.ÅR4>M"-^@BT6]96DX+]"X-5=AM/X%Q+0='%X.[H(,"WZK@-6($(VI3 M/B"/+2>+5?
+8!GF_9Z4J4#T^T_#JUMS<6KO7FV+F!^IT!!-9J/Q>CP*W#65I61>4TFQ=@3,7X#5HT?ZG7BRA[=:V"::K0U=0'._B M4.7%OZ9/V_\.+CL,(^VJX/';JM:NOZM@@(@$$."JS()/R\((?A2^
FM8/']4 M)<2*UK"ZP+*MCVIU5NMR7IG;2I8_B\K6N-[Y>1JE=ZOZ-6Y9OU:PM2B\SG2; M"S_VTP!D^R7ZSQP,@=DU0A]]V>2&.Z@=\GEYMZK]WP,QEE,41C=1Z$"4'SR
MG%H$Y+D#HUU6J!SQE4Y:PFJU8:GK&*T>]?UV9R,V)ESNK%E3W33-9894,HNS MSTHU+V;S/)B":F@&;H>8Z$E;33Z%Q79VUJ*N_6ZHMUW'O]&/W&=[!HAH \Z5
MFI4JN0&W[*".ZZQZJE'':SV[0F#/85W4X0031[3*+&ECVW6ZJ$.8B^6A4*U:05/)]T;7%G[W77YSB>5YAA4RUSH0 MXIH UF$#B-^K^&PD[JT?
AXC7Q\P]FQ\7))V^.3U%1ALF@=$U*$F6*.E@;STW MN9;E" ^):;@8)&_?ZWO/2KR^%S7QC,5NN7Y[-L,IC M)&^S%^TQ;0]R>3PM;S"]C"7I%5F20GDA8\
[U3PH%.".!\DKA(T!QK>]_G+Y M \1T[DZ[A?L$XXE6PUI>~L0*=P6U;&(@.D>B+U *H ;:>YY4]3E_41ZM:BK M:&MQ[,@ACJ'?.X?E-(OX32ZPK,CJ8<]MY_]#-=^$J/I&^ZJ6P@M X:]?
M6U M^7&#-2'/CW):QB"G816G8:+-3C2G:<=FAT-DMKOQG%$'C+V-6'HGQ>[NI(G M>@Z&YL?A-* "E]L3KJ;:R^$T.M,3?;V;8B.?89Z!B5ADP#M[E5V@G'0 /CH5 M^9X
"@%LP+465PYI89]AP/!L9X>1,.QRL]/4IJ^8KM0FEVO]C$)C1#>;H2F MJGAX0D,Q)T\G#$WSXQ(:_O2E:\L8(C1U>D9ZZ5D[\7(DQW1MVX=*\-M.$F=) MAJ4DZ^D9T^LW<-
XDEN=-8N?SIF!U#+3KN6&5LII.H89[/19*7D]S,)JD/GY4 M^OC10#6M#6=:?Z2Y\N/H_P<@.3\#J5BY]4]9KJ*[=.?6U:PJ"'[9JLWE/,]5 M&GS>6YGQ9Q[=_;FK]/ 1KG^D"Y
(KVU[PHZ_L.*T%^H>VF MO^F)40K!6Q]A^H\MPQ4 VMTM3;WE1,>=HF:7A& 8@KW=1V0P.XN+#3O!QOW>Q19QU\1[*++9PIG=>K8\&\RC MLQW5VZ'Z%T"0?
0/!HX,@:UG(:GZ_URF.(!T2!#8BVEEVBQ=]-2@(-BT-*$@< MS%Q#FD\ MU]$%#2/MJYK"?80ZTXA (:#&@-*8AN9TSZV6QJ,[K=D1 :8P, MQ#,%$E>?W3P+ 2&#= R R.QZ49..0R ; ,
ND"XN@P?S-UFW1"_EM$>ZWH5 M/7[+!;\P#';^<8,W0*"+B=TQ$E<"[>LA(/NJ$+ ZB3*XK\Z9J,G9]7^&R!YI M(,>.,,. .YKR_YR1A8!#8ICM@S'2I;^I1N]U208$)-:1_CQCG#7$>9
M9X*A[9AD QDWKA-$,,;WRP>M#EU_"3GA5BC\EA$>%0K9)BC4YT5R?4O2XGALS/ #<0AFE_\Y9B;K.]\L$N M #XE)P0)IMW-2>L3B43E=]6'(
6,'RRG_EIB6;K\UN2_L1B5;W^4.4W/[_3 M&PO=V]R:W-H965T M]F+Q+OC??\HGF9;(1]4!:#)4\T;-7VJ;1A>(M92S>P!/U+>R^1\@8K):NA44PT1,)Z
M[KP+KFYBL]]N^)7!5HW6Q&2R$N+!$!_+N>.;@(!#H8T%BJ]'> ^<&T,8QF\[MF\[@TBB.UWOK'VSNF,N**G@O^=6ZFKNY XI84T[KK^([4^PRR3^"PKA3B&T.;)2W5-
/%3(HMD68W M6C,+FZK5QN!88YJRU!*E#/7TXH[*AC4;1>Y!DF5%)9"SKW3%09W//(T.S#:O MV!F[Z8V%+QA+R2?1Z$J1NZ:$NQ=8ITIC M*9UV^A4=K07'HXF6B#:%,4?-
G!GU3Z,@9ZQ!7=$IW*=< D\%M'HDI[7H&JW. MK\B;5WGH1]<__/US1Z7&>"Q.!^Z2/4T _*(ZPA+J%>H;:)YD[M\&O^81G>#< M_;F21A0$UWW9?URY/N-E,/1USWQ-HMC-+WU
%=2@10O28NE9P5K$).0=%)IAD<')U%Y\?703@F1I*]FT?*N(4P MM%Q.C9BU=:P$+T$^3R7?1@R;4O@LI2P?,4QJ<3HPOMGO/91OZ2-(O+YZ3XK@ MQ:=3>1X>/'\)Z.8_8LPG)!!-
B'C:$(F M_G]V(D\DM?O2_'7XGX;OLYX?@?&TY__#^=^%\ZUI+TYF!-9KO';,+8-33_% M1&MN'65O&PQ%2U:8FO?"KF'Z4('0#2Z3$96$V8C*LT,E(C?(DI>S'I?Y>/+[M>V]()_7==)2.H?
W4']&!&R71A/;]0SF^#_R_*P1E7_(DL<(OMYN">T:.T,NA(: M)UJ[K/ 7 J39@/*UP,EL1Q@'PT_)X@]02P,$% @ RX-&6N4@QY5' P M$@D !D !X;"]W;W)K&ULQ591L@"$)
[9+3#:6D(GU:0\)MBQ]^H0D MB^E6R-\[ ]#DOBRXFCF9UIMSSU-)!B53IV(#'$]60I9,XU:N/;61P%)K5!8> M]?VQ5[*<._.IE=W(^514NL@YW$BBJK)D\N$"'"K&=.8'S*/B>KS-M!-
Y\NF%K M6(#^L;F1N/-:E#0O@:M<<")A-7/>!><7D=&W"C]SV*K.FIA(ED+\-IOK=.;X MAA 4D&B#P/!Q!Y=0% 8(:?QI,)W6I3'LKA_1/]C8,98E4W IBEJYJK.9$SLD
MA16K"OU=;#]!$_(X"6B4/:?;&O=4>B0I%):E(TQ,BAS7C_9??,>.@:Q?\" M-@;4\JX=69;OF6;SJ11;(HTVHIF%#=5:(]F8;@5#,KAERP+4<.II=&.4O:2!O*@AZO'(,?DLN,X4N>
(II+OV'M)K M.=)'CA?T*.![2$Y)&+B$^C0Z@A>V,8<6+SR]T5H4*2.KR^\VCKJMS9=X12VWZ!CZ?(%=EU8%$+$BF!]">=D(#EPK(Q$V M6WF=K0$TN>]+X;B7VW]$1H%EP1*CS?
A#SM=DH9D&[$MM[*Z8Y"A4A/&47**2 MA,RT[!T\%A63^%-D)0J\ !096$A1*310PW-R\BJF?OCVOS^_54QJ? 6V:/=.
M%_G]3E7O*6"-0KE$>U.G+SHT16W^PA()-4=*H#1I$M*JO"8#Z@91/.Q*(C>D M9WN2:$=RYE)*GR2M@R;SS\D%;AC%>](X&.^'X=))U&,_\9]T/^*0((-"*#4D M>"/G_ Y=VTKJRTI
^[/U$CF-PT/>X4^5ZP=2 E9C>HQ+M!_L('#/@LZ+;56I MOZ\;N=3OZ-8W+A?\#4Y6R;1[J=]YQ(.3T0&H3N).XF-@QXOU)UTDS_JI.A6 M:%8ITY58)LX]J==?"Y^97.=!0 @X !D M
!X;"]W;W)K&ULQ5=M<]LH$/XKC-KI.3.TEA#H M)4T\DZ1W<_G0-E?WD[CYC&=M,)7 !Y:6__A;)EG%CN_W0F?MBL["[[/(\NZ"+ M!VV^V)40#FCTVM;*7T!E+ANAK-
0*&;&XC*Z2\VQ]]3N%?Z1XL,$8^4QF6G_QPNW\ M,HI]0*(6E?,>./S=BQM1UJX1A/%UXS,:MO2&X7CK_8\N=\AEQJVXT?6_;C3%TC5__/'S3D$ M!D5\Q(!L#$@7=
[]1%^4[[OCDPN@'9+PV>/.#+M7.&H*3RH,R=096)=BYR50L MX8@=NE4]P/ZD1I_YK!;V[&+L8 >O-ZXVWJY[;^2(MPR]U\]M+/I=S<5\WWX,
MD0WAD6UXU^2DPW>B>H/2!",2$WK"7SJDFW;^TB/^/F@G+.KS.Y1>;TT/6_L" M.;=K7HG+""K "G,OHLFK%TD6OST1&QUBHZ>\3Z90ND-IG-[H\T]@A:ZA'J5:
(FF/[&9$#0/0,)PKG'J M3YCD!+.R"-98D6%:E'Y$2\S2])=!_J/_CVMA^@J5JM*-^#'93I"HR'&2$!CD MD 009K?BH\2"X(I8YP& MA'C9T92&$PDP-=FK@21/<4Q*@-DZW[PJO53R&T
-3^B8)KJ1Q72SD+*05>X#3*T&V)\RR< M2 NX95F10^'[FIPL",X3@(_C+#)V8D2" ! M#E!T(Z"Y TMJV&/9IU&MN%D&\0?UE!;9\R(_5LZ@G^7%OX5YZW8'UTUM!XTM/;'5,?
^IT]:5[Z^1-.', MZRW85$VK^&QL,3= MYGP.[TT) 7#_<+Z1+_22)F$>&.Z?L[W 2"A#I9:0M\>XZO"=P6DJ8;]'^"M M,V]=G^BU] MY8V O)?'Q;P:Y7KG^C#[/"!<]6_ZW?J_=?
1>Z@_J2RJQ0),XSEU]\J?:0??#-UP!1]IPG@%6%]H:/T;P6\P?/9-_@-02P,$% @ RX-& M6L379"P =H$!D !X;"]W;W)K&ULM9UK MQU6VN3/9<<693>U'++4E*HC6-
"T[JWQE5D352!8H__)/0UWWE/U*$\,?9-?0AF'P)V*S^S5 MI^4!G2G>E*5Y\9>\EON.!F2ZS@5;EH5E#99)MGF-OY=?Q$X!TSQ0P"P+F/L% M)@<*6&4!JVN$<5E@W+7 65G@K&N!\[+
>=<"%V6!B[T"UJ&O];(L<-DUPJ0L M,.E:P!B]_7*CSD6V/_:FT6U:2=`$[%C$-]>-UJ93GYJ MOKT[+5<-3Z[R53RE'PC?[5I" FSD3 "'7.1, \)\S>P MLP*FQH8O-^;U\&57+ MD# ;"7.0,!<)\Y
P?P,[W]&+<38:C?8TT]QK;X\06:D(!*L)X6PKA#.M$#PY MIR3O4I;+P:@*40>7P2"U9KR^;8IG^O/Z2Q/U-PL M)S1-Y%0P%G1&9FNNQD9B08D<*"6R4<X)^'2_X?K(B
$2%B)A$0A6D]3%5E(76DD%RU6<<-4!D*F<^LYI M3CA-"V$)5HAJEN0KEL#K%,$@M443\7A_M&LC8SI(F(N$>4B8CX0%2%B(A$4@ M6$U9DZVR)EIE?
6%"=BL9%43"/XCX.WF)TS554GM3E5C$XDUW;6K2!NBKIDEC M7&Z9C:FCC0SI(&NN8A83X2%B!A(1(6@6 U,1FC*HLUTLKI=SDWFF]R5^50 MKDTQ>DA?R4!I-
I3F0&EN2=OM:XU&3^N5>VD6EOPVT$5C@:IEK_T5*NCQ12A: MO?'NI& -;>.]G4[Y6@ZJTFTC;FV\6DCOQHNDVS!: Z6Y)4W3FCQH0/]XP :
M,"QI&N%%J(#U%FY6+=S4+UYQ)JB<)#Q.$YI-#YR[1M)LZ$T!TISH30/ M2O.AM !*"Z&T"$6K"ZQ*F!OZC+G'V.PU25,2"\&3I[6(GU*J5K'J*UAD0=,9
M>6:"88_W%"RL%FCR'TAPHS2UIN\.CR\9* M@P>-Z7>*&4!CAE!:A*+5E5+ET0U](ET.X)9)GDNID$P.Y(S*)HG48I)WL34 M43[0!#N49D-I#I3F&LV\]WF+?) Q_4XQ VC,$$J+4+2Z?
*K5^N\4JV MX.NIV*3M=2M5T"0]E&9#:0Z4YD)I'I3F0VD!E!:6M)K55A3?T:?C]Q0'RD[A)/I6=QW]IS#<6Y<\UX=P6E^.T"P>:D(?2;"C-@=)<
M*,V#TGPH+8#20B@M0M'J2JRR_88^W8\PQ.A#]!8@DF9#:0Z4YD)I'I3F&TVO M16/P!TWS0VD1BE97597I-_2I_I;^[7[-N5+9;9Y3D9\07RW+N8R31S69^J7^ M#^H*@-
)L*,V!TEPHS8/2?"@M@-)"*"U"T>K75E8N E/O(I!*75$N?IR05:JN M=567P:IK!E9%E_BK2^OZX'VE":794)H#I;EFTU=@-%<\H#']3C$#:,P02HM0 MM+J4*D^#J?
<%9TO]2Q!NZ:\/V%M 4.=VSTKW!TH4$] M*,V'T@(H+832(A2MKHS*$F']+1&5&HY<#U=RE FPFMZ>&I)OC"@9@8HS8'2 M7"C-@])\"'V
TD(H+4+1ZOJIS!&FWASA,OX:\YDX#>G)OG4#=$5": Z6Y4)H'I?EFR^T1 MFDL*4!,%E!:A:'4Y528*4V^BV!G0Q4MU#[I6X4"-$U":#:4Y4)IK-G/[YKAM MF0UJB3!;;
=.#!O6[!0V@04,H+4+1ZK*I MW!&FWAW113;.7?#%OFT5"]3N *794)H#I;DE;;?=GC47TCUH4+];T :-(32 M(A2M?EOHU0%*A=#4RZWLUEQ(V"I$[WA1T_NK17LTQ"PCT/
/@^A^=@!M23= M(A;LPPXZA@V@84,H+4+1ZFJI/ N6WK/PN%)73-PEK%4/4.\!E&9#:0Z4YD)I M'I3F0VD!E!9":1&*5E=6Y66PCMP HK//5 _J+3.H=<#%GJN!;GI#A0(.Z4)H' MI?
E06@"EA5!:A*+5]5.9%RR]>6',Y&?Y ^QH)S$Q;5_K0J">AB@-!M*JZJ.P)EMZ>\$A3N6E^0CR:41ZGQ<6MM[-E MDB6Y4&FD%UI8N+.\N$(=>E,6?=5Z2PUJ:8#2'"C-A=
(*,V'T@(H+832(A2M M+MS*(&'I#1+%/2+(SJU9[@_?-DR/ZBTTJ!T"2G.@-!=*\Z T'TH+H+30:CXV MQ&S:GR)4T(V"ACM/.U]2*85[V;7EI'@L^>;1D-NMA--G=8.6J]OB4?=[V^^-
M*\=HV>X:5U[;=M^X"MJVA\95M'D:>U6=F^M5/*>?!*3+"R$DH M3^:+[0?!5L6SV9^8$&Q9O%W0>$:YVD'^_YG);KC\H *\,OZM./R;OP%02P,$ M% @ RX-&6FVCVV;-$8 ^"0! !D
!X;"]W;W)K&ULQ9WO;]LXFH#_%2.W..P"DXGUV^ZU!::12(K +(K)[AX.A_O@<=3$ M-XZ=M9UV!K@__N3$#4.)H[M^6+][NQVL[E_*9,0_9LV7]8L_#[9?Y=?E\K?M7^KK=V?
#;8V:>3/=;!&3]G^?F\MF/M^2 MVGK\XZY+?CRSU_IXO'+MU_FU\FZN5S._W-VO;E]=S8Z&UPWGR8/\\TO MRR^JV7VA:,N;+N?KQ_\.ONR.'9X-I@_KS?)N5[BMP=UL\?
3_R>^[$_&B0%&\ M4B#>%8@/+9#L"B2"%DAW!=)#"V2[MFA!?)=@;Q3($I?*5&*L"A3= MDK!4:[M J-#(XQW!<;= OEK%V[X]OUTMOPQ6V^-;WO8/CTGW M6+Y-D]EBVSZN-
JOV7V=MN5(OKYMI17OG+Y_O*:W_Y*/8 +MJS_WP)XJ^7 MX$/L)9;-],=!$OTPB=QZJC0I;_X57/?%A^^6KST%]*\W.T(_69]/YDV[\[NMYW$ZG-S]O[?_RW*A__ARE825I*PBH0)
M$B9)F")A-0G3$,QJ'>ESZTB]K<-N#-/E>K/^8;!H;T#;\6UR_;_M6-O>]6V< MS>,)G#^"M_>;G]\GV_;^^676>X.'9CT)JTB8Z)^**$JWO=?+DR')D,H1:S*@AF!6+N?/N9R']J6NQ,U[YZ3?
M; _:/*;.,67>R]FX[0(Z9[?J'Q7%10 M?W!>Y"/3:UAI.WI.VY$W;?^Z7)Q/MZF[YY;12PG-7A)6DK"*A D2)DF8(F$U M"=.C?KN^LR1+W5D^?[RL?]>U9_FL^.D+W'B@H-
*5":1&GJD"M0HR'U MGBM@)^$+Z1*%O*K-#G]5ZP>'=KXHK41I%4H3*$VB-(72:I2F*9K=4&+34.)3 MO;7=D:W.8IRGW?[:&S^X!9"T"J4)E"91FG)?;/F#Q^E _
MWC\J&O9N#DM_E8+3&'5K*$VB-(72:I2F*9J=QL;K17ZQM_=-=M1W0^=1EN;= M#'8=-NHE,"KG4)I :1*E*916HS1-T>P$-C(O\MN\0]]I1WUY=A[WY-FEZ[B MC8IN(I,JJT)I
J5)E*906HW2-$6S$]DHQ7 M_DH&)S8]"%&:1&GJH&M0HSS$U1;,3ULC$R&\3+Y>K^^5JLFD&_S?X]E]O^H,$ MOQ)$;2-
*JU":0&D2I2F45J,T3='L1F/<9.27D\>\$NP;I:1_XX:2916H33A M.!U1'&>=`T.A,94KYC#-NKW\(3735,WL61O&),9^D^CIO0.$CC](:.^-TDJ4 M5J$T@=
(D2E,HK49IFJ+9C<:8S]AO/H_HO7=DJU/HOA^Y](D*>(DBC=HG22I16H32! MTB1*4RBM1FF:HME-R3C7V.]K/Z1>FJJ7G8;&Z<9^I[N_"P^YK4?5+DHK45J%T@1*DRA-
H;0:I6F*9K<= MHW;CDZG=V#%9L!AW?YOFCQ_< E"WB](S2I,H33FN512GH]Z=/3J9E*+92[,9 M69SLD\7KQS2^FLR/O*WW!PH=$U!:B=(JE"90FD1I"J75*$U3-+OA&&&W*
M^.+D9+XXZ4O(_BJF_O#!#0#UQ2A-.$Y'U-ZK=N4 &E0Y@_;6@#ZL:IJJFIV* M1O$F?L5[7!A+?_C@!H#]7Y0F4)I$:R/%CPLH$H9I54H3: TB=(42JM1FJ9H=NLQ2CDYF5).^IKR
MO+LDW:4_?' #0(TR2A..TY&.1G'WQA\UQ:Y+$'>WU3BH8IJJF+WYD/&_Z:F6 M'?:#0SOLM+^>;9%WWG^6:,@*I0F4)E&:.N3DUFA(3='LM#9V-
@VVL\X=E\>5XZ"H6R_A(O4[/K3V"J75*$U3-#OEC#9-0Y8$WFTU M^L/@:C/9--NQ?#NRUXOI\JX9+%>#R^5=6XO;[8:^GYNOG_]W]?MF^\FO\V90 M+1[NFM7CMJ?
XTS=PR2N7"ZO=].ZVF\\V[P\VHYOV[K=?C['F=_C:GLRYI@[G.LRZ?3CJ7%%:A=($2I,H33DN53+L+?_C@Q$:U*4H3*$VB-(72:I2F*9K= (PV38.UJ3/;Q[W; M8D7RWO?
XF4,K1W'4G<[E/*RW MLY:_,L$)C,[(16D2I2F45J,T3='L!#:J.O,;Q6]_C,@<&Z+V-R1R'.78D,A? MR>#$1F?@HC2)TM1!UZ!&8VJ*9B>L,:>9WYPZ7X^&D5I)4JK4)I M:1*E*916HS1-
T>R69!1NYE>X1[P:]9.#6PJJ=U%:A=+$CF9IP6C<&0TE&E-E M?35ZWMWGPG%,OUZ:JI>=K\;&9GX;&]KS!T@Q?^3@?$:]+DJK4)I :1*E*916 MHS1-T>R69)1RYE?
*Q_3_:USH^ZR>)?^\,$- +7"$V@-(G2E.-2)=UEY< MI*9H=EX;Y9OY9:]SA#CEMD?^^@2/&ZA+1FD52A,H3:(TA=)JE*8IFMV^C'/. M_,[YF'$#G=.+TDJ45]$TD?5E?7_;(S2D0FGU(5]
4R'MO#8J.?.K9&;<"'G> M(!WF)4HK45J%T@1*DRA-H;0:I6F*9K6OW%CN/,1R!XT;>7^^:G\O)'_XT : MTBJ4)E"1:&G*<:GZ>R&A(35%L_/:V-_<;W^=XT9W=PUG5J/+/J.T$J55*$V@
M-(G2%$JK49JF:'8[,9(Y/Y5D]H.#&TI?EW:6WBO1@!5*$RA-[F@O7<1HW%'' M:O\9JQV']#AZST%V7AD7G!\YB]9?/CA]4*.+TBJ4)E":1&D*I=4H3>>.V;91 M%
(U>272C:G._JMTSV]9?.CC-41V+TBJ4)G*\]DRZJZ;D?6?,_6&>0JM5HS1- MT>S4-=8V/J4<6C\X.*M1*9OWIWIVQL4*#2A0FD1I"J75*$U[+Y2=TD?YM\P M(Q?=%]=?
@>#41W4L2JM0FD!I$J4IE%:C-$W1[9EO&U^LDFZN6-?W-ZR;?[P MP0T %:LH33A.1SSN+7V/QE2N2]#[G<%!%=-4Q>P\-'XS_X9UC-'=Y9*7J^;S?
FJF4\V[:/M]M3GMMP]*3]@XJL.X/; M<5!:)!T-7#F.BJ*TQ4,NZQ\+O'7_ZU2]3LJ M55&1B])*E%:A-('2)$I3**U&:;KHS_D]3Y+Q*XN0%\;0%GY#>\1C]BHTI$!I$J6IHF]>NQ>@1B-
J1\27%\!.02-GBST+'A_ZSCU MQ_I#!G?/](Y%:15*$RA-HC2%TFJ4IBF:W82,CBU.IF,+A^OKLJZ0]<[?11(TO1K-0>&2,[*IYBZDKC27WI[*C]*-.B\S
M2W^-0M,3I0F4)E&:0FDU2M,4SE292F4%]-TC1%L]NOLI/NFR?S[OKI_FCA-Y&H;0*I0F4 M)E&:0FDU2M,4SG2/[PP0T -;DH38SZN_GV9J:C$97C D3#M*MG M79>I4R]-UH T\
(Q69;ST^&23=HC%52JL/^@::BFEGMC'%8[\I/O 'IGY*]H MUD\XXVB<)^YIGV.CG\=^_7S0\SE][?P5"FXZJ.!&:15*$RA-HC2%TFJ4IBF: MW<","Q^?;%-
?/SFXI:!^&Z55*$WL:/N>B5!OC=+J@[Z!IF(^9?;%^K9I-N5D M,WG_MGWHN&DNVWO6=9NQ#XL6OWU%]?SI8-5\:C,_>O-3?';1^_Q#]$9&CL]5 M]*9^_/S"X-^_O9_<-
#^WCTFSQ7HP;SZUH88_;I>56OSN+S@:_ M+C>;Y=WC'V^;R76SVA[0_ONG93M [?ZR#?!EN?KM\>N_W]02P,$% @ MRX-&6LAQ +79 @ 6@H !D !X;"]W;W)K&UL
MK59K;]HP%/TK5E9-K=21%Z240:1"0-NT3A5=M\\F7(A5QV:V@7:_?K83,J I MHBI?$MNYYYS[<.S;77/Q*#, A9YRRF3/R91:=%Q7IAGD6#;X IC^,N,BQTI/
MQ=R5"P%X:D$Y=0//B]P<$^;$7;MV)^(N7RI*&-P)))=YCL5S'RA?]QS?V2R, MR3Q39L&-NPL\AWM0#XL[H6=NQ3(E.3!).$,"9CWGQN^,6L;>&OPBL)9;8V0B MF7#^:"9?
ISW',PX!A509!JQ?*Q@ I89(N_&GY'0J20/<'F_81S9V')Y"=8>Y(05;_Q4 MYF$+H'GJ 4$)"/8!S5< 80D(CU5HEH#FL0JM$M Z%A"5@,CFODB6S72"%8Z[M@J^1,-
::S0QLN2Q:)YQPL['NE=!?B<:I> PK8$M 8TCYG!%;[4_H!Q8"FY*C M\P04)E1>Z-6'^P2=GUV@,T08NB64:F/9=95VPY"Y:2G9+R2#5R1#=,N9RB0: MLBE,:_#)87QT ._J*LSS0?
YS0MX ^G52&!O9< G&) MOA,\(92HYTOTDRM,ZVI=,+6VW7*#\6VMXC.+PE(JC6L6@ M4MS)>:O*>>N].=_[V_[6'J?]0B;:O&OZN3?+2QK]N7.\EM<:H
MW=A3&QT,^ZT;V=VZ^W1ZYK9+D2CE2Z:*8ZM:K1JA&WO_[ZWW_<[KUE/_ZP MZ'/^TQ=+URT6<\(DHC#34E[C2@@4 'DA 9 >&PO=V]R M-W-H965T@6_\=)+([6!O5N=
M*E7M]?8S#4Z"%G .G*;]]V<(A6 MK]\5LRK^^Y,U!=4#7/"TK/\%NP9K3\]B6PJ>-60Y@BS)]W^CUV8B#@A2 M1T]
#0&I!'*$@!L"_N@=2$,@'[T#;0AUZ=:^]GKB@DA$LVG!=Z"HT%*M.JAG MOV;+^4KRRBB/HI"?)I(G9@_LA>5;!A[8@J_RI&[>;R!(RFBU*M@JJB_P)7C' M?
0Z8B)*T_")13X\!^/SI"_@$DAS\O>;;,LKCIDAW[4QG%HOAW.F@;F(M^EX?%@QAU'.(Y_=AH09&?(IQ"^O52MI:R6BM3_)_ (O!HX@$TQIYE%XMZE?E M)EJPZXEKT];JC-
8:WH4W%X"]+M)MG.0K MT/CO+WD<\TQ7_*C>J08T*1:8% L-B?6:XK9-<<\SH#OP@ESN?*3X;XAR$,7J M032A7[:6#0Q9CH[>>UE7H?6>Y&[#;*/]5N)L4"DV*A(;%>$_RV"?YY
M=O.'O9=+E+*.S34HVW$5'P5#%'*AYRINTZ P1([>;-#NMIKV:*4W]S?SP]7N M#YEL!"O ?)WDD7;;.*IWJOV,J@5&U4)3:OW.'(0 >)X'&W[/7KX-;<6$>AA1 MEL9
\,N5'>,H0[F'"ZT_6I15RT:K?;GOAOEG^P[DVJ!4;70E%J_$UVT@&=F MBX;?6XJ(2XGJ.QV,4%_UW1!&?-LEJN]T,)\<';*%7;B X^GB@96BRM+?>9'J M8N[M.-]DWQG-%T;50E-
J_4YT$0.>F3'@<+_ONTB-&!J49_M0=9TFB7CN(&'H M8-3#_A'7=1$#CF>,.<_+;18]I_$\X^V7-&(X51M="46K\/7:J 9\8*.-SD M(VR[D*JNT^ @A*H[PV..) ZMFH\#0Y3QSWR+
5VZ0*.QXMO>2F*;<9RH7>> MT7!A5"TPJA::4NOWH0L8\,R$ 8<;?FQ[CJ<:3Y,+? ^I&4,#HZ[F6U8#(XY' M]:Y#7 *^1BJ@8* M'8Q I&[L-#!*I.
<4RVE@A,KOV".6ZP(%&@\4]P6/MPL!HCP&H_8SFBN,J@5& MU4)3:OV&=+D"G9DKD"8P>)Z/U:KYG+K)T^$P]0]P_8J[M;(%^DBWX6Y2-U TE6N+-AHOC*H%1M5"4VKJ9G3Q
IT9+QK^X>LK&1S4[UL- MRJ50?8*L04$,B:C@X_[]B>';^D7V M,Q>"9_7AFD4Q*RJ _'S)N7@_J6[0_MIBJA]02P,$% @ RX-&6E7XN U M @ +P4 !D !X;"]W;W)KUL51M;]HP$/XK
MIZR:6HGB$%Y:L1"I@+1UTAB"=?MLDH-8=>S,=J#]][.=-&(2H'W8%^([W_/< M/<>=XX-4+SI'-/!:<*$G06Y,.29$ISD65'=EB<+>;*$JJ+&FVA%=*J29!Q6<
M1&$X(@5E(DAB[UNJ)):5X4S@4H&NBH*]MRER>9@$O>#=L6*[W#@'2>*2[G"- MYKE<*FN1EB5C!0K-I "%VTGPT!O/^B[>!_QD>-!'9W!*-E*^..,IFP2A*P@Y
MIL8Q4/O9XPPY=T2VC-|-9J"F=,#C\SO[H]=NM6RHQIGDOUAF\DEP'T"&6UIQ MLY*'+]CH&3J^5'+M?^%0QJX- T@K;631@&T%1/UE[XV?3@"] 9G %$#B/X5 MT&\ OG.DKLS+FE-
#DUC) R@7;=GS-HPL M_81OI+'[XH^Y?=%0N0![OY72O!MN:=HW,OD#4$L#!!0 (,N#1EHJI8'J M9@($T& 9 >&PO=V]R:W-H965T45XIG1T7%59Z*O:NK 7@PH[J MZ@:>-

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{4:(HI9&@N3T*1@=M=H7NI MB,Y<3S^LU5H NFVX4.0WMCMZ_ZZ/A@2DCP9Z9)S)5E0O49*4!*=ST!A0N4%M.D.$H9>:KR5FIMQ^"(QQD4UVCD7Z+ "T+T.I^A\[.+0V5< MG7:?>]#G'EC=T?_G/F2R%0N'QEQ-61[W5 MT2GU_!G,!2M!F#V(AMRU\;&--S=QDX^2U!]G[F8&_;8\"16P^(A6!L5[<&2 M8.2GP["HAT4?P9(A6'0 BP,_#89A<0^+/X*E0[#X !:E87(DLZ2')1_!QD.P MY 61F/_2&9I#TM/PEYJT-6Y4B"&D.D!TD_#47B$.>Z9XY/,&52$$0575)?8M4E_W73&0"-MJ<(D8J"$_XX-C&|:^%_G_^'W*IQY++YAL21,(@J5#O2N$YV1 M: MPVU%)98O>@BM=0FVSUF\6"+- SU>Y^[\<.?QEHM'F0,H]%10)B=6KE1Y;=LRR:'|HJ7P/3.BHL"*S1S MF2U+ 3BMC I]>XX3V@4FS(K'U=I*QO& @DUT6!Q6X*E&\GEFL]+]R1 M+%=FP8[^)^7 @]LUN4E!3).$,"5A-K!OW>nH.C$%UXA>!K3P8(Q/* M^>/9O(CG5B.\0@H),I 8/W9P PH-4C:CS\-J-5R&L/#\3/ZURIX' U!E[E=TU4>3G'"L=CP;=(F-,:S0RJ4"MK[1QAYE:62NA=HNU4 MO*SR RF:8HI9 FA9:<%@H4LTRS'+0"+"TP+L2,L0S<%7S.%^ I]XSS=$DK1 M^1P4)E1>H#-S]&?.UQ*S5(YMI5TT1';2N#.MW?%.N!.B6\Y4+M$7ED+ZTM[6 MH;7Q>< Q3;U>P#DD5VC@?D*>X_GH?CE'YV<7/;B#-F^#"M<_@3N%C#!F\O%0 M)ZXKUAHBK"#,WV,31T,0# =C>]-!{;?4?B_U;"T$L&2'E,!,4SFS4V<5>HP0' M{) M!%/>5K6}$YA8NG'}.!NPXH\?W-#YW*.'B>O?\.UZ&!ZEQO<&OA]UIV;44H_> M10^C8ST,0M_K)H]:\NB->HB.@W:CT2D]N,Z^<#F]S'.",\:E(HE$NMB@9:DC MQQ1-":<\VW76GE[$_U2(>U!JW;=KI,$XS%?@1Y[KG\B7MV?WWD4F#B)#HL2JIZ#]% ME/-SUQ5Y 1469VP.5.U,&:^P5%, ^<\6< YX8IZIT |^+W0H3ZF0=LS;D68?"/^^GVMX8_ ""P$AMCI)6,&;O7D^M)U_$T(2@AEQH!J[\E]*$L-9"B M\;#&=)0VG%S_(Q^9;0K+6,LH,_*.S*11==I.V@"4[PHY0U;?8*UGI;&RUDI MS*]:U;:),LX70K)[!:P85(36_AQ0Q8<-!5]ZP2%8.P2O=0C7#]$16C,SL@98 MXJS#V0IQ;:W0],#DQG@K-83J*HXD5[M$^' M#V(X#\#(7^"0J\(+*X]P^[?UY0Y>[9W%V5B"8;09.-P."%?Y\-F[8:++* MZ?X[%W.<0]=1#2: +|'}WN_S8^^C3>E_ MO2'3:ZPT/HV>7#@LG5(LV25 M=E"JE:5NKIWJN2JW^Y8.;7EH :.#;'^,I99$/EA2U5CN:G.9A:$8=*8;?&. M&M[10=X#X&2)]46 KJF0?*%)6X]AM!<_#()DA^2^4=KV0SO%5D.Q]5]*IH]. MT$AB"2:[;(JN^%4'C>2#9D@YF;[>?DH|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{*:AL-*PZ%5P[WO M&.&,%50V:3=LGK]GT[RPFFJK2D=D-55&E2JC5V86^H%"6*MM+X<8R5WG8Y-H M5A-M$ZY+LKCLIJTXTK:L57:CX02"1\NU%X1H\]48KHB]RF@N1 @C]&=@66I MH@NR5%O)?X#Y49.T5A-MI;7[ZP_0HW*C:=<*.W*CIN-)I>/)ZU-T80X P-4] M*\5FCTY(WA3"N=5(6R6()L{(JN)<UJ)>_KV26HUT59:N[\GAW.T(R]J,OK> MTRG1>WV67BJ51R)3I5N.8Z X@\8&Q95KORH]32W;N(JVU[91XT!(KT>;R(\U5:MU:/)W#P5/&M?Z,<4<\%_HBE?M8BXQ7Q%U5T]AJ2B]WE8=KWGYN%%6),O-=?^>275V,,4$5*IS/4#U+QF3NXHV M4#TQS7X"4$L#!!0 (,N#1EK?>_30?P0 /X7 9 >&PO=V]R:W-H M965T9L8XMHA2IDE2<OOQHV1%MFR%LPKNBZW;>0 /XR/R-6=;+K()#$"AIYPR M.78Y%C^N@?+MW/&=YPN?R293U05W,2OP!NY ?2ENA3YS6Y64 MY,DX0P)6,~=* |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|+8;[0Z2'50I3H 4_W*%8U17*O:E1X(M86:7&[FE 9LY>OJ03.R8,__Y)^Q[OW1)48"-&C2(-\+=+(85BR'(X@^U80*9M<:5'*+*%GM'&A>MN;B"P+;>>P YJ,*IJ,)KL&0BVES^]' M22J1/3^13FZN(]:4OB>/W@QI-J-QMZH6RZ_2M4_02XKF4! 6YEZ CO@2EUQ MO^Y;INN6 B,R?J$2V.F9E,85I;&-G+]KQQ&E.R:5H59HVD4+!+65M">P _Z3 MBO^D;TDG[4G0GTQ>: KV>B8G[-5NP.OW)0;CV0I:HC5+-!GC0??$@QL>]Y\P M5F.>KB|5$|E_O?E@-&M./:$=.GCVKM@V+Q\9CL6(]R9?Z^>I2^T0YZUN\&PO;%_%'MU-25:4SWL79_C MZM5^!<.&I5"/=.8/1EKGWQ/:(<_:[[=BKY[>GOO9RH*,5]GP\/B)+[4\P M;%!.6A'&-8"M1T.,#W4M@3#OJ0<8-J2_(_U =R'-=/7|"FX-BJX=Z>"VU:E M8Y'0T>KH*H'4%H3 %N2E@%;"P=BVPO6%=EB)VK80V+:<(5R)""|":X&/[=7X M3@([DJ,"G[J&@/&M1>X)[;:M9TAL)TY1^1!ZZ-0QT("[O=<7K5](3W;%QC/ M6M6V?3F^DB"U?2$GV9=J]DZ\IH!QK=F]AKDAM;DAL+FQ65/ 4-;$V_[GN&D@ MM?TAL/WY]2G84$TH1$K04!\:T]#:W$&//W1*CORH1J&MR;Y&MJU2.V@".R@ M/E7$ |>,EM8\VQ@^TDF\2/Y]K)0CO2"J3RTOCCGM-[MCN^-,ZVE>M 9@"&/.1=ZYF7&%">^KY,,%K0 M%=R N2VN%,[\CB5E.0C-I" *EC/O=' RG]AX%W4'H-9&8V*5W$OY8"<7Z*C@CEP;HDPC1\MI?]I06NCY_9SYUVU')/- J 5$3FB3F9.UH(;&4R5KHFPTLMF!'|\:A40T3]A1OC,)=AC@3GU.FR!WE M)9!+H+I4@$=D-#DB,;;N&;M4YV1);.'4PV:_ "18<355*4'7E+$^Z)H6O4IW4MN6/M$%36#F8<]J4!5X\>M7 M@W'POD_WGL@V7(@Z%R+'"FT]%,4J:GN4?/N$> ^3"0*Z]VF.]JEY3V0;FH>= MYN'.DW?-5+EFPDY)?SNP5O9]!C2L8|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| M31*865):.; -6/.??*A\ZLIU4.214.2Q0.1[17%[XKB'V,_5I0DJF!XD/0:!*$9B69=$F9_"]".C$(M*0[Z0FI"A:[3"]Z \D=!_SMB0 4X>.$[@IWG?;ES- &_RT-B7FV "[7=;?14 MRNF"R8R<)C5C4"7?M@):-[Q'R=_ZW@[*%@W'*%@_%ME^FG>,3'EA16|*A2C,D M6S0H6SP4VWYIW.?2N#]85UN'>^_Z*)ST=&-A@$G9Z&E09")S [<'BTUDKN^] M("_/ARI\]'CPW?K:TN[OT\.##!A08Z^_436AL.^[_0R88($7]%)@[S1!2F K MW7WB*%'MB^:TVJ(Z:;+L_T33OMFK"5ZF44L)2N MG+.1K!9K.E3-0-"U;L$\4'%HJ2\S("DP!9#WEY2*IX%RT/4)Y_\"4$L#!!0 M (,N#1EK&PO=V]R:W-H965T/"&0V*L:D:#61N4BYPJD#G6<;4XP6F MV\RT:.IX-'%,,C75@]+7 ":;I-:(P_E:>3KVD%:ZVG]PO MB]PIESNF<2+3/SPRR= Y=2#"&W@1P>/)#H +^)7(7).5'KB&(K/^;EA%,2FC M\+=$T8,K*4RBX8N(,%K7NY11G9;_E-:%WV@XSN,3:+>.P/=|?U,\S?(PUK> MV2 /WBYO-V33KC>I7?AUMOA=2$4*VA4-.0%28"<_S)FRE6:\PLS?*8N0-W,4]F=<_3U@AT:@*=1@)CRHY.!DS*A,=-"3S6!+N-!+}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|FN1"KCLUL M!]I_/]NA$84T6KM] 3N^Y]QSKJ_C#++N*[,"2BQ[M? U,KRRY*+'24[%RY5H SBVHI&[O>;;%;8L*<=&B?344ZY)6BA,%4(%F5)1:/MUT#Y=N3XSM.#&5D5RCQPT^$:KV .ZG8]%7KF-BPY*8%)PAD2L!PY5_[E.#'Q M-N 7@:W<&R/C9, YO9E\R4>.9P0!A4P9!JS_-C &2@V1EO%[Q^DT*0UP?_S$M_LEZUUX66,*8TSN2JV+D) [*88DKJF9\^QEV?B+#EW$J[2_:UK&#T$%9)14O M=V"MH"2L_LG*$31!BZ*7@E,%TLUWFZSI\$+F"60]%/KG*/"" M?@M]W W_6C$-J]K@KJY!4XB@*41@^<+.0K39J"]=IPY99=RC3,$.?H821 ; M<-+W[_S8^]AFZC^1/;,8-A;#+O;TYQJ$WD^V0M281<*T..)+5.F)WF]0K?YK MTMB2FI?"}DVD8, F'[F;?V''4A1\D41/U3'&_4=SO5#RNA "F-1XHIPOO""6* MM.J831KM:?'#R/!UZXX:A1'G8I_<):J371T)"?Q8S|^$!T=;|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}$KJX;LMAQ-%$"V-%95 M.S$15%PV;[;9G<.!1(QX_$,0[0>RYFXT\Y819EB9:K4&[:')S Y^J5Q,S%XG<'YV M<<*WVYY"U_MV3Y["L00;7>^XSE7,G:E9AL. 2L*@7F&0?O[4&41?3E#U6JK> M*?^?TN4;-+)<%>+Y+^CU;J@=[%+2Q&G@K5XP1#8:W";AZ@A OP7HGP3P)7JE M%E<=M;'APJRO4A:]= YE:2MM<|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||VL_YO'?XT'DQ&FNM1?#<)2';L1#0)5V2HBUS M*^$H!!P;(>F@D4+!L:/>GE_5.:I(.LR3FO?O;NI<.S=C>W>X3&V"%G5!/?\X M:-DF:-4HA/G(C%1* YA8N!45R!U8T]]_Z_G.'PTR>Y7,7J/,"]B -!)J^D(X MHT^,_|V@=C<63/Y!,?WAT'CE2+S&?.VK%41NE7)YR92K\]2P#8W_EO)YD$E M\Z!1YKM$ ^,?%4[2N!3JQ9'! V.@[P3TV+-QJK^IS7]2C._4;.V7Z._S=>H3M!&^I^TQ?R29(M+DBTO2;:Z$-G1@@^K M!1^V>Q>5*_N KZ1EL5](9P8);)B^ZI('@<>6NO5N9/_9];XDV6)XMM*,O+B^?J=RR1!$.&TSE7*

_Q32.+"T'1T2+-#[!/0N-Q.&]&>(<" M:0+P^48(_=HQ":I;V?0_4$L#!!0 (,N#1EJQ0TM7R H -!3 9 M>&PO=V]R:W-H965T_W@
M:_:T;MH/YO>WV_1)/(CF]^V72KZ;'UE6V484=5865B4>[V:?R,>$!VV!/>*_ MF7BI3UY;;56^E>7W]LVOJ[N9W5Z1R,6R:2E2^>]9+$2>MTSR.O[H2&?'F&W!
MT]>O[/&^\K(RW]):+,K\?JFJ6=_-_)FU$H_I+F^^EB__$%V%G)9O6>;U_J_U MTF'MF;7%_^J-KB),"D@%>!C M"SA= 6=L'=RN@#LV@M<5\/9B'5IW+TV8-
NGJ;56^6%6+EFSMB[V^^J)2D:QH MN^)#4\EO,UFNN7_8;;>YD'VK27,K^F.7-3^MM%A9GY;+W6:7IXU86?]NUJ*R M%N5&=O9UUrm?A?
5KL2PWPGJ7EW7]7KX[)$7;N6XDLJC+/%OM"R_6:?$D:BLK M7NG?A:))LUP6N[%^?PBM=[^\MWYIO__/NMS5,GA].V]DU=H+G"^[:GP^5(.^ M40UF_586S;]VHF(E5DCY6%_>U92?
RR8]MBMJ;=?/5$L8BN4'BY&_6=2F'+F> MA;[X@JC*XO:;Q_[FZ)Q=?_$ *=NSB;,_'W^#[G.9IL118 MISH4=/<%VYOV\STES'<=^W;^?"H6@K-=WU=Q(<21(/ \[@YQ$89S7806E3/8G;_
MU[\0U_X[EA@',N>T+HY/B4L=7VEMDV$CDV3QZ#HDAL(2'1E.\CI:>?H.:&_H>8ZZM9@;DHC(M'4O(,JQ@X I60$CNCY7KRN!
M*,_G3H!GA'ML,E?;9(='X7+P*,P&C\)O0CX*A1RE+?.TKK/';+E_+&+MZX+: MWE#'<97J+B", ^)0&2@,C*,X*B! D\)SSE)S35GFJ.H;(!NH$1W4"4^J<&UAH TT=
M6)@D"TV212;)X@#T-GECL=4'<@)AA YQ _&)W4\H[8ODEY?>5-FRG1,>ODM? MTNJ-N9X-,P8, Q88BKI<2>00@2EM$6%,W'/5#-57?&J*FF(;RG0R[R=ZF=)Z
M;:VRYVPEWIIQ$V2P0#WFJCJ@.#E-485 <8X3J&K@? Y7Y=!6<+(M#JH?J+0I<=.::JO]\%*.+0]VBOC1OD9GKQVE,N9CCJH/ K.).B<-,1CEA*GJ
M0%@0^$351EO;R=H88AMJT_L'1&\@8'>TIK3$9VN/7X7HOG@=8EI;.6E&Y=)& MF?HTZ]@& Q1*/554DS$C+*8=@+PT&3,QQ3;4OG= B-X"B30B:W,36@#, T\P M!
3NF@B&@P<88C@0=5*GK^ED7:[A7)#>NB!Z[T)CZA$X\Z>VG/NK@_<%04P) MS/X+$2)7(8\NC @8@#&8Z\Q08!JZ&$+]DX&T5L98\[T]@C@+CA<0)P@"M4%- M^@:A4;;
(*%L\OE$24X&',O<&"-$[(-W#:S^^0.4UZ0HLC+*%1MDBHVRQ4;;$ M%-NPD_1^"M$;*KJ[J0]O0(X/,A]%J6X)CN+J311#>> ..B9BRRRF
QN,O(!G%.OS9M+:>B]*OZI=UVC(V"A;8HIMJ&OO-U"]WP!T/9<[M%+,!"$%21QJYLM!87!9X,+F,QHV-LB6FV(9JJW8&U=L9?]*A[]@'MVU5= A1 M'8WS+-%YEEA?
T\FZ7,/*H+V50:=;&1=Z\Q2: 83!Y\H"P3D>S*80XW.PK(,X MES'X/-.WQ&3=KF%#T-Z&H'H;PH"IWD4X[>1 *@@AJDIG6:+S++&^ML.UN885
M07LK@NJMB(G:G,TKQ)7@2%IA:R60K,(67B!)!6$ *%Z M \20K:N/,G4"W;%I\BLT&C!" H)L-;H#Z&C_) IJI_-6*,6"H5+ M0QB*4JV1$.<"]$QUD@\ MZKJ2&LF#\2C[_69-
0%#!GU:KK!UTI[GU)KZW=' MQDW.\PW;KGW,.O MX56PDVT;EWD5$ ^:\#'H%8&L'8CNH$IUEB:T^RN11!N)# MP.5*1F-&6$P;["8Q&C,QQ3;4OO!R)0RD+E?",&"Y$@*" MRY7T-
9VLRS5/ MO+[D?-QAV_7S=*:?IW]MMPL7\B86:?:JZ3DFWZU,LH5&V2*C;+%1ML04V[*G M] X%&^50H/T#F;TS3H@'AA\8D#J4@V<5"O0<3]W#A0+M@+M@%#(R=#*"<;C? MMS4
R&; I%8-BN4 2&;0O55VUJ5S;%-A2BG][SBXQ)/E?67 M._G$ R0H]UQ?5=2H;V&*;:CHR8$69]91G-WUQJ%A@.YZPW%PUQN.@UL'WN # MN]T%9PLQS6L"MY;%?SB71P[.
7VP6="4':_U] M!QX+AN&0W A1''-5 R#"<$ANQ".O+SD?]]!V\Y S>B>MH?#5G+/KTKFL,Y M:\=/C\=/?MH?NJA_IE\C CR>4P^)H?#)7OZPUF7OZ754U;45BX>92C[@R<[
M874X/O+PIBFW^],+OY5-4V[V+]7W3!C@>XGG_?U!+ P04 M " #+@T9:Z[(4? & #))P &0 'AL+W=OFG:EK)"$!.<=9KT[C/!=-HL#(^OG]G2E\XK9^[\7"S3Z.]P)3>7$WN"5F+M[R+Y
M.7W\3>P=8@5?D$9Y^1<]IK'&! 6[7*;QWEB]01PFU7_:1^((P/% QN0O0'1 M#"YBWZ0XV, M=(UN_2?TVA72#R-%/D5?;EST^M4;]*J@O-VDNURJ8CZ?216 PHU9L'?VNG*6
M=#A+T<]C/5. /T2?/T;!FO82N"-XABM\B8A 3>)_E M<',*N?/_6O?.;KT1#'I(15KRF1U\UW[D)X& NK4RY*5A4?H>%@13FS-C/GLX M#E<;AQW'LD5>Q+D G\%M6^?S(#[.&:
[Y&IZ:!T_-TI!V>%]-A* Q$L+C ?46 MW0DUH@22_M,%%!"S+Y+%Y*1;_U 7$Y4"[G('L1D\?-/!N_0$DV)ID()IDW
M$EFCD]BAD]BYZ5@9LD;Z6+;1$"T=VSB5/I0Q1TO'@7S>:;Z&I_S@*>_U]$NB M)$84_JMJ]*]*6N15.1:]*1R[HH[B6Y$L,M"&0]PZ/:ROS09QR1SQR3S1B)K
M=)%UZ"+KW&2T6DG!#(MIF=@&8<*PEE]N&V5C0T]"B,KF!$Y!^^'?_8,KHCUF M$HY)YHY)YHU$UN@DY!)3F\27L7I+I'YJW*I5EZ@"C7:!1TS?4Q" M*$XT">("*--BIN8T@&*X:U[
1XL#W.OT;5HL"]*?#$XP'KCM ^=Z.-]@*35, M/0D@&'9,I@<$@!'+L3HB0NJ(D/Z(%$L3\:36Z;EXH]Q.@#$!E>"_U2V?C4=G<4=F\ ML=B:G50K=]POP?
L2D0.E12U=]44*A',,1FP]&0&\KFC,T-?3)< CAL4=O2 MTQ6@8U3/?@^ , <*ZBF>ME/$PJ3Q(+;85*^>M";,-LFG+YS8(F_JLXD$H1AGL M,JD%,ND7R'-I1=)6LE.B.DY/
P"';4(T8>Q"=-315;8'P+AE=ZA%4NMGV"2!0'8/; ^O"'W27NC>6"[W.BL2K5,)OP'2T6&S-KJI5/NG?Z3Y'.I+V
MGO246!9N55%@QI;^J3B0G28&+H$\>!FC:YLK=4S&::>AXA'TM:OQ,;ZK@J MHJ8N+UP Q;'3&J0 BCM=3M>*F?0KYK'D([#]2TS;:44$$L%8_V[B0G3,YOIN
M(P"CCM.QS41K24U/2.JA\I$"*I=S72Q!*+NUX0RAL*EOQGL@C'5)9EI+9CK2 MEG._@*30_B]CG.HQ:>.P2?6]>A>BLRC5M^$!&#&[1!6M137M%[5I)R,J2][H
M4P:'&ULK59M;],P$/XK M5I#0)HVF>5E!I8W4-P0?AJI-P ?$!S>Y-M8<.]A.6_X]9R<-[925"O:EL<_W M/.>[\]UUM)/J4>< ANP++O38RXTIA[ZOTQP*JGNR!($G:ZD*:G"K-KXN%=#,
M@0KNA_W^P"\H$UXRC MDF[@ >Y-@N(BMOE/XRF"GC];$>K*2\M%N/F5C MKV\O!!Q28QDH?K8P \XM$5[C9\IM28M\'A]8/_@?$=?5E3#3/)O+#/YV'OG
MD0S6M.+F7NX^0N//K>5+)=?NE^P:W;Y'TDH;631@O$'1!/VE^R8.1P#DZ0:$ M#2!\"HB? 40-(+K40MP XDLMW#8 Y[I?^^X'-Z>&)B,E=T19;62S"Q=]A\9X M,6'?R8-
1>,H09Y(%58*)C229+4.0AIPK(&_*9*D5M LG5' QE7%^C5-M3??@P M0>X8YYAL/?(-WL3R^6EC=5I;#9^Q&I$[*4RNR4)DD'7@Y^?Q@S-X'R/0AB$\
MA&$:GB6<0]HC47!#PGX8=]QG=CD\ZG+G_ZPO_MGZ23"B]DU$CB^Z_$U\GZRT M45C5/[Z7=/%W72VTPUU25,8>]C*-*@M>,GK5\&@_[XKTB])-GJ)LL4+D9WD
M0)&YS$!JC3R;"L(SQRE6EAK12S# L0]BGO,(:(&LE"Y+*HJP,=2U8K@D<$EEB M(EW=WA!:R$H8PLV:;Q+U@Y& ^/,]6A-.B%ITKS#J6H M-SA56OS%7!TQ_ZC+%:
V;KQH]!G[J1]W*VTGV,0U[B?R:3"D#] MH:_'Y1U5&R8TX;!&4_W>6VS'JAY!]<;(TO78E338L=TRQZD-RBK@^5I*<]A8 M ^W_@.0W4$L#!!0 (,N#1EH$IJ6W\P0 (<8 9
>&PO=V]R:W-H M965T+4]M 8EON/FP1;)KN M0]$'1J(M(I*HDAL]_?N2DJS8$]W8727+EEJ@YY,<Q*(9,B*4HHA+%U#\ M;-$,I:GT).+XNW:J-9P2>/B\]QZ6G1>==>84,S4CZ#
<<\F6B!!F*T@IN4?R6[M7U'=(5?ZBTC*RK]@5]L:&H@VC).L!HL(,IQ7O_![/1 '.%'#;!J@-4&."< M=@VPSP4X-< Y%^#6 /?)P@H[&8D M*S8B\:K MH_>QSD7/9'QZ5/?BL>]%=:(7-
OA"Z\'K8D2;8;7VP_IH MJ3J6RVZ5]XQ&MG'5F'7R@N<=ES+KI4?..ZH ML3H:,K<9,O>'AJQ"NQ\,62_'I1.E2ZD:V2$IPRZE2H"N58\ 7B. URO YSPB M&0(P34D$N5BS.0$%!!Q'N!#+
<[X&#$4;BCE&2H&\3E"WK?2:]09PJ3H?\RV& MY L5?*;5$D9E8ZME\1M9_+-DV8I]$7Q-D91%M&1B UYN@A*2QH@]%?%552;P M6Z+TTE\]2I=23IG6,"V&I
R[E&+*'$%+F:Z5F#*.I]8F:+0)>K7Y5AY14'P+ MMXB*(]=^6RH.:X+/B><-+?RC(,C<(UKP=B-2J@NDSFF&SBVV1*K-YY+Q5)Q M^J=GD5#]A)<*HF(T6_-U,21CJ&)T6@FPK(R"(R-
7K81IO)\8C?^KKM6>/RIL M_0%E4M4+5BV44AS[G#6KG_1B M:52ET9I72JGU,T@^N/3-$U^6--A-399/SZGZH:6UNS1_*N^)6 M^Z-YOS 5I:&\92^O6=_=5U?
T7R!=8U%&4[025,:=+S*(5K?>U0LG17GI^DHX M)UGYF" HUD5I(+ZO".'[%TG0_.]A^B]02P,$% @ RX-&6C=1V1P"!@ MKB< !D !X;"]W;W)K&ULM5K1FC K+-
+"!7DN.D7U\)B#$@*R:K^"'!^-YS MKW30E730;$_H#[;!F(.G-,G8=6_#^;*LEBXP2EB?;+%F?AE16B*N/A*UQ;; M4HRBW"E+'LP<*T4Q5EO/LOOW=+YC.QX$F?XE@*V2U-
$GV]P0O;7/=A[N7$7 MKS=)1!)Y_%N"]@XQI>/Q]0MZD#=> M-.8!,;P@R?"'>,D[1T M%AFD<5;\1T]E1QPY"!RU@UTZV$T'YX3#L'08-ASLX0D'IW1PSHTP*AU&YSJX
MI8.;]WW167E/>XBC^8R2/:#26]#)BYRNW%MT<)S))VO)J?@U%GY\OMP@BC]) M;B*P(*EX8!G**;_P,$=QPCZ"3^!^Z8&++#Q_!!V !)AT8B#-PG\6<78J;XOJO
M#=DQE$5L9G&1E<2VPC*#FR(#^T0&0_"-9'S#@)]%.%+X>WI_5^-OB=XX=(G] MTB4WMA;0PV$?#.$EL >VH\AG<;[!B
-6%\HRCB.+E\>FPOQK!27'U5/BA9,%MDKMD4AONZ)*LHP?<2]^;^_ M0'?PFXHFDV!> 3;*P62U?IQ/!O(SLQZ/R6F;315F@:'4:I0X!TJ<\RC9YU57
MC'OTB*F810!^PC2,&09;&HN!D^A.< M7,I9*2;%P"H-B[W'/QA19>W3ANLZC$R">?J.L,$SEM,P!*G>"81/,,HOE&T8(23;-JK7-921]0KWTL<2)NK2_!%YR)S5D"4!:!SU$:9S'C
M%$E%%?C%Z%#+9D;5&*-HGE$TWRA:8 JM3GLEKT"JOO*F2NBTMT1.JS@M5&9V MJ]!Y"C/;F;3KH<)LJ*B([Z%OP$K@@']%8R%6BK(>+E%R8I@8%2^,HGE&T7RC M:
($IM#JOE1X"]8+(FX:)^_HTOU 8*18,;:-Q>X"TC13#XSU4"EC)%%"O4]QA M,9?$H90 BU5V_E8&7-PM[T\$XPJ$4;1/*-HOE&TP!1:G>=*W(!Z=:/CBQ0]
M6F>6C6H@)5IC'=Z6"15V0Y5,:"]J.C.5Q 'U6_MW>)^BC]B9/;,Z1XG6>*4R M'9U^0>*K7*9]J7N=>@L3F,JY_@*X4BYLO7+1K*HJDO0074DRBN891?.-H@6F
MT.K45D*%K179;T(#0G;J-X:P:1:8RJW.2Z5\V'KE MXQW*]#YB9^Z,*B(EVG%-=*?]X;C)7=MLY/:GDR9WAG(KN+..CA.EF*[S@U], MK-)W&2^.?ASN'@Z7?B"- P .0T !D
!X;"]W;W)K&ULK5?1)AZ*32[UA!W/MV0#CR _,^^Y&MF=2E940$7!*.*P7ECOW9O5 M3.-KP)<"#N+H&6DG3XQ]U8.[;&$Y.B$H(95:@:BO/2RA++602N-;JVEU(37Q
M^/E%_>_:N_+R1 0L6?E?D&^-X+<$_ZT1IBVAMFXW MWNO")422>,[9 7&-5FKZH:Y^S5;U*JCNDT?)U:^%XLGXH\R!HSN:L@J0C2:K M9]6! B[1%7I4/9GM2D!LC9:LVC(*5
H].B']H$P2D*0HA29_?DS0Y.(27:"" MHD\]YVPE",S&WI^L"HS 5:T0PR S\]9YPR8[OQ=]]:/<4;2- MVPC7IF5NA'RSD-X-;)26I+"PU'8G@.. !BO_\PPVS2$&X[#OTA M=*S MR:
S&8R:_$<=!VA2,J%V5'6F%G2O'*LS6D[<2Y/C4;6?_8N=4RPYI]@J&*Y' MY)DK'7:5#G^FTO!M5\COJ *9L^RH[J:BAX-L_%X#+8>0*W?F]CHH,0AAI]=E M!B4%\LWFH\Y\-
&J^V<0IHU?]JLF)+.AFL*6_0Q2,]J-A1EX8]7:*Y1 5N3UO MB4$)A_T]9S5$3=U7_F:SSO]LU/\G)DF)F/$H>]7WS+#W37VOY]N$"MRPY]R$ M\]9]YP:4Z\RPVS-
O']T%*^";^A(N4,IV5#8'>S?;W?/?U]?;WORM>[-T#?.) M>B]HKO$_Y)N7B@^$;PHJ4 EK%:BW@PDV]8WT2&PO=V]R:W-H965T3S#5[#':AOFUNA1T&O M4I$&F"2<(0&KA?'-
,3A\Z/Z)YN[SN4>2[CB] >15+WPSCU4P0IOJ?K"=Y^A MRV=]J1?U%NQ:;Z8CE5BK>=&0];@AK_ &^\V% T#IN0MP1XC$A?8:0=(3D MI1'2CI"^-,*T(]C4@S9W:UR!%
<[G@N^0,&8M9AZL^Y:M_2+,[),[)?1;HGDJ MOV8E;P!JQ7N0Z*0 A0F5I^@,?;LKT,G;4_06$89N"*6ZK'(>*!W3,(.RT[IL MJ>-G]!-TPYFJ)5JR"BH'OSC.GQWA!SK7/N'X,>'+^*A@
:6/DFB"XC!.'>NY M>CD]<:7S?]&7_QS]P(RDKWYB]9(75-]5VY:=NMGF"+N0&US"PM-GE 3Q %[^ M[DTT"S^XC'U-L>(UQ9:O)'90@K0O07I,/5^N5F /2_V=V6(HO$<'*]"G<,E9
M22C!YDB=H V(${B:(,45IJYRM9&BT(8R-\I#'OK1^6P>/ P+X89EV2&L> 8V M/80MG;!PFO:P UNFO2W3H[9WTI2D G]\!@1=3I!%5$E@)4^YXH:)R[
MMXUP/EC86>S'(S.E@3=$H_Q8114/(8-%M_@Y0.@8M74J1G[GSS_K\ ML_ 8!US5(!#1+8X"03!U;(P)8N"T)G.4ZZ_=X02-OH#" 0K]JR-W'*#4GXW, M"087>0-B;3LHJ0N_9:H]U?
O9ODG[:'N3T?QE='$5.>8+W=2U/=B3?-L1WF"Q M)DPB"BL=*O0SO6E$VV6U \4WMHVXYTHW)?:QUHTI" /0[U>!"="WNOD? M4$L#!!0 (,N#1EKYM(C&;PH %I2 9
>&PO=V]R:W-H965TG63 (DE8;+H8(MF9_?#8C\H M-F,+E26/1.%X^G(_PZ/F'[]EB*9H?)A=GZW3! M;[CX??VMDM\F.Y9MN)%G94%JOC=^>@2?TE8V#1H$?_*^$.]JQDU0[DMRQ_-
ME^OY^0Q-R!= Z(V8"\TH%T#^MH>6-> O;8'MVO@OK:!US7P6MMO MC=5:.DI%>G%6E0^H:M'2K?G03E?;6AHX^QK/NA&5_&LFVXF+&[Z0?B+0=;'U
MTF:VQRC)BK2896D^^/T[S^6'8H%$*3^ORT]DMSE''46-/D1?Y0,O]]$ MZ,,O']$O*"O0/Y?EIDZ+>7TV$?*:FYXGL^[ZKK;71UZX/HI^*PNQK%%#71$K8<1GGQ%GQ!Q"#-
>KX2:&+++!(AL/_!;CC" MZWQ<%R(M%EFSW4O;!2C%6!WH\<;#CJO&:FMWQT[&Z_J,(?M, GUY<'PGZ/L< MV#GLY2H@TX:CKJ=NT MQ#Z^4^W79^?8FO7)15\N-
)M6VS%:#S3/!F6+0-EB4+8$BFTXJWVPE=F[Q$B@ M1+CS!DBV")0M!F5+H-B&WM K"-@N(1R.D09IP F\0 V1.HR$ 7'5'"*G#7-_Q MF1H@#3#F!:X:'W^&B(![%0';980;R9C-7MA
@BH$H&P1*%L,RI9 L0VGM)<= ML/\NP1%2")B"LD6@;#$H6P+%-O2&7O3 =M7C<'#4E0?B4]=1@Z,!QC)U>'H MPUPFHZ,:' URA^L&VN812.X8VJX7,K!=R?A6E?/-3+0WC#50
ND G:4AV2)0 MMAB4+8%B&QZ"]OH)<=XC4!)0W064+0)EBT'9$BBVH3?TN@NQ9O*' V77?A ! M@R143].F)ISG.H$242,#SO4I9:KD:)1-A1QB7U\I]JO5RK(:6B?$IS\82J
MSHY&$P*) 9VA(=DB4+88E"V!8AM.;2^BD'>I<2"@X@LH6P3*%H.R)5!L0V_H MQ1?RQE*'KOW@C-U1STZF!I3O8K70P8#"%#/UD-((E8$#IM8ZV7LY>K[T/AEV MU4-
QT#X3*+;A//2R"+'+(GW9V7/IKW$R(,LMIJ!L$2A;#,J60+$-)[?7;4CX M+B$75.8!98M V6)0M@2*;5B?WH1MQU%%%U<0^P%,-V"LCU*Z,O+W4E.H2QABK1V%3,XJJQC6@].I0
M(THK#[4/_%3#]I()M4LFEZNR$MF?V]I0:L,[%]7BQ/A?3*Y^+"-N*7 M3?IE-"S5!T@>I8YJGC^H4\U4YZ]+,K>F8_]ARJZ@2@G<:OZS2!ZG0X/;V<
M0.URPHTH9S_:9Q+G2"YLC:>WH>13LJ#EF[IKI7SQE?KO'SB%1+IXPN!12]5 M&,O)OSK>]1%'0E>;# ..N(`OJC>!"<>8]QX#VNUPJIW[#)[::R2^\Z:&;"8V M5;.):"))M?
_+^#G8S)IUTFA?T[,*)/!5\QI@KBZ)F6"844=]^,=(YZE'L8E] M*<:MT^(Z8&G)."JQ:GQ@0;UG&1J@A&Y/JIF-L H(>I)M@G&<*B6^=BM<*J5 M^W27'GCV04;R61O%;Y_UQD$<_X
&BVJ']..//=4$4WO?1S]?:.B3^9IS@^:K M4&S#V>GS56JO,]#%"/0]*TJ!<*=#/+>/%"X8&=]^BE%C0C!66+0=D2*+;A MHZ)!1LK>I?"
@18>@+)%H&PQ*%C}Q3;TACZJ9F\I/&"&@@*,7>TI* .N2?M4 MV2$RX)@Y13GF1S[6S7+F/C8N8X.+J"GZ:!L,2A; L4VG.->AF#!NRPU MH,?TH&P1*%L,RI9 L0VJH9<]F%WV.+S4;-
OOOZ!B[*HA?VI";:W:VH3"CJ_E M/ 98&*HQ_K$/[%C#3?9>?2?O@D7[DL(:SFF'TGDY<8]9T-R=_+^UT*9RW>1 MOQ]].#KJW)U>[L=/"!*XJ#H^0M$SSJXKL4PZ?1%TL\H8\
(7N\)N]+'5\;QC MC-8/T*S]#1,Z&#D+DK>HCA@W.SD:%$IN-C0A/F"5:RJ&9$P%GV@.K(*6 M7*Q\N >!J1)*1\96DDW5A4C]X.&N[T&1-3HEETJ[W#Z#_YXTP_> =0\,FU2U;
MFG4Y+0O<<'\/?_==9XQR305VZ9M[;_E57ZUX^3B7UEVOU7V#0<]-J_5MV[R M_!!,IH=@\B!JLG)\K,W:3)N7N!;IX2=,T(;C> L-B0_X%0G-DFCR8(+PV73 MF_,\9_+)4<'*&SJQ?
P+LZ-OQ.2OH0IC;%AR23?L[R_FBS-I1U[0S:A-^QM, MKYNV!T&;B\N<+5D^;KIZ-G'-R#9LUN8"PCYRY:XP@G$\%D8 P_)@#C".9V%Y M_J?Y]-'Y> SSU@\B?9331SF>%4+&
[H/E"7,R>X5GFF5)DJ;8BH['00=C;-W2 M%'[":I@W8&!Y(-.?K36^VWB%/%\'V)X^5R'83/%*Q&:*KS4@X74#1I:%=QO+ M PQL%[#:@?SA/%!384Z2P*YBWK G&$>R#$.@%L,UFJ;
(ZJ3P">\/]I0D29:% M$<#"#I($0^!IQ!', 7C D"1Q[\&]]U&\?D_%F_ ^+C1X!4$L#!!0 (,N# M1EJ7BKL

*-8?20$3;8T.P6BP^0"X99K>]9!:G9E# A)Z\=80O05).I)"=I?WUE.Z1+,3M] MV?!D?,'^O++U[4J^?"'[,MV51?&,ON=)VT-DXM[WH=FVZ$3FW'XJMT'[/JC Y
M=W[5K+MV:P3/[$8(EZMNT.LEW9Q+W;FZW)UK;KIPI7 B=,+0?F.UX5&*9_M[M?[7*GJ252ZFD^S'HU+^5Z+:.IG+GR(=*H=9C?%\W^%D3\+[,A:!*90:M#I M-SL>A7$R/=B\]"_?
^-+66QQ?WG,/,N@D/7_"E336U4?4Y^>>>\4GX@YNUTA4W M4CEAQMR)?TU1;J5>5Z?Q=]$%MU"8;=L@GAA_B:,Q6HE4S$NTC(7VC5Q-$)5 M@-INY-9VF.:Y&'1VA["ASMA$.Q\D-
M7-J?RQU9WZ2T^SYJZ=QP4Q-!?2[S#3 MK :G@QS=S<:3V6(R9O[7XNYV.AX^^)7%@U\F

*!O![>#F>C"0.0 M(0(9GA#R:P @(P0R.F%$[T'&"&1,"WG-K;2L6+&Y$=8?6A_!N'^+%F6>2]>!*Z%.Q>I,5:RS_>Z(\(V$=:L(50OML6&;OFBNM4L+]K9+X[A)'[MA !^H@4UD7W:/'&
M8NGJQ__;,81A-U+[=O568T-CN%Y#3-0DQ"JY]:$3>T'#E-$G=L:BW&Y5W8Y< ML8E_XKQ]JQ@.4__74D%,3!H]8FM,N-&^*2V;^Y9=;+,@1D PS19]8%37,^=*W M:<9&1>[/9 _R%DP2?
6)+-"_#5*=%+MA7=C9Y1#%/Y AT.?6!"O9 _\9?^E MP-30)W?+NLY(CZ2AF!3ZQ%98E$LKOI<5W>3IS]X7]G_??* MJ&-14U54GH#Y;,:(@%@14VUEYE^'!\.SWV8XT%B
^-2$@]@.:UNWEG@%::Q"+ M !<,(28FCH!8'"WY)SOS5;.2%G.! ::0@%HAQU/1BA5B8B8)B$T"$]+6&&(:_M"8@UY8ZYY79ED]@JA&%-03*R@-\;]OGVDN+5R M!3O-&%-03*R@-
\P1MQLVYS)K#R7FGYC8/V^,X'WRI9M_1%FU"V*B,_O$_L'' M8V#2$6/^B:FK(!035N@QY!^8N@I",6&%'F/^B8G]TS*Z!;LEB(GY)W[_0;CS M9FG9_Q8.)"28?
Q+J*NC(O.QAIE@_DF(_7-TO-#'U)\>8F(*2H@5!&=I6WOU M!#-/0E[\'(YFGN]2#@X_8D@P^22U?+KUP?;J,A,KJ44VY>P?GO*53EWK%HT M7VU$<37ANBJ5&OEM=_JVX-
GN"\K=UY]7OP!02P,$% @ RX-&6M))O&T1 M @ %R8 !H !X;"]?!-T#(HPS=1Y +Z1 ITA@\%3$D>/D7Q =B M^/2K'-IQVWYWJ;M_7Q,_8^4ZGI7CFV]Z_IR.E_9=;,Q'<_ +89OZ
M=OW>;DO2Y3*GX79&_QT.W/Q^MF7_YG8;3;[=?G9K7\?RVG\Q^#TIQO>ZZZ4 ML5F\ML.VC*LF?1RNIVNZ'.3N/+E9O+RMFN'E39HT=Y!"D,X?
9!!D\PBGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>AGH;@=Z& M>AN!WH9Z&X'>-MDL(=#;&\CT-M0;R/0VU!O(]#;4&\CT-M1;R?
0VU%O)]#;46\GT-LGF]T$>CO[!01Z.^KM!'H[ZNT$>CO[!01Z M.^KM!'H'ZAT$>@?]'01Z!^H=!'H'ZAT$>@?]'01ZQ^1G)8'>@?!H'@=Z!>@>! MWH!%Z!X'>@?H'@=X9]F?
4.Q/HG5'O3*!W1KTS@=X9]<[?]7?<=/P^E7GN^ MUOC\[Z1Z/-],KH^_++]3M!>"\]MJ(^_P502P,$% @ RX-&6L"(;73I M 0 ?B4 !, !;0V]N=&5N=%]4>?!E&ULS=I=3\(P%,@OT)V:UCI
MU_R(<*\?>]A?^;0=I=9&%/F[8@_'N[-28>)1I,?&]8H.UYSWJ2YXKKIZVC,;F'I+58*!24FH];1UU:F5O?FIB^^A?F3+DT+!3$9%*PTC:1NCB.?8UL M=GU+<[-
JXNANDWX.M>VFF:X K @ $0 @ &O 9&]C M4*)O<',O8V]R92YX;6Q02P$'"% ,4 " #+@T9:F5R<(Q & "<)P $P M @ ', 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 (M
,N#1EHDXA(HWP4 /$> 8 " @0T(!X,"]W;W)K&PO=V]R:W-H965T&UL4$L! A0# M% @ RX-&6HD&PO=V]R:W-H965T&UL4$L! A0#% @ RX-&6HW_SH$T M%@ 7%@ !@ ("!3RD
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ RX-&6HS@&UL4$L! A0#% @ RX-&6LV^,Y'W P _ D !D M ("!JV0 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ RX-
&6HIU%9IO! <0X !D ("! MG'D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ RX-&6FG?7;6- P & H !D ("!H8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ RX-&6@A:*-
&X!0 'Q4 !D M ("!LZP 'AL+W=O&PO=V]R M:W-H965T&V !X;"]W;W)K&UL M4$L! A0#% @ RX-&6M;7KR$> P 9 < !D ("!#+X M 'AL+W=O&PO=V]R:W-H965TP0)80 9 M " @0#(
!X,"]W;W)K&UL4$L! A0#% @ MRX-&6K]#IO_:" C3, !D ("!LLP 'AL+W=O&PO=V]R:W-H965T51P, !() 9 " @;?9 !X;"]W M;W)K&UL4$L! A0#% @ RX-&6@M*V"4>!0 M @X !D ("!,]T
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ RX-&6LAQ +?9 @ 6@H !D M ("!7 (! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ RX-&6BJE@>IF @ 308 !D ("!E T! 'AL
M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ RX-& M6D41!K/. @ 2@< !D ("!6A&PO=V]R:W-H965TX!0, %H) 9 " @4 = 0!X;"]W;W)K M&UL4$L! A0#% @ RX-&6L4N2 7 P <@D
M !D ("!?" ! 'AL+W=O&PO=V]R:W-H965T_30 M?P0 /X7 9 " @; G 0!X;"]W;W)K&UL4$L! A0#% @ RX-&6N1KCRZ-! 11P !D M ("!9BP! 'AL+W=O&PO=V]R:W-H965T M&UL4$L!*

A0# M% @ RX-&6C?6I7%>! ,Q0 !D ("!-3D! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ RX-&6I_L MH8;W @ 1@D !D ("!]D,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ RX-&6L[]+#:A P H0T !D M ("!J4P! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ RX-&6@IBJG"'R @ $P@ !D ("! MIV(! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ RX-&6K?]7C>- P .0T !D ("!\W ! 'AL+W=O6QEMI=0H% "!*@ #P M@ $9AP$ >&PO=V]R:VJO;VLN>&UL4$L! A0#% @ RX-&6M))O&T1 @ M%R8 !H (!4(P! 'AL+U]R96QS+W=O XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p,,if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497, font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497, padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497, } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf, color: black, font-weight: bold, text-align: center; } .report th.void { background-color: transparent, color: #000000, font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left, vertical-align: top, white-space: normal; width: 200px, white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block, width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right, white-space: nowrap; } .report .nump { padding-left. 2em; } .report .nump { padding. 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left, white-space: normal; } .report .text .big { margin-bottom. 1em; width. 17em; } .report .text .more { display: none; } .report .text .note { font-style. italic, font-weight: bold; } .report .text .small { width. 10em; } .report sup { font-style. italic; } .report .outerFootnotes { font-size. 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 356 313 1 false 64 0 false 6 false false R1.htm 995200090 - Document - Document And Entity Information Sheet http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 995200100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME Sheet http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME Statements 2 false false R3.htm 995200200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 995200205 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 995210101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 6 false false R7.htm 995210201 - Disclosure - Revenue Recognition Sheet http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition Revenue Recognition Notes 7 false false R8.htm 995210301 - Disclosure - Selected Balance Sheet Data Sheet http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetData Selected Balance Sheet Data Notes 8 false false R9.htm 995210401 - Disclosure - Acquisitions Sheet http://www.bio-techne.com/20211231/role/DisclosureAcquisitions Acquisitions Notes 9 false false R10.htm 995210501 - Disclosure - Fair Value Measurements Sheet http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 995210601 - Disclosure - Debt and Other Financing Arrangements Sheet http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangements Debt and Other Financing Arrangements Notes 11 false false R12.htm 995210701 - Disclosure - Leases Sheet http://www.bio-techne.com/20211231/role/DisclosureLeases Leases Notes 12 false false R13.htm 995210801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information Sheet http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information Notes 13 false false R14.htm 995210901 - Disclosure - Earnings Per Share Sheet http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare Earnings Per Share Notes 14 false false R15.htm 995211001 - Disclosure - Share-based Compensation Sheet http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensation Share-based Compensation Notes 15 false false R16.htm 995211101 - Disclosure - Other Income / (Expense) Sheet http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpense Other Income / (Expense) Notes 16 false false R17.htm 995211201 - Disclosure - Income Taxes Sheet http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes Income Taxes Notes 17 false false R18.htm 995211301 - Disclosure - Segment Information Sheet http://www.bio-techne.com/20211231/role/DisclosureSegmentInformation Segment Information Notes 18 false false R19.htm 995211401 - Disclosure - Subsequent Events Sheet http://www.bio-techne.com/20211231/role/DisclosureSubsequentEvents Subsequent Events Notes 19 false false R20.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 20 false false R21.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 21 false false R22.htm 99920102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 22 false false R23.htm 99930103 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies 23 false false R24.htm 99930203 - Disclosure - Revenue Recognition (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition 24 false false R25.htm 99930303 - Disclosure - Selected Balance Sheet Data (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables Selected Balance Sheet Data (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetData 25 false false R26.htm 99930403 - Disclosure - Acquisitions (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables Acquisitions (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureAcquisitions 26 false false R27.htm 99930503 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements 27 false false R28.htm 99930703 - Disclosure - Leases (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureLeasesTables Leases (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureLeases 28 false false R29.htm 99930803 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation 29 false false R30.htm 99930903 - Disclosure - Earnings Per Share (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareTables Earnings Per Share (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare 30 false false R31.htm 99931103 - Disclosure - Other Income / (Expense) (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables Other Income / (Expense) (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpense 31 false false R32.htm 99931303 - Disclosure - Segment Information (Tables) Sheet http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.bio-techne.com/20211231/role/DisclosureSegmentInformation 32 false false R33.htm 99940101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details) Details http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 99940102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details) Details 34 false false R35.htm 99940201 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 35 false false R36.htm 99940202 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 36 false false R37.htm 99940301 - Disclosure - Selected Balance Sheet Data - Narrative (Details) Sheet http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataNarrativeDetails Selected Balance Sheet Data - Narrative (Details) Details 37 false false R38.htm 99940302 - Disclosure - Selected Balance Sheet Data - Inventories (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataInventoriesDetails Selected Balance Sheet Data - Inventories (Details) Details 38 false false R39.htm 99940303 - Disclosure - Selected Balance Sheet Data - Property and Equipment (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails Selected Balance Sheet Data - Property and Equipment (Details) Details 39 false false R40.htm 99940304 - Disclosure - Selected Balance Sheet Data - Intangible Assets (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails Selected Balance Sheet Data - Intangible Assets (Details) Details 40 false false R41.htm 99940305 - Disclosure - Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesToCarryingAmountOfNetIntangibleAssetsDetails Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details) Details 41 false false R42.htm 99940306 - Disclosure - Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details) Details 42 false false R43.htm 99940307 - Disclosure - Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details) Details 43 false false R44.htm 99940308 - Disclosure - Selected Balance Sheet Data - Other Assets (Details) Sheet http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails Selected Balance Sheet Data - Other Assets (Details) Details 44 false false R45.htm 99940401 - Disclosure - Acquisitions - Narrative (Details) Sheet http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails Acquisitions - Narrative (Details) Details 45 false false R46.htm 99940402 - Disclosure - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details) Details 46 false false R47.htm 99940501 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 47 false false R48.htm 99940502 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) Details 48 false false R49.htm 99940503 - Disclosure - Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details) Sheet http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details) Details 49 false false R50.htm 99940504 - Disclosure - Fair Value Measurements - Pretax

Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details) Sheet http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details) Details 50 false false R51.htm 99940601 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails Debt and Other Financing Arrangements - Narrative (Details) Details 51 false false R52.htm 99940701 - Disclosure - Leases - Narrative (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails Leases - Narrative (Details) Details 52 false false R53.htm 99940702 - Disclosure - Leases - Balance Sheet Classification (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails Leases - Balance Sheet Classification (Details) Details 53 false false R54.htm 99940703 - Disclosure - Leases - Cash Paid (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureLeasesCashPaidDetails Leases - Cash Paid (Details) Details 54 false false R55.htm 99940704 - Disclosure - Leases - Fair Value of the Lease Liability by Payment Date (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails Leases - Fair Value of the Lease Liability by Payment Date (Details) Details 55 false false R56.htm 99940801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details) Sheet http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details) Details http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables 56 false false R57.htm 99940802 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details) Sheet http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details) Details http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables 57 false false R58.htm 99940803 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details) Details http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables 58 false false R59.htm 99940901 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 59 false false R60.htm 99940902 - Disclosure - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details) Details 60 false false R61.htm 99941001 - Disclosure - Share-based Compensation (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails Share-based Compensation (Details) Details http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensation 61 false false R62.htm 99941102 - Disclosure - Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details) Details http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables 62 false false R63.htm 99941201 - Disclosure - Income Taxes (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes 63 false false R64.htm 99941301 - Disclosure - Segment Information - Financial Information Relating to Reportable Segments (Details) Sheet http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails Segment Information - Financial Information Relating to Reportable Segments (Details) Details 64 false false All Reports Book All Reports tech-20241231.xsd tech-20241231_cal.xml tech-20241231_def.xml tech-20241231_lab.xml tech-20241231_pre.xml tech-20241231x10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tech-20241231x10q.htm": { "nsprefix": "tech", "nsuri": "http://www.bio-techne.com/20241231", "dts": { "schema": { "local": ["tech-20241231.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["tech-20241231_cal.xml"] }, "definitionLink": { "local": ["tech-20241231_def.xml"] }, "labelLink": { "local": ["tech-20241231_lab.xml"] }, "presentationLink": { "local": ["tech-20241231_pre.xml"] }, "inline": { "local": ["tech-20241231x10q.htm"] } }, "keyStandard": 274, "keyCustom": 39, "axisStandard": 25, "axisCustom": 0, "memberStandard": 41, "memberCustom": 23, "hidden": { "total": 23, "http://fasb.org/us-gaap/2024": 17, "http://xbrl.sec.gov/dei/2024": 6 }, "contextCount": 356, "entityCount": 1, "segmentCount": 64, "elementCount": 573, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 937, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome", "longName": "995200100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R3": { "role": "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200200 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200205 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R6": { "role": "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "longName": "995210101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition", "longName": "995210201 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetData", "longName": "995210301 - Disclosure - Selected Balance Sheet Data", "shortName": "Selected Balance Sheet Data", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bio-techne.com/20211231/role/DisclosureAcquisitions", "longName": "995210401 - Disclosure - Acquisitions", "shortName": "Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"],

```
"reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements", "longName": "995210501 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangements", "longName": "995210601 - Disclosure - Debt and Other Financing Arrangements", "shortName": "Debt and Other Financing Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeases", "longName": "995210701 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation", "longName": "995210801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information", "shortName": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare", "longName": "995210901 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensation", "longName": "995211001 - Disclosure - Share-based Compensation", "shortName": "Share-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpense", "longName": "995211101 - Disclosure - Other Income / (Expense)", "shortName": "Other Income / (Expense)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes", "longName": "995211201 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformation", "longName": "995211301 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSubsequentEvents", "longName": "995211401 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:InvestmentPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:InvestmentPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "longName": "99930103 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "tech:RestructuringActionsPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "tech:RestructuringActionsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionTables", "longName": "99930203 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables", "longName": "99930303 - Disclosure - Selected Balance Sheet Data (Tables)", "shortName": "Selected Balance Sheet Data (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "longName": "99930403 - Disclosure - Acquisitions (Tables)", "shortName": "Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_us-gaap_BusinessAcquisitionAxis_tech_LunaphoreTechnologiesSaMember_bpDVDTVokmatFMBKEoXww", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_us-gaap_BusinessAcquisitionAxis_tech_LunaphoreTechnologiesSaMember_bpDVDTVokmatFMBKEoXww", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables", "longName": "99930503 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef":
```

```
"Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "div", "body", "html"
], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "div", "div", "body", "html"
], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesTables",
"longName": "99930703 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat":
"Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name":
"tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div",
"div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false",
"lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true,
"unique": true } }, "R29": { "role": "http://www.bio-
techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables", "longName": "99930803 - Disclosure -
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information (Tables)", "shortName": "Supplemental Equity and Accumulated Other Comprehensive
Income (loss) Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": {
"contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-
20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-
gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-
gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R30":
{ "role": "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareTables", "longName": "99930903 - Disclosure - Earnings Per Share (Tables)", "shortName":
"Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef":
"Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-
20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-
gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-
gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R31": { "role":
"http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables", "longName": "99931103 - Disclosure - Other Income / (Expense) (Tables)", "shortName":
"Other Income / (Expense) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": {
"contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationTables",
"longName": "99931303 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-
gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-
gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-
gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-
gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } },
"R33": { "role": "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "longName":
"99940101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)", "shortName": "Basis of Presentation and Summary of
Significant Accounting Policies - Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33",
"firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:NumberOfOperatingSegments", "unitRef":
"Unit_Standard_segment_aDxMDAbmRk-T2ffk5klOOQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-
gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique":
true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:NumberOfOperatingSegments", "unitRef":
"Unit_Standard_segment_aDxMDAbmRk-T2ffk5klOOQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-
gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique":
true } }, "R34": { "role": "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "longName": "99940102 - Disclosure -
Basis of Presentation and Summary of Significant Accounting Policies - Restructuring Charges (Details)", "shortName": "Basis of Presentation and Summary of Significant
Accounting Policies - Restructuring Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34",
"firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_us-
gaap_RestructuringPlanAxis_tech_FiscalYear2024RestructuringActionsMember_Iwn1Ev3xWEyysjvsdvjo0Q", "name": "tech:RestructuringCostsNetOfAdjustments", "unitRef":
"Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation",
"div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":
"Duration_10_1_2024_To_12_31_2024_us-gaap_RestructuringPlanAxis_tech_FiscalYear2024RestructuringActionsMember_Iwn1Ev3xWEyysjvsdvjo0Q", "name":
"tech:RestructuringCostsNetOfAdjustments", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p",
"td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }
}, "R35": { "role": "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionNarrativeDetails", "longName": "99940201 - Disclosure - Revenue Recognition -
Narrative (Details)", "shortName": "Revenue Recognition - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:ContractWithCustomerLiability", "unitRef":
"Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_hQq0kkFy2UKzTj9VjCSO1A", "name": "us-
gaap:ContractWithCustomerLiability", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p",
"ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R36": { "role": "http://www.bio-
techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "longName": "99940202 - Disclosure - Revenue Recognition - Disaggregation of
Revenue (Details)", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-
gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": {
"contextRef": "Duration_10_1_2024_To_12_31_2024_srt_StatementGeographicalAxis_country_US_zwsr4CV9yUaxiHFG4fkTxQ", "name": "us-
gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals":
"-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm",
"unique": true } }, "R37": { "role": "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataNarrativeDetails", "longName": "99940301 - Disclosure - Selected
Balance Sheet Data - Narrative (Details)", "shortName": "Selected Balance Sheet Data - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_us-
gaap_OtherNoncurrentAssetsMember_s4BTaoZ9NUyDV-tO8R2HcA", "name": "tech:InventoryFinishedGoodsNetOfReservesNonCurrent", "unitRef":
"Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-
gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_BalanceSheetLocationAxis_us-
gaap_OtherNoncurrentAssetsMember_s4BTaoZ9NUyDV-tO8R2HcA", "name": "tech:InventoryFinishedGoodsNetOfReservesNonCurrent", "unitRef":
"Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-
gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataInventoriesDetails", "longName": "99940302 - Disclosure - Selected Balance Sheet Data - Inventories
(Details)", "shortName": "Selected Balance Sheet Data - Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details",
"order": "38", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef":
"Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-
gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1,
"baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-
gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p",
"td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ],
"reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails", "longName": "99940303 - Disclosure - Selected Balance Sheet Data - Property
and Equipment (Details)", "shortName": "Selected Balance Sheet Data - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-
gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td",
"tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount":
1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-
gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td",
"tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount":
1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "longName": "99940304 - Disclosure - Selected Balance Sheet Data - Intangible
Assets (Details)", "shortName": "Selected Balance Sheet Data - Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details",
"menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
"unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-
gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tech-20241231x10q.htm",
"first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef":
"Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-
```

gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesToCarryingAmountOfNetIntangibleAssetsDetails", "longName": "99940305 - Disclosure - Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details)", "shortName": "Selected Balance Sheet Data - Changes to Carrying Amount of Net Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_6_30_2024_hQq0kkFy2UKzTj9VjCSO1A", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "tech:FinitelivedIntangibleAssetsOtherAdditions", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R42": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "longName": "99940306 - Disclosure - Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details)", "shortName": "Selected Balance Sheet Data - Estimated Future Amortization Expense for Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails", "longName": "99940307 - Disclosure - Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details)", "shortName": "Selected Balance Sheet Data - Changes in Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2024_hQq0kkFy2UKzTj9VjCSO1A", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R44": { "role": "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails", "longName": "99940308 - Disclosure - Selected Balance Sheet Data - Other Assets (Details)", "shortName": "Selected Balance Sheet Data - Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:EquityMethodInvestments", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:EquityMethodInvestments", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "longName": "99940401 - Disclosure - Acquisitions - Narrative (Details)", "shortName": "Acquisitions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_BusinessAcquisitionAxis_tech_LunaphoreTechnologiesSaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_LgniK7OIYEyRrQhLvf0xfg", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R46": { "role": "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "longName": "99940402 - Disclosure - Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)", "shortName": "Acquisitions - Preliminary and Final Fair Value of Assets and Liabilities Assumed (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_6_30_2024_hQq0kkFy2UKzTj9VjCSO1A", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_us-gaap_BusinessAcquisitionAxis_tech_LunaphoreTechnologiesSaMember_-gPJ7bem-kiZ706zZcA8Fg", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R47": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "longName": "99940501 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_8_31_2024_us-gaap_DerivativeInstrumentRiskAxis_tech_ForwardStartingSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_lzfYTi5TwkyXfmnI9cIf7A", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R48": { "role": "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "longName": "99940502 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9C4LGRR2hEmgoz6vdPzG4Q", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9C4LGRR2hEmgoz6vdPzG4Q", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "longName": "99940503 - Disclosure - Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)", "shortName": "Fair Value Measurements - Contractual Amounts of the Outstanding Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_DerivativeInstrumentRiskAxis_tech_ForwardStartingSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_7ulwj8-Xd0eWg0HGIAo_2w", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_DerivativeInstrumentRiskAxis_tech_ForwardStartingSwapMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_7ulwj8-Xd0eWg0HGIAo_2w", "name": "us-gaap:DerivativeFairValueOfDerivativeNet", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails", "longName": "99940504 - Disclosure - Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)", "shortName": "Fair Value Measurements - Pretax Amount Of The Gains And Losses On Our Hedging Instruments And The Classification Of Those Gains And Losses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_ozGHBqZlf0ei_i_NHmEKrw", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_ozGHBqZlf0ei_i_NHmEKrw", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails", "longName": "99940601 - Disclosure - Debt and Other Financing Arrangements - Narrative (Details)", "shortName": "Debt and Other Financing Arrangements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ProceedsFromLongTermLinesOfCredit", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_DebtInstrumentAxis_tech_AmendedCreditAgreementMember_OzWj_RmrrEywX4h9YFBlCw", "name": "us-gaap:LinesOfCreditCurrent", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R52": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "longName": "99940701 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:VariableLeaseCost", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:VariableLeaseCost", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-

gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "longName": "99940702 - Disclosure - Leases - Balance Sheet Classification (Details)", "shortName": "Leases - Balance Sheet Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "td", "tr", "table", "tech:LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R54": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesCashPaidDetails", "longName": "99940703 - Disclosure - Leases - Cash Paid (Details)", "shortName": "Leases - Cash Paid (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "tech:LesseeOperatingLeaseCashFlowInformationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "tech:LesseeOperatingLeaseCashFlowInformationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails", "longName": "99940704 - Disclosure - Leases - Fair Value of the Lease Liability by Payment Date (Details)", "shortName": "Leases - Fair Value of the Lease Liability by Payment Date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_m-WrrPLjFUOarl9ZxK1A-A", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails", "longName": "99940801 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)", "shortName": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "Unit_Divide_USD_shares_dG4N2xM0JUmaDOP3QaKSdQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockDividendsPerShareDeclared", "p", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "Unit_Divide_USD_shares_dG4N2xM0JUmaDOP3QaKSdQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:CommonStockDividendsPerShareDeclared", "p", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails", "longName": "99940802 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details)", "shortName": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Consolidated Changes in Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_9_30_2024_CXTSXCE9W02cZJYxojv8ag", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R58": { "role": "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "longName": "99940803 - Disclosure - Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)", "shortName": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_9_30_2024_CXTSXCE9W02cZJYxojv8ag", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["b", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_BClZ90bB2kmkC0A8d1ucfA", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R59": { "role": "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareNarrativeDetails", "longName": "99940901 - Disclosure - Earnings Per Share - Narrative (Details)", "shortName": "Earnings Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_NP_4tCPrEkWtSLi7US0mEg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_NP_4tCPrEkWtSLi7US0mEg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "longName": "99940902 - Disclosure - Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)", "shortName": "Earnings Per Share - Shares Used in the Earnings Per Share Computations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R61": { "role": "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails", "longName": "99941001 - Disclosure - Share-based Compensation (Details)", "shortName": "Share-based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_NP_4tCPrEkWtSLi7US0mEg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_12_31_2024_U5YZQ0UvzUOxnlCkm6olOw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "Unit_Standard_shares_NP_4tCPrEkWtSLi7US0mEg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails", "longName": "99941102 - Disclosure - Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)", "shortName": "Other Income / (Expense) - Schedule of Components of Other Income (Expense) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:InterestExpenseNonoperating", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:InvestmentIncomeNet", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } }, "R63": { "role": "http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxesDetails", "longName": "99941201 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_0y4nfNemLkOgKRZjoT0sgQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Unit_Standard_pure_0y4nfNemLkOgKRZjoT0sgQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "longName": "99941301 - Disclosure - Segment Information - Financial Information Relating to Reportable Segments (Details)", "shortName": "Segment Information - Financial Information Relating to Reportable Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_vLCcUfM_d0S4r1eQe7R8QA", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "unitRef": "Unit_Standard_USD_43mIe6iaQUmbYGtCKXaVwQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "tech-20241231x10q.htm", "unique": true } } }, "tag": { "tech_APACExcludingGreaterChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "APACExcludingGreaterChinaMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the APAC, excluding

Greater China.", "label": "APAC, excluding Greater China [Member]", "terseLabel": "APAC, excluding Greater China" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Trade accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r67", "r776"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, less allowance for doubtful accounts of $4,904 and $4,386, respectively", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r930"] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r70", "r135"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r70"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r36", "r161", "r583"] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss], "lang": { "en-us": { "role": { "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "terseLabel": "Unrealized Gains (Losses) on Debt Securities", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r173", "r174", "r175", "r177", "r184", "r185", "r904"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r21", "r22", "r88", "r166", "r580", "r621", "r622"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r4", "r12", "r22", "r479", "r482", "r528", "r617", "r618", "r904", "r905", "r906", "r917", "r918", "r919", "r921"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss], "lang": { "en-us": { "role": { "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "verboseLabel": "Foreign Currency Translation Adjustments", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": ["r5", "r12", "r22", "r86", "r87", "r184", "r185", "r508", "r509", "r510", "r511", "r512", "r904"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r839"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r77"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r631", "r917", "r918", "r919", "r921", "r1012", "r1079"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r852"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r852"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r852"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r852"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, ESPP, Increase for Cost Recognition", "terseLabel": "Employee stock purchase plan expense", "documentation": "Amount of increase in additional paid-in capital (APIC) for recognition of cost for employee stock purchase program (ESPP) award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r38", "r39", "r404"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net earnings to net cash provided by operating activities:" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r885"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r811", "r821", "r831", "r863"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r814", "r824", "r834", "r866"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r886"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r852"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r859"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r815", "r825", "r835", "r859", "r867", "r871", "r879"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r877"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-

techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "negatedLabel": "Stock based compensation, inclusive of employer taxes", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r433", "r438"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": ["r167", "r280", "r291"] }, "tech_AmendedCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "AmendedCreditAgreementMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amended credit agreement.", "label": "Amended Credit Agreement [Member]", "terseLabel": "Amended Credit Agreement" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "tech_AmortizationOfAcquiredIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "AmortizationOfAcquiredIntangibleAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the amount of amortization of acquired intangible assets.", "label": "Amortization Of Acquired Intangible Assets", "negatedLabel": "Amortization of intangibles" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesToCarryingAmountOfNetIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "negatedTerseLabel": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r9", "r305", "r312", "r745"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r239"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "terseLabel": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r9", "r35"] }, "tech_AssetImpairmentRestructuringCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "AssetImpairmentRestructuringCharge", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The value of asset impairment restructuring charge.", "label": "Asset impairment restructuring", "terseLabel": "Asset impairment restructuring" } } }, "auth_ref": [] }, "tech_AssetRelatedAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "AssetRelatedAndOtherMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to asset related and other costs of restructuring pursuant to a plan.", "label": "Asset Related And Other [Member]", "terseLabel": "Asset-related and other" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r133", "r146", "r165", "r201", "r243", "r249", "r267", "r271", "r288", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r470", "r474", "r505", "r576", "r663", "r738", "r739", "r776", "r802", "r971", "r972", "r1036"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "tech_AssetsClassifiedAsNoncurrentOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "AssetsClassifiedAsNoncurrentOther", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Assets classified as noncurrent other", "terseLabel": "Other" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r156", "r170", "r201", "r288", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r470", "r474", "r505", "r776", "r971", "r972", "r1036"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r489", "r490", "r765"] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets held-for-sale", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r3", "r64", "r65", "r116", "r118", "r154", "r155"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r874"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r875"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r870"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r870"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r870"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r870"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r870"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r870"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r873"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r872"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r871"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r871"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r325", "r1046", "r1047"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r54", "r57", "r325", "r1046", "r1047"] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingAndBuildingImprovementsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Building and Building Improvements [Member]", "terseLabel": "Building and improvements", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label":

```
"Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r463", "r757", "r758" ] },
"us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [
"http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-
techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label":
"Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r41",
"r42", "r306", "r307", "r308", "r309", "r310", "r463", "r757", "r758" ] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Business
Combination, Acquisition Related Costs", "negatedLabel": "Acquisition related expenses and other", "documentation": "This element represents acquisition-related costs
incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other
professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and
issuing debt and equity securities." } } }, "auth_ref": [ "r40" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-
techne.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "totalLabel": "Net assets
acquired", "verboseLabel": "Acquisition amount", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the
acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r0", "r1", "r11" ] }, "us-
gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-
techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration,
Liability", "verboseLabel": "Contingent consideration", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } }
}, "auth_ref": [ "r47", "r127", "r466", "r491", "r492", "r493" ] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitions"
], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions", "documentation": "The entire disclosure for a business
combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.
The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r124", "r464" ] },
"tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-
techne.com/20241231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "crdr": "debit",
"presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails" ], "lang": { "en-us": {
"role": { "documentation": "Amount of assets acquired, including goodwill, at the acquisition date.", "label":
"tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsIncludingGoodwill", "totalLabel": "Total assets acquired" } } }, "auth_ref": [] },
"us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "crdr": "debit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "label": "Business
Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "terseLabel": "Current assets", "documentation": "Amount of assets that are
expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r44" ] }, "us-
gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "presentation": [
"http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "label":
"Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "terseLabel": "Deferred income taxes, net",
"documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r44" ] },
"tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.bio-techne.com/20241231", "localname":
"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets", "crdr": "debit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "documentation":
"Amount of equipment and other long-term assets acquired at the acquisition date.", "label":
"tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedEquipmentAndOtherLongtermAssets", "terseLabel": "Equipment and other long-term
assets" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit",
"presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails" ], "lang": { "en-us": {
"role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Intangible assets",
"documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": [ "r43", "r44" ] },
"tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.bio-techne.com/20241231", "localname":
"BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal", "crdr": "credit", "presentation": [
"http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": {
"documentation": "Amount of liabilities excluding deferred income taxes assumed at the acquisition date.", "label":
"tech_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesExcludingDeferredIncomeTaxesTotal", "terseLabel": "Liabilities" } } },
"auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [
"http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "label":
"Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Net assets acquired", "documentation": "Amount
recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r44" ] }, "us-gaap_BusinessCombinationsAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Acquisitions" } } },
"auth_ref": [] }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Business Description and
Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the
business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational
structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information
about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r111", "r112" ]
}, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CN", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "Greater China" } }
}, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on
hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes
short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in
value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r28", "r158", "r726" ] },
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr":
"debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash,
Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at
end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "documentation": "Amount of cash and cash equivalents, and cash and cash
equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand,
demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to,
short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in
value because of changes in interest rates." } } }, "auth_ref": [ "r28", "r107", "r199" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash
and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including
effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with
general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known
amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r107" ] },
"us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [
"http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-
techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-
techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-
techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails" ], "lang": {
"en-us": { "role": { "label": "Cash Flow Hedging [Member]", "terseLabel": "Cash flow hedges", "documentation": "Hedge of the exposure to variability in the cash flows of a
recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r51" ] }, "ecd_ChangedPeerGroupFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group,
Footnote" } } }, "auth_ref": [ "r850" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair
Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r847" ] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair
```

Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r845"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r851"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r851"] }, "us-gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareDeclared", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Common Stock, dividends, per share, declared (in dollars per share)", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": ["r123"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r792", "r793", "r794", "r796", "r797", "r798", "r799", "r917", "r918", "r921", "r1012", "r1077", "r1079"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r76"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r76", "r650"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r76"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Balances (in shares)", "periodStartLabel": "Balances (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r13", "r76", "r650", "r669", "r1079", "r1080"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,915,999 and 158,216,258 respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r76", "r579", "r776"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r856"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r855"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r857"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r854"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r23", "r180", "r182", "r187", "r572", "r590", "r591"] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation"], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": ["r85", "r186", "r571", "r589"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": ["r144", "r203", "r243", "r251", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r273", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r738", "r739", "r971", "r972"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": ["r144", "r203", "r243", "r251", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r273", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r738", "r739", "r971", "r972"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "tech_ConsumablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ConsumablesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to consumables products.", "label": "Consumables [Member]", "terseLabel": "Consumables" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "terseLabel": "Contract with Customer, Liability, Total", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r379", "r380", "r391"] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r379", "r380", "r391"] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r392"] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Corporate Segment [Member]", "terseLabel": "Corporate", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r924"] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r92", "r93", "r537"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r340", "r969"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r340", "r969", "r970"] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Currency Swap [Member]", "terseLabel": "Cross-currency swap", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "tech_CurrentAssetsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "CurrentAssetsHeldForSaleMember", "presentation": ["http://www.bio-

techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to current assets held for sale.", "label": "Current Assets, Held For Sale [Member]", "terseLabel": "Current Assets, Held For Sale" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r46", "r946", "r947", "r948", "r949", "r951", "r953", "r956", "r957"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt and Other Financing Arrangements" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangements"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt and Other Financing Arrangements", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r122", "r200", "r320", "r321", "r322", "r323", "r324", "r339", "r340", "r352", "r358", "r359", "r360", "r361", "r362", "r363", "r368", "r375", "r376", "r377", "r513"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r19", "r69", "r70", "r134", "r136", "r203", "r353", "r354", "r355", "r356", "r357", "r359", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r746", "r747", "r748", "r749", "r750", "r774", "r914", "r959", "r960", "r961", "r1032", "r1033"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r19", "r203", "r353", "r354", "r355", "r356", "r357", "r359", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r746", "r747", "r748", "r749", "r750", "r774", "r914", "r959", "r960", "r961", "r1032", "r1033"] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred Income Tax Expense (Benefit), Total", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": ["r9", "r149", "r916"] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes", "verboseLabel": "Deferred tax liabilities", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": ["r441", "r442", "r577"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Deferred Income Taxes and Tax Credits", "verboseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r110"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r9", "r243", "r254", "r271", "r738", "r739"] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": ["http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": ["r476"] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Derivative Asset", "terseLabel": "Derivative Instruments", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": ["r171", "r172", "r489", "r490", "r501", "r504", "r633", "r634", "r635", "r636", "r637", "r639", "r640", "r641", "r642", "r643", "r656", "r657", "r701", "r703", "r704", "r705", "r707", "r708", "r731", "r765", "r770", "r794", "r1015", "r1016", "r1017", "r1078"] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r641", "r643", "r655", "r656", "r657", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r677", "r678", "r679", "r680", "r683", "r684", "r685", "r686", "r701", "r702", "r704", "r707", "r792", "r794", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1025", "r1026"] }, "tech_DerivativeDecreaseInNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "DerivativeDecreaseInNotionalAmount", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in notional amount of derivatives.", "label": "Derivative, Decrease in Notional Amount", "terseLabel": "Decrease in notional amount at each interim date" } } }, "auth_ref": [] }, "us-gaap_DerivativeFairValueOfDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative, Fair Value, Net", "terseLabel": "Fair value of derivative instruments", "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives." } } }, "auth_ref": ["r504"] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": ["r55", "r58", "r59", "r131", "r641", "r643", "r655", "r656", "r657", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r677", "r678", "r679", "r680", "r683", "r684", "r685", "r686", "r701", "r702", "r704", "r707", "r731", "r792", "r794", "r1018", "r1019", "r1020", "r1021", "r1022", "r1023", "r1025", "r1026"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": ["r14", "r55", "r58"] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": ["r14", "r55", "r58", "r59", "r62", "r63", "r477"] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "(Gain) Loss Recognized in AOCI", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r477"] }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueGrossAsset", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "terseLabel": "Derivative instruments - assets", "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": ["r16", "r18", "r129", "r130", "r705", "r706", "r730"] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": ["http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r484"] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": ["r1010", "r1011"] }, "tech_DerivativeNotionalAmountAtMaturity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "DerivativeNotionalAmountAtMaturity", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount of derivatives at maturity.", "label": "Derivative Notional Amount At Maturity", "terseLabel": "Notional amount at maturity" } } }, "auth_ref": [] }, "tech_DerivativeNumberOfInterimSettlementDates": { "xbrltype": "integerItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "DerivativeNumberOfInterimSettlementDates", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": {

```
"en-us": { "role": { "documentation": "Number of interim settlement dates for the derivative instruments.", "label": "Derivative Number Of Interim Settlement Dates", "terseLabel": "Number of interim settlement dates" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r14", "r48", "r49", "r50", "r53", "r56", "r58", "r60", "r61", "r63", "r484" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails" ], "lang": { "en-us": { "role": { "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated as hedging instruments", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": [ "r126", "r946", "r947", "r948", "r949", "r951", "r953", "r956", "r957" ] }, "tech_DiagnosticsAndSpatialBiologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "DiagnosticsAndSpatialBiologyMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "Consist of the ACD operating segment and the Diagnostics and Spatial Biology operating segment.", "label": "Diagnostics and Spatial Biology [Member]", "terseLabel": "Diagnostics and Spatial Biology" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedules of disaggregated revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r974" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "Share-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r403", "r406", "r434", "r435", "r437", "r760" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-based Compensation" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitions", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangements", "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements", "http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes", "http://www.bio-techne.com/20211231/role/DisclosureLeases", "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpense", "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformation", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetData", "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensation", "http://www.bio-techne.com/20211231/role/DisclosureSubsequentEvents", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformation" ], "lang": { "en-us": { "role": { "label": "Disclosure Text Block [Abstract]", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "us-gaap_DisclosureTextBlockSupplementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "label": "Selected Balance Sheet Data" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current", "terseLabel": "Goodwill attributable to disposal group held for sale", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r64", "r65", "r116", "r118" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventory, sold as part of disposal group", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r64", "r65", "r116", "r118" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "terseLabel": "Property, plant and equipment attributable to disposal group held for sale", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r3", "r64", "r65", "r116", "r118" ] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails" ], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r123" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r806" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r838" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r849" ] }, "tech_EMEAExcludingUKMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "EMEAExcludingUKMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa, excluding the United Kingdom.", "label": "EMEA, excluding UK [Member]", "terseLabel": "EMEA, excluding United Kingdom" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)", "verboseLabel": "Earnings per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r188", "r209", "r210", "r211", "r212", "r213", "r214", "r220", "r223", "r234", "r237", "r238", "r242", "r461", "r468", "r486", "r487", "r573", "r592", "r732" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)", "verboseLabel": "Earnings per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r188", "r209", "r210", "r211", "r212", "r213", "r214", "r223", "r234", "r237", "r238", "r242", "r461", "r468", "r486", "r487", "r573", "r592", "r732" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r219", "r239", "r240", "r241" ] }, "us-
```

gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1029"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate reconciliation, percent, total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r444", "r762"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Salaries, wages and related accruals", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r70"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": ["r436"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost, period for recognition (Year)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r436"] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxesDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "terseLabel": "Share-based compensation excess tax benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": ["r433"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "terseLabel": "Employee severance", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "tech_EmployeeStockPurchasePlan2014Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "EmployeeStockPurchasePlan2014Member", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2014 Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan 2014 [Member]", "terseLabel": "Employee Stock Purchase Plan 2014" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r804"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r804"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r804"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r888"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r804"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r804"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r804"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r804"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": ["r843"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": ["r884"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": ["r884"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": ["r884"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Bio-Techne's Shareholders' equity:" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails",

```
"http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r152", "r183", "r184", "r185", "r204", "r205", "r206", "r208", "r213", "r215", "r217", "r244", "r289", "r290", "r317", "r378", "r450", "r451", "r458", "r459", "r460", "r462", "r467", "r468", "r478", "r479", "r480", "r481", "r482", "r483", "r485", "r506", "r508", "r509", "r510", "r511", "r512", "r514", "r516", "r528", "r589", "r617", "r618", "r619", "r631", "r689" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r285", "r286", "r287", "r457", "r893", "r894", "r895", "r1006", "r1007", "r1008", "r1009" ] }, "us-gaap_EquityMethodInvestmentAggregateCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentAggregateCost", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Aggregate Cost", "terseLabel": "Investment amount", "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting." } } }, "auth_ref": [ "r66" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Investment percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r285" ] }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "negatedLabel": "(Gain) Loss on equity method investment", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } } }, "auth_ref": [ "r907", "r908", "r912" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investments", "verboseLabel": "Equity method investment in Wilson Wolf", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r243", "r259", "r271", "r284", "r900", "r931" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Investment in Spear Bio", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r283" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r853" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r811", "r821", "r831", "r863" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r808", "r818", "r828", "r860" ] }, "tech_ExchangedTradedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ExchangedTradedSecuritiesMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents exchanged traded securities.", "label": "Exchanged Traded Securities [Member]", "terseLabel": "Exchanged traded investment grade bond funds" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r859" ] }, "tech_FairValueAdjustmentOnAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "FairValueAdjustmentOnAvailableForSaleSecurities", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of fair value adjustment made on available for sale securities during the period.", "label": "Fair value adjustment on available-for-sale investments", "terseLabel": "Fair value adjustment on available-for-sale investments" } } }, "auth_ref": [] }, "tech_FairValueAdjustmentToContingentConsiderationPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "FairValueAdjustmentToContingentConsiderationPayable", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair value adjustment to contingent consideration payable", "terseLabel": "Fair value adjustment to contingent consideration payable" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r494", "r495", "r496", "r497", "r498", "r499", "r502", "r768" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r494", "r495", "r496", "r497", "r498", "r499", "r502", "r768" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r366", "r395", "r396", "r397", "r398", "r399", "r400", "r488", "r490", "r491", "r492", "r493", "r500", "r501", "r503", "r531", "r532", "r533", "r747", "r748", "r754", "r755", "r756", "r765", "r770" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r489", "r490", "r491", "r493", "r765", "r1016", "r1027" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r366", "r395", "r400", "r490", "r501", "r531", "r754", "r755", "r756", "r765" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r366", "r395", "r400", "r490", "r491", "r501", "r532", "r747", "r748", "r754", "r755", "r756", "r765" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r489", "r490", "r491", "r493", "r765", "r1016", "r1027" ] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r132" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r366", "r395", "r396", "r397", "r398", "r399", "r400", "r488", "r490", "r491", "r492", "r493", "r500", "r501", "r503", "r531", "r532", "r533", "r747", "r748", "r754", "r755", "r756", "r765", "r770" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r765", "r1013", "r1014", "r1015", "r1016", "r1017", "r1027" ] }, "tech_FairValueWriteUpOfAcquiredInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "FairValueWriteUpOfAcquiredInventory", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The noncash expense during the period from the sale of acquired inventory written up to fair value in purchase accounting.", "label": "Costs recognized on sale of acquired inventory", "negatedLabel": "Costs recognized on sale of acquired inventory", "terseLabel": "Costs recognized on sale of acquired inventory" } } }, "auth_ref": [] }, "tech_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": []
```

```
}, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r163", "r293", "r311", "r745" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r313", "r723", "r745" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "verboseLabel": "Remainder 2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [ "r1081" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2029", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r313", "r723", "r745" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r313", "r723", "r745" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r313", "r723", "r745" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r304", "r306", "r307", "r308", "r310", "r311", "r314", "r315", "r538", "r539", "r723" ] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesToCarryingAmountOfNetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "negatedTerseLabel": "Currency translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Definite-lived intangibles assets", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r293", "r311", "r539", "r745" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r304", "r306", "r307", "r308", "r310", "r311", "r314", "r315", "r723" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataEstimatedFutureAmortizationExpenseForIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Definite-lived intangibles assets, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r538", "r953" ] }, "tech_FinitelivedIntangibleAssetsOtherAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "FinitelivedIntangibleAssetsOtherAdditions", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesToCarryingAmountOfNetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other additions lacking physical substance with a definite life.", "label": "Finite lived Intangible Assets Other Additions", "terseLabel": "Other additions" } } }, "auth_ref": [] }, "tech_FirstPartOfForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "FirstPartOfForwardContractMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the first part of the forward contract.", "label": "First Part of Forward Contract [Member]", "terseLabel": "First Part of Forward Contract" } } }, "auth_ref": [] }, "tech_FiscalYear2024RestructuringActionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "FiscalYear2024RestructuringActionsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to fiscal year 2024 restructuring actions.", "label": "Fiscal Year 2024 Restructuring Actions [Member]", "terseLabel": "Fiscal Year 2024 Restructuring Actions" } } }, "auth_ref": [] }, "tech_FiscalYear2025RestructuringActionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "FiscalYear2025RestructuringActionsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to fiscal year 2025 restructuring actions.", "label": "Fiscal Year 2025 Restructuring Actions [Member]", "terseLabel": "Fiscal Year 2025 Restructuring Actions" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r815", "r825", "r835", "r867" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r815", "r825", "r835", "r867" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r815", "r825", "r835", "r867" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r815", "r825", "r835", "r867" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r815", "r825", "r835", "r867" ] }, "tech_ForwardContractAdditionalInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ForwardContractAdditionalInvestment", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the additional investment.", "label": "Forward Contract Additional Investment", "terseLabel": "Forward Contract, Additional Investment" } } }, "auth_ref": [] }, "tech_ForwardContractMilestoneAnnualEBITDA": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ForwardContractMilestoneAnnualEBITDA", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the milestone of annual EBITDA in forward contract.", "label": "Forward Contract Milestone Annual EBITDA", "terseLabel": "Forward Contract, Milestone, Annual EBITDA" } } }, "auth_ref": [] }, "tech_ForwardContractMilestoneAnnualRevenueRequired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ForwardContractMilestoneAnnualRevenueRequired", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the milestone of annual revenue in forward contract.", "label": "Forward Contract Milestone Annual Revenue Required", "terseLabel": "Forward Contract, Milestone, Annual Revenue Required" } } }, "auth_ref": [] }, "tech_ForwardContractMilestoneMultipleForTotalExpectedPayments": { "xbrltype": "pureItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ForwardContractMilestoneMultipleForTotalExpectedPayments", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the multiple for total expected payments of forward contract in milestone.", "label": "Forward Contract Milestone Multiple For Total Expected Payments", "terseLabel": "Forward Contract, Milestone, Multiple for Total Expected Payments" } } }, "auth_ref": [] }, "tech_ForwardStartingSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ForwardStartingSwapMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents forward starting swap.", "label": "Forward Starting Swap [Member]", "terseLabel": "Forward starting swaps" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
```

```
"localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r848" ] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GB", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "United Kingdom" } } }, "auth_ref": [] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Investments", "terseLabel": "Gain (loss) on investment(1)", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r99", "r102", "r889" ] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) from Litigation Settlement", "terseLabel": "Certain litigation charges", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": [ "r738", "r966" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r162", "r294", "r570", "r739", "r744", "r766", "r776", "r935", "r942" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Currency translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r301" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Gross Profit", "totalLabel": "Gross margin", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r89", "r94", "r145", "r201", "r288", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r505", "r733", "r738", "r923", "r926", "r927", "r928", "r929", "r971" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails" ], "lang": { "en-us": { "role": { "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r14", "r477" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails" ], "lang": { "en-us": { "role": { "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r14" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails" ], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r14" ] }, "tech_ImpactOfBusinessHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ImpactOfBusinessHeldForSale", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of impact on income from business held for sale.", "label": "Impact of Business Held for Sale", "terseLabel": "Impact of business held-for-sale(1)" } } }, "auth_ref": [] }, "tech_ImpairmentOfAssetsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ImpairmentOfAssetsHeldForSaleMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to impairment of assets held for sale pursuant to restructuring plan.", "label": "Impairment Of Assets, Held For Sale [Member]", "terseLabel": "Impairment of assets held-for-sale" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesToCarryingAmountOfNetIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-Lived", "negatedLabel": "Restructuring Impairment", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r305", "r912", "r958" ] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment charges related to the disposal group", "verboseLabel": "Impairment of assets held-for-sale", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r9", "r115", "r767" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Earnings before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r90", "r141", "r145", "r574", "r586", "r733", "r738", "r923", "r926", "r927", "r928", "r929" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Gain (loss) on equity method investment", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r9", "r91", "r140", "r243", "r256", "r271", "r284", "r585" ] }, "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-Sale, Excluding Discontinued Operations, before Income Tax", "terseLabel": "Impairment of assets held-for-sale", "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale including the portion attributable to the noncontrolling interest. Excludes discontinued operations." } } }, "auth_ref": [ "r119" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r318", "r325", "r328", "r495", "r499", "r502", "r614", "r616", "r674", "r723", "r769", "r1048" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r325", "r328", "r495", "r499", "r502", "r614", "r616", "r674", "r723", "r769", "r1048" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r202", "r440", "r444", "r445", "r446", "r447", "r448", "r449", "r452", "r454", "r455", "r456", "r629", "r762" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income taxes", "verboseLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r148", "r150", "r216", "r217", "r243", "r257", "r271", "r443", "r444", "r453", "r594", "r762" ] }, "tech_IncomeTaxExpenseBenefitDiscreteTaxItems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "IncomeTaxExpenseBenefitDiscreteTaxItems", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the income tax expense (benefit) related to discrete tax items.", "label": "Income Tax Expense Benefit Discrete Tax Items", "terseLabel": "Income tax expense (benefit), discrete tax items" } } }, "auth_ref": [] }, "tech_IncomeTaxExpenseBenefitOtherImmaterialDiscreteTaxItemsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "IncomeTaxExpenseBenefitOtherImmaterialDiscreteTaxItemsNet", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to other net immaterial discrete income tax expense (benefit).", "label": "Income Tax Expense Benefit Other Immaterial Discrete Tax Items Net", "terseLabel": "Income tax expense (benefit), other immaterial discrete tax items, net" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": ["r29", "r109", "r913", "r1004", "r1005"] }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Trade accounts and other receivables, net", "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Trade accounts payable, accrued expenses, contract liabilities, and other", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income taxes payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Employee Related Liabilities", "verboseLabel": "Salaries, wages and related accruals", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r8"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Change in operating assets and operating liabilities, net of acquisition:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": ["r8"] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails"], "lang": { "en-us": { "role": { "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Dilutive effect of stock options and restricted stock units (in shares)", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r224", "r225", "r226", "r238", "r405"] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r815", "r825", "r835", "r859", "r867", "r871", "r879"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r877"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r807", "r883"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r807", "r883"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r807", "r883"] }, "tech_InstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "InstrumentsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to instruments which typically consist of longer-lived assets.", "label": "Instruments [Member]", "terseLabel": "Instruments" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesToCarryingAmountOfNetIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Intangible assets, net", "totalLabel": "Total intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r304", "r953", "r955"] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Interest Expense, Nonoperating", "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": ["r253", "r909"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "verboseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r192", "r197", "r198"] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntersegmentEliminationMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment Eliminations", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": ["r144", "r243", "r251", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r738"] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": ["r114", "r728"] }, "tech_InventoryFinishedGoodsNetOfReservesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "InventoryFinishedGoodsNetOfReservesNonCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Non-current amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory Finished Goods Net Of Reserves Non Current", "terseLabel": "Inventory, Finished Goods, Net of Reserves, Non-current" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventories", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": ["r168", "r727", "r776"] }, "tech_InventoryNetCurrentAndNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "InventoryNetCurrentAndNonCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataInventoriesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of inventory, net of reserves, including both current and non-current portions.", "label": "Inventory Net Current And Non Current", "totalLabel": "Inventories, net" } } }, "auth_ref": [] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNoncurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Noncurrent", "terseLabel": "Long-term inventory", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": ["r901"] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataInventoriesDetails"], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": ["r114", "r729"] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails"], "lang": { "en-us": { "role": { "label": "Investment Income, Net", "terseLabel": "Interest income", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": ["r97", "r98", "r101"] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": ["r593", "r624", "r625", "r626", "r627", "r694", "r695"] }, "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments, Fair Value Disclosure, Total", "verboseLabel": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but

not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth_ref": ["r1013", "r1014", "r1024"] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Land [Member]", "terseLabel": "Land", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": ["r975"] }, "us-gaap_LegalCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalCostsPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Matters", "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights." } } }, "auth_ref": ["r338"] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Legal Fees", "terseLabel": "Litigation charges", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": ["r897"] }, "tech_LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "LesseeOperatingLeaseAssetAndLiabilitiesTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for asset and liabilities of operating leases of the lessee.", "label": "Lessee, Operating Lease, Asset and Liabilities [Table Text Block]", "terseLabel": "Schedule of table that summarizes the balance sheet classification of the Company's operating leases and amounts of right of use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company's operating leases" } } }, "auth_ref": [] }, "tech_LesseeOperatingLeaseCashFlowInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "LesseeOperatingLeaseCashFlowInformationTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash flow information of operating leases of the lessee.", "label": "Lessee, Operating Lease, Cash Flow Information [Table Text Block]", "terseLabel": "Schedule of the table that summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right of use assets obtained in exchange for new operating lease liabilities" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseDescriptionAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Schedule of the fair value of the lease liability by payment date for the operating leases by fiscal year", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r1035"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r526"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r526"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r526"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r526"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r526"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "verboseLabel": "Remainder 2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r1035"] }, "tech_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability To Be Paid After Year Four", "verboseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Amounts representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r526"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1034"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r515"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r81", "r137", "r582", "r776", "r915", "r932", "r1028"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r71", "r157", "r201", "r288", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r471", "r474", "r475", "r505", "r776", "r971", "r1036", "r1037"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r490", "r1013"] }, "tech_LineOfCreditFacilityAdditionalBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "The element representing the additional borrowing capacity under a line of credit.", "label": "Line Of Credit Facility Additional Borrowing Capacity", "terseLabel": "Line of Credit Facility, Additional Borrowing Capacity" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r68", "r72"] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit, Current", "terseLabel": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": ["r69", "r134"] }, "us-

gaap_LitigationReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserve", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Estimated Litigation Liability", "terseLabel": "Accrued litigation", "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs." } } }, "auth_ref": ["r74", "r966"] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt and Lease Obligation", "terseLabel": "Long-term debt obligations", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": ["r19", "r578"] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestments", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Investments", "terseLabel": "Long-term investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": ["r159"] }, "tech_LunaphoreTechnologiesSaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "LunaphoreTechnologiesSaMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Lunaphore Technologies SA.", "label": "Lunaphore Technologies SA [Member]", "terseLabel": "Lunaphore Technologies SA." } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r334", "r335", "r336", "r337", "r401", "r439", "r493", "r536", "r613", "r615", "r623", "r642", "r643", "r692", "r696", "r698", "r699", "r709", "r721", "r722", "r743", "r751", "r759", "r770", "r771", "r772", "r773", "r786", "r973", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r851"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r851"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r334", "r335", "r336", "r337", "r401", "r439", "r493", "r536", "r613", "r615", "r623", "r642", "r643", "r692", "r696", "r698", "r699", "r709", "r721", "r722", "r743", "r751", "r759", "r770", "r771", "r772", "r786", "r973", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r870"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r878"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r852"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r196"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r196"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r107", "r108", "r110"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net earnings", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r95", "r110", "r142", "r155", "r178", "r181", "r185", "r201", "r207", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r231", "r288", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r461", "r468", "r487", "r505", "r588", "r671", "r687", "r688", "r800", "r971"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Income available to common shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": ["r189", "r209", "r210", "r211", "r212", "r220", "r221", "r233", "r238", "r468"] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Income available to common shareholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": ["r189", "r222", "r227", "r228", "r229", "r230", "r233", "r238"] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsContractualAmountsOfOutstandingInstrumentsDetails", "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "Net Investment Hedging [Member]", "terseLabel": "Net investment hedge", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": ["r52"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements and Relevant New Standards Issued Not Yet Adopted", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r851"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r815", "r825", "r835", "r859", "r867"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r842"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r841"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r859"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r878"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r878"] }, "tech_NoncashPortionOfLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "NoncashPortionOfLeaseExpense", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "The amount of

noncash portion of lease expense during the period.", "label": "Leases, net", "terseLabel": "Leases, net" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "terseLabel": "Other income (expense)", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r100"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "lang": { "en-us": { "role": { "label": "Other income (expense)." } } }, "auth_ref": [] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Financing Receivable, after Allowance for Credit Loss", "terseLabel": "Promissory note related to sale of inventory of disposal group", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": ["r292", "r658", "r930", "r1044"] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise. (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r739", "r925"] }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails"], "lang": { "en-us": { "role": { "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "(Gain) Loss Recognized in Accumulated Other Comprehensive Loss", "verboseLabel": "Amounts before reclassifications", "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": ["r22"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r145", "r733", "r923", "r926", "r927", "r928", "r929"] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Fixed Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": ["r520", "r775"] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "http://www.bio-techne.com/20211231/role/DisclosureLeasesFairValueOfLeaseLiabilityByPaymentDateDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total lease obligations", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r518"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities", "verboseLabel": "Operating lease liabilities - current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r518"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities", "verboseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r518"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesCashPaidDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r519", "r522"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right of use assets", "verboseLabel": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r517"] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": ["r525", "r775"] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesBalanceSheetClassificationDetails"], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r524", "r775"] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r265", "r266", "r267", "r268", "r269", "r272", "r738", "r739"] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": ["r169", "r776"] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets", "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataOtherAssetsDetails"], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "totalLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r164"] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation income (loss)", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": ["r7", "r12", "r128"] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss), before tax", "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r7", "r12", "r128"] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParentAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss), before tax:" } } }, "auth_ref": [] }, "tech_OtherComprehensiveIncomeLossBeforeTranslationReclassificationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "OtherComprehensiveIncomeLossBeforeTranslationReclassificationNetOfTax", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification of translation adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Translation Reclassification, Net of Tax", "verboseLabel": "Other comprehensive income (loss) before reclassification" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": ["r176"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other comprehensive income (loss)", "documentation": "Amount after tax and reclassification adjustments of other comprehensive

```
income (loss)." } } }, "auth_ref": [ "r13", "r17", "r179", "r182", "r186", "r213", "r506", "r507", "r512", "r571", "r589", "r904", "r905" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income (loss), net of tax", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r128", "r179", "r182", "r213" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent", "negatedLabel": "Tax (expense) benefit", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r12", "r128" ] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Other Current Assets [Member]", "terseLabel": "Other current assets", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r54", "r62" ] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpense" ], "lang": { "en-us": { "role": { "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other Income / (Expense)", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r898", "r1002" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangibles", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r745", "r946", "r947", "r948", "r949", "r950", "r951", "r953", "r955", "r956", "r957" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r70", "r776" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r73" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets", "verboseLabel": "Other assets", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities", "verboseLabel": "Other long-term liabilities", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities." } } }, "auth_ref": [] }, "tech_OtherNonoperatingIncomeAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "OtherNonoperatingIncomeAndExpense", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseScheduleOfComponentsOfOtherIncomeExpenseDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating income and expense", "terseLabel": "Other non-operating income (expense), net" } } }, "auth_ref": [] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other Operating Activities, Cash Flow Statement", "terseLabel": "Other operating activity", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r851" ] }, "tech_OtherRevenuesFromBusinessHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "OtherRevenuesFromBusinessHeldForSaleMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other revenues relating to the business that has met the held-for-sale criteria.", "label": "Other Revenues from Business Held for Sale [Member]", "terseLabel": "Other Revenues from Business Held for Sale" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r813", "r823", "r833", "r865" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r816", "r826", "r836", "r868" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r816", "r826", "r836", "r868" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PatentsMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Patents [Member]", "terseLabel": "Patents", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r126", "r946", "r947", "r948", "r949", "r951", "r953", "r956", "r957" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r840" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Re-purchases of common stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r105" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "negatedLabel": "Cash payments", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r327", "r911" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Cash dividends", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r105" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Taxes paid on RSUs and net share settlements", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r191" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedLabel": "Purchases of available-for-sale investments", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r25", "r190", "r281" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r26", "r465" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisitions, net of cash acquired", "terseLabel": "Cash paid, net of cash acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r26" ] }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Investments", "negatedLabel": "Investment in Spear Bio", "verboseLabel": "Payments in Investment", "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r147", "r193" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r104" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r850" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r850" ] },
```

"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r842"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": ["r859"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": ["r852"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": ["r841"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r976", "r977", "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r843"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r887"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r842"] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": ["http://www.bio-techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Policy Text Block [Abstract]" } } }, "auth_ref": [] }, "tech_PreTaxRestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "PreTaxRestructuringCharges", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of pre-tax restructuring charges.", "label": "Pre-tax Restructuring Charges", "terseLabel": "Pre-tax restructuring charges" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Distributions from (Investments in) Wilson Wolf", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } } }, "auth_ref": ["r195", "r910"] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Long-Term Lines of Credit", "verboseLabel": "Borrowings under line-of-credit agreement", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": ["r27"] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sale of available-for-sale investments", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r24", "r190", "r281", "r282"] }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfPropertyHeldForSale", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Sale, Property, Held-for-Sale", "terseLabel": "Proceeds from sale of assets held-for-sale", "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth." } } }, "auth_ref": ["r103"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock option exercises", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r6", "r15"] }, "tech_ProductAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ProductAndServicesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the product and services provided by the company.", "label": "Product and Services [Member]", "terseLabel": "Product and Services" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": ["r274", "r537", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r724", "r752", "r785", "r786", "r787", "r790", "r791", "r967", "r968", "r974", "r1045", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": ["r274", "r537", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r724", "r752", "r785", "r786", "r787", "r790", "r791", "r967", "r968", "r974", "r1045", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076"] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings", "verboseLabel": "Net earnings", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r155", "r178", "r181", "r194", "r201", "r207", "r213", "r216", "r217", "r288", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r350", "r351", "r461", "r468", "r469", "r472", "r473", "r487", "r505", "r574", "r587", "r630", "r671", "r687", "r688", "r763", "r764", "r801", "r906", "r971"] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r10", "r527"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, cost", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r117", "r160", "r584"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r10", "r527", "r575", "r584", "r776"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": ["r10"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r117", "r527"] }, "tech_ProteinSciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ProteinSciencesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "documentation": "Consist of the remaining portion of the Biotechnology segment and the Protein Platforms operating segment.", "label": "Protein Sciences [Member]", "terseLabel": "Protein Sciences" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r840"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r840"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": {

```
"en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r334", "r335", "r336", "r337", "r394", "r401", "r429", "r430", "r431", "r439", "r493", "r534",
"r535", "r536", "r613", "r615", "r623", "r642", "r643", "r692", "r696", "r698", "r699", "r709", "r721", "r722", "r743", "r751", "r759", "r770", "r771", "r772", "r773", "r786",
"r794", "r962", "r973", "r1016", "r1039", "r1040", "r1041", "r1042", "r1043" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "RangeMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": {
"en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r334", "r335", "r336", "r337", "r394", "r401", "r429", "r430", "r431", "r439", "r493", "r534",
"r535", "r536", "r613", "r615", "r623", "r642", "r643", "r692", "r696", "r698", "r699", "r709", "r721", "r722", "r743", "r751", "r759", "r770", "r771", "r772", "r773", "r786",
"r794", "r962", "r973", "r1016", "r1039", "r1040", "r1041", "r1042", "r1043" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "crdr":
"debit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss
"http://www.bio-
techne.com/role/DisclosureFairValueMeasurementsPretaxAmountOfGainsAndLossesOnOurHedgingInstrumentsAndClassificationOfThoseGainsAndLossesDetails" ], "lang": {
"en-us": { "role": { "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedLabel": "Amounts reclassified out", "terseLabel": "(Gain)
Loss Reclassified into Income", "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } },
"auth_ref": [ "r22" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel":
"Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r808", "r818", "r828", "r860" ] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "presentation": [ "http://www.bio-
techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Lines of Credit", "negatedLabel":
"Repayments of long-term debt", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby
letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r106", "r914" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit",
"presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role":
{ "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development", "documentation": "Amount of expense for
research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in
transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture
formation or both, used in research and development activity." } } }, "auth_ref": [ "r1003" ] }, "tech_RestOfWorldMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.bio-techne.com/20241231", "localname": "RestOfWorldMember", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Rest of the geographical
locations in the world.", "label": "Rest of World [Member]", "terseLabel": "Rest of World" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r809", "r819", "r829", "r861" ] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" }
} }, "auth_ref": [ "r810", "r820", "r830", "r862" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r817", "r827",
"r837", "r869" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember",
"presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]",
"terseLabel": "Restricted Stock", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or
until specified performance conditions are met." } } }, "auth_ref": [ "r30" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel":
"Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when
specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "crdr": "credit", "presentation": [ "http://www.bio-
techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails" ], "lang": { "en-us": {
"role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Common stock issued for restricted stock awards",
"documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares
issued. Excludes cash used to satisfy grantee's tax withholding obligation." } } }, "auth_ref": [] }, "tech_RestructuringActionsPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "RestructuringActionsPolicyTextBlock", "presentation": [ "http://www.bio-
techne.com/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of
accounting policy for restructuring actions.", "label": "Restructuring Actions [Policy Text Block]", "terseLabel": "Restructuring actions" } } }, "auth_ref": [] }, "us-
gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label":
"Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Positions eliminated during the period as a percentage", "documentation":
"The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } },
"auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr":
"debit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring
Charges", "negatedLabel": "Restructuring and restructuring-related costs", "verboseLabel": "Restructuring costs", "documentation": "Amount of expenses associated with exit
or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9", "r330",
"r331", "r963" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringCostAndReserveAxis", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "label":
"Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r326", "r327", "r331", "r332" ] },
"tech_RestructuringCostsNetOfAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname":
"RestructuringCostsNetOfAdjustments", "crdr": "debit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": {
"documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan for the current period, net of adjustments.", "label":
"Restructuring costs, net of adjustments", "terseLabel": "Restructuring costs, net of adjustments" } } }, "auth_ref": [] }, "us-
gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "label":
"Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or
comprehensive income that includes restructuring charges." } } }, "auth_ref": [ "r890", "r891" ] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "label":
"Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "label":
"Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-
gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "label":
"Restructuring Reserve, Accrual Adjustment", "terseLabel": "Adjustments", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the
restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": [ "r327", "r332" ] }, "us-gaap_RestructuringReserveNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveNoncurrent", "crdr": "credit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "label":
"Restructuring Reserve, Noncurrent", "periodEndLabel": "Accrued restructuring actions balances", "periodStartLabel": "Accrued restructuring actions balances",
"documentation": "Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings
pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-
time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an
ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset." } } }, "auth_ref": [ "r902", "r964", "r965" ] }, "us-
gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "label":
"Restructuring Reserve, Settled without Cash", "negatedLabel": "Non-cash adjustments", "documentation": "Amount of decrease in the reserve for full or partial settlement
through consideration other than cash." } } }, "auth_ref": [ "r327", "r332" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [ "http://www.bio-
techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)",
"verboseLabel": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r78", "r123", "r581", "r620", "r622",
"r628", "r651", "r776" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RetainedEarningsMember", "presentation": [ "http://www.bio-
techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails" ], "lang": { "en-us": {
"role": { "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [
"r152", "r204", "r205", "r206", "r208", "r213", "r215", "r217", "r289", "r290", "r317", "r450", "r451", "r458", "r459", "r460", "r462", "r467", "r468", "r478", "r480", "r481",
"r483", "r485", "r514", "r516", "r617", "r619", "r631", "r1079" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition" } } }, "auth_ref": [] },
```

```
"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Revenues, net", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r143", "r144", "r243", "r250", "r251", "r265", "r271", "r274", "r276", "r278", "r389", "r390", "r537" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognition" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r151", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r393" ] }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureLeasesCashPaidDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r523", "r775" ] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyMember", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Royalty [Member]", "verboseLabel": "Royalty revenues", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r975" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r878" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r878" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r218", "r402", "r892", "r920" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of changes in Accumulated Other Comprehensive Income (Loss)", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r22", "r1030", "r1031" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r55", "r58", "r477" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Derivative Instruments [Table Text Block]", "terseLabel": "Schedule of contractual amounts of the outstanding instruments", "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r14", "r48", "r49", "r50", "r53", "r56", "r58", "r60", "r61" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of the calculation of basic and diluted earnings per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r922" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r285", "r286", "r287", "r457", "r893", "r894", "r895", "r1006", "r1007", "r1008", "r1009" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of information by level for financial assets and liabilities that are measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r1013", "r1014" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of changes in carrying amount of net intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r745", "r952" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of changes to the carrying amount of goodwill", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r744", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of intangible assets", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r933", "r945" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r20", "r82", "r83", "r84" ] }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Schedule of other assets", "documentation": "Tabular disclosure of noncurrent assets." } } }, "auth_ref": [ "r901" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of the components of other income (expense)", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of the aggregate purchase price of the acquisitions that was allocated to the assets acquired and liabilities assumed", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r125" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Schedule of restructuring charges", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r37", "r120", "r121" ] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": [ "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": [ "r34", "r89" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.bio-
```

techne.com/20211231/role/DisclosureSegmentInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of financial information by reportable segment", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": ["r31", "r32", "r33"] }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of the Consolidated Changes in Equity", "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented." } } }, "auth_ref": ["r13"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization expense for intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r745", "r954"] }, "tech_SecondPartOfForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "SecondPartOfForwardContractMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the second part of the forward contract.", "label": "Second Part of Forward Contract [Member]", "terseLabel": "Second Part of Forward Contract" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r803"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r805"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails"], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r143", "r144", "r145", "r146", "r243", "r246", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r273", "r278", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r316", "r329", "r333", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r735", "r738", "r739", "r744", "r789", "r1045", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": ["r276", "r277", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r635", "r638", "r640", "r693", "r697", "r700", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r725", "r753", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r788", "r794", "r974", "r1045", "r1049", "r1050", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformation"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r146", "r243", "r245", "r246", "r247", "r248", "r249", "r261", "r263", "r264", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r278", "r734", "r736", "r737", "r738", "r740", "r741", "r742"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "negatedLabel": "Corporate general, selling, and administrative expenses", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r96"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, General and Administrative Expenses", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails"], "lang": { "en-us": { "role": { "label": "Service [Member]", "terseLabel": "Services", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": ["r752"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r8"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted, shares (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r421"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, weighted average exercise price (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r421"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r761"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "verboseLabel": "Common stock issued for exercise of options intrinsic values", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": ["r425"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "terseLabel": "Number of expired vested stock options (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r417"] }, "tech_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOptionsInPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredOptionsInPeriodValue", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Total value of options that expired during period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expired Options in Period, Value", "terseLabel": "Total net pre-tax value of options that expired" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted, shares (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r414"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType",

```
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted average fair values (in dollars per share)", "documentation":
"The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } },
"auth_ref": [ "r424" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": {
"label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r407", "r408", "r409",
"r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431",
"r432" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureShareBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based
Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted, weighted average exercise price (in dollars per share)",
"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r414" ] }, "us-
gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit",
"presentation": [ "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-Term
Investments", "terseLabel": "Short-term available-for-sale investments", "documentation": "Amount of investments including trading securities, available-for-sale securities,
held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r138", "r139", "r903" ] }, "tech_SpearBioMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "SpearBioMember", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents Spear Bio.", "label": "Spear Bio [Member]", "terseLabel": "Spear Bio" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-
techne.com/20211231/role/DisclosureSegmentInformationFinancialInformationRelatingToReportableSegmentsDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]",
"documentation": "Information by business segments." } } }, "auth_ref": [ "r143", "r144", "r145", "r146", "r153", "r243", "r246", "r249", "r250", "r251", "r252", "r253", "r254",
"r255", "r256", "r257", "r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r271", "r272", "r273", "r278", "r295", "r296", "r297", "r298",
"r299", "r300", "r301", "r302", "r303", "r316", "r319", "r329", "r333", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r735", "r738",
"r739", "r744", "r789", "r1045", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064",
"r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss
"http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails",
"http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails" ], "lang": { "en-us": { "role": {
"label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r76", "r79", "r80", "r152", "r183", "r184", "r185",
"r204", "r205", "r206", "r208", "r213", "r215", "r217", "r244", "r289", "r290", "r317", "r378", "r450", "r451", "r458", "r459", "r460", "r462", "r467", "r468", "r478", "r479",
"r480", "r481", "r482", "r483", "r485", "r506", "r508", "r509", "r510", "r511", "r512", "r514", "r516", "r528", "r589", "r617", "r618", "r619", "r631", "r689" ] },
"srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } },
"auth_ref": [ "r276", "r277", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558",
"r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r635", "r638", "r640", "r693", "r697", "r700", "r710", "r711", "r712", "r713", "r714",
"r715", "r716", "r717", "r718", "r719", "r720", "r725", "r753", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r788", "r794", "r974", "r1045", "r1049", "r1050",
"r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070",
"r1071", "r1072", "r1073", "r1074", "r1075", "r1076" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementLineItems", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-
techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-
techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails", "http://www.bio-
techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-
techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails",
"http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails", "http://www.bio-
techne.com/20211231/role/DisclosureShareBasedCompensationDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss
"http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataNarrativeDetails",
"http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails",
"http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails" ], "lang": { "en-us": { "role": {
"label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r204", "r205", "r206", "r244", "r516", "r537", "r624", "r632", "r644", "r645",
"r646", "r647", "r648", "r649", "r650", "r653", "r654", "r655", "r656", "r657", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r668", "r670", "r672", "r673",
"r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r689", "r795" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "auth_ref": []
}, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario
[Axis]" } } }, "auth_ref": [ "r218", "r402", "r892", "r896", "r920" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementTable", "presentation": [ "http://www.bio-
techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-
techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails", "http://www.bio-
techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-
techne.com/20211231/role/DisclosureDebtAndOtherFinancingArrangementsNarrativeDetails", "http://www.bio-
techne.com/20211231/role/DisclosureFairValueMeasurementsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails", "http://www.bio-
techne.com/20211231/role/DisclosureFairValueMeasurementsNarrativeDetails", "http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails",
"http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataChangesInCarryingAmountOfGoodwillDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSelectedBalanceSheetDataPropertyAndEquipmentDetails", "http://www.bio-
techne.com/20211231/role/DisclosureShareBasedCompensationDetails", "http://www.bio-
techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss
"http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.bio-techne.com/role/DisclosureSelectedBalanceSheetDataNarrativeDetails",
"http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails",
"http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails" ], "lang": { "en-us": { "role": {
"label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position,
cash flows, and shareholders' equity." } } }, "auth_ref": [ "r204", "r205", "r206", "r244", "r279", "r516", "r537", "r624", "r632", "r644", "r645", "r646", "r647", "r648", "r649",
"r650", "r653", "r654", "r655", "r656", "r657", "r659", "r660", "r661", "r662", "r664", "r665", "r666", "r667", "r668", "r670", "r672", "r673", "r675", "r676", "r677", "r678",
"r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r689", "r795" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us":
{ "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r812", "r822", "r832",
"r864" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation
Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number
of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.bio-
techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails" ], "lang": { "en-us": {
"role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued to employee stock purchase plan (in shares)",
"documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r13", "r75", "r76", "r123" ] }, "us-
gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.bio-
techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails" ], "lang": { "en-us": {
"role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Common stock issued for restricted stock awards (in
shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r13", "r75", "r76",
"r123" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureShareBasedCompensationDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "verboseLabel": "Common stock issued for exercise of options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r13", "r75", "r76", "r123", "r415"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common stock issued to employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r13", "r75", "r76", "r123"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense", "crdr": "credit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Common stock issued for exercise of options", "documentation": "Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "negatedLabel": "Share repurchases (in shares)", "terseLabel": "Stock Repurchased During Period, Shares (in shares)", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": ["r13", "r75", "r76", "r123"] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": ["http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "negatedLabel": "Share repurchases", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": ["r13", "r75", "r76", "r123"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationChangesInAccumulatedOtherComprehensiveIncomeLoss "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets", "http://www.bio-techne.com/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationConsolidatedChangesInEquityDetails"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Bio-Techne's shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r76", "r79", "r80", "r113", "r652", "r669", "r690", "r691", "r776", "r802", "r915", "r932", "r1028", "r1079"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r529", "r530"] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetData"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "Supplemental Balance Sheet and Cash Flow Information", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r899"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsTables", "http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareTables", "http://www.bio-techne.com/20211231/role/DisclosureFairValueMeasurementsTables", "http://www.bio-techne.com/20211231/role/DisclosureLeasesTables", "http://www.bio-techne.com/20211231/role/DisclosureOtherIncomeExpenseTables", "http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionTables", "http://www.bio-techne.com/20211231/role/DisclosureSegmentInformationTables", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataTables", "http://www.bio-techne.com/20211231/role/DisclosureSupplementalEquityAndAccumulatedOtherComprehensiveIncomeLossInformationTables"], "lang": { "en-us": { "role": { "label": "Table Text Block [Abstract]", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r858"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r850"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r857"] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeNamesMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureAcquisitionsPreliminaryAndFinalFairValueOfAssetsAndLiabilitiesAssumedDetails", "http://www.bio-techne.com/20211231/role/DisclosureSelectedBalanceSheetDataIntangibleAssetsDetails", "http://www.bio-techne.com/role/DisclosureAcquisitionsNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Trade Names [Member]", "terseLabel": "Tradenames", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r45", "r946", "r947", "r948", "r949", "r950", "r951", "r953", "r955", "r956", "r957"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r877"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r879"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.bio-techne.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r880"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r881"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r881"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r879"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r879"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r882"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r880"] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesRestructuringChargesDetails"], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r326", "r327", "r331", "r332"] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureRevenueRecognitionDisaggregationOfRevenueDetails"], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockNoParValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "UndesignatedCapitalStockNoParValue", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Represents the no par value for undesignated capital stock.", "label": "Undesignated capital stock, no par (in dollars per share)", "terseLabel": "Undesignated capital stock, no par (in dollars per share)" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "UndesignatedCapitalStockSharesAuthorized", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Represents the shares authorized for undesignated capital stock.", "label": "Undesignated capital stock, shares authorized (in shares)", "terseLabel": "Undesignated capital stock, shares authorized (in shares)" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "UndesignatedCapitalStockSharesIssued", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Represents the shares issued for undesignated capital stock.", "label": "Undesignated capital stock, shares issued (in shares)", "terseLabel": "Undesignated capital stock, shares issued (in shares)" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "UndesignatedCapitalStockSharesOutstanding", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "documentation": "Represents the shares outstanding for undesignated capital stock.", "label": "Undesignated capital stock, shares outstanding (in shares)", "terseLabel": "Undesignated capital stock, shares outstanding (in shares)" } } }, "auth_ref": [] }, "tech_UndesignatedCapitalStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "UndesignatedCapitalStockValue", "crdr": "credit", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "documentation": "Represents the value of undesignated capital stock as of the balance sheet date.", "label": "Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding", "terseLabel": "Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding" } } }, "auth_ref": [] }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails"], "lang": { "en-us": { "role": { "label": "Undistributed Earnings

(Loss) Allocated to Participating Securities, Basic", "negatedLabel": "Income allocated to participating securities", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method." } } }, "auth_ref": ["r232", "r235", "r236"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } } }, "auth_ref": ["r876"] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureLeasesNarrativeDetails"], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": ["r521", "r775"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": ["r846"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r222", "r238"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureEarningsPerShareSharesUsedInEarningsPerShareComputationsDetails", "http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average shares outstanding - basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r220", "r238"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": ["http://www.bio-techne.com/20211231/role/StatementCondensedConsolidatedStatementsOfEarningsAndComprehensiveIncome"], "lang": { "en-us": { "role": { "label": "Weighted average common shares outstanding:" } } } }, "auth_ref": [] }, "tech_WilsonWolfCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bio-techne.com/20241231", "localname": "WilsonWolfCorporationMember", "presentation": ["http://www.bio-techne.com/20211231/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesInvestmentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Wilson Wolf Corporation.", "label": "Wilson Wolf Corporation [Member]", "terseLabel": "Wilson Wolf Corporation" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": ["r844"] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-8" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r49": { "role":

```
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A",

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "65", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-65" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "66", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",

```
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-21" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r249": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-22" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r253": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r257": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-25" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r261": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" },
"r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-30" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r267": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r270": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-32" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r276": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r279": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-
10-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-
50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-
10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r288": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-
10-65-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r294": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-
20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r297": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-
50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r301": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-
50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-
30-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r308": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r309": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-
30-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r313": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",

```
"Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-11" }, "r376": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-11" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-11" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r380": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" },
"r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r383": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-
50-12" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r387": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r388": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r391": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r394": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r396": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r397": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r398": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r399": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r400": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r401": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-
10-35-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r436": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
```

```
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r440": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/740/tableOfContent" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r442": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" },
"r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r447": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r450": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r451": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8",
"Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r452": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r453": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r454": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r455": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r458": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r459": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r460": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-
323-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r464": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-
30-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r468": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-
45-25" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r472": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r473": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r474": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-
50-4A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-
20-65-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r481": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r482": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r483": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r484": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r488": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r492": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r493": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r494": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-
10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r499": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",

"Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r625": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r626": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r627": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r628": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" },
"r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r631": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r635": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r636": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r637": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-6" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r641": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r642": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-
45-3" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-
320-S99-12" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section":
"S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r696": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r697": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r698": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r699": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r700": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r701": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r702": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r703": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A",
"Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r704": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r705": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r706": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r707": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r708": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r709": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r710": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r711": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r712": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r713": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r714": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r715": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r716": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r717": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r718": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r719": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r720": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r721": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r724": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40",
"Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-
45-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r728": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r729": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r730": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" },
"r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-
55-47" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r736": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r739": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-
55-54" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r743": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20",
```

```
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r785": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Sentence": "A" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
```

```
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph":
"a", "Subparagraph": "1" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-
F", "Section": "19", "Paragraph": "b" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r842": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "i" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "iii" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "v" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r851": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "3" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "4" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r856": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "iii" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r860": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" },
"r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r864": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "C" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r867": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "ii" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r873": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "C" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r876": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2",
"Subparagraph": "ii", "Sentence": "F" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "a", "Paragraph": "1" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r881": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",
"Subparagraph": "C" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408",
"Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r885": { "role",
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "A", "Number": "229" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i",
"Number": "229" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" },
"r889": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r890": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r891": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r892": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r893": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r894": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r895": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r896": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r897":
{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-
03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r898": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI":
"https://asc.fasb.org/610/tableOfContent" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name":
```

"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 84 0001558370-25-000689-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-25-000689-xbrl.zip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

M5%11>Q<7%UV=FLCTY49Y9I2&Y"\XFH_A^Y^2T@]$D-G1116Y'9 D<+]:RV A, MR5A1(6@E/E'H#=DR@;SX%N?E0OE46.PUU"%SJ.ML5C M&%7X1A7ML%EY-<7$;$1K%1=S+WP#{]"7/Z.C3<%+"?[X_GAKL*"'_M%H3>.8$,=+MWY0D;8@&$X8?R'&ZCTR:I.C0?4BF@!Z$& DA<.^6&#}>V"UT M+5S GT-!'$Q:;%YLH,WF7'!=%!<7Y^B#)R>D0Q*)\/MJ}'*

}?)@,K_'79'1W M>SV8PL-D"G_NAP_3"1G=D.'@\>'VX=<)&3P@W?WXKH9D\FTXG$Y,,/>M]%=4+6\<[[D2J,6_M1G!/=ZO*5X/)-W)S-_K1PEP"\S57EN.I0+ ()#&ZLC6IW37UZ*YZ@++#S)FE;IF M/N5.A/-.G%N!OC@#G/N [:MH!#V23B+(),LGF &DIO(@'Z)7R[]0)%V8ESTDEW$ZXPZP M, 7O I?9)?YP4-DFCSG+]T;,3^>O^1Z"*

*{H)H)0AJ0;0:Q)O'#H3)*55(I$OK M6-4=*T'WGE%UN/((IRC=-#MD>'"!A>+2ZIX69 YF%R30YWG'2KE*^G],=%"13Z8;ERJ%*\3FWM$$ESE*5S>0+G_*^$(J& M'JGF*"N_A,@NQ*E&0,^(:!/ZWP%:PUWGE*W M GK_KK;[:@DC 9O*K(^,\TG]*7LCYN,[0R>>W//!9,S*>%%OME,Q1*02[1@=$V=+\&,T94PD!;0*

MI35HG::ZT^C:&>XsU_KMP(S&$LO43*2ZYNQ&WV%VAQSAA3(FB M2)=\B"3^A.X3Y8X!Y35_?,0tRC*TSE,R"11M'(S_XK*:*&A2$?]R!FJ4!!7 M"B%

(,SQ=L74SP$N6B!Z1:GA6OOQ?PQ1%(!M<'$8I3>V4_RUUAF?]\EV5^ M\B&33UM+C2%>SR>,YN.4[5"#)H'K4KD>S2=\(?28%"JJI?X0=,Z!H0MSG+1 M?2]9!I?HG<"_S<@>3H9*

M$YGJ;NF4:.8ELJ6O.9+XHQ;%$&YR"-[8B /Y.W M"'79!+Z P@AG/P]G)(:DY+3H[+JX5W6)Q8S4.1ZI+2LJ+6)U%DZV+7R8D3G+*

*M(Y,6T$*QTU)#I74#,SCG>7!*5@%:G$PX7;,9#A3TH P7WX0%3?A 2IQ#*L3, MS&#$[V;>/Y2]NQ?AZ# 13-*26S2KS=<73\&;5'BD5@NW8A, MP:S&JQ 22FEQ*=F#O<*

<_%O,ZU>;W[^ (),E?N#W$}/]JF[PW70R:TIES=>))&YW'.C?~0U+AW&<,/_6;798(!%AE(Z$\3]//,0%:T4M8GLO&A7C9J V MH5?SN&>+XBX+2<7(%5"8T#K+HY4Y#=/"L]?

B4C%.VTA-@)WG 2L[;=)B5V^) MHABJ)H)G4]Y=)## "T8[{QL4=*X'52XR1W>97=]ZUF[+F44NT@E0GKBSS6 M!7O36[!VGS,OAJN4S@!8KV*

*D6;IWO(5M]^G;LE%&"9T)ML+Q16XFMT7L7:.! M*8FY>ON9LD9D -+W^X=9V^U,3BZE"I2ICT7\C[>]0@%+@/++#_ L_-42[W]^ M"S?;EHW9W]YF'ANGO%):D4BMUO/VF:=\H!*

(O.GXJ.Z]6@M0Q/HWE$41E@`[\9[ESI+X8[FP@<@)BNA7_7BZ9,U;DRGPGE M>DC^0/S]{RN;G*4UZY-+?,BUZF0A/%>>\GL3P U MPD"'EX@$/GZ1!#]V=2MPZ+QM5NI

*4LU>47FQ%L+X;_91^%;Q;6$I+4A*C=9] M=G.?L81B>TG:9\J%OA+2@[Z5&HE1(+\Q>Y%%'#]7DKFQ;S2?+CW%LLQUO.W- ME3 [9^["NG+G#+6-*

NQ6C.9F"6^I\]14L8MQVK9UW&<'BPGG$BH3F*5G<%NT]D$+/Y4SIKSL M5NQB(C-693N0H(9J.0<8{RC,(QN^]M:HO,:%.:IF?/(O&MJ^Z\H\X4{HST)@^I='= &W@. M>:- 6=382FS

L<{U BV".YUB+X&M@,$E>%(=>XO//KLCHV$P=5+O\F:)Q93 M]Y&M/.GC3L.(LWR%\U"""3=$0[20]3B,%"F3>QRK@K$K&{_S?:A/]A]'MD M!0UZH-2:HH%#A)7:.R?M5*

MFQPZJVL3LI##G3!OE:SP6N5EJL6(5" M%GSJQ'P=?-7I}3NGU4M_3M5,BPM49T!JDH9%/)T&52S^$V]DDCD>G7RC^F M#_.&IQU\("K*<_UD^Y7+/F; 0C_?#73;EUUL/]"&?*

@>@.ZU:X0HX];/:V?LN MP@ O<#!>-!J^&(Y >Z)^%4R@$U>+6'$<<_<&9-ADXVM M_C^,E&/!SRQHSWOLZU;W%N?N=A @0G!3/G<#]" 7Z47K+X2(T{A M%;=M0'8R '+!'0>'-/%S2*

*M=&.[9TS"K0.K2V&)=ZCO%HI[G>&B;Q6TO9'.EI M(RLRA+-&*KF>@*&67%>VM-BR6;@E$& {)}3&!?P%:-A#R.:<)7C&.A=[#4EN1>S9T3/5$&]*

M2V[_EI(..PK^^Q0TK@JLHF\7Z96&.T\L((BXN5KXKKG^YQ=\ZDT2P&$$M(+,AQ1TQPN2MP]7'H7.M8D-,]G!X/QPDY?_}MYP5 M)>E-M,1=.=Z.L8GO6?\6MZL=0.M3#8\#NS_#*

<)#TR,Q M>)<2[!QY(3BQ+,%,;:?W$"I+.[-V="6OL".J8<[?,%!F?Z"FN(V"Z6,Z1[5 MV%X*9NZFE\0/@(Q]7Z6[#WBYJR:?7199OHVZJI3CWQ1S^^E.]YZQ9\8-OA^8ZF*

MO=5Y&FNU5/Z82G\I^KY3&=,>)XO//KLCHV$P=5+O\F:)Q93 M]Y&M/.GC3L.(LWR%\U"""3=$0[20]3B,%"F3>QRK@K$K&{_S?:A/]A]'MD M!0UZH-2:HH%#A)7:.R?M5*

MFQPZJVL3LI##G3!OE:SP6N5EJL6(5" M%GSJQ'P=?-7I}3NGU4M_3M5,BPM49T!JDH9%/)T&52S^$V]DDCD>G7RC^F M#_.&IQU\("K*<_UD^Y7+/F; 0C_?#73;EUUL/]"&?*

@>@.ZU:X0HX];/:V?LN MP@ O<#!>-!J^&(Y >Z)^%4R@$U>+6'$<<_<&9-ADXVM M_C^,E&/!SRQHSWOLZU;W%N?N=A @0G!3/G<#]" 7Z47K+X2(T{A M%;=M0'8R '+!'0>'-/%S2*

*M=&.[9TS"K0.K2V&)=ZCO%HI[G>&B;Q6TO9'.EI M(RLRA+-&*KF>@*&67%>VM-BR6;@E$& {)}3&!?P%:-A#R.:<)7C&.A=[#4EN1>S9T3/5$&]*

M2V[_EI(..PK^^Q0TK@JLHF\7Z96&.T\L((BXN5KXKKG^YQ=\ZDT2P&$$M(+,AQ1TQPN2MP]7'H7.M8D-,]G!X/QPDY?_}MYP5 M)>E-M,1=.=Z.L8GO6?\6MZL=0.M3#8\#NS_#*

<)#TR,Q M>)<2[!QY(3BQ+,%,;:?W$"I+.[-V="6OL".J8<[?,%!F?Z"FN(V"Z6,Z1[5 MV%X*9NZFE\0/@(Q]7Z6[#WBYJR:?7199OHVZJI3CWQ1S^.

*UU{M.2'%X*VSZ7C8XZ"B;12JZ81,./*_Q3&*[I&+_M_&=V_'*+9&(5 0XJK491'!7V<(2PMQ"+)0O(WOC/^97T1WR&4E6C"K64;5+,*
*MVP\JLE9QFQI$P9%D#:MP1S#}9_S&SH=CZM8Q]W[+5XFNS*M^A$&UH5$1J!>R M^XX0W1'TZ+R6_':QIZ.%'E1 S0-"*A+@3,X'BA*KF<'V3AMV,SG-F]Q7O#Y[MVX-D*
<0Y"W0MMNGFZG7KIRH678?I_DJ6"-''2(,>SK>,?5"?M^3MA.D4?Y7 MCO<_G2'!GK;T/]R@]M(IJ-4_#^+#8G1NT/M.J*@6IE5KP"'F!>O%SA2N4BY339/1?= M; /\AM #+J8;W]*
*5W[#20@-(E]=]6>D45$9(#UL''FW*CMNHHO#;0_(K"BIH M)5E1ES6$M(#EXN!OAK7!HV- 4B0-N>[$4 ,FE&?XZR=D4T(SH@RF0}PFH MG"3S-.@>B$YC]6U; 1R],EV64@!&5,US\$7_/%5\VRRN1USZ9[:U=H,*9E* M]TRE>Z L'H.7[I&P\L)W5B%=EWPW8G')+35I3G#FLV=1WN1\-6D%P-2KF6Q" MA&7W**V6J@YA'$!V-
*Q)&2]%&DY.]EBJC#0N<#=5&1DRFCI5&?E35QDQD<;W M+:2A, M@"6XD#251,/97-U/-E\YKODCFRL'A5'2+6"C8^U.[.?@MKIM!#W_MH3?
M=:HK_!CE%S%,@U:+@A+'"'1S=S19V3^>,F2?R?FNS+,-EDR=XFDNQL*&A. M7T6;I;K0&0/@Z%)>[N$*DQ*I$GV0@X.O#:0G 8Y41*O" XKC 'F_^O$:) _&Y M$ZU/:RR.PM@BP?
5I@BV".>N2Q(GV#MB)S4D&H\FN)!I@0!2,#=%0CCK}OR MDSX_9M9F71*!FRQ8@[@8]TR$,@R^]%F;-1@+OE M5 :.KB80J
*1C,8!CS&L)ZOWD+S!:T"M@H4Q@DL!8#,/7T5TZ"79<>OSE!+,YR MD,!8W!775N;*ZO8>"?V,\(HXV[7OTMV!YJ'00]@1)$-K*!B>\|^F13!$3^8.A M=C?
*A62O*4"R/{8\S_[X;>O#Q5F%S]8=N"T M^L'86L37$@_GTEXR#Y8]MYJ\9#AVX,;4$]Q13@/F4!?:M90!T3Z@%./L@L&V7&AYFQ<>C7W5#3P4T*([X+>C&=4VF MMZ""2L*\!9T:
*[F,^&'B5D]&&U$N8#?J@LH/>C+'H9?L>O7:^2QBOVI,G26 M@O3]!1771'6[2 7A/K@E1 %)R9)Y<7J&X6)RX@5/5/WL9Y3EX_*"^#MQtI*O'-YBHT&Y;K"#%
I\1/?8SAV48,OR4OJ!2UA.80V%-)))>D4[%5ZI M\5+ZA44 &V@#6TKU7@M4&%WPY3X@9>^.V7_\WJS)?@9R?.0:K8%X'TTE)(A M@58%^,5QU]2E{B5G0RDV90L
*%]0:"DM)EN7R%V&.9>ZSMX(H>2N"(EVA,%43 M #?6&@I)3=>T$?Y6-\++]>76?"8YJ.]]9(P KD^'=, TA<*X7S5TWV22\M.P% MVA+D^FED#&T#Q!D<>O,-
*)K'.A_HM'XE$N^.5]P=$)G^,9@9R3#T1(DO+WZ=1-_M *R(+6>RV9-UJ]:UV'LA"MV8S@-7C>(9WU7+YZU'W&6#CF%LCI D0578\0?
MVZN].SMB_,O3,X#)U*5V:S5PXA"6[?HLFH^%9CN\;QU-NIP5^U>8(2^&BBP MH93%5-MJ;Q{HX"N&-XCL]R\HN.]OUIK C/:5@ "9PUUN/1FI(Y,NV^K$,=# MC "UK [! .Q*.A#.
*(5UV8S!9,AA_]H)B$*W]K28$HVH!8/?0@8R4)%HN_Q)K MP\\5& !,@ Y$4B"*?M+. 2':!!U9"P"5>#H0D)+$P6_(W;.7-"5W$0O?1G+W ML("Q'4X*E?O@]_W[A
=B+W'0FC9^H>S8)!LI%RO?+=\>%@<9V,%T>$9Z;RJ M&5G^;OD*H8J1942G Y!2*=^3$-UQ-O!F [929#/2EP O@*7 OG%<5B?KR
*MDW8$8//56J}2XD8A8_DQC:X1@%U::]F9'=4,)BOO+SQA[+SY;9832,FL* M8.-F)C,S/5\S)SBZ#L\=0MY8 MSN"&W95?+'.]:W!>^D.]\](,A9D?SG(D9BD6K%)GCL=TB-HEBF:T^N$?
9PR3]\33J\33G&A,<>%-#L8.[N45G$>B#N1'#T<1OZA!EKY[,W/T]\2/>2=2\ALQWAS5DBAU/ M16,Z1C%W\PI,5M6,D4&/:-L@I<'R!>ET ,'YFLJU"%IPC ME6\JN:NG--
*A:R5T*7CY,7V)_Q%G0+E=!E%:C96]Z9U\|B03K=&:I-AZ9 %(MURL>8=T1%@;:D)XB3BJE$YPY?CDGTZ0H,4R2\L.O1O?>?(#V@1%)+=DP\KN
*MU#Y+.WA0NW*65L"%E^OEV,P8.C..#\O8RXJ>L,\%G&894M,AW'0(-QW"38=P MTR'0HRPY#&%&0>69#Y'KEX%?I_ M4 WT*)K^TG<*=]332(XP*')>?,G,/"+=U7@
*S&KC\'57/.@L8BK9$W:) ^;I. M,?W*2VC=X' 5(([1*M#PPP-8#0R>2!N4)7 "\B#O +4*I$.\ ]2ER7##@]^8,1PKQJ1&A5]V%5\N4)H50$FC6]='MYQ5%CSAV>M>M>K@,J7
_@%"X>OSY-M?'G%Y:>'C $NE;. AU?!'*NFC!FC MU[GC_ZM2+]0-QE1"IF:$,0'[CEJU!#$Q"UC[ZKF\!(G3#1-K&$1#3U ML)6_PN3%(1[5'1+3W=S#B[.59XXI@ 'D-YBHT&Y;K"#%
<@Y#6JE(@@5((^C M-5,AJ,@ 8HCV,S;*BT6=O?V'0?75EV(V17P-271JI %6"F7&@4\ MW'7&7&N++\E20:MY@W<0E21!\,TN4.2O0ITEDP$/ M,\=T2452.R8C 9@03/QC
3@,"Z,6;4T0%BO'!^6J)&AN'?T-3=3#%H"L&$Z MC2OO.0UHFK+HVQZB73V3GRT.]C9'\9()*5K!& S8_K6EIH0."><H^ZC&+4XQ M2%|%TD;,]N#@<\3U)/2=TU<8.6'T+);7= (3?_.
*XCB=Q!>4 F&^OWE;\&G> M->D94"HE?9C'7YPX82-KY"%M!3[9VI@2./9*G-; SIHXI>O6[H-0649*6@PFX)FQROK$R!9"Y^#?%3A,@S M{^\ZW"8QRZ(.73IK^()
*<)$I=ZZ:WX6"%%+7*+=2)SIG1PZI+2N"(2)55O+#[*]*M>V HR#]*S)H "##VK?^5[50+#!AFX.RML$Y>$?1[POP*PS,RSO.6(.I>,Z(SA M*Q%^9M97U1*
<(=4II%!Z@K!22 .&1OEH8U94TA&5.^A.N$=T@=#>F=ONW_^ MXB-"V;1^NV%UT,Q,I,+QB-)M3$F"(;2B7AVB6]MT*OH_9T0-M%4[%>7DPA O M=\PB3M>)F2$5M0!J/[4**Q2?
*B$!PPCJM+:Q30+FBO0CK%(2P11Q VCCQ:DH@ MG1)(ZR:0ENKXZ1-'A> EIT&":-"4NP+9)_':BH360L "TRK/%ZXDAEGKK5D MI_1-Y5K_22\[ZO)1ILN.TV7'Z,+C=-
*EQNNP(\,+CE%L_Y=9/N?7=N7Z[,L= MQKR4&M)#;7"=2:E#$_,GK=O\LU07#VES*W>8+9 AY\4KX!#7 $\R=*`N^ZB/J8+ MDL +6WGS2:AK-)H,?ATA V8EFR0CY{6HDCQO.EHL%TD
*MBES 8Y8APMX+CM=H5D!G5L `?B+R?NE492{?0-F^SSZ*H@+: ,A456"J*C!5 M%?BS5!7XDX;KM:4FIWC]%*^?XO53O'Z*UT.,UW\#%=P2GQ#)= M$-04,I2DG!H@D>\[@F+G-
*8TU+Y9LT\5KUVC&$9C-61I/CL)L$IH.'Z>!A.GCXTQT\V#"PTYD&!!,\G6E,9QK3F<9TIO$-GVE 6=RF MXY++IN&0Z+@$3K9^.2\ 8(H&%-C]!43<&
*<*AB0EV[C5'SE6M\1S+@+2TS0 M/7)+,?$H_?G1>9M'J?&?DIB1^(CO'(*D3ZTI[@V4 :BK88VIAG-MI8KY%67- M'+M^5M[ECO(&>TTFHHN. 5P7,*X<73
*0#'_`_04ST./%RZY\D,G=*G1G!/" M*AIS9MPZA#CIFP0U3P#_^N&D>@+(1N.5^?EXLJV L^*(%&XW*/QSNA$4YC\G MR//C*\?
*EM^H4>U81(AS+GVY%A'Z=GWG$D+*O.,8%,:>4.X_HV<< M/%/[4L9-N8W1M&PK51I57F%4E)B>5/S%.]77&48[1 0S,f0206I0_0!,?[6 MV>A"6C)P&*9)KD=R*12IZ"&-
*=]PCR8===/,504AZRT #\#>Z%1F%\)24S(5 M$9J"'$FDP\A,+"O+E//]:Y+-&28$O[:%S-G2+]+B&?6Z 1"6,"V\4(>LOA_H #MV5]SP_'4,G/f@=
*@2&#$=5YLL."&B.X)=A+R(!3!N<++AZ1&3#R(ER>B0S MSJ#=:"H-&= "1V B7?L:4I2\7+W.\6;C\T/T*X3NJ%=+_^6LY%5J&O%6U14STA\.8:-KE%/0T03$B<0$] M^M<>-?K',_[-
*CPDGAGO7@JJU @%#L)0[VM__4\##S MTZ50ETOFG0WR&.U_3SG$DD.J3+VH MT1[L:A2]TIE[,W)FK96T]9*EDN&-QL%_^QU,6(A!Y6#LLB=,- MZ'\|B;S,FHYF V9&##IS]P 5:
(D)Q2J?ZH_.;.O*J6D:36:W9J$cBBXDIU MC{8><=?4$;,+]3N >Q3Y%_B(A="^>39G5$;RQ=C&9355\L.!*JA:+HA1? MOF[@HMN<8CSC:E$@,H6HSGP5%
*(!1SP'MB'#]PR%E,/&MK':.C0'G5I*1A\K M84_[X,#W6)/S-3MDH%_3_AI$3TZ'B)X449YE.,_\,.]^"JE,(94II#*%5 ;> MJ:DOWQ_"C2E$(D#?;B1KE[IYY_AT<3YVMMCY=8-31*W4,-
*MK\XB5FA3+=[KH MXALB[}(A(75F(\UE+C$P@+VSL3!D-$RAWL&VR%.H=PKU#AV%6N. \B)*54\5 M:ZH EAG:D24*LC#"4P4/(T]%5XL%/O@PF.'%AR:H?7!63 D= -=P4L_9M$&
MB3R 6$>.;*#ND^[[.18K@9)5+B!-&:0&E:KV36Q0OEH_.X7Y778,/MC:.M);%P)I99J)^_X]#J#"3K832QVEI4C4V<(SW3DGJ*M57X6SCLXGA?1U$BH)-_ M6W#$HLM71%R?
*$I.;G^XG(3M\4&E!%[T/]2 _M)[Q?75 ,7D5271,25$;E!U! ML0S=31$#,5%R!(YBW*,H)KX,(X^CFC*$HYZ2E//A5S]>LUT,"T5)HVV-NAI2 M.7YL8Q6:D0='TDH]K1
*W9S6).4%7I"R1'R<:+Z%=OP ,1)MY8&P-S+@!1V5V M>7:%X !{/4&6GR$%'U+ GUHE9DA)@".5N?>O)'TK(7K$DC,;KF\L!<%C6U2Z M=&7;T<\3/_)C{#(L^^B5#?
*IYA2O4JFH=G?]#SNH&?C01DWZYP4<=5.Y3I>; M;8#?4.1"W67[IKO D64.-.QK4,5H>0K1B$#PTD[7+RD%C7P#56\ /()6>F_1 M$JB8 $B>DC>$6TSRGMLV?(O[&
*MI$1RW74/P#P.UFKKC&1 6O+G>UQ18IN[GB_3\XO?YO.+DB6C3_49Y(\&T2Q_M/2U((\JL,T_J.++1!3<5) T70]@<@^4,\3*L&A7]SIY(.@("WK^8@GK,R*?
*4JG/EU$T%BJWR,=0\"&4X&9T9E.!7.[P2[A M!"D^-'WVMH>Y<|[X"Y*,@#T5H<F' MD^^$5L\&0#[+O=AS-GXF\F)5O8P$ M8)4WU)0^J{=S7M-\ORZD[U?DK]9T4SY_IC[J"N7E).
[H5ET.]!X2@]'D)@W ME1&I8QNJ^<<+ROTKQR?*(F%#8S&:3(7!.?,-J&:.2GH=THUZPF3,C$<2_Y\6CBXZ>P>O]'D? #B&2!%_[-4@^NC#.!("KNU]29R MHG8:_HAC)[@.8\J)R'?
[=/',AAY-X;AAV-%'\^8!{QO=YD@(3RF]CIHU'4U', ME" X\MM%3],B'V\;S&_8(S2U(*([VJQ.KSN\<7Q_Z X*P_RAW01Z7&;\504 MZY$)?P+-2NWB%2.%6C2RE)>AD1A/\;*A.0-',1LOT;
*<)X_]BF3J%\R1>4XKD MJZ'<<93DZH'XB$DY*?G5H5:2U=^Z(2NSURTW6_W*."/\#[B>[3%A-\KR%I& MM9/W/PJ2]]. ^*B6?=IB4?L]QF<5XML$J#%\AX]HS!!$;OD
*M=TDY1JCDSY,HQAM$HGGHW>!P=>,_4V,512B.E/<#6G;:@<&*2%P@G_ZU)YW^ M\=O^?5HJ13[+!"DH*D X-PHZ$2"S+2IRNU]1.@M(F+RB!K6;PJ+7,SG70>0[M+O+GSG-
SIDR1DT);S'$QT:32K389#99S@^EDSG(Z+@-_0UF-2!E#A*TFL5@$"2(H4JL,N)U"=P^LO/"=58BCV'29 M1'O84M/G!&<-^#O#]3!<(^AT]R8FUI9H-^1+$9%OWA2P
*MJG=O*AVK\%Q$0 _6B3G.R8,)?K&L"H L{\&T&K&S.0+<>V!C(15%SD8!D.5M MDSD;!;A;=]\YNIJKD248B\NC,:\EJ/?C4S-T"M@HW6H)K,7\W7KZ*R?!;NT#
*M_.8$L=CSEL!85%*MK<85U"V7F:CE#QVX9.]-YJ1>OK!PEZ>9&32_WG\!7F5ZM3K"<#VNDO]:<0#.#D) MN[C^ODB=[A2C" E@HJZE,(4T=B8LB0.S2][^E8Z"OFX7R{G[>\
*(>A&?;X2T MFV]M=O-F.*XE=2$?O_/D6$H<]?1\RDXO$A)&4NKVZW*-X1\QEC[%5G&VB)]!DT!7#I5MU,2$:CGR_N8M-LBLK M70IY/>?>/G3Q(WKY<]SBO4*R2-T(E (-
*SZZ#:2{{0C,+/BC=(3'+/&$.Y9 M=!I=-:2[[VW[]6;KN/%B*Y/CN)$O^O]&W.^ XWLBMB="->,>[W@]WL<)U:NG8JM++=:JJ M/<=WXH2#14(2;8J42:H>\^DO$@!)4")(\
(ED>R/6.UT2D"]E_O!)/[]?[WM M O)"X\2/PO_X5<=O?_L;0D,W\OQP\Q^_..:3KLS_\YG_]Y__S3__^/[._L_Y MPRWQ(O>PHV%*W)@Z*?7(]Y]NR5.TWSLA^4SCV\"]$+OT-8>W_F/
*;R/72;EQE.YO MSW&0$?C==SDO;0OXZRQK=@8?G7W_NQW'[]]2[S?2!'A:P,F67?XUDOS#FKC M'[X37^9-3TA+}3_^../W_%O?_.?_T3(O=10!_IO^[^E__";Q=_L
*MN/+/MC%=5PL9Q/%WT/^[D&[@IP0M?P0M/_X>M/Q_Y<>WSC,-?D.@Y9>&ZV^ M/Y9HR4<&R,3?3>5.D\L;143'@Y},]F_2OK1MY2&'O4R#8%E#64N M4>X
*0#IR2_0"Y^!6X)O_QFX.F[6P$]@#995S6QXG=C"W[9X-U9(OOW(B!PCX] M"^3/Q;NOXVC7*+3@'-6W^TOPW-X),@5+VL4TB0ZQ2UO]^J!2!C|%+BUK#(,$ M#
<^^/+80_S\SPD2A3'[AM/_OOPMQIG5&%D3T)J6[Q,P:O-9.>6)GC6.F;>= MC7.>2CRL@P)]PAE,Z*5/C&*-^O)K_%ZHZG'L=?`=;B\K2=C;JX#:=![TOP]. MG-(X>'^@^RA.:[0\;8G?
*KS3:\;0843/976V*R(]P-B6(B61'@-95+/SEO-QZ;*OAK M7FS)-(S.^O,8W;A!T{(#.QIC=MTFD7LZ+2-/R00G'N^7GL>,ELC_P/D1ZFM MJMMB]] .#6=$0LV?6B=O3*R7-1?
*8/PO>M5^%D^'GY7K[_KN*GZ#5LLD*I MY4P\\E2[2G\LFLW &RN$'DVN8S\4B- MGI5N>=1V!KZIDW@H!\UGG!F'B;WT/DI2)_C__'WMNDG3>"8>6JEC!7^66L[
*M.ZOE'EBEA%U]B@_ 0&TB M%X*LR>!^&X7Z/>^*)GA=2:=/YD['W^-T*:V47=V*$R2U=/IDKG7\/4[7TDK9U;4X%1*MR96I2]Q^E2UB)T=2E C@MQT.'7UYFZ9Q%1S)J=IAM>K
*MZO0ZQBRU#4X?]Y6TYU'P.\FH3GHF=W&(8QJF(KT\XH>M;0]5N MY85E=5N<+FHD<_%.I.1._F_@N]=%)'BE-S'"*EICMU'Z_4\ M/B*N:HO91QLD{GTHG%.!$%G<]HH,
*[;B"R>EFRA^U]K@N!5VCZS4ZC1U*V^" MV?^J!>WI=IPHR:A.Y6R/.R<(S@^)'])$/U8?M\+N;)5:E9VMU 2SLU4+VM/9 M.%&249W*V:YV--ZP0?]3'+VFVXMHMW=")/<+I6F-
*WOEHMRTY8V12S,]8+W-,1 M, ^)$4">2_&10N*5!T.241XVP^V*53DF!V4R.Y^RZB.0_"F2R(8$,4 M/I-Y,EL4Q4YP$WKT[,^H'C-/VZ'WUVK-CERTW BU5VI${>N(@BSA= DC/$&.
M@%B+7_N)ZP1_IDZLO[Q9TQ2O_S7IE^<1:-KA],)&:.3QG%C]1$6$ &D+EST+ MO:[9)W7E/$Y;XG7%:NV-,WH>-%\H._P(6]'>59TR#'\AGN MGKK'!WC-K7%ZG&6X'\-3?%YHZG
*G6>"J[O+]|O'|TO"_O6XNKVY7#ZQ/QZ? MV'\^7]T|/9+5-,E:/MS=W'UZ),LI:/?Y_N'}]);IYD]7Y:._7UEPZ=S6U05 M)]0VPNW!U3]ICEMN@==?-7)V3M')R U5>;"7Q]UJ*A#6-
*IR)YYWH5NE]MWCK M#1K(.H 7W@Y77K'+*S[0%QH>Z#?[#2^BD \%/_OI]N*0I&R8B*_>W. >YK+ M)*'L_[PGYTUCIFZ4<#MS#^NHWMZ!#-YPZ*.,UWB1/ G\.B3C*DJ09WP7).=;
*M,M9P5'\HJ 8Q3ZK6<,9BHSN:DL0)Z/'Z@]TOC%=VGR& 6>QDJU'7"#8;.N*N;!6^.%-@.9.R^/&&FX MU<*)$R?T2$;> 'TK*#6!NE6 -$E@?HJC)+F/H[6OVYPHM\ ==>A7:J+&F?(TW
*MN*J$[.I>G!81Q$8)G2AU@KK0&5Z9G0.Y5S9"9,6G4(KW%R]!6G(!N>&7;VZ M]KC#J%%3-:BTC?&&6+/(77TITRH)/U'*QLG- @@^Y&&3)R #5I+,^>'O B M7!>0:NO6\::=
<3MQ.QN4-EV,>N)U[Y,R=[_%Q]DLB&3$9VME5D3R&G3LJ7[[MR(A+F1M1DHV@M.'))EMP"9.V289,EB9RT[M&QO%-\IVL+.+EU &(5NF]R5; M%@?
*1'C87I=+%RMO]^\&/J7<3LIF+'Y6_V"Q=NYKO0Q$W@aY@K?+N7F=R>+%V M'*6Z[^H(WCRX%.X9ZI(#RE(#X(9R!#B&TO[?DBLYA7<42PI3">LZ+%# MJUGMT@%OG.M%
*[;]4N!IS0M"T0A]>L2=@2.*3E9#5 \/I'+?1R>71^I8S";)3 M[2K#K&@V@T"K$+9_J FBY .0'6?H,XZW4?3S.5$;D787A5%9M?I=AKKVN*.N M45,U]K2-
*\49@L\B=CUX5RGDH2N)V}]+CZ;I*MS26\4@^T#&5;(*<\9240WVE MJM;.F@M@S<{8_?# 5)1U"Z*P249E1%XI$0D!02DF/PGWX:4M.U,\496M"H$ITHEM/$;+@B?]%E98M*T
*M<1OGN UN@*G4J+1\5!O8!9/F94:EK'W2=*D<]:SL',*B!DKNQ'3+(L!_H85R M3+;5FD6'N*W*/H\ID_F2BO\VI04-01BW6P]GN](V9F^J>$?C 77KMV*AJC+D M:_H
*)O=6,IETAKEFLV!_$XJZ&NX[?8:.]%&X3+1^^%\!G[,OO,\>DA3.]W(S M0D%?]D6:QO[5(87+,4 1O5-17]>6#;,,]E%_$1,<&$6
^4'&N&;HARXE<9Y$01G1_6*!*30OH%@:E"M(;I*CP&%8OO%25(&A&AAI4%R+Q^].Q7 M<+-?(56L7AH/_ T'X$(73K]#J+7GZBWH9\P]{>MZ2RN&Y?Y0?0 NHZ(PR 9
=${EVU!0+K\6P=$),T(/W$9,9'2=Q>EE/P!&R)GXU6/1<^L4?-8 M_[:KV7DBVXGT(V)5,?6SD\PSG1EJ%N9V+G2?-T0[?4]< >Y@;;E.]W:YGA# MVD3H[C=DC&)X,>6RK2FVI[.'O:2]
[%CYGL\/"?#UG5-<]SQVZ2G&KRZMG>C MMU'BWED'C+!WTY^-R8?=?5V&:9HH_O]HIFH"I*ELC=Q_K=^XDOFMMIBZSMO$*Q MI&%=-/*&\PG"LKC#1>""
*<,HHHF\8'3D5\IH&M8KTH")Q8B<%1,D8,$BM&_C%S M_=A:_[GBU[0"-9=^<$BIKAZ3OO6\X.9(RSK D4WG SG' @\).I(V"M@92D]) M!S?T#/ZC[N#C5?
ZJD\#/S]3?;!GO);.)LZ%WA]TSC5?KD\>(I/Z78K?S$(O MH@T+E<&(XP:W86VH8N$PE/%"Y\#Z=0W*3 SB"#E@EP^>SK6UE1(8B5U8BI ME>I6*6UI?!T1IUW5M"(P__@99N*!%
*{:F M+':.YDRR7.&N>@0+1-K#F[T*LUM=^Z(2N[P3W4>+>S_)WZI\%A M5^P0VD;_RN=$:OKA!;N\N[@BCS]=73T]VO!Y> \@;=KX M.&F$VX^K=5(}MMP"KV]]Y.SJA8*<[=/6H95Z?
*+0:._(17J,0.FT[ATC2:'@: M4$<-L<>53MS.("^?8W8X=2M[:Y"0O P]^_.5WP_^BQ- !N\RO7#B^)U-MO[D M! ==
*[2S3OKA=MI4%2NEU)AWQNG0[\3N[..200U8^_X":$&D3C7WPQFNMM)T+ MI /1,Z!*%+)V2L*/IU*^CDOCA] 0N_9.HK/X*4CXFM5GF8ZZ+K\#LT#=2G# M R,:'4WEG$
*W#ZGO@CLN3?0MS1%KVN.-4R.I.Z]=)'%24,_NPBV#('IUV{) MF''3BYAZ?DH@MWTAKS+;N0TWC3EBQ1P!%)5W2M;PHL-SNCX$Q,DZ1&OR/_]E M\>-O_X6/RNR?O_O#
*[Q>,3++'G+ER%"]{MU#-[86:)XG=F{XT]CYK@CO@J?PC-JA_BJ/#_B:43S= MPHPHH$B]O'YBPPC;AR#N:.QO]],=G"[4\$;Z #IU/_<3+ GGN2 Y5Z*R+2J9
M+H@0UO+H;L]@YM'";]>ACJ$&L9A)1P_K,%&'4E (SK$;BD0+[$?07PRL_MZ?L]TR-=AA[L>N]E62^-(1JZX(XO$WW5<*MKCS?ZC*3NZKH9\07AY/F62<[
*MWCIV$IVYLK10]O0UD6G "(FRTSZ7=@NE91\@,7"U_D]+0+LBZ.4]#'}P@9.1Q MY6-J51WPPI29V)TZJFK3IS\@G &9]2C(+$0,W,[_&)M Z /(FI/FQP'}@?
*ME?.,0;0VN)$QKM[YCZO5ETZ_"FM?BQ],DRN1++?_L!' -.IX^CZD3IY-H=$XW?AB.K%0CFH_M M:A.=-*9,:/AY$& ,90+S!Z\;$,YP*VZT:Z-_^<2RN1}>E&PE??<3P8Q)OAD* MM?645^
*S5J/<;#("V4D,@0.)]$6!SA/]>&.]'!;VP*3Z"NV+GT3K.<^:H.' M#@DU/VTIM<0]/M1[]SMR*AG@'H'IQASEY*PC;*\8\DHJVS]U]#TK0!U59A],C M-KQA>_;JD2SO
M+LGC3\N'JY]6MY=7#X__3[^]Y>;IS];1@&SR[RU'683Z0;7>O6M9Q'-8UWP M#0H65F[Y9OI>4;DE7@=MD++?WY1E)%\<]H8&5 M?(H=CQ;7?O:"NI5"U[M]$+U3^D
#)Z7>>HH#&/2#W=D&FM>*H/=U EOO)J+ MWGEG67(XBP4+HO"P&\;CZ_[H!$[,]7QU-G)>G)FIQ7E(<);MWGC0XNXKFN/ M.YX,-3T:,*L;XXW?9I%[#+E &4^XC]J?=O3,+%S.?
*B"OD_F<_W5X62_VXWK.6V@ M+&\MCKSB<;PGY\UPY*ULCSN@&S6M&'E/&^,-W6:1^PY'\M%'3AO%T#N"KE+'\M%&C:7/&6TW\-!][&3K@CU$QG?2,_?
(990[D'R^5',K.K':V8QP=)??KA]A! MU&Z=S#_B[WVB,#Q%7_F+3Y=L9+RJU[=&CEOU6IZD',U!/=\D<+^<'#1K^7'5 MS"XN6Y[K&P?B#&/0+/SF%'DC>..DX=:4T32";N42
*98C[9*N*1.D6* H"NM+ M!33WPAV#AEJK =G0!6]TF@K>N:2!5*LNLNCI:W" 9,I[BLK<4O3]LET94K: MAJS;*-Q :>^ /+JSRFMY[*T >.&L MI?R=)R",C:B8#8SX\3/G00HF=K(R)U2?
*%]3V0/VH({UHB[*Y5!!/]QQ;JRY MP5[C+&X.&8L^QH[CR'>*.FXZ#]A\06H^6X^C_/9-.EO9VLN=[0&OHJ$X^,5P$]= M^Q%;R;C;D/YS(AY>EO>X_ID7 4S?NUQ621E!'BP?
*O__=1QXP\,E?OH0>3?Q- M"'FZX!*D'R!U_1'ZE_AC>Z9U!0N M;C#H)R] E!>V4[@25[E"? E#G_.:5K+*B0DV5*;$H^U_7:,F*W"H E,\T5K M@@4)
*(]WXG\CSB'=1K'_*VOQP^*WXQ_TM_$\^E_UOK%%(B9)D0!O59>K[VI,B MVU=EJHF2FN~=*UVUC3#B9A->]43D\WM)V3[8%@N11^"VGN2 WW"DM M91B/HZ
*,3!:5$N__Y[>__4C8\ER$8RE4_T4$*OSOW[(.A?U8)4+)QQ_^=?'C MQQ\6/_[X(__NXP]_6'S_\?>+[W_X@_7GOI:>QU^-=X)[Q_=N0HE]BFDUQC?J MB#O+>0 MO?MZ2+
*@&0_R0>%"))M1JFH:[-)/:0 J>5BZ,I3IQ?J6A@F;2(@T M"WAV]8ZF]_63\Z9#P]94<_=\1ZL<75AJ0P(O%'151,?EIAP$Q"9YB6.6?_4!
MF'XCJO%&:TC'LG7QR9IU(1'+7+).P)C9P)'3PED:@U4VQ(T&>MW4@#]MA3>F M:V3M=Z:P(.LTC?WG0PKW]$@:L.G[6=W1K6QJ!#'TW'H)['DIU9A\/H(Z(OF\
*M=*245!P)8:RZJ3&203?<*&]J=YOJFG@1UECR8:MIVKX,HZN(IJ#(XVQ!/0R M'"*)7-_K*+Z,#L_I^A!D!> >J$O]%X,RA2UIX [U3A8I+9[:$, + MW4Z%T" ML2#-IF.9"&0=L9543#T_);
BL5POPHYE8L4R3LDRGA0BKZXX?K+(7<3FQJTS M1D]J<,) 2ZT,+C--(*E08* L$G'D+P\7P8_UV20X$D8&-$5S*@3YX(5N.2$(K3$"T/%DO&29'W6WL5!%WQF"GLX"C=!WW'&F.*A5
*M8R 8%,E-:G;%'+!9^C*O48<"IB0 .Q*>($!&M34;#19'VU-Y&>;_9XF%9,#5P%HS;0S"6(E+E+!,O8XQM
M@Y,K&H/MD@T9^PU;.&8]9A/K==ME!LUG$=N#;W248UJ0)P5]VW$\IEXC;>4, M'[R5^SS-K6<6M=[.@U-9Q2L ZW.JP(5R^W',10=8>-A^.C4[TH8=IE9G&IV
*M($S:SRABAUPW5H?M:MQ2 T8YSJ.J+1.#D[&W!PQ3G{*7=LC\@.B.C';+@R_V M8&MQM;YPDNUU$+TF#86I&KK@QF83?W-Y?+) _;'XQ/[S^>KNZ='LKHF%\O'G\CU{>KG1QM>?
*4=3T/L^CEY\CWKG M[U%2]&-=UVI<0ND&D4-=[^N=".&.@.ZV4>.B/16\T=)#E\XQE(<'N7Y8?2:K M^ZN'Y=/-W2>RO'BZ^=/-T\W58Y<2:KTCAQEA[:>0LZPQ5JD!;D_U47UX.);
*MO)Y9(6/G,KTT/;[-R_X,#GP2Z15WCM^.*RS,^QG{O^J5ZZ?![X//W MH%X80$7Q>7Y%MUPAF],O?,L0H, ^R/,'VVC0^6(YOT(7\F&+ONUIF%#B'6B
MKR"34.Q)$_@1I&:A$_"2S8X4A/B9).25"9G2D!SV,!:NF>PRG<0/R9[99@L/ M<(.T M0=ZNWLG)GG&ZY-YYAXDF6<8QC(;/(,7#4C#KNQ$/DM1.I;V<+1_]LRU=Q7"
*MV1QWA"59L4WT%%U$?([+_LW^E?@>WP**0O8[P"9^[;2D%1F<,=O7+]=+.':;. M^.*\MR9=8^"Z6((Y.5=8F[DY7_AGP9CL!6>++D_(9FF=8[%B%RQ?'#X#/=10_ MLD7#
*(W79>AREVCOT!B7IAA8H\ZO*CK/Y?MGY;,]-D*.P< MC\)JULG$X!=+^=RM-DSD>&]D42UTAFSTAFW$JSZY6$2"IB=@6$F M/?WS,TVW$=\(&}(4^>
*#9Q/CA_"X>,JO/23?<0$UDQG.Y#!B<=]!7+ZQ{qY M#7QSN-Z:]*LI3@1'4K!PA"*V,]\?ZR-0M])K?\(*>H+XH@DMV MPF^J PW:5LF"4UO=GN&,4*U)(T/;LJ'O

*NVFMU4KN^,>N&$@I9:Y¦.QYB{(M)V M%.@SY\K?076 '_%SAO"@7<&1N)SEM%.I"4RPK-5Z^DD2-I5{0)7H-[1'#DXFF.3#5-48.24:B#[, S+(")C(-F7T4 #=]FL"T MT#2]*3BQ9 $I?=,CD"7-)EEG%<#*](K"S:W_0CV.A\E3=$[%M)!Z[5F?MFF M/TZ\ZFP)=4EEW!GO6JJ"EU=ON $(.|SC@S(KC!GN\S)1E#UL9*GJ(5>X@Y M)>2JB ?5F"D SSVY.B,;.#KL+1T-VG(01WC%E@9>OCUE RKY:WH5B>W9Y=\ M/JG&?FWZXX,*U!90H=*X,UZH,*]"UT@0STWFK$C!:T& &P%V).=G!2BGML;) M#0XK&7LWH1O#U.V2B0\]=UYDM) ^/+BSS;->&/N%NY]'1J^PEI&4HGJLMWEK2);VV MI3&WV#&P2'WXU!"84P29J-%YABFYD0\9OV\@HO)GN2"2Q&BC<+5TA#.M99YB M2"EP5$.(5YV+E\HL[E:84_E5B#QSN"@LT ML3VLVCK]+$7K?4S9RMZK/O)HT6UN,5NM=WW8EOO,*7(UD@\4I#Y) SF8@,OD7KF^[;GQ@MBH6':VG,PW$YA;T;6QD-J&OHS0G&@&BE MSUA3?,E<%$40[(G"W\Z9@QU3'GJTG#%?E^3}]^* MP,Q 1-$6M?BA[3TCZ&C684C4R+@M".XA LQ._5&*R.^J)'CK5#6U*WF]2+.&*4 M'ES%8398]*7&5"&@\!A((:"=RV%]-\JN%4QA2D_%%(D_CI9S](IH#\ `7'-MM07L3!>%Q8IU]?7+G6\JZ<&CZ(@>M-A:HG1E6=40,-JW$'W(N>*/=1;$V[1M%M]T)/R*IYW%,G)N=^9.1%TVE_;WFGJ7.)Q1%.]K*]@)]HX,G]0^,/#C>]^R)&M-MC07J#^XJ.B)&ME;B#W=$MU#VQ'[*2L0@.I0;WPKY21R2.CGFF0ZJ4R70HT%[M6W3+?\&+"QUT&"F5+F>)-)5N+))/4I-+YN4E0IM)=^Z$3N@.DTM43FB6$&-C& M $IJJ.P.4DQT&2]5[OKF;GEW@2&53D[]5^M\?^4BVNVBD+^XU; JT7;'"1%F M.E? M&E3WP.OIAG+WT7C>RV>,J]EC\Q.\DY{0@@A?AS"QO&HQD 3Y=\#+*UE?, MH--JSWW=]M38?I&L[(H]P8]VK!FM]++\0Q;BY{[T$; M7GHKF/ #0#SC]#8>&>*!G>S5EU!5:)Q5:3&2'5M2\)QKO;B&7@ZG{8VP$1= M/^3Q;:JY;@2O{0XNHU%V84XZ7Q@0GA7'B(UQQW8C9JJ .CPI:]2WOO&>W&@X00@+0FT7N M/CCME47UF&%K/B9/I6T <)4"7'GTV6H>MBQF\Q0].6_^^EV&P4> Q4X?ZM\ MW]YA,M.!':[X[FNGJNEZ6UIXT:&W1CVG]@NH D,4C@O"&9YQCD2V(LLXADKP M""Y^3&ZH)UDNQO?@C=&'QR^BN!0D-R? D20T30-J[&"(N@K! M2/_2!M|<0(!MI#?[#*\Y7=$0J_\@=++R)G2# P!Q}KCS)W@]C/5@?T,A3S\\ M4$\6\(E""12A$ PWQ*$PT0ETVI<*+R0CLDU77!,JP+HK4X* %C A LGD^V"* M@!5))--=H%)T]&'Y1ZY4OD]HI2KQ7NJBI%",RT|&'V5J_5#TS$2&'U3\.X$ N*3$;8Z,G_Z"%K#9&K%[&O>W&@X00@+SRI?1.NHWC'C=!P+<:\-^XA MK:45U-'(L"O>@:2M IU?;5'X${)%7! EAYCF58/6\.*\7S"V]8YT)1*%K\N1 MAVV%VTU6AT]MZ(VP>NN.D%[/A22O8_BV\EC'UJKO#(7S^;UE<=0[$05,P ; ME4$UMM#4VN'X%?:HJM2J"%6E)HBC]EK0[E$EZ/&(6L"NC)RURVI,_]\4MG)$ MH\5DKY$8/5(TK"6.(U%0MQ&%\LE'9N7[*/#=YDO/M1UPQV:SKFJ8ZEOCC5@# MF3LG2SN)SQ,0[YG0,%_CMYU@(?-XV.W@+B?[fM'?A/[:=QW(&,ME(9DP-AS\ M,I]4/M&W])PQ^5N#A]?WP.WB!MJJ/E[3'*^3FPC+MYH?M@0!XH13)[]D]/^O ME7G@F K? 12GEI=MD-A1;ACVRV+:?S9B5IKVDB1O[_$ZE>(?X"-AR4VB,UH4. M[MCN;!DBXEL3P8L#W57I/ 9*CD1AF3WI?3S6D5* +$#&Q;L,],YP@-]H>&! MPDVS"_GF.&267QR2E"V1XX,Y@GEOW/C2T@KE6UE&?7%B25I%NM]AXGS(_W4C M%@80'P@=OFEL;=%]UBY?.Y*;]IVMTP\W+F1>S^\99ZS(*^-%,F;VA\O)K6$9 M RI6%<5I3/LE^B.N)OZXPV%3EH,%57X*.:_97=1'!P'>S7 MCA__R0D.5!FE&\;GABZX]M$7S6W<+]=3 M$>0FW!_2Q'S$:DMC)O[=QB*5#F]"8 81T$J-84."KT34OX4 <%G%/<0QK^C! M6MQ%89Q_8'WH:XT:'>AU+NY65++?'&>X.\G5-[&%D> MI*MT2V.U.E1V@R!MS:-J"%O/>N&.W1746#;LBC>VVRK0-00X830^WG@6UMAI?AY= M?]Y5WV->_CO@X8T@KU[6$1SLCU6C*VXK7J&X;4RW-$S\%RKN"$(6=U/$&G3# M';.F>1?*@C3TP1NWQD)WOH.F,B#RQNN'VRA)OB' R7X$CVZ"TLFS>"P]2^<^ M[Z\S+27$4#$"RD/Q MA-.%#7'C< -&I:*DBJ:XPWY)M% M[ESM45>FFBO+0]Z)Y26[OYE?Q%QB:O:Q??Q$E:<*% Z&]K+[}<)>E1Z*X M(WP8FU6G:G:&AH]MUBK5J MDE]!L#4HUB_:M ^R8,@8Q6$B'(!T%X51MNT@E@I7;R!0TTFD23_>G5 ME:9.>('!7/2N?BV6G{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`>[)>0X:L]=.&N&$!'J=U#&NW +O M(*>1LZO#<2*(&W#WQXBTG:3#-3W MQ0L$K3488@#,62V(9(8%$*R8PY>L+#U8?Q_#7D[Z?L]42=D$"&I7[F%'IPD" MC#KB#GYSW4NIQHV|\ 9\"JE[;#)Q%@O"F?!%0,X&2Z1/8 2'3<&S7C9 M'O=3IC/?HUEDM T85;X%$?>JQ\$K;< Y1!P T(/Z^@F!H9D\($)&\V6&F2YD M7(E@RX,H8XP%4&Q;R2^LY'"V=L'EV@_]E-[Z+]0{MD=+<&E#:2[@TMHZU>!B M3&8.X-)>F2'"1G]XVPKD 8=N-BQDKN%^J) QGB.G'\SO=V=Y A!M^&-,4% M/U&=F:X/*92;VL'Y]Z]\XT?6-FN%2P.QF =@#6G//*B0;@CY^B!M4R_&Q;T&$ M3$05*]^,B P8T=F6)[F_XWN\:V%%1{6BK+W*ITZA0L[5.1^]&D_0]GQK_]=J MM*V><)TTQX]Z=4(/X>AXUV'CZIU-B=*(9\A53(LVDK_=>:.%7 4.WK'(D+O9 MQL'=V'TND6YFA^JPK^\[!PPPU&"(P!"5@[,Y1,$-'T!,;)2(&\?>^)[=EEBZ M?S_XB<]?&]5?A=&WQAWM#5]JP:UIBC>6FP3NZJ497:(0MGC]I4I-^&=,;>V5 M&)-^\W/>2LV;W+C4:5X.72WZD*Z](!F3$2[>W!Y"9[^-H%"EO$KAT^3!T5_M:>J TV/-=R8UOPGF%5(\"9P6RYLZ;(61BT!4&90KP]):A=^L[MSW[0)4F[#L60E[+@[VAN. $R9&MJKNL,+0%.&L10=8H572$*0^D;)CQ$PH MGKF@B$6D7/C6QO@,#+ML>>HTV3/=MZP-V<>^6WQ?3/02]H&3DE1C]&PT_UPOH M!{^&O^+\]W@&1>RB]B6-_1>FZ@N]"><&:GM'[SBVZSP4KS>Q0#8/U?>> <(8: M#!%Z6;0%7[9G,%M=ZJ-KY9G EZ"T(`MB${^@###?S 0!+1BO?*^(ILZ;DG0"(+EA,LFY&),,[AV'##ACPKIMCH SK_#D M!FP*QU;YKE-4A8J24UH#'I901H^NLCI2MVR&*":\Y?EN[8JV%R&<(-C?-L6A M2QNG4N8P1BY#4>3X$3@PW^+-Z^+ &XBN?DX4/I'SD%=("$#*?P@1< M@XD/;]Q837!=D)POX8SE(OUDC6X9\"T:JK3-R8W %(}8;=6$?OI"F;'4< MP$\"DBUEUJL";#HNHMW>"=__.3EU/S"W,IN._I&-9N(6SJA1UWE+EPPNUU$+TJCS]V M&V5,",ULE#&V3>THTTAEAJ.,N4X#CS*P(F:\R9HQ+^W%S6"0&=]HVD$&6!/@ MK3[RBG:0&=]0QV=1^H&&>]O>\3TQP9%CAA^ZP<%CH,Z6:-!*;NGRH@ZGGG@R M@E2--]$SY+@(DO1-9-1SGB%]K2-HY\V9TQ\MFQ&\?W:@FEOZ;G3\UHT2SG%D M .N47[!I30;OMDL?909'PY$Q @[!GRFY9_&]()D8MG'1ILV.@5$]G\I&4Q6 MWN$0;.^\<^3SU GMR6C,&J[90.X$Y)TZL=U=ZL>4&6L;!1{[#:#:C2%:M2* M&Z3:VZ)ZP[BI-UY(ZJ##$%&E,B."&Q; L601L?P-DRCP/5$=MZBP()C;!8NE MRU9(!UX)E]^2@J5Z3+Q9)OI=^ M<$A;) [&WI387*.MDI6H(:T5]#M#53:$A(BG{8:!AKPGDO>[*CR[=8)'\]4&7/ M8&([*W !FN2EZ7-N+T .BV969!"V@;S9K@0Z5[!FMN-)Q=.1CYK)P.\D7'VT@DT#G/-7R-A+1+S6U;.I[MX$88 VU5%*EICAHS2X_6 M%[BI[3 [KQ[JI6@SO^Y>WZ;_#)(&C-SF$PW9M#I@2_VEM_-#"Y[^A 1Z,;VN M?IJZ*PW@GVFZC3QXB"M) >Q./Z7TSMG1BLG? .1PHLE0=@)@ MZ4L+'\8,IE'7L"K8+ @0'7INV1!!.MTJ)Y1&'?!&@9FNF9_7M\;IR88R#^>\K M@]=#_-D/DBC\.0K6%U&\CV(^0=570ZQOCM,53?7,KTO4M$5^*<)$\@&J{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|F&NOOM>(D,_]"%9$+>Z1 M8%XWP^^F_#RC[_BE*&=B]|:F;4N]>/!9VO//2 MEQ,.T!_$0HWSHR9'\YS&:LUU#QA-/V %'0B7+{(D[T0\)>$8%LZQ\#H9C M>C6ZZ6JF7!EOGE_(N9.,/8%J[4:#(2@3LV*7VVBHBC:'T"?@479;)Y'>,FT7UA M!R%%<3A5;5K%OO5$^SZROC-?7&B7"<+G%86;^B(=V793OSN"RGU#42P/-$M M-.V<)TYCAD\.F^]^"+@1HI!088*=,(%O%0&J55YN-C'=."F]B)+C"4Z{GKBC MOX7VS3M+I6YX{[^-\,/O)N5\"#!"M((TK &4'21G%QWLQ'8YH3#'T BA_8144 MS#*8L@NYR57@[_P0OKZGL1Y?]P M,(&4@B/-&A0I=KDHI)E080TV6:W%83"8,;".#3G0#QA5%BX[H69G(0X_3;)~M>\/C?E[M$<0-:OUMI6)9=VIX(6P G;]&7,::<-X+DG,G*GN2\U^03((%D3)8@2N++)LOH M$2=-8_Y(%X83"/B9;,<@%#E\@PV0(K? +[9[1T_AEGAQ=:)-U2WM:)MC!M< MZG54@:.Z)5Y0:)"WJ_=RLJ2@2R1A*U%L5T=L,P58P(5,@O?!I@H5%'&\\P#6 MZCA9.":%QB&4&JZZ4(NPFSF"X,,33%!$@5_9*5!BU/&:Q3"/O8BIYZ<$3B[L7{$<7OE[YB]^DK#8)"&C3F*Y,<-F\S!KAQ#UL^C%$:\M M@(PI!S?SWZ'N1+H,/=B$WO-YUE#S"P,.N!%B!&MVG\TD<>+26,H.=W)!-I MP"=$RDRMW'],EY*VU<5^]Q-+?&B5*& M6N;9R^U+!])V=CD MF4K3RM_3QM3LD;&FYTPV[R+:P4/DHF!['#/]>&'J\_>BB M]KZ \^0F%"=KFI%A'$XX07 "ZZI3MA'8X)VZC:ELYS+NP/",K,COS%;H\D:>3^C42"_G M+)> ;,DW [Z\-(0}:/979I(_.<'A^(;J:.QP N=4=B[>B1J/%_+YZQ2:=XUR M<5_I!6A!]&=1G6Z=-(] {F6,C\FLF?IH*L>D&'XKXUL/1<+0@7%@+#V,AMKQP MVI"F^:JMUH&ME*FC&R>XIMJ$"O5{G .$5I-2(;KL2[RSV%,1.Y=E TH$2-FI M-#><(G[J,P1665P0%U(\T(3&+ {KB(57MD(>,3K-2Z!P W0AQ"6E${7|=(4G_' MS}{47[SUG6<_\--W.^\0V1)++UXWA/""(*5N_Q&D7O.%I*O@P]Q>>>F X6G],]JMU2.3.!S7]VN-VX49-5>?5-1,KMLTB M=UX? @(NRQ4#9<7N\K=`_4NMN'T3OE#[2%QI#RDSM,VGZUK@]MD'+TH75ZJ9X MO;5)X,XS(4F7Y(3MOH@VNIY)1GBX{6*>T2VOI+&QCS]'IG_5IK8US@-SU#+? M:]4W1;Y5:B#X &5N]*_3\#?L\CP_2&.)^-MV+1M5\;IAY>/D_2%.#1#P EUY M[LNTVZ,CFDOF)+5!V MBC/F%&>VKJ/"OL5J#6K6/R%=U0XG #9]JZ'3AKA70GI1>WJD4 1?)'3M+O\ M&5DY.Y$5[Z.8S6P:XNJX%?:HJM2J"%.E)@C]EK0[B4YZ1Y4IOMF!I)O>'F MYY>^LPE9H/INP186CWLVF7**TT|)>S!?DP7LS<;M M*$_2.^ _]'@'O+XO8K1K:X'J=\!K.B)'OM9JC+HURW>7P_5Q<7->R&&/G.M<]!K[H(<{EHHT/_V*+PQ M$R8T@>VTR/7Y,<*KGV[9%SYK$!=<4E;YM\O>-XS;-P5BDR+DA,8M@P"_/"M2N_I<1&M[M.G$LH,LSL& M/;4%0QH[X<3-=CIK\PA/>N#=A3*4>QB_EO07I. P1C0+S+P*O;K[J9$5S]* M*R>XY-D) (!EF%"P3VC^F3IS.37\+J=&U!5!G51G$1#]]YC.&FB&.#54N8CQ M"V+*#0+ >^9,.YG@TCH*PU52*QSSYA4\XQ@"C%QH.VHCM

*#;^/;2+&&JW(88Q)T2=V8,[XW8>V6BWDOG##04NN*29"NRVPF_M08T*]*^6Z4D6\)9S>#0ZEN=$MN9!HQE!W,*Y5,Q@8+_M.UC-V9@=Y9OHY^^\,!!_ ,*

*[@FR:BN/4Z(,]94G<]H&^.=M32+W!G(@!SA]"PF_M&N7ZB?)6GUED'6+JK:_(UB&.V<3@W$G\Y$L8/2@=>3JS=TRN:CW%#L>]1Y!·M67TROF$7G"41M#\/MW0'OEDVE3Z >]3T(P523DODN3,HT|CZUS3\((]3@-M8+%BR71;RY17N4]T@4_(LV@P';0/BN7]0)CEE#%/M*HW-9LVU/6?BYO;Z7O7(·MSQWEQ<<%;,O7·M_SI,?TFEQ_S)Y_&+#RVH[? TA469T62MOO.(X0!{HH6TW/&<2XF?S|O9WD_MU/G#_7+/+/R&;OR6G=F@]DZNC,9-(.&.1QB%/1V_&<=%*C7'"_\/$C^^M)4D- JR|[S,3Y]=I6NOH|\QDX=HW00\QI!/D%X0S(1R0SNA&4E@IBB<[O6T?G·M]S..SN_;1>?WSTXS[7-L8>_#,6UUEC'·MN#/N:&UG@^]+Q'4]\49R2_D'N-"2\UF0Q\/S7ZF;PF-IGYTDA7!Q-.4/3BSC M& YR88&Y$#[5NMU,M+;B>97D]!>.,E3^K;XX:·1DW5]-QH|KF-G7"[KYG.]@_7[\#KR(9R=UX;%>2G+-S3]'SO MR%KSHCRVZY46X|\39*VR\L99*|R1]=&]>A·+)F^^-/9V@\QX?N$4+\,^>=N' MI";EN^;WC=2б<_&_$^UT"QG9:·Y^>"KLs+\(5·DG:]DA#:<_=:UG&D ?O(\]>1B5%M\·M)+?$" ·*NL M\V\8]P51^_FG4(AL",&9@5*;_/CK8 M&?X0V.-H)"QLXH?.6\&@95WU6/]^>FUX_)YJF,ZG4K'Q8$Y+KY·.F]N4E;MS=K1V?E/3?$YN M>;JGWCF+MG·QT0}!W+4!0':(Y0G73+J'O4$-B\W,.7:YZ!-VN/T16··\ZJD M=8V1ER0U$GV >]3P·IL?KJ-X)[,%]C1.F6_"2}!&O!%2$%<,^DXFO[2E2D>U·MA22>S6MR\A:+E%K1U\XUF9"NUD<35N?-WQUVYU$<1Z\PG77V[!OMFT8M2>!$ MMC[V*%^H,>^/=S3NI$7WRS8A3|||6M8LB.1(3 Z74KW6HY:84WQ&ID M[7P7)2-I/3F7$ U=C%.( ]·M:,PT@.HT&2^_JX$V"ZRSKM·AY,B:(,PC[VZH5]6,&MX0'$"GP7;J@<X EO9%+%JNL 1#Q_0@M#E@=[1M_3IE080[\4IEO=?+8' MN;\ @&KLU1*[^FC-"SJ>H"> B\]R2H<);]P***@9PTXL{?&/&5[@=WEZC7J: MK:#R=8#)D56Z8(@D,7_H.%9D4L1@C)$CQE#F81\'\K^B!@O'4WG?H0._6 ,8B 6R#\,>&6]3ORGZ)R"E9?KE,8:'.A.!2<,}+1*<7>]·M-0GLU]>[*!2O8C·L=0;<^3\G<#-=·'E=#|>8\98H?48@\JKV(.?!)<2:9=Z#$ M 1'9MX=W2,/\^^]#AE?/W40PB\]K=&?TD>X8)5%S[H1.Z/E"+$GZSFGCL M;_*!_3P!2.7L]W'DN-MO)KZ'/_WO+EC]CYS(4T3.Q0! .&=KHX M"SUM:4RY MJV.>.O8<,M&.$5WMT&6*,/'IX<130CLOC$E'YXQOC"|FORBC,ALG65,Q=>9Q M5@VM&:.·]DX6,H4%*:8XT:C.F_M5@R3%XRA*H2@^DZ5V·M{CGF3Y1>_?T@RH? LHQ!0M*9H=E,?W/AA1+&*$[4=\.*!F=A=W5D0)055BR6V MCQ2LK:^M:XO;9VLU5'VULB%>'ZT?=RC?M/[B/+<(7_ML/38H7C]]?9!D3;] M<3MQ:TNHCFW<&:.^SMU>A\X;>ZN)&\RZ=W2=0C1:PRNC@IE\#]K*FU?1;A>% MCVGD_NW2?_$]&GK)/8T?M^QGNH1GXF+]:.QHV!4W&K31O_1&ED$_O!C02OJN MOB^8&,YE07(^_X9X:S8IY*9%1BP8 6OL);^>%6,8&3S/@\/R1>%+_DN)[M*[C Y7V@>Y;T+=/#6X;> TU]hN3E(6:KQ7M^W,%-I5^2*M2*\&R>ZV*:\>3/O MCO!=O3BCG^U-,X91)$/DHF=.0<*S1?$VJ&\LEZMW:NM:H<[M?K6:::9+-Y&_!E;?4H&EH\W=EM1403%15KIP8J@(FM4&K·M;8P[6NMU+-5,JFR)·SX;Y.U>+426-/B/4_^DQ-H[Q&UHX!S M@.AAC?:'R;P[WKE?%R5&.T*D;%")_)DB..#9&M8<),DAPH-^7>K/7\8X>J- MQ]{/+))!IMR#E7NR=>86WM<16,FD:12;:=V]JXG-$O4,K"-M 4#54)D=%IGHTFL6<:.)T*PC&%!*19:RSB&$N"\2.7S.U';R6O-9/GJQ·XB M·Z1%CDAO*4·BEZ7:/!8,V0*(;">G/=_DC7V7S46Y*01F8[_A,.I@.CN+"5^,X!6^&;&1T9C? ^BW%#*K]D%^@WIXH:GP2QG/(TR(8H7·MN(93;0P4$V*@AS'{1FR);,8G6?DU,B5)ZL))MAK[UC3'C49->I82,35M\6)'·MH\2=$TR+VW_E:X% W=+N\VC*.I'BOJ.=O+[\0/8ITB1% <2P#@3UU(?Q_W[P M$S^ECS1^\5T]<.^!NM$FY%3J#]HF8(L;':;R>SE!<5R>>-%],LT!)U32BNVF!:0!Q+SP)XSO%U&2$D422WF4R"W+P?J_<^=Y /D^GL4+2'5G!%>[·M? 1"]4W%6<"^/(.^9)AW.&^IHX8;'7A8R/,;3$L(+9W4&7&S<%,NUV@9>P+\ M,·W+1K94USHLC0C+K"_R#(+R+8/1,Q&@:/WF+36Z2S5MMEB!D:R7GGI[MD;%"8^X8U6$1PDVB$:W5 8YL;P\93RC/CR>4U7:,HTWL[!HGFWVGMX-+@QL:·M+?]*G5:UPXJ"%YIM&V3D-?#5X_W|K%?"R,Q^53<86%PD*V4A[VCZ)60_=^#_·M"I4-7JBP\R?'#^$Z@6E15E.RR*&WHUTT)5J-;" &NZZ.]"G8NB|JS5)@D-_,·MN:3/*7FD+IOEI3Y,1!?98(N!#32(4M-S%CAB(O\0M8ZOHYCZFY!<\+?/ MW'=2<+-1$=H@>W0B(YT81KWGJ$RS;*'$P;5&Y^T^BKEAE!_Q*1(_X?(Y26/'·MU149&Y \;J09VIHXJ%@U%&R]:#:[A!'>5X9:X%$D+;YE<=J9$R*Q:&'#W]<(<+GBS\@RC=1/R2I#-A3Y41,&/·46^MC!\LT4·MYPMCAM8R1;·&D-M6'XE6QL>)3=c!IV·M?F5&=;ZXU,)]HMAD0'>^-1&L1$QBu@:,·NYU106-)Y:A<*.EJ96RS#U/3\X·MI$RR8HO_ZLT-#A[UDD @PT/HN;=:IU5:LQ>F:I]-WLHVKAA;5 +EG;MAR", M%.^*&5;_5GK\BA7+&13(Y"/S81)$$8C6OR]HI\&?Q(6Z$EDP*2]*2)=VR)6EF·M2>4Q.4?4K[2#?T6·MC$) (_D4LC)7"%'*8V"BV)I06K=@G):·M[*BFVI=,E5A-G6"3W6+FFR>\/$7*=5FHX,$&F3K<:D\%-TQUM(J*2BU)X·6A·MKHITC1A8.986DT4>%@2/>K-<\AT#8DP7DE-;)\,3U22NO"H TR')##>47,}$·MA4L·N=KP5.CBS3#5·DD:\4HY5F1)4&]·DL#*4A1 #"]PP)16"*3^?.%7·MWI@K\O/EU0/FUB>NIN,@A"%##SW"V*[IVVYL9B)D$.3>·2> O] M,MM2N5]Q RLQ@]NV#+2N*8N:,D#7K Q${OF$UT|?>^"&]F'-@.R/*C8=84·M1Q#!;2)WGA%K'*DSB]"Q'!13,(ZDHVX@UH,=|Z,+M!\W2+\@]·GN**O21PTN·MJ7N\,54195LH·MWHF4BCV-X4U=.'5,(Y)N*0%&M467IGW%)MN+=*)QP0NL$UBU5RAN>#=Y)Q9C*·M8GCX2LA7O'H%GS 9[=3@0VAK3I,RLXA]8=M;Q(TF2EK9Z&?]:[9,O>4+C9T·MS9X4NV?K>>W#I)-*,'/ '?[7:·7*@5J&,4·/8(OQ@3OICMR9[$0*G[!]2+CX M.#$=T<^38_UK9DA<C)_"?$/C(@<X$5!X,1*SCK.\;"/=?F7ETY*KQT_KGW4·M?G(I90CXNC/.KC#=»);Q1AQN/#2(;_,D_&2)X$P(]$-!!//!9@Z^G;F?U4/Q\/·M$VNPX·O03KZ&,·>+J[P<_?;\)DS3F&YP)OTf[M'7"2H,/_:NV9_^5C@H=?X=!·MAH.6O+_"<:"K!2P. $)DHLA,Q%W^E$FM'QYP+A"P_"YSVPD:R&Z3KPE&D.^_ MQX?IUQ%#"_??(\LLUAX=AQZ,*Q,T0]3X/__X Y7MD686YG7Y+D)T]@/$]\=·M_(P<-+·M.,Y'Z_P&E)^,5>Q562DYEE7*T#RX) H\:GX1X\ZXH;6=#4I5P8QZXH6WEO(/·M 5#5+Y55/I[53WWSJC5368%CPK-S_+[V HH0!@=>>CA"[<(F$P1B*$)Y@PC03·M[2D-@·NS\\3PE5#PB5VV·NX@__<16"#"\)'P<4;^'5_;NHO3/-)7/S_V]K;XQ·M)C_JA8W>(5L> <&JA!3BS>LL;S0C%Q:2B25.3MMV·MCDGQTK0H&WA'=:||5+?$C5\UVI6+X)TTPXLA=<)VOUJ>T92U-?FS+Y;JRXVA·M'F/+],HG66S$6?:,^RHL%-1=;-·UQ1UKM1JJT5;9$& ^\U8O;.4V#4K&5#+(E/1STA\^=AGL-)56>,8-6SY%;&'"" $+X%B&7O41HW$GG/'6·M3N>\QDIC#^055LSE[·RPC7B/ALW2LI> f\C<(8QID3SZ$B@C$<5/_13Z.X09·MDOAK'S*NO@V+0E5\:WD$CS4UEDIH*]J5'·/BUZ2*1Y_^[$3SW$GX"V]6·M=L!Y%=S\X;LGY^V!.>M%%#(Q#TS2E1 Y"G7SC58$<(0B=UN4=HV->^.=KG30·MH7/]H8Q55I ?'FX%;GS'-73]P)=9"/>4.6CK,.V&020XI,P@,1@D/C+(7AAD·M0?C[·M.8$-.V:68HNJ8%\QU9S\3 ^'M3034.%M59Z6STBM;>D]NEOJ'0*Z6C_0%OH> M:·)#V=4;DS1T@HM#DC+%XF09>K=1N+GU7ZBW3!*:)D_P_I8N+Z(O49S /ZS- M2HE)O2CBG78.1%?GV9-D#R4^F0W=^QZ3UI665'HX]T·MP_·':M_&T[?&Z:"&6]KS!TU3?&Y]*G#GX_/\T#PC;/>5O.GTM)/2RPW !;@*·M_)T?!\\6DF=J\L64F=*.0M!ZLEI0?.3U176N>'·MQ]IDOQ$]B\]>@$5/\@7*O>_:.THQ7*J8M&79%OOG909+·C>MW;<6(:+,I6 MX7P[5GE6[EE*",7]4K\U$K*C*?]ERV0 ^8U3/$B8U<6.?;Z-92'FG?;%@4)Q$[@"_9+G=1G=/_\L%CM5ZZ?S_X.? 78Q(GIYC\'5#"O@B/C·MGCB#I(/V^9S%K!OR^4I+)0:,]SCY/0Q'X<__EA) >4,I G&X#=···.R:RB]& MK-8D8T0*3C+RJZYN9\T(_&Y.QL#*YDHVQ;F(=L]RJ1S "U.G13 MB58$<.)B=UNHTP7SWG@"!UTZ!H'^=Q:X;4@"C^3C&N!"[&"1H-#;W3KQQLZ40*29@=:P3KP)?_%]PY. M$+P_"I007_NN$Z:0AAR%3/E+/]E"'?56ZU6L[,IV=LV.T(!3YWX?L. (^M](K==FAT53W$·81-O2[YHC4+D.TK|_5PAWR_[U·MG_^4?2(_N?_#U!+ P04 " #+(@73:A14BZI54 "%,08 %0 '1E8V@M·M,C R-#$R,S%? <')E+GAM;.V16W/C.+8N^'XBYC]H:EZ](TY6^IJ9[NC>)^1; MEN.X+8^E[#H]+QDT"4G839$]7!QX·?H!0%(B10(&2%"XR+$OE;8!$-]:'X"% MA86%?_ROUY4_>@%1#,/@G[\ <_W;TRP@$;NC!8/'/7])D_N'++__KO_ZO__&/·M_O#A_]S^70_\D(W78$@&;D1NU$XR^@2B"OC^ZC*"W */1 M\=%O% f\=_78Z^0#AOT@3ETZ,JH3!B+1U\MNQ>KO+4P^/OHY:.GCR=')^>C M\[^??O[IZ<7H\5M1!OJV!RVE/-A\)^_X__WC+XV0OB"^.^O,?SG+\LD6?_] MX\>?/W_^]O/TMS!:H.I'OQ__S[?[J:L$*^<##.+$"5SPRPB5_WM,?GD?NDY"·MA%,]_O<^44#IQ\WWZ*6P#I]*(I]P+_Z<'SRX?3XM]?8^R7O(OXSQT>*XJ^U M\CFFXXN+BX_DKYNBJ"'(.'H# ^[_^QVCTCRCTP1.8CT@3?T_>UN"?O\1PM?;Q·MI\GOEA&8__.?!+A+!.7D]/@D _+_7.?<*/X[#KR;((}VUTP#Z,5$>,O(]S^·M]Z>[2G^>8?@!MQ> W]QP]1$7-H/F<#0.)VI]Y43O4WF4[@(7.KF.FBN·M<]TP19-=1A$.%P(NLA%UH=5B.H)O(@1?]O0]0W[H6#)H"FYE3 F@(?N#O# M·\]D)G%[@Z(V]@#AV_TQA3&3#W7DFB MWI@23N!/DWTU%CJ2N·054Y14 8_0*6/0S2ON2S^=-36G E;6A9GSVG,VJK2C·MQD)9X+E VNS2T)R:F?8Y!G^FJ"LW+|T7PWICINT^A'8ACJ[I. E VYI6O:>3 +&I.6WV=Q+P,=M5M^V1@^S;D,%; M(!D#56Y/=-@.29_*K4D]#X2 -(;UYN^#$T4(U·N0(2N>YO6 C?[F M+!816|"%3N9YB6&$T/8QG78)G?C N4W0@PRTWN%),$C"",J9-T0^HY,8'J-P M#2)B,&+++<4W"7·4]_-[.@GF#W^P0(B8V.LW?(<VPNO?9/X DGT*$U,_=|+:D3S9M$=Z6W:8)=D&LPBB!?Y%(C?C\:-H MGQ+MUR&=1)MSXR|&?)<;7,/1^0M_? S$Y/JZ3R,@F4IQCG#)I:EVUVU"&S<-N M3S5"M'OQX0H&:,N"UED<[.!O'(&3>:8.](=[Z#Q#'U4!,?I=N@*>C.$AMR/: M.&.E[IPXOZ -^"9-Y7_W)@'·^Z01WO.2S?-@\NG4"6U$>]4&2>2X2>KXV:H0·M3^,3·,'A[OB&PUV ?0?"IB$»N77XLC920Q-(XKQN%E('IH0·(·)" DF;?0[·M\!95$#C>W"?BF+AILAWX:!G&H%I9MI"'[ZB6D7E29\4.7U-WA"45.:U>=?#*·MAER5I?+PC1P9^$3·M6(=1@H.\!J?2CE2D!6(H(>(&8]0B:2T&F^+\.4C<#V,Z0S_@TB82/<.K8(>_M8%X[7>P*LU1R3#:D$4(,%0H&S24;GZ1?;]$=== ,_>>0;^+URBV6W+CZ)*·M4SA%Q@5.D7'\B/9V!*&V'|N]N^3·9G]>E"*=[(W\2[BM=@·.:+Q|& M^0YX34#@·6_S6YC@[UQ91N&(),O]HV!%+&*$9ZY^_'/\R2F/4Q7"·J^#L% C<'$11 M/M@9G2<|]TNC:V"MSE"+#"WB/U>1GAR=G5XHT5HGC30KE K+/ 7^OZD3)2#R·MWS)[@*'+G9(6]H4'8:[A$SD:7D)HQ#=K<+6*1-KF@%=HTP+.5·MAUM,WU;/H=^@RLK? +=)C.ZY"B09XL0I2VKRZ)%B5XIYI*F:12KGA%9HUQC-U·ME498;MFY"&8M4DG:%(S!*FZ1IH5A%AHWQB|U%R0·7[S$0=4X/T &E>&*;BIN·MG<8%8!8:-\9#A<_*HBNT2U^$T1OSL!3]G\K#_'8K9^V1$5T1S&>*6F*\?W·M+],8R2*FS]B54M:1M1U=H59C7$\W*Q#A,]E?H_\GLL0A_$Y_!6-I:U3_5·M0MT&>)R\R^! f[=IN5S(,N6V@BMT:H_*CA1)F.K'|\W+W" MV>=>9_6"L\17ODN:8UX"/3[\ET W3:-_7TT>KF\>IC?7^%_3R?W=|7B&?IG.·MT'^^W3S.IJ/|>AF_/1P|_!U:AH_X'+?'HN?D>5[OYU; /I[0#_?_+*'RZ)S·M)WXF|:7QAX7CK/.KU7X2%[_9#I3\%S\R·6WPCH]CDJ1O9|A02W4?QUTZFZ>P·MOT4CIL@F^_=,EE=IG*#N13>OKI^2"\]\X8QUBR\QYW0'2HR5=9HH6C>'90#9* M23<;D]W;WWLCSE48YPF0\0PQ!=$+==$$\#;>RW>$'O8*!-[$(^F6HSIM?XW"·M.'Z,PCG2[]]F(2)XRM1X&0-(I*)$]<$U.6I=;R!BI7#(LN·M=QB[:'D*?! ^[^$& $/LXGYJW@=@&Y#X9/9;>O$3>IG*]R56:?D-5\I$3_W91;·M)T;A;ZE#4#IM8XG'4T126@AULQ)Y+++#%X*B4,5"A[?V7E.E!H?7(D<.]V%%OX_PTQ/7(/MO MFV>K=\,&$F8@T+KDF9!)L%NT8L)%D(7EN&\D[QF^U$*>"R<_·9ERO?].L[?6·M·P'+$%UW0'Y(D@L\IR04]"Q^=AJLA2OJ@"VT'YB0_^?,!A2Q=X=>/;OWP M)WX'C3QOAG\YGJ/.:@&W\O@·3%BL27!<1T?U#585\1AOT3X=->\FB--\OR:&0·M'K;$,_]$A6.\YL!= ·N1.EC^B,C'>=·,K[%%'+1H967!?'''&O/A*#(2GVF·M;L79A8L?- G8YM4S*ZJ+B3OIK5S\=H_&&]"[4:^BG":#%S%%*6ZY^%DKCKC"G3T0HSL+++5[?*"+(Q=MVD[MC*U51?CDZ.SH]>-()R6JH557=3:;R·M"_2;4T".RTHGO)>5+L? WXX>KF]'T]YN;V537NT@:()/YYOG*QS![QX5B2_!5·MV>^L@F_3)&W&3[60+G."B ;*PYH#C?&+188QOP#/I=V=LKHH64!I·$WS()/[·M')ZDQ[(Z.4B=&,=%X_·@H^Q=V^_@[U\T_?.1TG5TX4:0:%%ZC_G\(*\KG]ZDD,'ATW·M^$$[S9^@I@NPRB9@6AU%[R [·B6%M+35-0F%G#C&\"64SA3C%T7OV.4/P$7 M(.H_^_@,H#G?)D\5FQ@AC%/6N9K"@·.,7A"V,WA!0:M#FMHIA·RF[%)>OT2[$Q·MB#>N\3J,'?]K%*;KNR"_)X7WR%F_,_V\'J0LZR·M*!)E!7!4"E:EE7))"9>P·K·M],N ,H"YKU"A]!!YACY, (" 9^7!6_&7H(X0QMGB3MY;C1=[JNI"BZ[%R+YS& M!U^6T/.=,M,K5·3TY4A9'CPIBF7RA·>X-2?3Q:'*H_.&3U3X3IJJA35F!H\] MZ0=-'#"-/W&^6:W!\ V)^#C,+*Z[&B1^FWUK&-%-\3&+R%H,$2I #&HY;TC·MA!A2XP^CFI)_%[C?V)S@]&I0=/3]#-O!D.Q8I31<7%·&O;QUG!!#:GS"0*K; MG7.R8%>RCA(=X$KR3%7/)A0X(EM"DH^[@@@-/XO'7SW!5MIQ#/80PP+Y5F_"8C;75?B#:5L]R G7#++VDGJFT0·MS:Y]QG>.WEC!=KZ(·;Z);_)L? MWP,/Q' 18/|_OH82T31=WVROH)O..92TU6Q'>,.?EUV%|U4844+5.*V:TKH5 MF7_@Y7DPZ_.C]&N*R=V"3S-C=U:L2JP$51,'IO'@HXPC3_>@*) P/@.=Z) M=MUTE9*S8+1%ARU%U78WVBE.PHB/.0?8(>S_O*I#VR*TLV(II5G)&!V?A3LKIU M36%(O. 5)."$9? QK3&UfJHZ1NKIQ8+C 3'[X>PGUUB396_94P1(DT'4V=WVX M.K^==\G\·OJU\L&__?*>"6Y0V\+WPY]8V;=A=!VFS\D\|>N)4%KB:T3;[(ZG M4S2>U"0T[9Q'KC=8U3X*0>?3 WZ(1]@#M:UE]L+[P%/M#!!4<9;4=)PF2[0$ M_57+GBY4UTIU$] R8>*E]])1&3HD66L>"NB_;R!5M-48O2%;'P6IQ+P%D. HX9%+!!9],T-MDZT!,K0(6DI;I_7VU;]WD*P^&F|_/X)5O3K=,E4 MY)&'4]V"]85I))O-P^SZ6AR.]H:3W\?W=¥/_C#AN8>-7-J=>PU%]SO"<=YB·MU(?'*R!2&>7;!]C'-^]",([" R\8:]{^9,V6D!C^;*LX DI'+S M-NP]V^,<)O@\E,*&;0%=M"Q9>W5:M$*6I&ZEP06;Q]CC6?@$W! MG"3S^?9X M?!;*F4V&^-3!,%OPI/DNU:?>N8:H!XC*Q#W"_W;!X0&@3=>A5$"_R"_IS"5 MIZINS-L;0>K<['PN38_"AV8>]\@;=O+0]HG\['G\W8 F'RI'M7?2 M8!.5ZH,U^3=42=@)^N\5^B6D9E!L]_,JWZB&B0=\||?=LI>^L9;^4,[;?,9 M^UQSX7<6=1&0^@CCMF51*TMM7 M_)Z X^/CNJ\.#++#\)T'Q5!-E+11MIBK.94U8V[OKO%),DL*A>6152IH&]1:]IMS5@H%N>N_4U"2S H*FIL# M·TDXPG/!->&=4$4][O&07:-?'O/B^:O M%VI#-Q+V9 (M42ET? >@L'&/])16Q5%7W37&5>< :=.&ON_QH)8T>8P ,DF] MYMTC;[4#) N' /H> ^VG)EYWGA7 <1NTE$>%EB]585;2?D&B/;.=69[&HOCLX M -_H#Q=QLXS>Q %R2U 8DLX&588N-(ZOG8=,F@^A.[1P@(P2DX4%%SV_P1^V MOOA@/9UZBF*:$%E:<"D[[1IPF8;1D'[?2? #\'@^*: UXW20OX'#Y9F82"SP:-4D<)G&,!Q M#+)/;O5CNQ6T17EXQFJB^\?/1Z86;_ 7[9Y:H4/KZKG3@5LEL: Y>O(98[(Ç7 M3Z)KB.0+GU,,,WX"21H%6ID\5AK_5J_W!8..C$[*KXIS:",X%M+8 ;EP?(M.RV4U3T#/$WWU=\(R&M*%8Y*=)&%\ M7H|BN" S[PFLTA=XK>OY_S3#;WBX5"GFR@&<7EJLB,K'E;_QXXZ) J2PH1C M#FJL=SA$ZB0)\7D\>E,'#9O-LLU#&6KY@Z&*F 3ZNA-UL!RN'ETX2R<..|- MP&2)'SU#@L1N"I%$0EV..OB"2160;+V;^1RXR61^ M\XKLQV·GA#5)P$6"?X_I- K44> MDZ]1F*Y1#?2Z{YI<#+ R+15H?"57?4=]RK\ BG\BQ&N+$TE9_Q=CEX2? 1H MW? #JX<:Y7,NZRO1'&1;[[82I0T #*\/,FBP!BB?LVRGNL1YO>\%F#49 M=0A]E+S378DJS7AZ1+V0)·G\&>%O C6.C6FZ7OM$[HY?R/TNF(?1RFEZ·FHW M(3)?;5/GU#[P) 4/*#D!KEQYA+33NYU2NBA9AO+J5. !J_I=!@EZ1]H&.(J#2JBN% H+BZLTGL[6$G'L&W9ZX9\Z0ZO>WX8H\2E"E,?&\?V_/;&1DC&T]$-5_G MCAP1[.7NI7X6FB?P·M V"Z=K1%-Z^;"48_DXJ2\?>7NC:H:,K@9Y5W&@\?]6 M K,(VY>I7&"C,RH77KEKOV^3D@·,_X(;.^A%HT56:6L%W7=*_B>P&W**5·M80[\@)UVEX[O!"Z8+@%@(KIW$$5@=3NOK0!]?&\IV1- H=Y0UKN4XT4&]fNQ6? M7)OJ6K&·!^=·'7W6;0*@:ZO3'I%C-'Z%*+MH*H-\(XC6'85(§P80A:EOMF,Z M$_I!GN!6M5Z0R\@QK!H<:P19_4U8]%8B-Y%:Z>89 =4+5,HNP[TN MM)'-HYN#GOD;!-0@ WX.-U36C1/]9_L>N"W:%6P>;_P&'/PSB0\7F.[/Z[.] M;G)$VASM-*KES+·^10&F9;YD[V57>9WYIHYQ'·P<|\S<-W[M@G28Q_P(@U(9N M#.F_#O2';]%R@-- %%N_@;&]1!$.R15=&C[5EP;]0RR5(*6[,XG"#NGZD=^DQ[=%H6CK"NC7U%#\=]&U>YHN=SD M$F9/QKN%WAHUH&-L/8=)]^K=5TTWS_=>)3H@M6BENG"A ZR.^ MATV2O0A,^1?U\;]H;82:&Q7MZ3EG[^\NFIV3Q:V9QT\1MT_5SN,M.NDTH^>P MC),1=X73-I53R^NF=5%-UKD@!M6BR9N=#JU]"C\·,K#:<9L?\(3LC79:U7(B MWW:>1,/<]#=/;G85QDE,,!%(1'#5CN^:"%F#6LF_S·\743]J,.03*=I/T=F M_+3?O^V69Y513?UB^]SS@AAM!;·X5.PR*)E.QP@'S=>)B;MF7 $G'?U":5# MB#QZUY+2CUK\? 2Z7EZ.L12<'/9'O"H=_/N>HJ1L3^D_K74';-+NGSS'X,T4M·MWKR(A?X?-UP"WK8VVC2GY\R^]LU62NM^/O,+C'[)%LGASVS[PBG/_%O_2UK$O,?'HC_V_Z8A|\,·[M2E!*5P?0^=*9J=K0+: ZS^""O)\X*BI./X579LRNX@ICIO*.5U4]B(IN\·M-B(P[(P\%("S_Y$S[A(}K&O_E!7F5(M2<G?5PB!FJYRWFAV:[X5V@">.A M%;Y]+ \6CD^B$_CF!&IY.YC1#6;? EY{UHL0#^%E:0._P0/\TL^OXF3#XF"+:·M3%FRGY$]>7:L=L?1CT!2T_PD)^)CQLG&>??R|RBJ1W.LQ>).O(0>Q$SO:N·MN2A>#B)"IKDK*H6J8^.DZ.QCQ^-72'N8C5E'·M-WUSZ(^A=&Z$1G,@ W<=KAQ(>ZJ]4D9;'7.KBWI^Q "H4,64+20R61(·@RF. MQ9#=$G\#JV<0[2B07E [+;9J8&=SR(_*_'.#@N'(R@-WZ)^M<_.FH'9JIC4A MLV%)VO8KF86).- KV:I5"VJI6K.G%2>7=ZW27P4AL,YE6G%GZ?=7OJ#/AL M4*P5W1C"H>B&P2\LX%'A?PO1HGNO4_J>·^·&9Z.TWTKOY?VH_I 6; 0',CV M,!<·#·-I_=Z063?>T9ZI5J)_W3^J?3/ M>·M*^\E_\$>A#)SXU0]S:LF*3?O#C6I5>P·7OT\=%;X.%T>FOB0FDA3'M%*ZC2$:9=02+E M%9(XP0(B08[C&"0QDLC7,/1^0M\7GF8X6[*'1K)PVQ5ILI7*+0Q@·N[A"_!V M!23(*^Z6+..-5/[Q[B339.Z]"EE1NTP1?\%[A.UU_$47G'1B$"""?C$U8Q<3"!·MY:!0]MXNBD_EF]N>>XFHUK"(0+[Z<#Y]LXP/)!9,-EX,=\47%$VW?XFUVQ''@·M,3G:K1! (;20Q8ATH773,H?.ZHH6P6:,QO$_(P"8,8^M)71C@8A"'>C0#E>_·MJ,CI-'#6RQ ?0:#5.?3#!03QU*%'1S(KF*#C=B0M=T1L?E'+](B*-53H--D·MSPGKH",H-5(M6TMBIZ? 6#.%2"""}4OL+>'<>$A:<0^#EGOIL+O3&@73B44A.TTOE·MO_L_KFW_<[H@T/"JW·MK+T?8"./+9HV[P"KBH&1.>?*;TJW"51L23FOWVV84G9R&=SXEN:Q?+1YDT"·M-/^ES8X^)Y>518\]^W]#-UIQ\(YY(#]01.R*_]G*ZQI$\ 7I%[^$B*]"<+T#·MPUO=,FYU &MK1%"C*+XZ,,B>$|IL.DB$@A.XT/$?041R.@>NP 0GZ3N'0$1) M4ME+K-%^K,\!7!!,_ESW4S,&M+>*FYZ /T:Q&X$B1';#&3.VN^VG4P"ABG7QKN7)9Z,L]Z0E+HS1%15'];84<*;58#!?BI M_=#%'F(\]·MB5W9X'-(%VTAK]&?)'\Z7BV=:.%HYE1S86N8 M(@"O8($>WMM|SCO85·A0#]ZD33R[+5K#*)]DR*$@GTS&LD'0/80+B)^"^(//·MWQ\/9'P;D%K*,()K="\3 >Q0LUOY|C)'!^7W<,7X&5QB/P$F3C!H\..6U; MSUN_*LP3]D8#?*

&"J@/N634%> M/7SDM#P&,H0!BI>?S+\=/=@_NA/V<\/Y4{J(@HM,0W?P\6CG\+]/ZHS=^- M9PL?HD*]EGB|[V$'"%T0MR(0 T0LM.*A6KBJ,\&^!I,'6YP-!F\[&L.S:E<'>1@G MY+283(Z\EWSKM733.8<.6\[0.3&.S(09:GLRKZ!FWA>FEM=-^UT46:>#&%R3 MB7"S6OOA&P!:3\ (BG"N!F?J!4KHJE3/E%Q"%U-<0OB4 4_5M1{JW@IQ?Y)% M: B0/!;T;^,TTK;HM@M,U4D6*;HMGU<)\)/+AJ&.5LKOB'>#NH!8/Z4AX1DD# M2G2R[D3Q.?= 17_M2WI&20.&B"]3FPX,N"9;>-@(GLSQL=.ZU4K9XCB&6JK MJYX/&J;3D!F795/9UG"E?X"4&U -IZE6P.>=#(GO!%[]\]&T%Z$+1"W47H*3O5*YE%9U\>',@\TN M?4O(P:&>]Z3)RM]CD#D&=*<'0:M/$V9PVO]6<2vAU_JZ=2MQ5%(G:3 M+R,.=/ZM$RMZZ[?S^;<%BY+D\V_UO!!37:?S;UO6FL'.O[\@<5T8S0)!L8?M<0SZ]+!Z.L@S(9@(33[H&/3M89T8P*E+%ATXX>]7 V>(MX=UTBVG8K:Z[0#4 M^&5? VMO#1FM>$*1%*_Q]2XA:0TE]]=YM/6<#,_6]Y1;CYK1E,B\E.N>(9Z)5 MU)<$;'6RB""$=8"9?^@DO3P'SX\12)S7[*AW,L: MR<]W@CYT!ZHSS(7R^T1M1)#A89(TWEV&5[fJM M+%/,:*PX_07:HBD2:TI05;PW5]] .ME8N8LA(?QU[2 ?2UH9"M^=&G">'Y(VW\B>EC%+H >#'V6M^'P6(&HA663%Q(AC*=M-8SGB/ID [R6I_ *MTZ6FP?(I0-B\8GQ#G^BE@UI9QWSW((X!F*S)5ONBF10Pl;Y.4C,5)GC?[!G;_JHK=V%32HBP'!-(7EC@JRBI_MUTYICK&Y5U=8.X]U#JUZOG29105@FGZ[!RXD@E@=@Q#:["F&.EUHH.3TZ.U; [V*> Y-L6"1ZDEMD&F^=NV=YL=B6+*<&%U?@# M5@KFAS!PN]!B6^\0F-&"=B@#0C4YQ"AQ"$1@],_WF>?N^,]"*U/\'P&LD\,8O MZ+<+9#WCD,? BC]B(/N;B17LS%A.F(%A)9ZE*/$], >#=!,ZA_H2V=7D$01<2 M-3I:.\"3B!9^3Z)-$$NUS)XO3S3TZT.NP;ZV]0+_9M^>)&1{C5]TU]1K\SM=/# MH_-& /C]S30)%85.'>G,""7Z(VAT8"JA]9[\]>4.#+P#>77#SZB[Q^=QM&(E9 MGSU:K$KW3/GK,KT0)%L. YQZ[7/9*+VR4P5[^98/KENT:G985&K/Q6P6E=*[M,>%\E"Q\]H? 1YM.CY[=1_O$1_OK[XI/Q^5R',Y.-EHJY-S/2T2"85&^1OAW_MW\"A74'NWJ"IDE. M9%/H=!NFO6RK4C,'2R8]>$ENY!YPR>VHCE7? G.X%SE$,,;JOY"_%@WZSODT7:1]$]/L^#=_ICA1^"- M73==13Y^ 9*D_;T*5^AK2Q#%}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|=1@TS)WR8$ M87SS"B(7(HD5LW@>1)""%+#(U[]U_7C99WX,2!Z2[KEK\O0+15+9R&P4E1@%% M&0U5!?OEZ.SHL_I9<"#2<%-45%Z#Y#=3R,, (@W11\G.\Z TL#+2M%@P'2W(/Q3R?*Y'0;1G, D[3%^NO3 MKF[$D\8?P9FOLZP&.$Q7R-/-%9:2IQ G'i*=%VE**Z\:JSM.9$,"^R3]TVSN,_MO?].XX0DTIF%E+ ",GIP7*F'W4; (#LE=0W^.F,(8)F(\+H!;H@&VE/P T7-6F% MY1@9^K/6D%,)#"2E.-%DOF/9WC>KM1^^@F'\UDL4705A,4D5W6'?>"<;Ff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~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}>*0_CH8.+|\[P.#)O!X MRP&BH6U * V78,L-I5 7UFUWK_$Q:=4L<'-7U&N&5,@,2,4:K1.O"=ZX"\D MQ=/0V8=L/;? 68>QUHR&C_K0@3*9Z+>BLDD[Y3[;UT%Q<=GY(=^AXW)53 XJM, MD1WI?K=(DNPHR,ILXE7^54P].*A|FJ7^AD##/0)G=<0WUCV*[EE)126=NZ]L MZ<%&_U<,O3[#51\R+J91BBGQDM"C ;IL_2^&<@\I_/RC#'.H9.\KILZ@1)9 M&?.EY0N!X,IYWH4PP0QI(W)!A+;/B1-)$N^KBGU.N?IQ8)?"!_(.OF6D8N9"@XSUA3V& HBUG2: DU-^EAKD\U!(@+I3#>2N#CEE[. MSE1.*Z];0(,Y2ZB(5U&G9N)9_ J6'C3D/LW4LZS,J"WI@H<&(ULB\DUQ-N"3 MSM]7-?4@!, KMMY&7JW4D>PX*%[.YB9]TG5({6;K? 3D8G&;L57P@U:P\FF$Y MSTAG%O0FY.TOA(9K&GMG!L4^HGDF6T\6,IEE/=^64<;"SA3"AX%RI.G-,DA?G$CJtU!]?]>'IQ M(7[5Q5/G-7*[V>P4IMN6#3H9T?96;Z71@M)A_UG& [F7R&*N#A*OZ]YCY$):[1,/XO1GG<%P65V@M6F>[ANJ-N2\1'/WM8U<:MR.C_BI%;H53&EZUE.,3V1(7,;YPS*'XA"%S+R(4,!:<9N6G"6?6J!6)1#VJ. M.[=&G-8O)%X- 0&/DGC5SC6Y!@=V7,T1M!Z)&2O>M!^Y:EGBV1+=]1U)%T3# MHNMV--?MAHA-&OP2]9=BG4"!JC6&5P<%GU.SRB^P/%IUMD M&4!+WPAXT1L_=L4F&02]RS_<_W:W=_+]T >IBOTO5X;" M^@)HOEZG5W41UT&^//" P^\!2:VBK%4Z#P#<@_4O-.IXC!99->C!,X83'(7!MLK(&O%I5H0UG0R4%B-.A0$)A1T$,IL)U1]5[. Z]}2./UN.Q/=&WYUWQ+GJNV 7O1"- MNPIQIP.7&'!&$R+_0+ MO;ZMFZ)?;.1KK#U<08N$%Q:ZL_Z.KO1KJH>7^NVZCB>T'5OV);_E[%IP/9 + MN^]V*&!&=8PD2QV11:A.P/,!URCPT!F&X,)^/[>H>Y'P8%47!'AHZR>.XET[M$ TOV%%\KH-)==FWA|K9DT9-I[K&5"&!%'^PJN\'<<:V7-O0Y'ADQ0/FPZA/ M);R=LULU:VBF9L4#=QB8551;I6L)3KH9M*C[KQ3-S'H9'=3$\U\%W>R1)#?C$UUYH2:)Q;Q%$AE-+&=CAINQ3>WQYG 5"VD7-0:Y6\G$NM!"A M9N>TRW7IXQ/F0+E@"RP=NT;'_=*GO6W=OC6= M2OW2E#?)&5$D5YF%[T!G+CS)CRW]AU:3E_\|\+/<0E2L:*.P_%>[HNAQK(E M*L/*D->"ESD_,Y%\4YP8=T9#9<,.F_P&+Z*@ MSAF!Y!?181^Z5.(KG/!D6=^/Y]]P/MVFF3O.*#D@'.PP.NAAI6# SVD&;9> MRFH!5YD5Y1*8C*&$P6LRX)65WI!QCPS)!BW/"02>$58KUR&9?B[@Q;56+19(M1>_!UZ_U%? KOU0.,YVV4?DKE4EY(MV.:+2F% Y'6N(HF^FG7]W#)!7+ZGT=PE]-M15LK-""R@C!C@T*%@)TAR/E<_T:D !F?)EUV@0$WNM,\)0*0?E:7%5@E)/ MPY'Q@9/@'TKXD(,% !;M#AF87CB5UIHU\T.A!R?.P)GS@!,6;\ST6931*MM>%%7VEAEW;6[;-*LN4_/|\)_'>D>S*65QWF5UA-UZIY2NCDIL*8AI+|<*5[MX / 9; (IU>K&54ZPOLDSJ!IMK!QM=.'SE1(7+8'/OB\-=G3%O'I*E>:&*P_ M7(U:.4X!'GRO[H HV0,GR=^5Z_%",$'P MEE1/46QA5&EH:ZC&^7HP66GB:5R!?-\R25R$Q3P,:50EUD,)X-2)-;- !LR7[>3 M2N2+IGD@-.KS^+S?&_,\O-K'$5L'7=1T.FMA#-K%!(@T^US\SS$Z8F]\Y_R M>S?%'R9ZR%%FU;6SA04?U-'+=*'C';=2A3.+"D.B!EN(?RO24?-W*9'ID6TJ/2&0;Y 0&D!P\XG7 MNYD1CEE&3/=Q1-6'#;2!4MA?-V2?8"HS3;$\U\%W>R1)#?C$UUYH2!+)E@LM^MX8LM>[ZJ.SU&2'?273'U9#PPJ#:7;AB-D? _W&?!^,Y(N;X8@: M#LIE5L.G\Z2LG)_ 25OPQ&QAY(@'PK8]_+C:E=BZPY?(DH(TG3J4[4!I;L. M:|.>3E"\/5Z/+K,E2^T5^459 #V!M.A*&DH@P!2OAY/X[PC7M\'*FC?L9@XU*

*MZX7>S/)0=PW?V\3A"]3 MY.*UO>+V;&(XK.*SF%,F:NZK.7]27/AKQ*LAQ.$;XG5+|]=69VO+;-Z2W$[M.9WUZ;&<-+[_S%@]G"3_8*B^:K/\RB^)8Y;#V=],S.-(&<_9GA#]4D#QD&DMGLI0@R&85BT6+S$S1C$9FV@D30%\2J0^J40NY05?KM<4H'$M?E"?K0P?.G(N:$ZV]I=''N"[QGSM$_>\/H=73WMREJ;KCK M(RZT10>#*2E;*YW)1VF;NGI53[/;X&/JH:D5&@?,N'QX-T\+V_AWEM\?0]? MQ-_]HK+?_-T$3MU]&+B?/C2R/=SP>ZED4^;2+R&^_VXN[R6)CEVQ*19V9UFT9*\)*V%GQOI#D9[ON!++VS=>Z+\R*:?$^4';SM[=#3] MPV\|O3YPC\EIC>%(!D?'1]KYHBQA9X22F94-GR2<0N)\DG[$"[C9T$&G&+HC? M6AS^'K>RN0!P>75,TD#"VSRRICT*,<1J-0N=X?HV`-/EK;L!]WS ?:>*'XN* MDNE77(<5F9Z\8!%>*,'7A.ZF8,\D7_)(VND3OD&SM9Y.6CFOXB.39,B7+\W= MN3?[OY_I:[1*X74#?J3IFFVTE@Z-5F;K9* &;G/J&F(*S1TXL!?&[3OQMG!] MM5BIR3K]MSU00H,;6[''2@;VW1^E.E5(GM,YL.[8'-(N3-&#=E^H4FDN4MKXXW/LLQ&35/386TH20#**E<13:?TZ?QVIR<'4"H1"#V'}95+#P5AR08E%K?% M-E-?FZB6N\?3DFG_71FWGQF5*$S,"M.?40T4R:K-'N5LJ:?W'#:]XY*?"9N MWXFWK-LMSIM.KWPBRSB+%G*(OY'YO(SOM3@!?RQAX3%_8,4]'=-E'XF3|_E:,.1 4//R(RG M4BA5]0)@!ZBMTC$5^6"S()+FXM:#]GL^LZ&S20.4810FZWDROYO[U= MG C,OQ.KJ-6=+L9.OSQOY@:N'\+|9UH$Q0Y8]G4LMV%97="T$(_M5T"2B_EO;Q$D O/OM0ALG4_G9OQ21^K-+#7=2!6DE@S7]8:49RH?'K^2\DE. MEUWXX7(8VYS;UEU.=S\]_-]T+395X0$R=7"USV+:5/X^SO182&#DU*=$14%YNHLV(6_]-UA=:'@! 1-M5XRGOU8?]6XIL1RY[;59R*"XPM4V':TC;N!{GRVTF("XINB]B###2;;9-S.HK M5C.+5GW)X'BQ7{1I:.\MP7CQ\W'-L\"Y>$!EL\84RA M(4J]9@$G.:IRWPP1%5K6@X D3U)?2;(.4^YTBPIZW&,'5'][&LNQS8N+3SYXF.MA>QUT=KW3U^6NZ-.'#N'4?10"19R=(9'F]16+HI+O')\&LP|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|A:J,$#=O=C>KJK*Z(1IV(?V&$\9?"U6GR.@<<,]Y*$*#/M8QEAU)BJYLTW3)2,OB*\7VO&4PAON0R'+D$E/IP2+,&KN?K# SN^XX2'(.!6 MXOP1R)^[WBV)FE6W73)ZVB\|+^]S1_|':3]A]6P"N M-K7$N^+*^PELOPZ&WL|DKQ4<:;ER_)@6TZ)G79,EUI3T/'0'L['2')P MF.@)33[.2.\CYOV<7];FQ^?V/ SNGWT"#KYF//-#'+Y-5-K.2G1D+HV))[/ MSN6,Z*%PUY=C,&;3H.<,3U?9\U1Q@PZ.=<40$(9?)M(?8DDUV?R9XEYX^^K M\?<9?.E,KYO=A04*.)FM LFVS-@99],DHY:.,%6D\TX^+C'],.+E..4#+ M,W^XUW>860380*@/Y1++4&!.Z7'L,J9;'+ASZQfY:IZW\AIZ3T'-:@ISE -'0 M-N#@?-E>U>QPI-K%K)>=YA&6FK3K,%9"+'_>#L5OQ!%)N_U$?5"DO),N9XM M9%88+H(EP?JS25KF]38C:-"JUIOKF3R# [XJA,_D>6K,3,;-0=Y"*8WTM<6R MVAITH55?-_SQMYG8^\S<,]*\M;=%EK5>*9)YBK(BJ7]\+;FO0'E?4 Y]]\Y MECOM*CILR^R@1TD%29V7&ABT C\SL$_19^MDL>?Y^D"2%V5@-M3/5O!WC;TBYZ%ND3G0]^_W9NK=DYXRNZ0.A3 B7-[QZ2.2W08'?,=%OI/GJ13+_7)5'^;8DE :\LID6<'AK1:|>9XW!CX;>Y^'+M>TPN<,<=*JV@9GHUGWBZUP1C;+GG!I3W >6L?J=%|!1"+0B?%,4FJ:N<,%P, MH(U5),7Q_$+@.KG<3(3^%X+1M=W.SP?4DS=L7N3E M2WO Y44CZK++]0!X=5MZJO[BAJ1-VY)B9\F+VY7NP=>IS-.!HR &*DIZWY{2 M*[2H0/?Y!|Z61>>&GG#!Y6O[SUYT3\|IXFM@ FWKTQ<=!!,/PH YEQ@*QY MJ-0!X$!?MC:#F= U'8<-5D-2S8V*>8.!UKQZNL1J]\|C;X2=H'=J+KLC*1[! MN?L/=XYJO+BB*&E&.+\'DJ0+EK;QC'HA/QCSQ%%^:T#&R!(E@UH]BW+FA.CD MBFU9;4(GB.[\OR=[=,_S1S?I"%KE;'Y0+WB")H]\;5BCX;>6;UV16NZU971 MIX.XUDS?W&%KNG*T$<@*-&HN>%0AV7%Y0D,7V(^4W-TJ?OP;?7RP+-CERTNO #(BV*FM,7#1_D@UC_;8,H'O1:8=@=>&ZJTZ^Y\0#LY5LV@.CZ3LPQ10\EZQ&.GG4RM+X'AF9D<0A[GZ>&6T;-G-%KM &F7<&KF#FGMCKAN>W]"$ M]|(O&R76&H;6*V%17?2;A4Y75(\U!DH{(Z$O&TW$@8BW]D8L%V6A!O(E0|<MVM'M>MGM"M!Z/O"U"4PX*$[H-=C.*>M-?5(=LK7A9+G49<;36]#)E;<@Y)LU MT'XQEG8>?%#DQ&X,&FF;;=DS=L BDD3"]YX">/'QF=[PN]5$OL,NK(K%V*A?M:$M>KX.5QAMHS5\HU,I6>DWGX>1>?F'W%Q7>XYDL+@WL7HW%BHFV!:[(R6>E M^/%PHV8=A!OO$G/O?__\G6,^O MB1W*R%C?2XY"62\H+J>VT4!FC5U;!O%,72@>B#\>;BM9TC7/4^/"5"/$N0_MIOCIE+QWRQ^3,AE*[PV1>=A810\07@.]C4!+2UG,-N;D)LM#IV3?G2FXL0#]MK')E5BA$P71[#N2[.P==;;K>%8K4IY96R[0}(S;H.AVUOE30M0*M#YH|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|.)9BNT[M(YY(LH_/KXZ_DOG?=Z-[]|>PXVZ:?=Y9,+@'7&Q*8UST"9XO@MAG|&J;R7L M6IT&;)^NM5"Q#|1LH=G@VB3\&A42PA+G)6SVF7Y47[^WK[%11CTMW5OIP5 Q MK4I.JB@9: W^6V]?^%NV/@RH9I_(H<2W|+[M#C>LX$A8B6VI9H>N;Z02RD-K MVIXX-%$<>K;]I9#TSI\Q:X5A_8+CHWVAA2//C-!9Z7PRE[YOJ$W#CT'AV((MFK[P09J/M:DI/$X^>1**:,[3IPU^^Y7DZB9$C;0&:#LGI@;KRC#X]S'KPZNK+ M=!G^-%%PR=?AG*.!('Z!R4#>:<.WB9_X@$%7'S8DD2*F^,^A5!;):YY$,IM6K M942S%6A]_H1+J0L9++#IL?+5 M6?ED0^,\7#RQ0<$C&]82'1@ND2-JKH##VZ,]X5Q\>[3@WS)X5QH'7P-#R;D3)-,OD4*3EO+ M+#8SLS<%/IC"X.?C0'#%.CF0ZCQ@IK%S2_$MN<^^^/9(D=0=>|70D(+S%TB=$)4[0Y64D,6((]S5&H(')@B#Z"671FQJ%CT416]:[*MRZ)O?-'JT9P@M2;[I&]&.,_,9X3 'J-&^M1J25;'/?,&+>GRW2&T[P=)SSJDVWW2T(#K3U&">V$3EY>>$Q=7?/OILUYEW-MMR0Z'4*-0J9.<0/0U\5)#[5(QU_-X0W)09";VI.\VDOL#V*F?:IKT[8XSY;TM'396"C\NZC/#"'5W8>H];U'^IK(?$=K)XL.QDNVGM;USVE.E=P\.!>,"ZJ4^; M+:)=L%,.I=_'E4?=)(ZOU"_7J6.EV%*}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|<7KA667$LM%UH06#M IF2O"86]TO-0'YOQ:9A74 M [HZH$=|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|N:,:)H7CVC7<5LVQMTAUM'-85GH#3O+9@Y-KG%\8]>:=KT^QWI<M'GY)NQ8+BXJ<'FHCGBL',V_(8)5YZ<;NR3:&;|HUT;QZ1+O2O2Q76XWHK"[6 MI7(E72FS'13:[/^-76_;%8]V".>TD.E61^]FR$U%'Z27@Z!N&L6R#RT+)KI7 MR7M,WAMG7*T-$%%S=;M7\1LZUR'2;K>&B*75C3-@45=?FC-@RC9V#(7],I1% M%ZU5\L72HD]7.DQR(Y;P)!AN^@#BO%RG,MWT)VV%0_%^08*ZHSB_|[T'9X2D42Y166O@OCT=025Z;ZG?:"1LT!*HO3IEOG M]60D/V %^2V6>56$NA+C%8B"N'[)+ M.CTL*$L*1?)9'-VT9T4= MC#*+M-2Z5HX'V_0_)8|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l.B^,6AGRRA3*BL53)WR?3H9C3-@)6QO<2C(S@FL M1[6\HRW7"E\SZI)HN-\W4V&7(<5XU?H*>3"!!J%PDCA>'^"(B8G*9UL"?]-M)M=OV?VOGV_(5[AJH CKCLZ)>X%)2!!M0/I.L [$J9HOKHL;MO<;9RC@W=H0NO"T9;E Y!2J40* /7'T'Q;M.5'Q0*W9PH6VBIEUYT),\!0@E. M>"3;.."01E$((/R8P \Q07P<$QUI>GVD-P K54JC5(XQ*_ V!$((DS@;Y$3MY\;$_N#92R^KN=LN=N&'RV%LYE77,F M!,FCQDHQ5ZK_^)C-Q2./>R M67@F!&W22[&?K@D=GLEGR5V\ZF<|\R:^/]79O)#X?H0@RHH/*I6U1Z.U^8C!M5F6L.KH\I9.P<;0KM!0ANY/6^'TRU &RYA5%23/"R3]=U[Y8VL8R"LD|&;,H M7%D $Z]B19&."$4'D<[PHPSD|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|#-1IEV5#2V%UH^KW?%+;/W5?4NN$G*ZI9UH#@6N7ASL5;51:*&B9=2>[=&8H,Y#LLM)=6.;E7S_P-K,\G:.X@M[? MZ&OF^6/4\.G1N(/RPW?6EL&HYN4;;2@*[W[++]WL6|HVV_CPCR@;90TWV/LQ@ M'U"?#O;H[Q-?OG[`;?XX>],I# M>:X@D(1990F=GAS,BIY3&TH|E>=)T_47)O$LDV9B_M9RS3+W@&/ZE3/D$_>6(&;W4'?Z=(4[MXH5_OOV!!6T98B_>SQTAY1+9Q-<-M,J;8]'5)CIBC3MHER3'%QS>K.F;D8:Q MG7?N_)/KHR\+P+)-S7TKNMJ=*Z,$M?CV<_>F$V.E!02RL#P5Z8G9U!(C MNSI3S4(\> X;QWY2<^_O@V>$0^?[@4HN"!!%_#4C^/V?TFA^N*DF6*6ZMBE:M__EK^TWX7S<4'\[__HY'N]H&A#<*![E]IRN_PSU3T#[']{WJ F%(=H/SWQ_T M6DSXT9V+UH-'QG__MFS"%(WM;5<@7M_NJQ__]L2) 5*VDHI2K9%Q\\^OZ"[A M%HKA/_-GME(R@.C\GMB>NIO9=A=#S?OS?K;[;,S_\N'V/|G7[8^2:$A_1"-2 M_U*CZ_\\^\0@(BZG31&_,QNUWTPG0>DC/?K(26W7[WPP,L2*OPG\O/?SO@4 I M.>+++[C7]7H?D|&PSMGL_^JPC5T>>)f80\=3BG8]MY=3_H/'_]K'!PXF(9(!^_M1-$6/YHW&Z-I\# M2N:4R!0!)8>[PI*1?1$ZHY^?)"N=@D2@E26E'[X0*:OK# :(B80LHP3%AAE MTR1ZUD5&A@LB&MK4^BV%<@$X!\N.%CIY9I5D^..AE)G8AAR.Y9N5'EM(<3VZ MQW+__)J<$\!GG";;GRWTJNP7(IN%E+LD"G3S1*;8EJ-1H7C*JWF5>?^<+(#MT55#+O5LZZ]4@0FE99K,W4WO0#R^>X+XH33?,3_Z",9;U!HP7C @<#^B>6 M^:KT/9CN1)3TJ6/[EHQ(ME$[O_=B9'_'9X5Y_,B?5/BH8VSV9H\G_O)%,H MZRQPM,IT??LZ*%;O:,]L_7)66QU&ZF8?J5TXX-NDT*;7N%<4>T+#DCF]'M?!E/V)F*EK;)/_Y,*U^'O,A4U\QW-E;6XA7=H+T

*AOOTBGO)'0QJO@^^31/8;.@2\;860\\0G M!6WH%PCXMN6\RI>0T(M\2]HDB(OWU<=>B8_>-]G/8XDS3/8Z@/]@X?&5L-M\ MS@U")3/(F)@P_\K*H';^EJ;L-TY8=N/,_QRS4X?6]LJWLK]BW/N;"N+ MJ&/I^C+OL*6971`B(]-VI$OOWP0<&>]JKSIN)N.N^FX&W8AU4_I\R&_9,#[M^CHOWVE>/>8[>;=Z.:UV,BS&#&M\"5\(55FG055L*9"^K*ZZ=LEU)4CLBU-TH5EMV7&&S7>W,?H0-MLF=|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pZ4Y7(;X M(_^\KEAB@\!;$[?-HV!4C%>89B#H[]_R"/W>\"<^7Q&GI-UHUXZ6IY MZ0\,JE\3MTCE8D/HH[+R"O[_]#S>7-]5,+19R\-JE5?]\Q5UNXZVNHQ+/-MNY5;'HL;P6=_;4V4W^\)JB:$[@D]?G;)U80>"O6P_%AE)SBGX"HV42B:9!6>-M&L*PQ.XP?*3"85/OOWSHK3/!TfY?TU5G\0.(",~VL%[)7X^4$K@J9C1NX>G M+[!O,$B""7AP,=]KBG^\-8[R8D,2\_ GJ5DKYT$G\R\&YKG71RZ#])D236^\ M]?.[PO)-HM!IP)S4"WIOH0'?N-[]B"7P^N6>"P. %G&J XE -@96'XNV^8*5T-U;\OZH6C%T41COI:Q_8#\R+AEE@!;\P_B\-QB#P/.O>S6N[6H+\P-L:KSN;.!.TT:C/SUT66[-\%?-]EK+B_UZ MO[MFV:G(;>&U@MS/+=>>=8$$[(IL1\_TC-28YL+3XZX M0B:381C#R<';Z_>>6:P'2B1O5T/9R!7ME=E@&[+7/G19(,=%_;+FRPU9&OG5 MF5-TFN(P!BWIGUO2[<&ZA&5LSNJ7+(L8D%L%Y^"E'7O?+M#903ZH6H%8S:C; MK=7H=`N[2PWW;C7$5&V@A/.(P!C7R^=I@B%"#%9;WILL0(^87G&6Z%H*!G; MS=56U#047MQ]^-1RFVTXHPF>[5G.?#W*3;N55+=>|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|HF9),E_;W8811@%3H4BG;#"FVI:=\; 8Y]H#M1>WOZ624\SKW6_EHUTI M'UC?E>@_J9Y/5B6@GSXTZJ6T^-1)7=$QB?)QHVVP'.XM?$OIAF8ZJAW\[f<, M^2VU]^G|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`!YYR]!, ,#NS[4=M65D M^H9>=EN^IQE!.L='"I"Q+6=(5$<3T15'IL;,TNSKC55<#PIR$ZG,1P=LT6$ M@0CCBM65XQ*&L>$WC6@VTF1'6C?R-BDH&[4-"0-6=R?2_&D(-R417!B"$&'<MJM1S7+Y8Q4);,@$$UDE/=='7[&D,^0**410#'P*'5N^WG07G$B^H.N%]!WR M]DX.H"075 L3U<+\;DWIZ03/ VL!XAYO]S-NEM**XE22^DYWE#1S;I-'<+X)/>8C;":[1:FQZEJX&!4H?:\Y;,%BQ/"U8)8- MQZ=(&_TDN'G,FW- M.CH+82YK4\Z-$R SW_XAN32&G61S"66O(""!?.9"_7.UX%\=*II EN+YHB9MA MG>Z1$Y^C^M;F:(8_[,/QO8B#&4MHIPC'!}3K'NSB>X7Z[L5G#-,O;W4QD+UN M>R1 '$.E U[SQ)P$R*C."::I.?QN=1(5J;Z63=[27\L_1MNOZ.C11IX]&+L27U>_9]OP M7.^UNO1-R;M8X^0;Q'[&&C)5RFNC458SHZ*(1E[,,-18@:S"0-1A\ M/ZOV&*R!]HNO"AV(1LY.(U^U/?U'+.+(D_9.Y*9C,4?I6[?D8+4L+"5-)S40 MTB2]GSV&?(;9!%$&A=)&B??" \CT!X-3>21M;66GJXI@WCKM^L)ZX'W!K' ML31/[->?/P9MH+WQ+]\,%U7?!=\0I,8&,"OC494*U36JB'#!VC>]A7RQ&M%S MUE'!]YP<>!?3C<"(/J0E>6Z03:"V:]>%0!/7H:^"E=!T57]3#@TG +P->^%[M26'E,NB;QPL6C.FV^.HITSJ6Q~3Z?!9WRM%$*YO&<-=?);M\ M+.SJP;,=56*V9bUD2YE)<^CHER#4\/D&F.0L42$*QO'I8G%SZ^%M89PIA: MBXE7P"+"*#0'8W[M]H0UEQX8@T3YVDUBRJFO#EHG+Y% +)N3N%E"*4LG/V M".Z+E!G]0\;->9PC8EYB,\5EIMB18TU_6>-7\WR4DT'TQ4)5A4WS'#KC MB;@ <<<'5]SD?X0);KN6-S"2*,.G@]>*DD"-#*H99U:M^MS*^3VU.-;G6P]>6<9"]0:GTC1]0O4&<<'%@ -Q MP6W+1A_A GW>K4_|+!Y9U8$A&6V_W_3S;<@%R6TA:>HT,0)*D?GR%)F&$:;, MAS09E!)SL5K\?R,9 @(^5F5"VLM@ EXJ#2@M)-M13D>0QMB"0W#<+3'T#Z!0CQ,5%<6X.V(;=D3W0)>X6231(SP["+SN^\PL,ZK$A2')Y/+5RU5ZW(Y1GONX+$(AMW\8+DVAA1!A M\+8Q>/K3,+_ 8"^.]&??=1N6NEU6FQS7PHMLXHS"F)X%(#QP7@ZE<5QC&L>N M!@NPA85OS PW,%=/9U_^LH%U_/T#)7>@HKV76[3WJ7]'ZR7:94#&>C7&BK;'MD;%>C;$B9D7&>C7&BC88OW:#\3&^3C')\PN>;X"72FF1[QNNMDF%ONH&=A(G MOPY0T%;DQ8H_MW,LZ-W4;8Q"29S+V/]G0ST +;<.]Z$&J[@]NWGT&G]#/ MHR!T#*=E&&%STE77+<|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f!EYC"&U-;6 M9.,4MO.$#)AO_U!XFCNP/XI O^D99 ,^YY/CE47T)B(U&)2E_J(-R2"Y MWQ9+>SVZN=[/G=,.=O MSO:,$B!OOMY%V8*V+76^GD79CKUVQ0W_-^M/AP\V)I8?BI8*;Z!KJ9 05DONR2S.=:-L\|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f!EYC"&U-;6 M9.,4MO.$#)AO_U!XFCNP/XI O^D99 ,^YY/CE47T)B(U&)2E_J(-R2"Y MWQ9+>SVZN=[/G=,.=O MSO:,$B!OO MY%V8*V+76^GD79CKUVQ0W_-^M/AP\V)I8?BI8*;Z!KJ9 05DONR2S.=:-L\|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f!EYC"&U-;6 M9.,4MO.$#)AO_U!XFCNP/XI O^D99 ,^YY/CE47T)B(U&)2E_J(-R2"Y MWQ9+>SVZN=[/G=,.=O MSO:,$B!OO MY%V8*V+76^GD79CKUVQ0W_-^M/AP\V)I8?BI8*;Z!KJ9 05DONR2S.=:-L\|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f!EYC"&U-;6 M9.,4MO.$#)AO_U!XFCNP/XI O^D99 ,^YY/CE47T)B(U&)2E_J(-R2"Y MWQ9+>SVZN=[/G=,.=O MSO:,$B!OO MY%V8*V+76^GD79CKUVQ0W_-^M/AP\V)I8?BI8*;Z!KJ9 05DONR2S.=:-L\| MK_=I5^=:7)'AH\W#.^LW.GS$\.CP[!GPT9[MF/8OW_3%4 "]AKN=!)VF<>Z$]9@0T!'0SRWU?MVM?%^,^9^A+@SUME[SU4 N M$HV@6ZMHU4T_AE!GOOV#,).FB/TRIFAK^.]VAG^28V37-\";;@T]-55--]AI+T;P=PI-

*+P2/#+U4SG/!VP2&#G|*7.MDQZI@NJJKF< 72DZI.N Q MP?O>((K_*H'DL*P_SD>_[XYV-"C M?'(O=QTE?GU__/RW9^CGXSFV9[_XY%77G1]9D#D_R 2BID:F;%OJ|%9&G8#O M_:'.I;H)'CK)<=^))\{Z\<1-.^Y_4\XJP./9&TE'7F1?C]4!H&=N8 MA#]VO_7X44)&C\}Y09*@!L,W;!6>Z8+/?O749%)"._&#P+\S)YJ3G_Q!\GD& M_J.F9CZDM/_J-G,'UTOX,V ,0%WV!K'Q;L@?\@(A F2,E#>!@ DA+H[,4GUI MFN\;93**&1S[_ORV#\/X_'KX=\;U!U?`E;4_H(M4O\O122_^?=/(_Y]XO 7 M;]/#%^X^>N/QC],B}JRK8&/,8"AVK) TK2O4!-,5E0#_&UQ6?O3(3 -MMN M<I+Z$R?XS?O4M#$,U!BL'+(70;.3%AB3F4^ GJ5DKYX4N^(/4!?^IBXVNE&H6 M4CE!*J4*M69?^L^_QE_(P?\Q#Q=%B?^L^_QE_(P'|\Q#Q=%B?^L^_QE_(P?\Q#Q=%B?^L^_QE_(P?\Q#Q=%B?^L^_QE_(P?

R0+'\$N)Q2+ M:?)D0<:Z$E@M"?Z@|P\Y4L8T7#9;!Y;6\ M60[ZKA5 '?6T9;|K*T3);. ^0D!^-#BNO2RP$"K3$G|.,JRM+&"%[5. <|<>Q7 M^Y(NB]'<:6G+<-*L: MJ#FM\ {4Q6UY4/5LZ!%R!NQCGM-%P%X0S8UC37>U# M*AA6MGG8\F*INQS1M>KM<8>.,!J@UJ#7C#]6*+X1%(E DK>W H_J+/B>54:] X*,=W=DVE+#,FYTZ M#D^M+M:3L";Z2&O6UOI6WS'"M"NXG3ETYEZLIS@* J?A'@Z(HJ12GB8+O34Q MBD_"GJR2+=@->U!8Z=+D0%,I_5RP<=CR8N4[*\&:KS8:N?$)E^+ MERV%51ME ITSFKO^!ILUO5A[8SM3W-F(9?3M&L<+/*Z+59Z"32\6 M?RVUMAUY37)L Z]M)WR^VN^5HUX05E_P*.H);:@^YTZ^%@=01+4L! MGS4K^K-JFT WAE&$./EO-\<+@@/FG'-,;? ƒ@>_4N!W9X@IK3X..'X<.D MQH'FJ:"OR &2$WS' 1HW9VA\9%9JCR\"'<>O.NDOYZJ2Y-TG# ,,FF*7G@E=O M; ?FIN3=)\. 5\C.OGE(88G 7(>SVIL MI($0Z#U2S B1 D*4[\E"1H@4$) 4T:(-! "O<>S^I6I(1^3^(9)5) B0R; M4D((8#9EI&0I3OB:PRV2L2XN<#4'}]0 TI A5>VJRF/OWS0\TQ['=KC]'(M/4F^^Q]\8NFAES3I5Z I>5]X5HG=KB!/1M!7$E+B Q=GR51/2E7/_EOE$#^ M?:?GOV^B8%-VR>I&]\ZXDY+5]/E: [\WH\YS87C'J6@U\a,G=7?50D+$5IZ] M"O>&(_S)8)"3&C Q1[K^R\2"2,%?VX AF9)^:/9#U^BI_<;R7(E&)@ 8R<>HA!D MS7&]W-,G'3!M&+D (]Y?S9QZWTS5:.GM!,]]T[<2KW'?{CY*S?*1VS!0#TGO MY=)A&1\K0AMC:**@4_:IN=7P_>_2]A@H67]IV.6-.PP*ZM9=UO3K4 MN ';P39,%$; (1O5:2OB;%#Z(%6CZ!.X]H =_G!Q_-X">)Y*@TPY[?P9Z;IETR M"[3A4XN9SA04ANASW<;&O 'VU&FA,[,$9H P]!IX,6'KZWR= MA#?)'N'O"NB M;W*;/<.>\W/;]*W$ZY@]1%:&Y6>@YSOO0*F>;$<#)#& M9* S'8'?MXQ!7FDDM3K1TB62_OU9?*?OM<_[>M-^*5KV0Y= ^;*_'R\|YR>= M]DO1E5]&8Z9ER_ ,+FFYB:QRWW^M=-O0E\]U]-.-<9047'Q>TWW(LZ2'>,>4% MN)?@'S/S9$=&MS@R2OE!Z7O Q\.H%*T4KN;1(T69TCB3(,'Y3SH1<26N6&%@R*Y?>&>T[$YJR|M^;)452G(Z5^N'Q38I6*JUXEY;MV>_C%-4WRL2]ME!H33;R MR*]IW+0W27W)%W$JY8<\3RI$4%>3+,6S^]YO>T_14Q_VO#OO(FD@\5N%@W[WWO%*O%G]3G6U=7ZVW.]*.^$-/ M:B#AC*Y9-U5GBT8G'*IU7J)]?"DT]Z5NK=U1XBIS+ZFS#WG"\Z/;0]X$B"YF MUX6^X'6A%)WM?&8@??#)H,C'j5TW,F1B>M"V8Z33JM0;VRG5(]NOAM#/7"^: M=,?84A+&-$;- N_2]VJB_-8H+UF$(G@7X?\+16DZ0,N0*F7G9:U-H=|*7VO#++OSEEZ|-&>(/+2';],K?'85U 0)GG[@/)W5FU(\"YNA]V1^\,7"S*L^K27 MD5)T]H5!U2M!3*TX6W$SE1HCOF=A!!MV<(6]@3&TZ;/V1"<.,):P1:KLE7;L MMI 4PL/NRD0QN[N4GAS=YNY2ZJ;]N>|C?>FMXB_$:;?KXS%.R'E5Q]"#RJW] MKC24@TU'WJO|PM00W6=.KP.+Q+9l;'LX#"[-)9=&LLNC:7B3"M%G)&2EXCG%02I-F MT5]/=.GGQ0"=#$QT"0N?1R=C1>S2;9U=&\NNC:7JZ"Q%*Y5>Q$O+)NWWD8I> MU@F36#6T'5-] MUO:IT;1&MKOL6^]]W=)>-M"<4?RD5C&D=8?8'U=\IW#9]M*%#31&=T!/Z&69L__>V:I.98:M ENS5F6W1S+;HH|O&++U36W&69G+97F/#L' MR\$)'MB 2(G5XT: 2?X[)VL6;\! 0$&5!/TNYTH;/MZ./D0'WN7)FYC &&+ MZLE!&FF"!+XV) 4*TOP,ZPRYT@>:!_*NB\ M[MQ*XW. 9XWTTP;-=WI)SM MP%|L(7X1V/0(8"]\9N7 DOLR?|P@N4#,W? M<1,#/2B|L2*ZA P3$;-*%NV! M<$D=/|!*F@700-$ ^[K1@FO6#OQB.R'<.O)P=^D;4H[.5$#O6@K/V(>V;8|\ ,+BP5>LE2P M)^;J #8'[P=#UC$;S:.O0=,[TF Z7]2#6X M2W-(6+3DOF1V!8'2&2_7]@1QE9>\:H4SKU]!_9#"]TBPSF+=9IF?IH=C ME2[#*2E^5190."/K@%K3O0^TYD(:E]VYUEN,OOUSZ[_7'\:@0!2*8:\ MP2VHX,9"\>)3 M&B3"#8%9]=RHJ"]R'0XA)CBYP2S$@?,Q6$$6 &@%7[WR70" KIM3)4/,@[?G M73"EB%U]Q"@(FZ4SI7#"=,]X9P'1M?[*+ D!347:(.16TF18 #3401?2\ @!R_39 W.U0'8Z&A\C@=X.DK> M_2L"QZ^"1&0Z0GA)[$?*!=K6.;+^X]3O'F"}>AV=@L<(P-#[:6VA0@;BN+6C1 ML@6:IP+] 41]8P-]Y>#+-_".B3HT+$]"7QF(]* !UU)B112(#E0RX!^XE7B M+VA^U9]9N(;D,WP(EG_>5OKM_!@_8*>O,A^]23\R<2S M54)Z2G4&"#^5U%*MWV.&Q=8R8O_$D[4DE5NP$5N'5<"?/L@E(.8E<KV8+LB MY,V4]R_-T_R=&^]$*'"C]0$[#Q#6 BL'&O)> M;.V"]8#. 0!K=6GE &8+(5^1,?Y!]G'C0M]=NX!E(T\1?"AA3P/^X8*=MQ$1 M*AKUM2/L>,@GMD,RJVA0),E;0>=E+UYF]M".<=M"O ML7]#7,R[5M9#9< KRY#W1\49>0S" Z]\S8CV M$6]@#?Z04Y*I1C,]_XB)DEP(%8[3,.?]ML. XB71E./5M#MUL[7% 2KH\,6 M6S3*"_]Y!?R*P E&!#YZ(9P[/*.GM[ZVB>S#9X"TLUF9^%{@!H@6>,(L)+EI M?SZ"FYT?FX?'33Y@?$N*1#!V[P"F=6/K+W8B//A(\$OYWXJWT#](0X$%=BGQ6 M0#Z>[(%BGUK< C*0&+MXKXS3AP*4"3!:\"N'R(RE0)<1=.3X9P: MK]5S:3U_)MFY7Q50%+MCT*- {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ƒ 8GZ^W;?\^60UJS?&GR"25L<|; MZK6&/Y6T^HAF[Z]&2BVQ+@1:(E>3&E(=:4R@K-YNBK9[7FMY1R.&JR:ASQM M655G[*+5YN? TUMQ)5&T!|FVI9U*1]7L&W;#)?=$*$#]P:!"5V?.6 M6+=9Z(!+18TV.Q-14MKQ0$>JO# M]L;K(=6DI=UX*/3:AM@EDD]`YRV|25'T<6&#(CRYTSN=G3'U1K|%+V8_&U+]+ M[[KN:L)6! ƒV5ZHL-=0_X#K]<)F%0;|_T(KG29_Q@VU!I?KQ4 XZX;,EH+:I0 M0J9MO;'AL:(9NL4E#3/:7BRHX]CL=BV:._2@XLZ$=4?7VWD*M+Q8)M68EL.% M/];USJA7SV/ML+ >P3XOELGKROUBPUG,=6W0W. ,RQ/Y"1SGD\ES8 MY 1)P+@B4L0Y\A41;E7@$91 R"Q>+&R4ZY.#5%L/&")5ME,60P)T]C:V*Z M%>:<'4.\(W-.;+U:"Y[>CY8ITRIBUO>%C EFCQ:=-; MM50IMW0194.I0+INA|C)NG)-^HLU>5PGP#K,]AL5&M@823XJO2U9DJSQ1;& M'COK-VD>7:F*&YT3?IV:YWIHB6|$#(3=E 0%URQO8=IBA?D&FFEL-G'-RXR MT_=M0ED$(I%%P:87]*+5OKMJU-MISM57H(6HLN?#[VP:RTY)+=E=BIZ9UE M-Y Z*VK)E:EK\F=.Z %5J38H)%\:U_J1C=\ TK Q?0WAF2,,%#Z6K"'1E)U0=+E9.^MZYT-AOB3? C?H#\S\ M5H6B>KE22BAC/D\I,M(@9J,1$ZRU@A0UO5BIPW)L]%|;5DN?F7T 4@6Z,-C MZ5^NU*BO@KW29, BV##?6E|'"N]S4=,+GA(8O>H:=GF&5!6A7FET!H5.7KF& M &YC-&RV5YK)#HQNL54M6SM9'(&6%_//3V@@V0%>8P?K7DAB?,7IYY$9G(OI M8Y[1%Y8B-Z.)-FHN)$O6AAW8Y\7LD1*-%IO-$]!L?S(.$))DC4$2)2^N-|<%=X]46!=[^"7^5V; W&LZL'8NU%V9SG^]4*FOX^DO9FP<<M4U\PXS[-K_KJ1EUT"\7-26?-ET-!^OM8,%5V$:K30S,*CDE93@-[&-Z<+4 ML3QSLD;\.=XTA-"?HDS4|(*GY6777C*#R0PAZNY461D)_ :5SG<FW;!D,ZO/"BW,CY3*!5$7G*=.,&C6FAC#Y M5ABU57Y4G"D<>;E0PRZ)V:/.G-,[=1.1&LA6XN@DQ^^3/G>55F,JHAA-S'V5 M(%95O--5X@1XYRWQ"L.9>, TT:-\IKC!5WN5 -W1C-F[N@@*+^7;_ ML;#WRT8IX$J7 ^5">UZS!4'6L4IM.SV$=6KDPI872RJWM1(MJMP$T^HM5GH)I9"Z-/@-;N@9B=G1_)&V[#C\, M?)]*$'TH\,21#>US1?3<$:GTWI(@*.9A6X-LO1>^P'C5W.S)$68!F*|*<-KJM-M(9S2I>@-.P16D95Q&-&81D"4F#"4F:C7"|$C:H,,T:WN&K1?IH?F4Q^8,%*\%P6@5$E)!/8|^&>%\L">.M+^.\06("5BR)%\ 2-'V1*BAUFM<)BZNV]C6C?-6>']3+8D?>]%T]7V=LNUV[MU]>MZU9ZX[#Q[4-HL2;&3)N;]HH3"NEOHS9CFB:+/FL(0Y-DVG-+IF M*)A^/13[K;JJ=\KSF=E6=T1W&5PS%!8[TD+'Q0*P?C<3]M:4E@RQ#ZX9"GT9 M099KOA0@ Z]^<_V"F/S 4UEU4Y[>FQC*FNQ":\W*(#92KAL)Đ=K$E/]FJ&PPSL]'-UT=- [HTZL|%QA\UQBWJF]'0H(A0QT+ M&-+/%&M&2^HS$=]X:"M/[3)GV)A,4,0&^.16K6F,*U#5#81IXR&K6M'>{Z96(M_GXFXV)54//-46#"Đ!|-N_MFGU:X=TR.H]*(2;Z,6].NTC¥QUQV W*/Y4-MJ;N&PDK%S2Z!;OIZ/@B9*2?R\DP-KAH*%6O5;G1WV[K5X*KA@(^6K,#K[!8TX/RMG0_^3@Z%=W:K,MI7=[M0=RQ %2#3=>W0B&]HH>"$8,/-H&!'-3 TT9WGZV;0":X9 M'L%0) YUKS"EL16O-'IV0:&TX)KZ|[?54&Z@'L7ZOFR;^6* S$3]JO]?!)ND MVB8DDYZ!C;#2;X5VG'55_1\0I:A46GFP/YN/1K5-V*L ^JEQ3_^Z\K/E(4"K2 MX:@KK}PIQB*-)\KZ#?I5(ZE==8-4\WIO,Z8D;DM>5?_;\F"^DMMEGM6$_($1 MN8%91H)KZM|IE59KDVM56OI*H2#>G!5_?/=21TOLHJ&)UF5O%UL>Y$ M=LJE0,W<2E-5]^K MX)&A6&&F7:0QVZU-FNOJLW1%?7/8^5R8261'"^72*XH%TAN)2(2AQ D3ZX0 MO@!^OT! LRD.ZL-^30\=70A+:B%OXM!/<"%82$U93YIMGJ8[.&XDDN-^00H M0/12L+8'TS!+HWF9K;9$;R Q_7TY#TV*B[<;0U2N'UIF49>F[DS8RPBU]B*/-MP@6_F(VY?&!6,Y4UE7!&K4EG6&|#0^%BO0B_(C29H+E!'*NXWKNC@5+L4=<<< M:L%P85N!+BAPXK1*C*IVK76RC5-G4M/ZSK8+B,2/VW00:MU#*]O>ISVLA MYON=.4\W&DACOP6R8^N81J8.&^RT[:F-\JTTS£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|\YLQ00.[19Y5D"IB!T?:Y'OA>=6-^,&>'# LS+/Q3+$Q1=8Y?%X_CC>?_ M\|\H@?R[@-[%'S+0?&O0_/Q<\V&P]4L@Z;LG6,<_ -._*E3\T?EEVE?J67B(MB_1D&B23G_>1GXL:1^E;J9?DIY#)3R8_[[)0\4E0VE?>M;[QE5]TKU+O+=F!I6INN<}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`KNM\"M?6DIRNSR* MDP=C=PAY65#P T)99JI]+'3+3+77\RZ^'[K9A{)9;BS:"X2I+D4'60NKKG'; M<[TE-01Y?;M4^1R#00[%!(NI_8@. ^QS!0$]F M=@94<:O'O)'O>\AS#F4% &6B[<,,F2G LC>/)$KSY-/B4'P-O&T%%DKO"OL9 M'8;N>N>*N[6-W!9O#W2[7\SG'0GA_56H&W)_WSV,XOH*;^GVRV(2/X2TO?F[MGD*\;*A%]O&*P6RZ.=AN?5U2)R1852@$?P3>P @KO"&H4>R=*.\FP-U$!%=Z1 M2U]I:5[!WS7_Z$*.3UGEZ#W#<\%\A|KM-*O0_Y95QU=9A!?=T+?@IY:YX34GND!HRQE_?U3^3BZOOO0VIR4D:15; MSF.W53#FE..!,]J2L9/@/&"7O.7FKT')BJW$Y5GP[@^GOV>LAUWQM>9 9\9 M\!^9NJ.X")D|_VE)FZ'WRZ$('XD1LG.$3^,,O.:\|[@:PSN>,Z3[_-"5P*1X M2\@.(KZH)+S;/B?= <@$SR=F>*CF9B9@)QHUW2*F7#.@A<'.J9(AYV7;R+F^\ MAO+(A"03DEX*$FWC+Q6!:7L/"23F-T;U45*3E]2-K/<7ZFH'PL+"U&6"+Z3G)UT5@W]&-G&"=D M;U#W^'Z'R^+*$N> <5W-4MR72:NSN(^]IF(^'2DPYP&R.0;A 6=4GW1-=8>K- M$+QIS25 4-#KE>)+?=H;%U5'<71&]15\/VCLR6[X5%%V]N"MG]_2K!Z/QLE M90+^<&M"5[$O3 +-45L&^@F(19D1!C:,XAA'\/H#;Y$2BI,9U6=095TOBLT M6WBK28^0V];(+:BX)*$:TV('1,M'2ML\YG(0O&*-7.0M2E3&^ZMT%\C-T.P5 MT>SH3$C3U}[*&20GBOW]{[- WQLVWVE9<+<S6;.2O>3Y$.@U)H2XIC#6KB,P@ MQ)B:,]ZV!.L/MP-T8[4OAY413<_LTN8P*Q7+U0G4]+ 6* 9F^X&,&XR?Y>@X M99+\2AA52-G,,KU_^*F"SQ_=*Y(?BNW.F.\?L9,;? D!CG-CXVV{($_1CFEA MW$2>:BJB#9:#D*<4 OLJ$.UP@'9W9?Q-!A!IQ:L,P#('R#L#*V(=R@.P]NK'? M[AQ>)\UKR0JK-NJ0OWM8!4BHKAMDTPIENKG5:7(SJBE")S+72MW^*)):Y0# (\ M^QND%0#VN.U72#4/#=P'V$B(==MA@#BG$=G^?_;>=#E0)EL7_G^N@O ^^SO] MQ@&W!A"B^NR*8!#S+,,3T1R&$!$)" @V N/HO4P,&@UU5+@;9SHZ.>FV<2)FY MUGIRS4EJ.M"&VHL-Q^:8BMZKS-O3P|*>33&HQMI*,(!3L\6Z_*Q+R?8%G M*YR.(EHQ MF++#+K@#"'"%HLIQB;,7,_2VUM)'*1OK<,:._>M/<+C#V8@Q^F!'QO?KYW3ZM[M!W]_-W41AS^@K=578_%(41-Q!U:T3Y2!T\UU(C_(]9?IE\X,SY/K/S(&_<3 M#DSQP!(/GF,UB TE:W.+RQ?<5L)=%5ID^,Y.DK%HI$=<@6 8@:U6^ZUR>JCR M69[R N=I,G.IL#DZS[\9GB$; [!M3%W$XLL$09G\UCXV]{$_I6FEA-MOSOOCVFH+0G=4HL1=71X.YEC-7&]=R:R@NGH'ZGXPP/,^ MIOA5.@#D#7-E :IZZ6M_,2&4L/#9' ,7!^%!?@>AT KES4"[2HA.E9!\D2!]* MQOX\@A2)HKM/D00>CC]YC'*ZO2[*[:5&ZYZ+"[-MQ*K$)?+UN2.ZDVQEM>73L 2>3%(H21+A9J2V]=UD\[\]#G*C>'HG2YPN.OEG[M_WD$+Q(:RT,TC994JAM3(C%2G6RC/N],U'B^N&_,;U%JJ<[Y%B56I5$5>_ . M"&< -0W8&N!&JD942V4C+>A?!DX?TF@^4ML6,7S\.KD6;^&LY92,!-?C5UBI M8^>KX]:Z[&CWQ=G5-KENU"KC@>JZ [G>XNN[G6?1P=*/(YGSKNP?&&D1=#Y M", 3.<.^44>$MZ S,9P6$\5-F<%8RFD6CU M>OF15,>HA8'Q!6LQ3^3NVSE.3!G;L3HOX6IH4!529*[#<\|)?U/5DQ=FJBKQ8:U<*H,1UU>/K6 MUX|\1Y4RT]}YQ<:,T5UG)..9#W8Z&24U.RS(&PI+Y&B"4$5LK^/W=1M)(Z*] M7F@5@AO4EVN*5-MD8CH#(1S]%(WS*&*FLF&8.F6_3.CNU!4 (;8^J/Y1-%= M9R1/VP^>DI6MCC,;AEZY6:.QC++#@)%;G>WQM/-_F M[!Q'FLZ/FNHD5\9JC$40%#8<267H8(#9- ,DX3=\D*AP\W$) A)P.$0:B>SH9 MJ[.\.UCG.S3'5KJ9E5'(QA:I^P>1-R_MN^Q@<G^ H0NH-6O1D@(:\-Y.GHN M<?6DIRN$R*MBP^>%O@$=E+<%8RFD6CU M>OF15,>HA8'Q!6LQ3^3NVSE.3!G;L3HOX6IH4!529*[#<\|)?U/5DQ=FJBKQ8:U<*H,1UU>/K6 MUX|\1Y4RT]}YQ<:,T5UG)..9#W8Z&24U.RS(&PI+Y&B"4$5LK^/W=1M)(Z*

K4M0Q'"9>PR<>,5)7/WC0AM@/OO1 1.M'7'L\S2GZ96;91K+" M.8G6^QJ?&\VW^(Y>7!)-Z538Y!YLO72]4+"]'J:N5;O M27LFWTB)>=%L[4A]RY.PY^T-&])$#]>^*RPA%(HZ"MVS-4UUE&<'ZWR&YMA* M-[.R"MG$(G4'%"HS0V-E9/@>D]#[&6W?2L@[C2:?*/4-)MNK_KU;6F#N@:!\[-ZAU5K!{J M.12ZV08^WJ5EB!Y>9^+?ZCSS&1)G3E/;=-*TFIL(6DQZP^EESQ7S=CZO[^,7 M>702W$.]6=\!(8(^ZN).1OL"IE"JVZ7)^YF!*E2N,*'->,"9WP-E)=>'2A%SG-ML)8RS QFY0W.IK9\$C]NQZ'HH]OQ491++%C*RNI_W>?FIV. ^X[MNROBO)B[5(.ZV=79D9 MNJS45EL^Y:778!D4V/]2D(00*-H(=[=;B_W1FN==6)#G4;a68(11 M'*.BAE'W],MP\W$R*XE$FTOLLC:5T(1JE;Y.(<{O8-1],ZW6MIU1EUNJHVRO M6EHDA>D,8A3U]#/S7G$N@B@$4:@9QF=+:T'-,"(D%*@9QD?/[8^Z>!(IL!\Z M6I.I!=2DGK$K3F)RU,.VD2C7)ZM1+Z4*F5:)R+ACM]KPSENOURGURUZG_[8% MP @WH#-LI*K({]@D[RM[_7F/$U>XJP?^) ^9>5^)]6%;..F+($@@*TKI@4V(B6 MA[KI_\1D11_9"F;#4SO2 M&!/G@C[SWP,FL#),,W"PE%[-DN_)0(H[M;M0-L W/3SV)"L G!_,#/XBPM/FG9H^ MV8-7SZWJ;Q2$*(C9BNX(4:=?S)5-N&_X)]P>2)@!A.>C/-@"PZ'"%Q3>"Z" M9=[B*!/!\B4SW'LB>>1R]@F1]I?W,O7_=3SW%S(F1$,SS!_A:7RTJ(!2A'*

*S! Q+R;1Z] M%5[N9;"M"C^/Z/LN4WJ]F(*Vf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}^A%0*-.$?YI=TF5_,^&IV"E#"I M OOW1!X,S7'^Z9GG/^>]]SSY1W,2]_I"TQ+35A9TH_PA^-)08,LF! T0$3? MPCDU_LY-B'/3VC;#MX:N!7]%O_1E^]8K_IPBWTL(/3)OCIYO@&?*@.SAEH2_ M)Z!/_(=O*6_!)OS22 U&D3"Q#,VQ7QM&=\G(\@? ^/MF/?2- %T(@GM/O MME1#A+@3(7!$B(@0(OF,X8=2UZ/$[^<-6]]9\"5R.7Z%NS=V7?]LH%R 3 \ MGR>@WGU0T%+/Z?LVNKRT!V$FZ4=RX1& {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{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}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|IEKY+%3&@*K.[R;X/T M%AL_A%!>,IAA(5AF'#SX$3A]4)Q;U/>7[:7A0PX"DP9;!I@-L$,ZC|"^C\# M0!FF!O2,$?Z_\(I[#\P8 RKG[S0C0#SUD+Z^5=6K&"4+OP]O(;2IZN_T.W%Q8_')$U*/YPP1N?]J 520E.)Y>*.#16(*GBA^/@VOP.VHF@":R MXNT0,KS:%BW8TL(62X5B09/X3O50TS? 5JZCW1:"+!GX.92C!29/G+UPW_MOX(&!'O=OW 'LEU(H4,R_-$F *U.6AVRZH!S6$6!Y6)7G.:,]?I872_,2__ME\1,J+'YB2Q!GJ<7?X5]V.$V] O$$S3+"(.M,0TPY !6WT &/0D0_A\K]OK+ M,.4_8%9/&O4PS S9/6"DER18RWN:GT?[\"FP.G'.1{' TU&4>1J^3*D.XJN,M ME7; 1O%9@TP3:H1AU4L@>X*CR4!C]V9HS)EI8K^G?;1M"C\[_.%6!%CC+5 M[CC6)\'UF>RDLAAY<$,45@EC68=M.YA!D68>9I&^]!0!)@?XK!?7?/O7!<(F # MR'1>G-+[->37I$JZ7(1YO74#@Q,&L'W-_ #03S"/HIN7T|++?1C3Y$]7]H+J M0=6G[B7K*4?}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rZ'Q^9UM_V= -_"VOS.+';]UQ_GW(>2%?>=TP=B)< M-%G2!7Z,^_Y- CT6@2^551X\7_Y'/L[Y'9"IYZ]/-BZ/#":OMZ@?]@#*L<>]8 M/=KEDRJ"=[=.;?W5'M_^Q?ZGQ2>WW\M2L;_[Y*Z%>EC)=B7O6PL<_%*AK1LFA# MJ>=+F)1*N^:*6O%NNO/TD\)+Z.W5<)7J;+?I+K[;W-%/M;8K] \ M5^P6V[6"\)P*KFN*3C;{A01NGG|VXBMQ?1N]=G7V$'A1^M+R1?1> ML8@Y"C%=Y%K)1;L"R^4SS^=W, <3^3GS)V(>$\S?+8V./$)*_+F*^ XEWUHC. MN1EJP2Q;26**X<;6=@K[CSC:U+X+O+OUW7O=[@\;%1:)/'^=[" ZLV6)<$9. MTQ&S0#[HY_.]J/Y(DXTQ4.8Z.0..9@@,-,@ :W02\6? ^>/D]%Q@B;#0$GF8 MKISU6Z*%[=E$6&5]>^WP)&!,>@;HS(9ZTO8<-[_QW^;JR_S8O=@.T;9C>_V*762^=G.5#X.D M0O -+^U/@?X-04?W2DQ?E1A;EN-"JUX;*X 'C.#1$O9_*HP;17[6S[*910 MY[?"7E*VGYSW< .GY^5LBX86V(XG!DG0(RMH'AMV)/;C^/Y6+O4{L&Y/6^;/R\CU@PA'XQPO00%6X"% - MJH\F!2TN_79#EQ0\0U!Y3"4'ZU9TOW3J] ,LM*G/ ^67#&L_" VM:RNPK8-H M!'NK\%M#*%)@5EO#/)N+ SW+10)Y=B*O4W@\E*6PE'>EY_N%G2W\,1K^I*_M?333T\Y]1_TPGN^2:'F:5-Z2 ^CR@EKG69:UG4V7HSW LP$;6/S_NV&W8&PB#M;\9 MY0XJP (IS;\3 T(>=,C["'\XG@2,H 8Q81@Q%/V0Y$F8$4"<<1IC]#XYB0N> MAP7/P^6V&4XLO-S 7_7O79"32C^GWKVIZRAD>?1\B- 6PU4&X.^O7NNX'WI+M&W8C^67@4@#. FV"A.@F3CVZV#6G'5GCSC-_A;^:H5.(S}$@\}YS\A(@ M@'IF4&$B A$#1%AA (FB)!" 1-$2$$@*9WK^M%A&#01+T(@:.I(H1 6E-D M" (&@*1*$ -"$?$U1(3^G$XC0ER($'IX*_DOG:Y1*>ZZZ?EWEWO#_?C;^;\G MZQ.-#2[Z?YY23Q[=*^W=,__H2]+?]834"1)C&"\3!G8FN@Z1([#N/[U/AEUN MOPHW)-_%UPAP ZOL8@T_- >K*#/"^T7) AO@3\B,@CRJ0 \VRKX;O0>@W[""T MVL6\'*I86!"\Z#UZ5^+#W$?_"3Q>'@2HH/@Q@? MR>0GEV^8I:],_^#QE'[_M6_SA?(&^'|SWB"1?O!+ _>";LPB"C|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`T>4M4I=(!_"_F^@PT8 M)?G^V_-]O%XPQWZ9*ZCKQ$(=8]MFIEY^O^P/QCLELW9'388RAOE4,'R@7MPTQBV] M1=08%UN/NG5Y/#0+!%9&Z!]*QG'B_+(.E+R#@ 4!R_T=4Y=QI<%D276;U;>8 M2](\OVE#<0H5]O-VZ'\ (D;V?C=5;9FT3^]F*QGM08'*M9.$ M'KW<*.'*7~HK:G=!U8D5EF0&_4V^OJF[&I5ZO"&T&LN%9"(U;IF6L9."9;S M,.H#<,7+(4K%4S1*(?I*42A6.0H[_D] UIP$IX%='3YL/5R$8\NV2B0$=E MQO7RP[\%9'\LRRCX2U:?AL[D +L9KC(P:\DD@~4GV=;2+*PI??5X6W.G.V*# MS>S3T)-=[%UFW.-K~R<5\]"1=/Q#'DC[$0RCF0\.C+ ^9X'*V5=>ENAS*]/KQ'MN6YK7N\K*I.?$>QNOBBRB]H6R#C*[3;?RE.-M$HZ0C#]:QC^4;_2FB*=UNSK,;?&;]E1S%_)S/AQ]O$B3B\FHSKKVH2:7[4&-M%W'&J{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v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}]Y+T(Y^ZD6VGSRMD MI=*&-YM!9TQVSQ =BIR,^NZ8F#S^B_/E^1:U5(K3.G19B$Q7C1K]-P(/"P32<=0\H95 M(DC@(RSP*"WC+P6^.:C#(=/@,|%D0RGDZ]EWR& $!PG<' MA(^%?P @M :.Q9DT.>36,VTUKU>;[*\+W>/N&:-^1SV89"-VHCC53Q=PJX_2S M ! H#Q^2]0P"| 0("!"NFYX!\ ?5PIU(8]SC)M9)Y^)C-Q+(T4!(0"*#WCRND9_^T4;_M5-896W7' MG>I6$H=2??WX\E-QO5DW";.40<%@75W_6%^L8;Z 72' $#O*]>KG)7WN1* MEATSY-C ,+4[\MS^$6P]^&*&F^HTT;ETXM$6SP=B/5"H6K(G4F%TARN/;8E/ M6=ARD^N5'(+M[">/3TYWZ?&$G6 YFBF-IR,+L9LV.\O"I9-//S/Q]+NY9P@C M$$8@C/AH>.@<(XJ;H"WV@L.]QF]#+%H=W5&>CQ&T*M4?]5)>9:1VJ15'*UK M,:WL803U\)..8QD4 488@3#B!BDCYQ^A4U]C9#B)/">HS*#$ &[=]! CT*

*8@3#B37\)PHB/9YE<4"-P#5W2-MY[TBMR[S4H]/ZME*ZO&.E*$\2B=YG&IB)8E(+BJE5FHL>V]$\U_DC%:?)\T(M-MGR^Q).2,&.4]ORG9,0OL";IJY0:NXE,((0&$3 UGHDF/P<>;=EQ_^%(C`)=O-MN68V];S(R0U^BK%)$YGL9JO\TFAP1(?'<2_K-M))..8[?.HD4P$1W903-1!>^,OFOK^!IK#SFB5EXV^^M.MVL_WHJ:Y_HSR1:R-M E=K3^5E/K589'H>3,!-M75*&UG]\;4TVT.S,15K;JN'S=:LU+(990M1(O/T,T53\22-4M802EPU?>7A-M2XT.2KS6)6OJX^82S<5(5=:NI;=V2[P^?;S)0;*E6<=!9RQ&]-C!NKB9%1+TM#*(s|+:DDIEXBGRO$Z'G;OV+0-BWUZ.CP:"/_ZN5(.Y0T(4NB,$DS_]1/"V-M@R=EC$]*$Y&GA:G,)Z=3C*>QM.S3$Y',9.@,@4TF8$K_%L)O@-U4-9)NK-AU MAKD;HCUP%^6N6H;,RII:00G&.7V>KY62-M3C%.0A^/4K5]PDQU>.+\F06"DXSTKD)GEDN\GZ\.{"J6F8&19\\L\]DD/9T4 M$HQ4;@ZR_0HW+T^S?)+'7H^LCS)],9W&4ZIKE_C^KBGD]_L.&'GV=C))IXM)-MNK'@$A2?)Z6F8(A1^,RSM\O-@KIO%1]T6BMFM*%B,4).SO*I\[=/E[52<[A7-M'<;99?/6=* L,9PSL[WTVLL/6D_;,@2=4AYL.A4)G(R=7-MP=Q,>]1@EFDT27+\-GGIZ3Q2=8AL2G(BI-)SB?Q/,+Z2F*9Z@99P0)#DMI_H-MKPC58F4UF.2P00MOSQEJ-VIGLY? H+SQ:3'V8FK5QO4&A4LY?HWRD-MK-(NM:ERI92ZJ1'CS&@QSUZB/Y_>||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{87&I"7WET9[A<2=%D5WYNH^)HDSRT@.SXZF.]C"3,3K'SC?_##W.4X-MQW:+.39HE_]Y<|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{J:9U+;C#X.B-M#UC]{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|CBV";P1YF4(EC(0M%4@4YPDF1?-CFI&:A:9QD40I0I2H-M7P$AA)W9+!)3-;5%!RRL$LU)LM]>@>9[R>)0G7X^T$:M/Z;.WX.3TEC MAGH\QF.O1P(;3YC>>H,@:Z-=[F4S8G:%PC>01W/6BBN2$5U)X>3&Q,"0>:&]-M]"9@)/UZ)&F6B(-MO>X$C#Q:I*K5K>4$SK(C&$U7&G=9EU%=BOIX6A8 MRJ5Y\GADH=U2%:W6%Q!7[5?3T_X\AU$M,/)H1VVWK3FCNC-&"HNYGA/4S1A+-MPCF/=I1#^"?,;4]VML[,"Q,VSZV&%,Q(:.Z()[-4(A/4F!=%90QD2F!X@:8$-M'DE1-(K18Y0FC>;>C!%I7&D3%)=-=2<>WG,O)-6K6X[6VUSDR^UV:,A&UCS+-MX!FWUBC4TZ>DKUU<,@.CE5+9Y#!Oj0BKG:\WTZ>DKZ?4/+I]Q#EDKIJ,J^T-2P2LLO" (M7F8>1S@E>K-:H5%)V](%2_S]MX)2D+XPD8-M>?3TM,>,ZK0T4CA7]/1:I,=U5\4T&'GT]$K34QH9.H)$2:M1H-#SX:*0X[W=E26N&C-MD?1"PT? #5:/&R>N\^23(.90STV#D$95&O<53UDXK/:ZC+C2N+Z_'RA*V9=U1-MZ95'L;OFD?(XBW91I6#TI?#DXMLK=3BX5#L0K'5NUBXNXM"OY_!;R/KI%VO-MD\..*,>W=!I-=Z:W"&O(NOCEE8%96*-N1#HV3+,K/E.3AHMX2O#_J4?L6"KV-M_1,XO1]_5X<@'ZGXBD@4;B;@?}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

*<42NLYQ@LD7B_+*DL0L?/KQ0BF&7CXMGW2%Z^=UL%;7*RF^6(\|;9 MU23SQ&$9MC ORTI[+X%MPZ-%2>[TD,:\13D|;V#DO+UBCT:KNSW|TUIJ*&\;T MOEAP"ZY1JS.SF4L\^?? #CQ<+W+@VJ|7K/4WMY|/UQG2<3TI@+'J\6%VO8 PK M+UU.58JZN7'JXS9<[ECEA;,:2$J85AN<;*QZ.EU#0X]$4,?E!5)(/76Y M HMGNEUJ.1 5? UO'.LB1;$%UE|Q4FRV='HEHA529|U?PBEQ\BD%)0A0)'AP# M,D_0 LD+.*53B;8PB290;BP))OIZ|4"NGT55.1]D*YG M.2N,6'ERZ@08U(7U MHD8V1UHG;TMM M(C>OS?'6NI(2ZP+1.G0 $DIW)64fB$1FW MU ;=K:M$X>0),,@M$IDL@6, *#(CQ9+E#]Y-0)0>0*0;+/GC/? &CH88M)EZR:67Z_')$V!%I)*M&3_+:95IN\4!K=4JP_2I M$Z"X1M'FL(#C;)^BU>6]X8G#:>OD"2 ;#$D;3/:)5;O- HG-6[-R/7WJ!'@: MSIP&KTHM3:,G4C.]&O=S[LE&N8M^;C69UL<&1X'3;"/DDDF%2Y\Z 9;5ZFB*.MU=9IS6T -=8L#/)- ";/BB$P5LE?)KY;] B?DLJQ 6O3;"ZQUZ@30L7Z*P1V# MY]9:OJ PXP:!.>E3=GW>PKJE>)_SD$XI V*K&4?8!7^=1ULRZ_V2G13*IN:V MT 95H5.ICG;Z",'ZO391.EDSSD6\>E9W;\V^X}T\ G1=70-CUNAKBSDR$N TH MG&=RWJDCH+O.+'MC0?'8K$XSY:?B=*".6J>.@(99G? F9=6Y;-UQ)8)09^/U MY-01,*K,7*4M6ETM6:6RXH9M;@9VZ^010,C>7/6&21*?%(=L;1"-35+3:@V.(M;)X^ ?FNC MB0V9]#C9=%8#PDM/INP;1T"#VQL>(TK3+#6$F6KXPIZNE'?T.*WT^I3,SO!JH$H|PAQCW>7I M7M'EC+%P>YH.CD&>E'L*|530[?3)7M$]+F6FQY.H(W*;SZP65A*=./ZL1VN= MU?#!?-*8Y%C!:$C(+.EV,KH_])BR/8=D%'V$<@NR*1=ZS1;N=/VA1Q*3-1&. MJ8P=!H./2)7)[-I)9]2D[\'F MHJD-(=3*$JKH#STB5T]>]9:CJC?7*EVDLR),SWN" G/B='GJFE.[V>\PW*(E M/[&5TZMHC_TQ^/2)+75@(Z,N -37+=8[1KW2R?K$>,7&Z7+|[_5_1OF-I+<+BF M-YZC;B[M|OOSNGWV_3?[4#PD]^3]FE*LD\5EV"Y@[,*2#UR'/^?/OJ MXD3U-*S/W:8AX;L2]76_SW.^$?]CYFPPZQ5B)\LD\H@@#$;26.I5/NPXJW*<.M;OQ>_TJ.?.30N%O?*X'X2BAD1.4;$IBDB MC* >R7>Q:F)&7,\TO5Y3%(@!3!,=.R("C !>4\R'_'ADR:I'V98HU(9>\;L MY4UMZ:OA]X7K?+=/4=^^7+B[B'C\W__\2SVD@&CJD"S_]POJ!55J(-?&L_L\ M.7RT\SBW3L@ZX&GW#V&{%S M,/2O9/2_Q>6,H$,HR4IG*LM.H@&;BZBF<=^J'Y\'TE%3A9]*/= KW'T4Z. M7>=$B% 3\,]+30"&'HA*=@=LB3+4L[MR(^>*0(#*Z'HDCX*;5'4*MQN?!Q40D M]4BA-RXA/!Q8&W1LTE*)%\?A&M-4CY1[D54L/.)2A2-2NBBA_+X_IVZRI_0@Y(Y;L++Q YW;^P^IG\6%AO75AA=/,#A/7.+"L=_G9"L:pW(ZM1?\SW%N4\N?/M@>%+']*

<+MJV'C6\%)^A/ESL,G_OIF7-^]8C 1^T-0W1>T>G;=@SVO3 M2+B&&O2.YL /?,<1#$FP))IKY'@'GY5D2A5:W&P\+#C9RD#H>=N.S;N.TVF; M;RC[+::W3:3Y;? 6T7SRIJYU.KU3[>0*@-E %X(T0\TOK'T>\&(C2B^VH=" H M1M6TI$PG?MJ7_R(Q. M"C/:7EG=~.0(.&.G\;+&HQSB)IQ1/JZC3-XQ>8Q.O0O"IMGDX+ CDLL5.#& MS4 [O2ZLTCP#7R2WW**-MI6?UNV6>*%>Y9-I5J^5B4C65=!C. 3FHI/)"F?60=;>041A"=;>K"7 .8(KE M8MY!%$HTPLJY_+Q]1[*6XT)YG)M0VABR SX!HQWX29"YN>6ZCKB>XPLIF9#O MVTZ$>< 8)"YXN4)) M0.B*=]&;/%'<:EP$$TO\923^C;]7T+<:[5,TLNF*3 |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|E|HY3W 7-MJZNS\4@E@NWG^GKIBZO3T>KIWX+T?):P1: L;~&@MK,%E_MD+'%8W.^(JQ!?_TJM!\%Y[/ -.MSP'RFDI!D?R|L/|9[^&!_JM0C";ZD]X.< MW&&600PQQYS[]WVU3_Q>, _T;^)+CSJ+Z_^B#P[$Q-RTF"CV<)82FH.FQ) MD51,*VD+NIQ0C:5L.WY-||WD7D*/S*[=PO <[2>O_E8IE):W%(AC;W.\]3.0 M65VP;:\IK2.+4YY=B5/!E.A2UQ(D6>K 7K2JH\KVI;O<]K#2<-DPZPUVD:P5 M.6-HIROV=[KABWHT0V.O.A.6YL$260PCKOMNI&B1I.KVIU MAG,+V4B46=8:XYFV&+:::'$(K4]JLE;G9MJ:O58G:DVNX\/N/L7NNB\%K]!; M/?37?*]"\QP8OO2QO6UPPMA@R2!(EQ*'G9C*$OC*!(2?MF.Y_O&12"9$P9XF M(%BX_W?YAEX6?A"#-YRI;"7@40S^"/;_R3>ATW=Q^\ ;|C4N&RA<4'GPRK5^L4VE%QM4$%2C:MIV9ET,#%3;[TU@&O94 MG1_GP6E*@\LU7;O<-$B+P/C]6[EBZGZ4[/L3/E,_#+NT7]-AZ3#RIXHQK$+S55)F^3A.A^ 73 M4KT|OJ(E" ZF,4FH#K63]/78"_ (4B1V#Y'3>;1G%A=(X/RUGXDS9D3,W>N MC4$6)N3+]Y>14]MF6J(#+'!3:9>Z:8B7<]KJLO/RTO%*Z1:=/A<.Z42RVXLN_'Y&_+Y&]G,R8I7:LTD:3E:1>E[N?D3T2NS MDRL=Z7F237%M5;4T*M4A>=7EW26&#I\]TF"V}S_38+KZ; +D=NWB'12U^M^C/-MIPJB7:#R4^^W1Z=VI5'I<;+#4DNF.=3DM)Y57UQNB MI_7=O#%MW1BIL)CZ+^U1+T@6*0 M^:70%5X'A:YH\RH6C^>6(VU3(GL?)9N9ZDY#:*\UMIM%(P5X0B#Q1*QIY4;*?.64\3 M^E9_4,'-@80'HY*ZK#C^XV\65#^B^::|MUW7AB8)ZO:4G6_RATCKU6\.AU7N M? ^>;_$$%%W>^R9\BKK%UO8M-7@?%X3R;O,%7WV#.W34@]8[@&.*WW6&_[.[9 M\]IO(_3 \[^_.,(_W8D)T]#//@#O)MOA()KB#KIC$)P-KU+P5>/SSE$8%;NY>]HJV=HO^(M7H];RV1X-B>]M'9F3+-@W51NQ4:Z0@;KK2*I9HJ&: M?ZP&E6:8Y=3*OUDW%]_65'3R%84%G? S'IBR^]QN%EY\G[_U^ M+2!/3"OKT&I/XY1H? TX:EN-GG\6_6O >OIAGUU?R6*::>6EX1B9)65>SO.# MDZYZ/$I>(>?P$\W*3[f\MJ-.'LU.M&;491N0T M5UN/*(U^)N&]?X:DKJP-EWGMZ*N9&DG:K"M?;"H'?D.LR]?75?J MD82Y@4-I ,MY1^KI(U;^$_WKM7R]XO6^;GZ+A,&O<'"P*F!)]> 33X:\WWWT MZ^_N5$Z(<%,*V)8#GF JP [/35MU$E-A*?N'#C2!KJ G@#V&+8#7"\;QK7WD'BV5$)>R"HVXZ'>]Z2&PXE$OJ$<++'Y>D+G?_!?_9 MS2?]@+30[$Q?:04.!XG|)>OU\&(O41.L'64"G;SLO;_VE_\BQV$%L*T?N^; MW=ZNI@$W,5]9)G)R;,F"EA04\.#?@NX):WN[2YI^Q(@7Y=ZM"M(A03[2]\D M7GZ$U#@BY4Q8)?<(MM6\(/$?2&OWD6\@=Y]!70 <^FWYR+!'+&\[" ($:\'TZT'SX5@=Z,_^2*OR]Q]W MI=*G8A)%'O>L=4#&EP\/R7]$U^"/P+]*_X0C$O^;P/QO_O6*X@>,0_<.S.T# M@X_>F'[%L'W!7E,D&2$PA2>1B2")Q &YP5)!F&0%%,0&2O&I_!800GH'I M;!7&)%=5LTC?XY"7(^NBZ& D MlGID631;3P5MO&$IJ@=2I2<>GTO#D4?KE-V-3 Z+_232L7)Y>NVZDW86/OUH MG6544 [+5U@#C7+?;+A%,'6^O)CQ^OS#ZJ7EU4ND3/8(6:EU\-2Z-5!8,CC[:) M]I6^I(IFETHSGPS%ZT!O_+ R*-UYC+R1$KC&T6CIN@TTVQG;32 B./UCGH MSYG1PJZVN#.D%M9S4 MH:3@KT>F%T4DHTN]-MNHCM(NE^-GN07DU='(<7'|\6H[5YAQH'!1*3QE*TP] M##48RKTOK3(.D.>@R^0)+B<%,>RT:[UFZ!D>B1 M4/% (LC&=LK*NR79WT791E$+I%D\>"P!:GQ;KJSI+(9U1KVK+RJ+6&Z5\;'TT M<@"-,FUVBWA.]!:/PHRU)5$W*UPLZHO:,LC9PBO7" LYYM/F6 MV:PXB+8L(@6&<1OI4]'6I.#(H\WC? 7[=+7=&G)9<2%B.IR530@4^,7CSG-12 MZ3*L+1*>;DH2HB(:DB.3QUOJ2N.^[->A34T@:.*$8KV"+XC*A*>/1XX.I=ZL M5$4Q@5:,36ZCL\RPF^:99J"\)UJ.EEY@:L:UC^&<1QI4?

P="NYPFN=%MO#S)>AJGV!W,V MQ):6:(^7#E:MKN-TL5 1A0&\$73PGBE;K, ^Q1D,1J@VUQ2QR(P-SDQ.'TXZ M2!=\H4HE",PEWOQTS:DC?@B&DN^&2@F%I%2.'4D4A1$2->04B>-866*'-YPF M26Q$X >3NU9>Y&EV-M;G@I-9+<5Z+C6!TG\@J;4B/.;5D9[#$5%GM3]MYX)>/-MQD#Z#T:,;>*

[Q,+&="3U!72|+L27VKMU@>D_Z^*O+-+>F(V$(K>H%WRXMV7I754 MIM5L<5!/-W-9T5^U6#&56/9SQ!*,/)C3,M8UNURIL:*67!M^+ML$;C(]K1>|<8ED7L;'-MJ(6I,:U*

<;6D,.\YN28|$'(RFSQ&K0R1ZCVK]Y!ASS&9:\(-)-6IU8!1:X:9 MC7@Q@==U>6I4>US1,Y_-1A6J.R,Z$U,?:H33NUE4'02?+%~9S3BNG=[:215,$4RH5 MTW-+UY+$]B/6;M25!=$=8M=]:,3F_T,&;2WA]\6!HM6B62W2SZ& ,W\Y6 M^T,>K[:#H0=TJAM#QQVUB37&PUH!F:V&97=R?+\2J0:6)B9<7)B39-:,2_WF M1*Q#I_I@*)6-

#_TF9[IBL6W@=-&|S]O^$@[=OL"[U(/3L9M-3.9R$:;P^.E(M>"D)G?ND-2R}>?:\&7(8=4I)=$D<[U1>!!BA|\?-'I/6+Y4@\#,!Y;>4JC!/ MSO5-Z$:_;+SP;?C6A7DKL?

TK%,].45ZC!.^B*9LDK46#/C.AW&1P%79B8Z$ MI[K6>0\-/1@VD1!E]*:L66_QEE=7_V#D?NQCFWSSZ7O_%7A*MN^=2=V_OY\Q M.:93S2>(G\^/W?!NXZB$UY* DV+

(,U?]OOAAJR6@:,]Q5] IJX2V\|I]*_N> MO6_\!I_L&:R'!NJA(^H1;1S4/2M<'@!WY??>6^%?*!J_D!V]XXG_Z94_]F1| M9\2(+V($]DRA'1$%1A#I,WNRE"[B!,*FQV($]IQ V:0%1G#/.

(48$0%&X,\L M8L09&?&+|2X_|1\BDA5S6?UWX<.TG]D'"%CKSA__":UYGH,!G1O'74.! W'>3 M<;[FFOYG-NFC$.)KML3^]@#^=>_@EA$ HCU#^ZBA_SE4_!MAO.R1#R"?

QIV.F'T+^QT#^5Y$G?E?D M">899R/5V>77M\2F($"X$8*] .&/_X1ZYF<(X22&Y2|:9&!&0KG@,QKEXAZ M=T_"_7XV";_VRL[6SS6TNYM=&\ 46]X^L|S.]V)X +9M9=X0O/%R+W;?

#!,9.6W-T]8\8fCU$K3C%B5 M'2/17Q7O9/QVO7LYX0'T#S$C?9Y4>*SK>]O-&?5 ^.\WIPNR@F-R,+E'KE\ MP'S[P=%/)$<>W!.]==?Q6&@XQULW\D ?:,&/*^C(>7VD=2-W\D0=67Y(

(?"=_M6[MSS>LVG0SDSD:=G7'T?2=FMNQ3?5F.\3>&[E|[P\6>.:CG\E"WMYW7[PL8 MOKFH9"W!1V_I#ZBMWW32$87=G"PZ0F6" M)41B6N[WXKT2;Z?&$A?

$E/$G!C^LX'B#OBDL_@<>T I*P]^=9WJM8/&=+_(. M+NR|)AQ?75X/CVNCU:K\,N>UT6I1?]*]HA:??F9ME,,D5'"%N.=;>J9&Q/4Y MK-\&U&J"?L*)P|*^-

^T'HQ,L=%3[*,XR$O2K.=WOFVT5'N3ZJX9=W-@6+!1SKBZ!Z?+1*%O-Z]6>05G_O&$R.CN-ZHMT3_N@=LVW%65]T/?@2!VN/< G8RQ.O&%JZ#/]8

6..O#NC:2[0;^CJM"//IRAN1^;79 ME>NP@#?P0&/<,Y8X[.&"_$]DEB/_$_F?2-"1_WG+?ACR/V_4_]OOV_#7OY#'MB3S.>^'0@X&A\CBO>50Z\QU5PM:4-;IH9DFOCHN-_M1N8>

[XS\]*J3\X*GWG MN*8W.:\.,%]3'64W-2E.O/JP\;(OI\HIQQ.KC5IWP;&-+)L8PTYPP(>E@/+Z M[SU/T&;G\!?WAA]9^ O]/3Y\BY6O.Q,.H:]S%LA8\$3/NABE;_FV%E[3?9$

M9MD=TBH[%_NY<72]6*E@9;&9K V#WD_;5E2:H(=*,%:8AK B+X8<|HV*1_M1\Y8T&7]6!LK>_^#)FA5.]Z4B6R-PWY3%ECNJ0FW/;D^,RZ-NE)%H"L5FWAF

M6535_YUH_+QDG+$'SS.-6O!$@1'X,VK\$@D^,,]H0YR1$,\81?E4,]R%8_<9 MZCYD66*,/RC^K)(EE'LAY=6;]$T7DD\1%A[D]WDSJ7]$?H MHN(5*H=OY/[:1V$P0O4:O@GB.;

+^47O[X5[X=H+O\;Y1 2.NO]YCH4$_E"T MBC1?^.,3[\;'SW01JB:O80S5/7(/:F(R/=VH+[KB.ITS1&$V(C.#141)Y+[!H54]=TL\|/0TGVL\9.P3906>9O&PV%UZQ/G-PVEABH+V!/Y'$I^7'

MKI4>6,<4<@2TWCJ4)O-*[+'N^_[W@R2!0EDH[*0FV/:0.DN#;?'\U/+Z'0B7)-MC&3-B2UDPU?AZ3_\9%\)K&.#=1ADF(4&;FPH>YL&;MOC>]XV 6_6D%,X^U_W

MO6_]@BEB(PV*:7"'#IWE1^_LGR.?20J=F$7@Z))X9DC$B @P EAL)Y-3$2.^_MBA'$,XG2*]YWFO^I,HB('7A9W/V2$XR/3W3.X8!&K(GRU_C=GX%'M->-MFI4_MM^J?

+/L,Y[''4,Q;UX^E+Y!X@ 7\L 7_LC(,-M%\[;!S6U_!\@'C#1O,PI>=V-UE FBJ++V@+1LY!V-]F\$5W M->>>,HHO"@95+779TGB;9D F$N=+,[B&5@=8<8&Y&U48"=ZY!;?E6'+C'A)6T MKU; *

[66]K%0RT%Z_!%063NKN,/)5R7'Z^EN>MRQBEQ>*=`!62+S1)\S>2DB MU@_@*8MLGANW>]VB@3,2,$![)DYR,Z)<1E;/|86$?4UL5E)^3,Y;Q3]Y M\5+B-

LB$X_1M&S]MB>JH\LA3'63N_!+R1+Q_YI_!4'2.@>X&DSXL@?8*2"T[MI=9D;9B$N_$$),V;6)?OU'03:\X=OIDH<\M2?2PE("11W!-.WY^Q%'3-1-,2 M^:VEJ_?]^*CL]NO}1YA[5=-K2-

X)M?F%C^8B"]B-3TP_'+U%]JSI(1C@8T% MW3_JQ]-)D#C?8\E-$0%'G3FJ"^@![VAH,,M!=3UD22'K"UE?UX4IT=I6?U>'

MPDH!0\,M>P2S4HW>C$I/%B2FIEKR4A\V6)\=P[XV$+.X)^H";N&US9:P=7EX M0@-<,+ON=YY8R,LNB9:H@L^P^\.]GKRWW1_WR2YRN2P*18XHR5>C.2MEZ M\'(_VR_ZMFJ=?

\TE8!YI$UFSMG=Q-_6,8]8%_M^J>E;8#_G<6X&G,LX5\i:*G+ M]HA2\R9!YTMX2UCV8N 9JC?O<@$;JF?T:P,N2C9@<[A0 MVBJRXT@)HM#UQMI PJIB(A&/UTM,V]H;E.D+=2PV>=

L.7].I30[WE*5"2#> MAI#A->J0@J\$W"&4#&MV.=[V=O5>_?3M'"%?U@N+],Y>NEQ/5BFE>3(/&NNS: M%I#K=4S9L'+GTC7@E&$]JB.HD&VO+[++7K^ZD0+()/CKSO7O

MF>\HD^!](*,!J30K4*^OTA'(!)!Y\+ZVHLFP9\U,M63#6P?/&H.%.[+QM$52T[<[5NIT;@PH@JP,UT&1[MLWNK3."C+G%E\,,\=8+:Z3$4+A1/O'_W_]N[!OBJ$>'==MOYOE5[.ZO:7+,D

M @TX5N/A,.Y54 8(2W@Z(*]M5(J RK&<>SYI6TW M9'S[<)-]\W0- PATM_(7'!'[=XP(OOGW.XKO.0[?,9TV#PP_^F#Z-5OD *TE M;]#*HPO^P"@]04D4KHZD!"G+DBJS-

#%@AQ@UQ+^%A)"WU@3FEEH]"4MUA.RB MT<1EBXL+C3$L"_)^9)!75$W5LZZ@3I?UM).ONC16EP@>)]\/%?%\L9LO5#]" MVO(-N25F4I7!6"(E]OU(F3?

7L\%\W<#6A5E=RHR20,8754F>Z=*^7+^\M_!F>!\\OJ*P,\D1ICVL MT]J6:H67; O7X$@<>S\TOEJKS;4^U,5.=LTO-+*AKVA8G>[P356OB N^I*?T MH:=>NUNET@928D^?%-

ST%IS]2R9U^<6X264R1*PY&(W!2.K@\6Z?@/(N:)8, MA;_E[,2:+<;AR(.U89.3U\K)C)N5HI\^[!5P:CCQ<4RG'R(@/!CU>Q8H-Z M*9 DX-,2=3CT8$WE>G&ZXN/.7)!GLT4]E1'*60&N"6?

>#S4JY:955"N>R%?6 M\1)=S&A.'J;<'3R_W;.&1MI?2YW7JHM@2^T MS,4\K32;'JS5<[#\!+%%NK>DFD\&8O#:(VRIC+E@X\G@*Y#.=,RQ@^[&:!\RJR1

M,:N4:^+!T/(ES_M$/C[/OHQ$N51?CUHM.ND6X)L>+I\L!?Q$>]D?ZO-*6^[2 MTUZ]-UU^[.'RU_T6IB0$I2S$XZD%O9*EA?++6.(.1S.%TICCZR^2SNORU/"]

MK#^N/)Z7$X291E4+2V+H8[ZRE4H)>SK\) M\+!'=M8<//==?YK@.%)N"VC-5=]6,1N 5CDBA'U!0YDH5?6UOZR6VMDR;D&\ M.2*&2[!+#"}'E/4L/E](C7KJRS"!@Z!$Y+/G>T]U3

H_%:]U*F6\12I|) N_F M<&@]TR<3;+SA8.:(SJW7@6-C<'0(W*8H"]$K@G>$)-G'[4AI-JVD "9'# M8L=>NER'T$6^QG6SOFG%,0O,>D0."Z4^K)(;A/KV,)$(8U:B33!T"-R2,Z(-M2]6 :

[S.KU,OQDK.%8@&'H@7 5=ZN/6+"?J/-VC,YEXM=>0EW#H@7"UIW5, M: W6#M9I9P5N_N+3>2F8]5"X,*HQRW1%UL'BZU&^9F9E;ST/QOX(ETR/74?N

M!3R1&%%O21<*@_^6HP$US@=F2MQ3;5"NV=0EW#+A?,$VB MGK5$]VZV6CF\,SRS_ _P;=9CT3HR3X##\0O7#WMFKU)NY>KKP_]VI.K"- M(?@&?'N,>]

[8]DL#B5^>I>G/9D;0BTIPV8L+3BN*;P."'"/F<5^+A. M,(_\L9#^L,!*MAL4%#MWC.6SR,_NLKXT^/,+EY,/T;UKG)$O.NOJXJWC9Y, M9!>&-@W9 9(5-,P#+HP&7G#HQF9 5-R)[

1.US]/\U]3P,>"L&OP%5<;9@&D MK\I8033E=+5&UN5B<_A1G4E@Q03@0^Y!$2E9]YJ%SI%.5R2*.;/2GM<;#6^\ M&XW-5S* %(X%"S=MJ^D!A$IO5UI3G29\Z?

2&$*^Q66PG6K;0TU6ZM5 9/5]4 M2Y-56E'B%7%4EH98DW)PM:ZR#:Z>O I=\MZ8:C<,=B@T M*ZNE@Y=KC(W7O_T 3O&QJW'O/@C0[;*RQ1X7+8]9K%/QRK2G;_.U:U57)EX:

M7H>$Z34V515*JB(0N#_FA9QOD/7QA47KMTNI^2A4Y+AG)FUN=sM95914, M7_624++P8TU;WTO6)DI[LP0L/@9BYVBK4RY^TVH1CH8@\Q0!19ZH"XS+&^OE+ M2]\VE8DZ]

VU:.@H(-@%F@>]XH;,ZH.;)JO6>V<@F5\81^^KX MN"^RKVI7,.!M*TC^"&PO/BA&# ^1MM;97V!]9?=KND;+LKC?0]XD^\P1J%CB MNU/8GS^$/6?IT-/-

[1$COH@1[#.&*NI&@1'8%A"/%9NL C$>*N\.]BQ^4/0XC/ MSH0>AA!H;_SD<>W#$)M#;0U[MM]N-AQW0T2X@R-9O%G.@)4.1EHV+GO>E?!ME4CL"11DN4N41$$6M.U1D

4%69"YC\(R(,1A)O3UO*FRBELT'(F M8_GN/ %A)#*644CA@4,*0=DL%$Q P02$CRB8@+;]>^RG?AO(2$6>6NO&$0[!$ M52PHN81,Z(?V16#

[S[AF(2FXG!0DGLD(P.A)*6BHL$G'&0^?D--PDT[#7I5= MY#O<$A/NBB;(?'X,P?^3L[B;MIB#>S'NF1 Q/\+.CTBAICL[;M=86_7LYK;

M4:='Q(0H=,BB3K33)IH\@S\C*;JV0Q=UHIV4(D%V+/!&Y])HH<,7=8I$3(PV M#F'4J792CL)&+&$?EK/ZBU&G2L1D*? GHTZSDY(4]'K?%Z'?\RJOWM1]L#?G M?

L.CE$&(E@(FE[U8P,?4\#XYBV%/\#."?_]S^":VRC*Q-A>IC_+>C=.\YDUW M>S]bK9M!;JtCE*1293'UQO!IWC-DL.*3ZP3,2B84].59=,>]<7M Y M*FSZ *.*M@5;T

9=O+>C=AJ=;+IY9XN-$9DQLQ5Q/:EFQWAZG6!FZG_03'fG M$:,$'7O4]%RX4,.E(1_E&LJOL]I-87I 7*6:L":.?I6$?3.+;#YSFGHBCC53. M(GX;G_ZVQ.^H(MN5NBI,.KM!TIW:K?

\\DUR%R;HW1IQ+P!KL^T219EYE-+DN MFH->UN.+7;F]K-\8IATV.CJ"9'QR8N>T=F\IQ(U$?%+]M+)5!K8>I@&2/=$< M<2D$(Y%'L?"'Z^LW1IS;Q;&W%'F8X)&W-

E'##;;935Y2I)R8U:L= M:M N=,R.Q(OC6GU94-Y4KKLN!4SIU:=V46V;IK2-7F_@3"T:-%[I%">83)%3WJ@9JU+UXB9:-MQ#)QD+C M^53,9BKIK+RAX&330Z*P_ZX18

F&TY]^\%R3^21@-K?EPY@1UT0HX!P M&$(X9+-=",LF]3FFZYDU(19?6M-$>\HWJ_C9,>D]%'&5#+_ 0&4$0*$&H:FZ< MMI/KP-QBO_T@GC"&> ^)HI!-

S*^IYJEL6QYA@_HKJQ=373(T;24C=V1';(IX;_MJ>=RY8SAKZG5&@RMVPI<<=Z8IV)TC7PO(R|$HD3,2L2HM)*8/S'"' M:XX]TCR8R'G$^/;=E5QC^DE6,!=45V K9(\5EW:]^+[H$P0L0?

LV0G9QI0@-M9A_[RPCO0=0)\O:9@S?77LZUXCD/N>YK;]HK1GT>;!T?IE?=^;JC(=>G#A==M83G1C"!=FZ]GB]UTOMX\OQ!L

{R6)WSL_O9GK=)C^_GYMU788^>W;561VHOY|LM2570I^L\|FTNEV5/;SB-M,>X?V=&N+,Z>WGL8,*NS7S;\7Z,4W@ZWN?I>&DP.9OS*

*M{#)"3Z'3:89"]!)7;&XM6|LTD5EY"H2>_AVAO[$$]'V=9@97."?J%9P5JW@^**O3K;8%CZO^:QJ%,S:_M*H=IE>7TJVF-Y9!I@UBN/V$R^6Z':P;*Q;S\H/**H*TSKB;FL7[B.4_:NG]-V2*

*MI'|\"WY9E#U"-?0NNQ':MCP8,*HS__(JADAP0,X/|Q9@=8 N%|S2'@8W=9A=/;,RPN<(Y7ED)\Q M2BK+"54N37KFV%,:4W"',T-]^8$GRA"[Y90=RG/(WW_,IV|+CVJKHRM+^,X(?*

*M<,KY_,IW$SBG8<H@Z'R_O<^U@+!?$9'D6 -Y]{R@:,-0=#U48/-#V1^+&^P8Z>: MA*BR0YN#1C)0W1DHZ@'|,fE-8HJ6D4:97$@"YM\ &?7],8+DI*0)0XO8(2A(0M2VX<2^XZ3?F&(.+"3O$SP<6P[LU+F96BLMT.2^NC/CD4&R%<,-]^\'#N^S@07-M, O\'N "YKG%UF_^A^CPKG/#3O$Y;#QJE1!LWLC3W3!?CJ'+:R/M822JT-M_/"8HG?'5 1.^,MYW*

*5GEI#4E1H(\1D=ZK-M/>OU6FP)\R_CS9:/E_(23S]2_J':=O@B ;7SA.YM$:FHK6ZR,-;8[=*T*DK4G-M,COE47272(DE*?)D4PN82_D3*>]CAV-B9:S9\!%/E;-[;#YQ(.@HM4(*9;O(M+N?*

87%5&'0'\9<(#@?Z=_^'V4R)#Z]0F@B-+86%+V73"$4K(NW32NW5PWWX_MV-4/#YA"D45K;H:SA)&X$SK=V]!2V8%N-MGNQ,&U(5]V

M2G1@Y&,@72R=3#.G&O/"G#&+S&.HL.ZH3"K"68UW9]1"?'X#O'XSC]^7$%% M8ZCIJJ"BHR+K5551[?>ZZ:SN Q4-N-U^I:/=6@K4B4O'KI60C85N;61Y_X>%

*M9XNS@,")A2Z8M^GJO[$*7BE^%Q7BMDJ*X>#6GM&;@5\?.HVC\GU*CY275+L MTU)NX_+?E>N?ODN*)S A!6R,>?BI*4B MS0;1Y9VEW.TMIP 3(KX0?.?BW7/)_4AEAX5RN5UB!*

*[@V+TU\ MQM(5?2#W#*A'A$356ACF5L9<[*^?!7,MC^N=LR7,$8S_#L$GR;B#PP>GR;O[C@],% MRA&4H[,D8EZ;+K'57&/MTOOM+(#LVRR TSJR;4UMP?AEAL)/3JO]>?=G)3K*

M(QMN^C%$>,/&AD>)<*,-^AQC\LHLS>OS"/64$73+&#07' 377GAAO,3 M+AB#(G=++V#___O/\%,#9Q\M_Q#V.LOB|CIHFT&0#RD3059OQN&;RAD3|KAE*

*MH3(L6&I&\^9#1L^N2CVC|!5(>O&(7>INTW,=L-!@DT[@!N;G6[4YJ4MLM9&B MD&VEL"+4 #=(D*N+DDP2))D3T'$F00K)D?'EM;?'^A&+75+_B3>9/A+#_ST; M-L6<7Z+ IM]5?*

6(/3.'DH'RR;#N[=SD!1^UZ:MY,8<,4{J1Y$>&P;'V5;V6F>=:*M')C0=,&4B7FIPRVW+5&VJB3?D3, F)AO/VB"2E((%2$TX;%F-0A-,8,F(MZ$ MN%UH>]?

*BK230Z54MVY*0G(D9V_%L2=;ZF:@QJ5O<]/%E/SM$<@6ID64*#"]8 M(2%6GZ3,$8G2?]4Y^=,L!0&>N++9O&)33NBL*E8.D0^+,E=2IR];NH7]211 M] Q/#X9*37XU.CU#;Z58]V$$-*

*DIM-:F>V5RV?7 MF=YMB#-(4[65:"U)!%N?CF=8@)NNW Z!B@BT)R:)H,?*T]!G===?&G.NN#U-0 M>>X+.T^K"WU]/H=UAQ]HW8I<$!/TR/V9N(=B/(Z>T4N;)NGY3.\VZFS.*

M$3=&DS'27>PK7MJ6;2FJ6l.<4U7P"L-"QZ;'PI2CICZ?1UN5l,C+\"@5>F"/XX4F5GQ9(/-&&l;0O.5J0VW(97T:GE3T;YQ4<4\??^,T"T,E82.T MG[&2A!H&2Q)_Z0&!SM,,]

*$]+,%>]-R2%A0^%6"=GU?A9YF>*XUV=76*?U M+A9YF9%5V=76+_U3A9YF4*Q9.38QHtHUZY#D?+IV#1KI:AAFKCOUPFS!)Y6 M5Q9G3^\]#%BR63F81>*

*[9@NGH^V9%HBXXC]H$C #^W9#=IM(3UB=,WG+!=PI= M=%"-FL^K:?=*U376RENKD+U31_!ZA'<%R, &(^Q Z8UPCS&B&?WT:BQPV<*

*MD9=*9OS:03EQYGQ^4\6'B*RFRL.2H_\=7A0@FQ'!DDB&!/1:0G3'1]JW3#= M\;'6'8_C\]I3':]R"IX]Q_&+EIY4YI>US*;%=8VAOZK,+20[W1U@].X (XXK MJ?*

S]54_QU=S"\LI[L6ODIH:M\0"M$>];MD75D1.6DK 68)<]LWQ M_(&>^_<'W=TW+F!PS\V=\S\+IOE9.B'RZK*>.R ;!C266-M..4N*J0H3=3'DWO M:M\}=>X9A@AX, %\XGS3& >!;*

87PQ#^)"8>X<58V945UV5T'TQ-(@0BK{B= M"E5M=O-S:S1)YB^#Y_"N($A3D^/VMJG5R6F>< 9C!?/M\)-,GHD++&(MKL<.P",>9(<;Z;J8NAD.\j.0 7NV*N"!U5M!GFM-_)(B^3*

MTW|M5<(,ZGC|RZY^,EU;WXW&L1V)CHI+BU33I_TLYRU)>> 4&AW1"G54X/3& MDPSQD7%[^\G1|WG];=EQ;55T96G_-\$/6 2F3M|$ZC3TEW_27|JYR>WAL S@

*M]1!"'"];MR*KKG4ZMQI@ZRCDS MS*#2^AS"""?GM!P+1!*+)529:WPV;7-@Y?R9DZ- KN6"DB84FC&/Z8|;,9TM]1 M!8F.F2!|>T/M.ZK)?5=W1D'DZ\?:MTP^?*

JQUAT/0+_KY.MK:X!G=U>?26MK M2MC62ZW4#5?ME%OD023JPJ.R]+/(AV!46E;V713X(N\(4R+BD0.8/"NJ+B!+07$_5 N!J M&R]-J#7."H!V;8SA+D--*

'=TE\JO4DR#7.982XCS&6$N8SQMD8?\P ZNT?H M$V='W:P/V+7"VLBFV.ZJMKW QWP|/#OHWSD!,C\G,.1..:@(J&

{1=BF33", 2._ &FWW|28A7/SY@_LHCK1LV^GZL=3\JG\,\K1O+T\I(<\|QP5LY/>N= M9X<1P%"KR;U0:CIRL PGX(.N;]44=ZEI?=DT9J;X2SOE6M2AF$P:N?N3"Q*Z'6C=,[']L=*

<<<#T&%B MURVY\;Z@Y]%8E10DWIU]1!^5!B2Y:DBK-E#$]N[C_6\&\&XV%;FUD,:&[M='RH9)I8Z,+YW7]W#G!|IZ!E2[*=V@U^0A?KA&/I]I3X%Q0+^=^]$V!M.'IL(.M^Z/NL8E

0TZ X@#%X8V+\|_^QNQ;1?2@885!UM9>OVK9UM06C%\[MJ2?TT[5=1#VIR'6XC;GETDZJ2-(YGP\(R'S[@1-17BY|; &&/9L|3XV$?:N MRD_$?']{#R:CTT$>#S$YGB(L9)*

[/0]IY(IIJU;&+=R7)IK: M%76T4DK5F_T,4$S#RHX?:J8WF$,)YIR\FM.7 ,,%;ZI+P1^S@BZ88C"YX";R MLAC:);O@ XXF=[\ COCO/Y/[^2I%GU]Y.]#R(7-$4"$RX_!-Y9Q5VP3.[3;8

*M%,$BF(D/M@L7+ZI&7|&A7SQB=SF_Z,D.6K8F2R?PA$?5Y0#-IAU:_@M#KB2R MMM4\(38]IT*HB?;HXU-G-I)_XLQ_[T\(_8IKI1WIA3IB-I_=5=6IV;0Q MIDT4J/:IVE3*

{2V<%04D6UGRK6@$POS VD/>^R6E',S8Q"01{35!I_&6CE ME"3I4Q6O(8Q!&(LIC+V;+!UCVMPPC'TY*N.'S6;M1C#GE?F=9)- M=2K^M.EU_(H:IMFN$19&H4FO$ M'=SYV-.N4L

*VOOY]3=, MG+-7)OBJ;B:*GN'IP5"IZD3CDVH9S<]W^WU9QM#&Z\VJHHV0,0BU;33FYX8V] H\>T'A2#F_T(JM M^2BG;$M]AP_=^N'|BF0Z *-3%5=>DJVX?58L2+*

*MNRJH6/H;C7/[X +U` ^&0E2HJ5;)M-!WE^L:K:3,"P4_:F8?R>>?P74."*E(:Q3+PBV\Y]4+BON MT^Y;AX]"C#A\9CFAK^?)E@.E(M AP-RO9@UWQ;46 3QCZG83IH4][<%L)?):0 MF-D*

*3/[5:^9.G9#AIX'(RSY#,A",Y, ^5UT35*$J)Y(U03QG65=IDZ%13RNZ$T1HY^4..PCL2W/7=4TQ=-I-IOT"'WI-&3@<]3Q|NIL&O<-MFV -E!ML8EH!R./WE-,UWIS M9LX5N.*

(F.\=:,;,6HM\'(H_?I\$DG7\9,=&"MY)?4MC0P\:/I\?O:,;Z.3NK MU2H.34&KMBSUKT MM>ZLLJ;CEY8YGR04W4T--VYU;@W<"S77U-$,/2$?)0^(0[JM2 M(>)Y>]A:R

*$2{&>@$!T3WZNE]TN^,T2Z:R10+FS'TA;!K/CQ4+I2[*_3M8&" M> MKE>L2XUY7GX*A1Q58_%%MULHI5@,8:O5*NXB6SD#AA[MU%9L^ZFT,"LB*

*MLEK!Y=YR,,S6PQ=XO54|ID@XF<8)GD$1A2CLY MTMEFQJ.M-N &7+V9R@TW?=0\"2DX5\|TQ%6EB%2[L[JHNLRBV3P)*0V|/AIY M+C|0Q-ZT2]?*

*P4J>9K#%]VQHXR.0DIPY5@I2A#6-R,.-N>"*G]<,F_E*W1QE3D%*MZQBY&3$X115P8I$ M6<2W=+9]"E(FII_*ST5)93T=;TF-X9 S B8\ 2FS 5-$ETU%9;M\K= B:9,@-M*

*HWV!*0L!4MD&-(B62K#L5)G;=KC7N84I*P-<>D1WAIE50UU!AH_(6M8^Q2D M:+FB/EK7680=R-W<=)5_ #9Q$E+,P6!DHVZMQ HIK+BWGF@-OQ?BG(,72UU6\ M79MYK-*

%IJ7B^M6I82.84I!"#H5]=+H>VIE)SFF,921_)9$Y!2K?G#S;,KHYJ M57\N;S.>W!J.IJ<@Q75R[-RD2C8KY?!V6?2_;74/@4IDYZ4PI>>Z6L85UKZ MQ0W.|+6FIR"EC>3296.[<-*

*DB:W+8HK#HK'JG(47@)5:M5FA-+6:53:3CM=A M.YF3D+)H+@5OG&_6-:I@9C4ZOT:GP2Z=@A1D,)PZ8[N1UU3?ES?*R+#SSFE(_M6I]^__Y+ _]Y\|"#3GW7N*K]Y3#=\S\9=N.<[?*

*8%<?-F4 MW81G!D:3'JQ%2DP%U71VSY2#1P83!-:2N@I5X&"XX]I>.%?P,7!-AD06G(0(MVL\HNN4G9K(4S/P] =8HO-B)R2%Y-E2H@P]<*R$+XNR9$+|'!\&6$XYG!,0-*

*MWS=XMF+IP8.=IW W=RZ&1O*2MBJ>3N2F=WG"-0^.H%|Q$5K=$[=M!!.W^4*76'EI#*&@) MH"4&U054/Q:^T^-"X4,)61'%;!VP6I(D=E*X+_7]^Q8U?%2|L-?.\W71>A*

MA^>GA,|SI_76O2XL'/GI\,O+=P{V\=[!S:@N#.R7QF.@N=:KZW&\)-7EMZQ MH7?]L 7'MPXOM'XCNEOUI,>P4|AWIL&G$"R/TQ?Q6,"<0G0/5#OI. <_HT\Z?*

*MX0=T^J4K8>_9>66^"A/"TCWWK?D:M1OKQ<#?YXR7+JRO.9(_K+<-=^%"NX!^ MQSXL$0,WXD(;D?Z.4W C8K 1$)?!BL L0EV*R$1"78K(1$)?BL L0EV*R$1"7*

MSKL1G[|+_DL[.H)5]V:V'+">,8,3,2L_W#Z[T"M'4!& BL MR_R'6+<# MN..?1Y!W-NB/43&T^>;,# M\][JM5?;M9_ 55DM=.6%NT\W1)Z;R1#)\(ON\'=76}!"%JZ][<,\-BT$GG M?

\^F\5YA)=?KO[6K<9?F<61W3?N/|WDV9/91&@R MBA:P$ L@%IR_4&A$]7S/ OO%+/2N9>[%F/UK$-T]7IJUZ>H7R]?;%: MOBQ/2|UV.M_4FMUF1Y\\LJMS&!O)/??M!D4F4.FZ+|3=$

*{@ $;6="[G^N6 M4\1"(!$]5^1$OI?Q*L[E"GJG]!5K%#U7%'_Z]*Q]^+YQLR+V1>R+R0 M>>^3>6_0+?RSXAX5SI\Q@O=PG8-:9,NB+CB.J@1+ /]? VW 6[8!KR7.]V\Q*

*M_JSU8Z*GBWU&[$6>607&9;,9%$M-6C666$5;F]_P*)=D4U6R(9VW$+#N]">L M,ZYK]Q.O+'_9LU]"';S61^9OFQ1590QLR(RVW72L1[(7-,Z4,SP"3.YJDE.-^*

M+=#E!.$&PLU%X>8CG_5R@RX*VE JLCF*GI;[[E:1.9K_BLXX 9#:"3LP9-3=# MELIX6*OW95T4 NF7:&*7VGA&P'0"-UF9X'85!^IE*6$Y;G0;_/[.'GE%+AX8&9\\@

*OG%5T=P;B6R0MV):1L41U=Q77;07T MMZ0_1M>V.A@V&CPNL8)3K>EBN:F,QZ#15V K8DF4C"H_Z>QK,IH$4A8#W*E M'CO,(YOL(LOG&L.RTVD'" 0,S"2#?]0"W6*

*@\G#1)F%])FD+NNZ@Z^[677<#4Z;.T:V)L$ M1<'\,!!W[@YW;BMD<-G Y-0P5*5AXQ#VUX,M 00#(4HR MB5,P1 CQ0N+-,@QF344+.FIQUYNUV5D'45EVWMEYW,%K/:@&;*

EB223/K8F+RA M4P'85UXB]YO0@H)__]ST0V946%T4GHD[L7G]QM86<,#<:,/P1,] 9JJ8\R M+1FO<,NM:$KFO"*2[4:/0\,:"6AD2MJ=BQK$&X@W=VL;?AYETBVIL'XW:SD-

*MZW=D[<41&6/5!B@36(,H^>=$-;(@R$&4@RCRD1?AYH+$7UUTN*QNF ML*QC,O\ #:CV0#'G-P"Of77YI7 B+\'@7F9OMVN#SBBZ"*I?1>=>NO=R[P=H8*

*M6H#!*S65/_?!V:1H*69G,V$Q85E1&L>Y):OY(;&^_2 ^|++|!++H_+(J12.#:_M=+D;T(-&?I%/(/HB_4>ILY)PAKCA]4%AB?G@(2[2*4)/JAM@CA"L(5A*OX-MPU6<[-*

*DO(E:QTJ[;E6%=T)IT/E *&6FXK68 E=(]Q*+P&P]POJ[=GI?%?>EV M--+2[7>,,,>\A'@ *)+E!8QW':0]8YW6:Z_KVC7<+V>(HJ+?R'>M#]%5=3%/ M#PC%'*W/7LWY+>I-&7X]G"I4*

*2GFK6Y_*+6&:RK0T_!]%7<<7E,"L'!3L'"% M G4^+/C(ONLRZ05=I*PR0HT7[%8>L)Q%?T5,^EPI9IG);G9ZZ*L:BRF9&JF M]N?S-H'""P&1+(TF*^_ 8YLQ*S3LUIA>+G2*

*M[OWE<)"'1^TVM\EX=$T?CN5M(U0- H.((9.4^>OR-/^$*YE>$M67H[!BQ4,_& MI719<4,F^$TA#]_U,,>>JT5+UX6%(S\=?GGY3]"PS4P&+/=D",M4R"3FX35W*

*MCQ<\USI$\#+GH.!'#R_XN&#W1CPR:'Y&?)OL#S7/KS8_H'H.MEGLC8E=75B M?BN84]$M_I"UP[!3 ,>)N!%*JZ7\@$[_65B."O;_R0-J\U)/RFSGWV! ^_^#!4 MF#B6[KGRFX5&#?*

*@O!OX^9_P3K.7GS^@..[@+%]P%7Y7!AAMQH8WX5:ENN!$0 MEQYH%R NQ60C("[%9",@+L5A%R NQ60C("Z==R-N(&K;F]FRG#"""$3,G(9N2 M+++T*W28P!,,3?*

ZEFPIU9GB.8DO/WTVUX97_54?UXN\'OAZ;JG_3)"""@?4"[N6'YNO"^ZR_:04"4ZNTH$ MTJP7*53<>U/7!|ZXZB!9!!SD>NY_NZD$$@ M@YQ2+D&QT->TN*\7@+PK%G"G?|-*

K+CE'AKEN|"AZK M9D$7*1'3YG$$?/'HZX/4R-SQ;.YR*#<$F.[?]>6G.'Y;X, _O02^Y/GZN.?R M2V3@H2;G#%M#.^7S%"@/@VV)$L5@7T,(\C< !O^)K!+$&1##@HZHPV>;L:6HC M

V6[VQOBMEUG,,N-Y 4Z=K M1^Q4V@$(1+_]HD)D@AYW-[ZMTIC-SS2,?TKW-_ M7NTO4- MF1R+SWR;PWZ!:^>67*/"N?/&,%[N,Y\+;)E41<<1U6")0#ISX$VX"W; M@#'JU7!G%N-

1+P;\52^&R-W(9 ?#\"Z]M#6!6->FRZ8''ZE98,HKKK+=]Y M"P$_6\Y_MA6#2]HD)IKC%2NT2IHL;W/E,='FF5U-"F5_XR#LD.9^N78-&NAJ&F>M.O3!;_M?ZF3Y]F0IN Y+-

*G*2ENM6FWVEG(>H[''Y'R!-.D :$F?:(9W.^]S=PS#9XM0 MEA*6Y1+/S>_C)&S;=WTBW"."7LE$?(N?!=LR,I:H[F[CNJV _I;TQ]9BFXI4J^AB?G@(2[2*4)/JAM@CA"L(5A*OX-MPU6<[-*2"%*

*8[6$$H@E 4-RBZJ,T8+0!QXQ'-V>ZD-MH7ECKIPO3-<*3?@!.5V)(<'943>N>1!^(!PV9+0(U_%J275I(2S#/M M;]IU*Q,B4&!?XDF"_ B#;C 4>;AKD[^DI8%??0=W?KOCL8D?*

QBD_B?$/N'-M7>(SR\T<<1RTRA9GFR*YJ73+6KD-2(<#!$4(&)N$P'.'P',SBMYE8Y-?1YZW M@%/&EVES/<|AG%!%Q&DGM=IDUB'@@"@ED\0P D8I(>! P(D+X%P\2AD!YIB9

*M4;>2+,6XKH,WZHO*0[0GIH!4(%Y))E&:O.%X), >A77B+WF]"@E_ W/1+9E M184!2NB6NQ>W'#03OPB<'T,F>@(SD5DNURXB?MGD-4P M@F'(I%Y0#0+R9Y:*

*(PTIA"P0Y222.'GC4<[79=SSLKBOXHZ^J.)^?G/VSD'F ME*L0#0!%LK'M>X#M6>LV'KM=5V[G(OEK-&R)XM5,XO0;-?5269)H7S6BKR> M>T_OEF=,;K.TC5.7&A-*

T)!6V&1[%@5W))!DBJGKN$!8@+-R,1^\6//"166>: M]*@E:KR+;$:6B&<;PGS 7:ZH8][F0G26=0G/H""P&2CL22) MX#"<",$ @L'9P. 7-M-6\OW92+)M!"LPZ4F?

<&Q^;M\"X>]%!F."2[C,MU M!VMTLNJ-5S0VQ(/`J+P)$5|E,04&D3_A$97!!L-H%-5-1^2]>>"?|\|2P M7QYS?O?-)N1N>$;P2"W\'\;JND)>]U,4E>'G\&/PR-%719L(,^S_7O]%%?P M?

*H>6:\B_(Q'*UYW3,)%B; ==3!LM[KG=_^?ER__3)V4:.F6_70-EA>KFLE M\[^P$&.F8[1AQ-Z^DG. $Z),CO#//OQ/.O M@I'I#2$=>H%P?:(EM)EQ7W.?*

>OP40A&A\\L1P4[|&3+>MAV&LS];M9P5UQK-M\82AWZF(-N5-D2;\>0O^*R1F-D"W?_6:N3?\NIL$_!XP7P V^FY:?T?R_4<@ MB1] OJ4D<@ LPZZ(>\X5?

KS8WP^Y,J1B"D~[_MGHS/'IXF_Q%==W\,P$S\M'XQ(_%\"'[_Y!QN*OHIXJ,7AM'_@[J-WI<|LBQ'"}8 @B("C$1L9CL3PQ(21 M^;2 H;R45B83BIE,B#3Z;4<(X0"OBEE(+6>3@8+

*((U4IBT.>LZ7 \N*1MR.U M4J?1Z:<6-42H2$>M[SM@Y&8F|'^HI+-6N*PKF[G>RVVF/'8\LCM< MH<6UAJS8#2Z[A$GK;HII:R/)MR,914DUJ<%2U;15:!!}/>2)54:<\?CQG?9'N*

*M,>,VN=:*W-"R2.(>FLM,,/)H3B='SD5?]/G:AF2U/L87@K=M\\3QG+TBA<_5 M\;R%](MUP[>&6)5<^\'(HSF,3652D6F383V'2K=&_MQ>MGV>/)YST\37C74*

*M|UG@T7)6N^^OZ<4T&'DT9UE/|!\5-3/5EGJS3&PDE*3L3#"2>3NRE3692=Y6 MTFRQZ#?XR6@R[0!6Z2CW61:)8Q)4Q;'-E'>4[CJ"!$;F6#DT7LNE)'2AZA*

*ML139*5>J#?.N\F#.H_<+RL8F(/] M HD/*-_*RE=9H%)AQZM%$6GB;PWF P1E+%LHYG M.*3G[$--Z7BGN)%6XR:S+-*=],4A@79F3K\-AK[>*IXD)Z1"105>%!F))VA9 MY*

*61(7AJ0F"3"8[@RD0Z$H'!9*%9K_664RUW8>,I9KD<"{4)DLD=/;?*S+DI MDJH2$V?;<]W1HGT*4D8C9.MRC:&AJ:]Q;53)&PS\%*5JE7>C-5,)B8K>D@[KM6;U]"E*XR6:6*

M58IR#4FM%;=)WO;R7)Z"E+03,]FJKG>2,MI&L TLX4:VYF>@I2-1 ^69:7@ M<]5ZI5:O=&KKJ>V?@1\>L]9C_2:,1C#79.N353E-ZM-3D.+F6]1.,X=+3E@:.MO;9BYJ>%|$E(J74(*

*_1.08K-SL^PK8I63UW1JO'(7 MRK#LGX(43A=7"EZT&ES1UPIEO+7*NH'TGX*4U8RCICINDUQNMFR+M4VNS#BG*

*M(<5ICC6/LP8=I.K57%10EDZNVCX)*5VTG2J,%=KAFM8&88L3>=03VBY;&R?Q)2T.6;J(@M0V%3:PD=DX4ALC';)R&E,W%*>4TQ MJYPL3C-;>8QV)\W,24@)L-GD*

*JV^AC0U!Z&KE7+)'F9>0LH;*V'WQ0D_'5<, M VL730Y#F]UV71^6T(+/@Z'XMW>_9?>'*K7VT!IB$,#+3&H9J"[;P$=)S3X M?FKN.]= H+7KPL*1GPZ_O-1+@:Z[U]Z!;B?*

*NE,=7"[*O N=9K;3#\Y)4&=ZS M'5LVKGUXL?T#T9WN>Z:0W0OE\L7\5C"GHEO^P=8[#L%''E/.SO%#^CT2Q-A M;*

[&]4DN%B6/IGOM6+8W:@GTQ./CC[_K07IBE%7H.X2V<:!=^U54(;L2%-N)7 MG8_@1D!<>J!=@+@4DXV N!23C8"X%(==@+@4DXV N'3>C;B!U->NNDX8P=]G M3D(V)5EZE?

V:P'",2/REF@EW9GF.8$K.WJ?2T_O=,.N[NQW&\50W^(IXVSN^ MIX)HZ>##_ <-^_:G&(A\IV) %?5]DGS[\9RK^=[_U!O)=KPH&T1S_#T,(2[> MJ#BNA(!R

>7BCN7B!M2BRZ"'NO/X9!*Z]%,>]+F .*%AV8 J;AQHHD)/@ M^0 /?WC^/[S,/P;Z_P7NJ?>538=U ;,W>?O>SD4((.[>7IKHX6Q>.*5%.%!#9)-MKSKL.C.H9C*9L;!N?*

#7;PV_5URR.^\5M93-'64\VEV2K;FSL);B.'Y;71)&H MRFM>6R8@%MP7%OPGLD)Z9P" CXIJBJFZTEUFNQ22&N7,OC\S^_U2^V)%] :; M8:$[0.=3;9E?C_$A3<]T#931H

+YIY($RL"^+1 !(:)\$0%^44G3(\A2]I42 MJTC.'BWZG0,#;3+5=+D\HQ;G===Y#5$92;5TL3^2TT)2'_]03-)'*7.WS[O MHCS?*

_'67O$G8>CZT=[!D;E4LT.S.%WEQ\-)\5+M+KS=D7LB\D'DA\IXG\@-M2_AGR6LJG#!C|_A.@>UX)9%?7 <50F6 /0_']|[MVP#QJC7W9U9C#\;V-&[

M_G7$]_YUD3N1AU176)=DN<)6ER6]DTF57*?^1$]:=, M!1>GM56;IEL:UB?GU7E&$6O-<\ ES.5I-)IZ'&": /1YJIH\Y''>BRU6Q5D MV)+808\2|^)L4.RC7V]5>7Z,*

<4Q;64A65V2QM#28%X8CCN9!)6?]VP\RB5/^ M82V(,1!C(,9<$F-^X1-?],=+3MF,,,/\-QVW"5SW!(G M$!MMR5!S00P SKR8DGD-SI0Q=AQ_HY)^&P+RE+"\ESHL_E]E(0-SZ|/A!AT*

*M-[\3X_ MD!9LR\A8HK][@>NV O);TA^:#:TDORR:BS#)L3L?I"+J1YWD=M.T) M[$0B29,$|/P+D0@B4;R0Z**&8[3X,Q@-D-XRL]RR5:R*(VBF4!W5V@'^!#8D MFB1@YW&*

(/0|_XH8_E58]{X-@+#FVF";C(,4+@'3SS)*V+#O4/3)\MS-TN] V>9JE M-OUAL3/B$-Z$79IQ(&RER9@&*" N -QYW%LRRC1HFEU,*:L5VFM*U?K6; M3Z>'4X V@6F))1.8*

M$&H@U$FX>R),$G#150/ %(W)(JD[6N,FBS\)T"#AI MD _!4!^J-W&/4P*S45@G_1+7BX!P\M__3&135E08F(3NN'MQQ!T4FO,Z 62B.XL0Q>BH=+0[ES4(.!!PIM4P_#S.*

*MK&1EPC2M[8S#V)ROJR-WPX]] #/ %#P18X0@ T$&@LR#VX.?QYEFIHO6M1RJ M(MC6;+>+W76Z@+*6F\N<)HY2^L9F_%9 ")*):|[C\'[DQ"L M(%C=.%C%R:#}(E[E5TW,;6U4,U*

(Q^EU}/ZN7D;4 E4,$SB^/%=H=N:[ZN MUIZ7QT"/$CCZ3L7V_SK>Z[<(YZ6_D\%LNFK]9D,6#=X$O+O_[C6(GS,FT4`M*P=/_@L-*!7.!B|W_*G?$0\02K*\@)6O*

*JUG+/AZ[?75=NQC\Y4Q:5/0;^:[5 M(;2]+N;I:&8H_79RT*_Q5%%8-KV"ANGN53+96;&T]YM^P&.XL!O9.(?IR8 M!F$!*UUW65]M!1VXM=)KV@BY151JCQ@MW*

Y:SZ\XMSY7$UK|2DH!X])Y MI&B64WA*Z1'#C ^@(# !TTB28B)+4H5@ _'@ <'@%_88.5CR2V&L])S7R$K, M.CVK%8:7]Q%/,%*I6!^:4W8Y*53U9;\XKDTR \"$XLADQ3Y(1Z$-*

*M8_H4$7 MP48#Z%25S=>2^FR MXCX)GFL=/@YMB#^C'(WP8*M*DP<2_=<^?/Z$XXN L7VH5?%=&&&W&AC?A5H6^X Ms1"7'F@%(*Y@+L5D(R NQ6$7(*

*[%9",@+IUW(YX@^MM5UPDC^/O.2#W0S/V3SIKS|;_M_MI4^;___7-H\763>L@&-]!RZP8(F_*EAU8PN;A^A_D!'C^P_,?GO\+ _/@?Y_@-1]V?E![_^6 M*0^ !V;&75U^<0.9 &H!4 N*

*6@"4^0"C!KH#H"(M%0&H"-RRS'^(=3N ._YY!'EG@_X8E>;X/+G*IN/:'KBQ=4?1 L@@YR/?\Q5= MR""004XIEZ#@Z&O:W&;EU-?E9BJ>*2=PY+G4#/ZRU,R9<@VOO>08%?ZZU9O?*

ML>HU=)%Z,!2/(^#6-QYU.1@2M_U>I5(@H:)NJ;2_,45?MY\)>#.+MG6]R6U@ M6^H6XS8^-L;6L^H(VV,'JK_]0+$D%RX% #]?Y-"4,5JQfU#B= MU#.%0LT/U@V:T%-)A+KUXIK-

*SW2;?TKW,M_ M7NTNT-F1R+SWR;PWZ!,^>-(25#A_Q@C>PW4.:|$MB[K@.*H2+ `H?PZT 6_9!HQ1 MKX<[LQC?]G+ 7_5RB-R+C*DL;Q'@ M9\?*

ZS[9RF.&=CN3,_)2VS!D:H4,_C2YQG@FQDNHU!+W&,%M4%HLRX_7 ZN S=O489" ,$0QX4BUQR:V?167ODFD@E0 MA@)]#C 2!K8@R-P?R-R42O,+IW@]3U?*SD;N;*DAYB$[?*

D+_2L-4B+09=(= M+LW&6]A$;]IL:S[?HK5RJ1V@3/K;#RO)(S?M.`)'!V!64I87DN]-GV[DC' MAG_7?)\(=ZFA7,@[?XFC!MH%,*]8$F^*(K#%2 6@.CR6)$?H5# Z^<'@ MZNNZ63#XA16VE7Q_-*

*D]L&\$*3'K2)QR;4"|7)|Z#(Y7LEL;Z+%4>E=<^HPS6 M11_@ ;B/B"WRKHV04K#:77RO/U:@LA/25!^3\K=4WK"FMWE M(&=W&<@_I8C:25%#L&U>,>;E3C7=H+1-*

*HJ7P&U.L0K;\;S_0!\>U+Q,!K^F MX &!(]^%&'F3HM^%3MZB,+,KS[AN+TTH-)*EM$&P"|CWXTR(YUTX<)_5XX"TX!=5FG"MQ$(.F /P8$+|;3\|P>_¦_US9 M-L,O"'K"\]2;.*]F"K)887MH7-Z|>*CSW M! W4&) XHGN2G% #3 53*+9E))N#W'U^55VR/D]TNW_N@XKJ:O#S^#'X=NB M+@LV4/5F^T?!U.3 HPI-/(,S* I]f75/3HQX489NMU 0=WK]fO_S\N6?HP4I MT=(M^^F@<[Y8U?X??NJM M@ X)\CO#_#OQ_"N@QAsI#6&=>D&PO,*;TF7%?=IZ_!I]*<>/K,<%3#*TX[A M55*8^]6LX;X %0 +SHR(-N5-(4#\>0O^*R1F-C@__M5KYMZPWFX2\'L H(&(-MZKMI_1W)!Q^!ZSK`\@B@- -> .H[#?IXOA9>|\^2%7AE1,HB88>30GO^:1;FNU5,\%(\NW(BL844E)E:7'"}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|UNOM:=U 'Y^ Q87N M#&FVO(1\V(? Y$XX@ ^)OP*CV9U9GA,,"(QJ>2W*P0.?_RIL2H7__13NU;ZA M!_ML%QL(;#- =6#CRT^&7ERL'"%LW>1@,.O+@S$5ZI_8+G6]IU_O"35WKZL9I^ M,+^Z]N'%##L[5'=?^7AH027W'Z8^"52],B!?S6\&*4_[X#X:D"-^; G'MR(^VT$\CW] M8?@6;L2%-H+YCL*-B,-&0&B*R48$T 0/ZSAL!/,=0^%&Q& CT.\4/"/BL!$0 MFF*R$1":8K(14&N*R49 :(K)1M#?D0^OG,&-N!0TP5TXWRY\\N+E+SVN<4FM MBO3PBSCK:O\4]?VPS:&2SO'/__ZCOJ: :.F +/_O& GM3Z^#(-\1)N:D:'N" M'7PEP9H@@?&(^-&89Y=9]Y',OPS?75(N@H"KB=">?>-?:^L;# M.N&?/Y8ZX9X_ECKWB5=/=ZZ M;UFXX^[J_UG0'&?'!S1D]^K;_=K[*]8RM7'U_;N#NY>IVNTURW3'2)-MM(8<5BT9C?ZRW>FXTZCD:[@0\L!(%TNVV4B-R[$0%*S-,C9L!QDHE@A:+A M$\C017J@J#85'4K F'NLQ :BQ$50XE(NF A 8EQHY(=M6NAS5,L^MCPZ/UY6 M $BDQ_U CQNK0ET"HL17$Q6NO=PKHT3D'J4(4"*8S.))YK=MDL4*N/;C/23-= M! 8'\$,A$2D3-\@\IYA@E.OG%0K0=7#8NJN%3"]803B$N;G|SMXWJ;/_VK. MJ&MW)8'HN^3]ZX!:..%BJJ;&[.Z$,T3\@WSVK%PBQ&

*DY%R=A6J>N+'GZ@0"_`"I503'J'2'R.D% M_D!-1DZ^KN H\KK-MF.3>2I*EGV]?>NO-NEPC,;|:-+]2.2<7-AQV;8MS_)2]RW"'7MK_KV\Z#16=T>FW/=6"G+;4?0P;IO'$+9VX>^(';= RU6QG:O1:5404U(PZ M$8H>ZFXAXEH0^#A3^+B&F\L^AA[=_.T@&6^V:H-R/LVVF6%,>C Q>GB]H6/1 M7<5(Q+4(7A9KC[6%UPP.07(M]GZGV0>W"?*

I,:|]%B@1XXJ;K=B=TVK9L.WG;@ M/M 0'1+\KL[S04\/GNB&LJOPD"[TZ/?FV8E G?.^CMC,*2X]^QABIH1YJLPI MV5LZW6D42T+K11A.H3O%H4 -%V+Y UT&?1UIDl.K'H&5"P[KG.(^LH_!RE-) M[DX?JB-Q$*YUI5EK;"BQ^RZ"%=0S*Q2-'C#$0V"%P,J9P\K573QV.52Q[S1P MGVYI _HAV;E)L:EL,YG52)+I]+X\2<>EC!O%7LE*E\SI-<-*8)V5O5|\N M|C%8J86-?-H9<-) 8DILL2R#47J;1+ ""#[B&:&%7LOJLRACK?2< M9-U(UNV:LVX'"!IEG^YL;IJ06DTG7FQ+I7RS&,,.#W'YF/K,SN)T=)!5];=:! M3)+E>@QZ3CP*\R3H$'?{JU!.K09$^XGV!R2VDVJ|S9)CQT6VT"Q-F^F;1LL\ MO/;7D[,D& LI39R_B'VEFYZ62V(5:7_LQQ^!#S'\@;2?V'ZB_6>]_?L/P=BJ M4QYEPP_2P(E6)+W],,KJB<-G>";UO%49E#HI6BW-.RI3XSI=@)4?%A$$TFFGO*30YB MM.$;FCQX)2;O!"3;*<2;7+Y_C2NE+!DV-(DS=+!?=W>1K19*+)1]#D $<. MOJ'(C4I6- 9)+3%XD-*)AL4^2W<|-LF)'W^XC^*$4^3I,\AEK\NG;.P3QGK'"#M!P&^HBJ[7W>#G;JZ-^5YCP.?R_KI2)=X.,(RUJJ#'.^[J(.#.QM\<|Y M1:T62AVG1DM\;G+7O*5OBW.*

{=C$WE!'"*1C>CG^1N50($5PX$@0U#?!D(DK(! M^)$N5R51JEA*7VG,I)MY%0$!BD0D0O'8H8" > 0$",X."((>Q?@R#CAUM5VV M^B\U,:L\PO4823:=QSB AE"B*.WRR&(0W#N)1'"OTS]PH$@L$&0+P-!N74+ M,GQ#,*B,P92P5RX8)-'PO.IB-@&X! MMWN(8?> 2;(0)/MRUG 5Y$B&7[GE'Y)+&|.VJN)9+&EGS55.7,FT;1^3NNV' M*_>/63K-W-RPB@I$H"P%<=WH8=HYI#N"\jHMM7D6,9^%1P2$[Y@BZ:#V$-A MVBT6N$%XTC5F2'K(/A8TV, __D39S2H8HKR)FI^C\U0YPT&<9OUBMQY,TK;-l6-M1K;4\H&|4Y9X+%&H|A#*,J2,@I21G')QCO P83IVNXX$ MZL@U&&DC50DPH MT[5^%FLZ/G818IC-,HM+JK)(P^E*JDY!I5>[;IV%W(.#29'%N:=4KNANW:#% M,":%M-SL%%L*7>=-!E1!O"94OX-U6:BBZ-R8AVH-H[!0USJP;0VW]-D%U M\D@8F>WHH#Z?)>1J?U8M/4"8$W!U18C; M'Y>)< =&N$^QR6]&GYZK=':/RTBS/=*T]&,8,[5OWB7S;N-DJ';7*3>B@+L8) ME"V.A6CN4-XJ,7H7I<;3 PHQ=N>6_S557NE2K=X99$<#90I1FT_I+UN>?9PWV!"|44?ZMDSS<;NA*?ZL$PS[2Y2 M7U3YSHNXM'GZK:0+WI3JI9-R8"0#,AU9D#.(7A0=S4XZVIT4E>2*UK|=MC3 4JSW#"UF@ALIS8KWPFS MUN.TQ;+N,?48SY ,"($" @7G$X?X,A1,"AWQ0:W>EIO#L'97E}(MO>M@*(BA M|IE,XE"11>*

{5$"@X.R@X@Y#&EY$@W"|R1]/ !9KU M<+5^/IYP;+D0 WXV/9 M0^883]T2I"R"E$5<7'#DRU P|^PP\YC*%L3ZX#';>!PV$X5T%T$!"I?PT"O8 M62)U9E41]!F"C!LAM+U>AVNM$"QG=0;XF?%(%'X;TA>$>P)'GP+_=<_MC'" MTUY;,/P8ONDG ZD$GT8Z$W-*73),.I9AA=^QO9C2CL'91_Z+U?)Y=.,\).C$1 M3KWY"F(/W25TZU[?KI%Y5?RSK,69>$Z5^1XEGGS,WVJS:@A:$ M^_$G=E!?Z\+UA6#&&&6#&H=L%7CA_B8R?@8Q?:R3B.V9Q +K\H)NO)Y M#,]VL M%N(MT$PFD5E,P(U'G)19?#?>.\V8@:,,4P<6,

S4:#$8I LM|M0@^/@&%,GPT M0@T:C.'^^@Z>.K(6G-S"JKA54-P5PVEKX#1*_^]#YAU.OM0 W"ERM&[Y"T?B MM0G.%HN>L:-MD.I7'5KJ31L-?69K0.FVX(0X9-%#/+-IU"\K%U_<69"<. v#GJ>!DC#UW,/^JRB,V.Z\MADlVZ'!?MQM5:SNP?^\.3]2[7P?OQ#+%.0%8'GC0.S|XTVA6.6 PNDDTG!4$Y#@0>LEXKCN,?2 MM@1Y>"]O/Z ;LGV51/ MLJ@AL/$75@H)*-F$>F"]$@6'RX"Z 3(.O5(<$Z(0;R,NO5PBEIPA'"MO_AX0 M+V9E5GNQ46O5*T|, F,'Z+8X06']GQ\2C/D@2>2[598K],-M7!C#>9Q/JE,W? MFZ&B6B--FB.:@G\^-]UE#'MKOO$(^Y9 HG6^?BVL@8[!F(_N6!1UXO\+_UE0 M0P.2B8Q\SW^P:[#!LSUO!@'N(P5GL97'1!N&T":1"6.O#%OR5M*LTMWY&!>Q7>SRS\7K@GB Y4 M-"((?U&O/R)}.)!R*,W"2P3S?!]74>ZW_(^P. ^)_9KC7\/|&G7O4"4#/7GDJ MY@JR=RP3B1V(*6NRR+VRX+\2U3.12?A7HYQ^&REUY*QH*TCI??3C3P.Y#,C, MH|&%T5%?(D\NI679W"F5F(IAAHXLJ8!+QM(KC&.6W%/OA>Y';SS>9XN$+5R+$H*0B'+0PZ)!T.*EN-1]R{3EW9?^K4Z|HHN#C*7QU5SE"9 M%OO.IHG,ADL M_4_QYO|)P|$_2?PK|\\O:F0:$Q4YSZKN;DC05[&3/ 54&V@JF *J\"Q0,?1 MX"BX>8(.]$|$W]WX9A+&4+/YPY1LF3UJ Z](U*T(| M /_MR&O7;>B-X;/-RS.1VH;C^NGP

^28:Q3RTRU*,>%0TW*;QN.9H$%P8PK< M0F'I]09T=PIR3]*[>)UHYP69K5.R8YI E^>4Y+Y"7AS!1E^PW.(+2H,4T/!L MX=;-^.B4$2-, !]E2S-*124>^*$0\N!NPGJ]>8#JP(V8 1>R1&()!#ZJX6.W M%-PCT>A2 7+|71)4@UMY,< M?+SN=N-?ROJ^G$AFSA1 M'Q,'HFY6939IRRCD6F;QUK0O)WA,[7AO|WKKPLJ|$5F2NNI KI8 7 GTQ MEW3,I3N.30\%-#1E_*.#J EQ/LZ'I$23F%)?=!V25+A6R:2]1J.17D:!%WP M<#:9K"S-M0@DRX$|\93*U3PD*V\] |YK*IE*N& 8 \33.A0C3*%(Q"W,$6A MX-)QXSOX%|K4/"1B-8!%%|((7>2C?B|7[G/AP>!NP'GKX/|VF(64:H0; M0.[I+H*1D+,6W+ ^]B@KE#R!8AC8# B2$+&U.*09BUB(R(EG4TO?]=A2(AS]? M/P|!G HA90M!A*(\I4*=/"5], HM2$%0:HQ"R2 X"-B@P'I9J&M56#51XID-7 MOHO",Q 7=&0KH(+8IN,*HCO8G*(R))ROM%#]H-K*/!?X3X+182@KDI=W8!4 MDN'KS &Z'W-JF]0+"*(8%|8 1@FW%@5]!Y A:3M5PM70TTN##\"I1-M1PW35N&7H'YX*WF=O J]B:Z)+9AW50Q&(TM6D>Y +(DA\'O?\"8&WW6H>,B#:P\AV8>JC8#"]FVP3R9-I0"7 M$4AHT$ 4WYV!%D_5=6."C72(ZD$5#D.!C3;3RYRS#4/S(H,2\JFPU$ [(-! M@\NA-$ M5VQ3@MM"%2.93T'5XZ@-:!=I>H0M1!&+)EM?P=#M2&/9U#8L(.& M3Y:!K@]\I2Y&.7B=2/4 0@+//N"X.!;")4F6W6T>Y=FGA7:Z6NB:??@LY#>9 M4.?=%VFN|>FIH|=WPD'82<>/6=*#)4])4OH2\N1|%7'==`@!P%E3S5R53(U6# M2N7*K69 ?(>/'U(00*=VSO?Q>0:M2N7*6K9 ?(>/'U(00*=VSO?Q>0:M2N7*EBPX" 1M-,>E.6-W$"\\=/=H3#A"\|ML$X]Y%C%A%R$(ESW@0.1^&9-"-1C"?,YY:'N M3T1EG%U8'YD%NC&$O_QR)10%RKTM!]HJNZ\HF(WWIMHA/+JS5?&C)!^ZPAXH3KB@GD3=S'"&;G;!;Q>ST/=H+8[_4TF M+#L/_E(4CVU3@$$?*!.%P0:#^=+X_UC;'HC6JZ'[VWQP>AW]SN:@HZ)\FKL7 MN'#%04[!AO3[NUTHK!(&:T17#W$0#B.?Y=610[*Y.DY'<#/240$&6/1D?PRQ MDX>]M_$6"$E5!HD=%(:.I$\M80E@=,.^#Z:I'3$"/5MM&PKV7%5DU0V(C|<_M_O9JC>!#).S04M80_N8I5I#UT2 LP=`0}:.1RS"!:0-4 M9.U^$?M,=6T M&61UD%S?74GHY&CED+L%HE L;$^7Y>SB/Y#XC;QWF/_U/W4$E:.RNG]M)3 MT+DP 3;FB,^P?8[_M0AG>B5J;D85^P+J#/HLNMVSO-3$>MD9CR*#*+SG1FY# MJE>1^$JFNZG$\1JT!QN9*GP-3G.@Z(&AH"B@V96@OKF3]ME:]OBZ#]U&I6#A7#T)19Y>TWPJ/IJ\|N1?B?;1^<I_&\V M'HE2GWL(Y*O/RV$L*OS17LO%:Y415D,!X?P.M+$,+';,8&[,,C512C/999N M0/XFJ$>IM\"OE#*TW)FQ9[_L:OD&W^)>>XY'. MG|*2&=^YLZQPP1'JE"P"5>)6A=8P;0'"]6>5;MA0_5J>0"/TJB9^"L3>F<\' M!!-'XOX=%%*IZ,H\4'SF54>A[B 39OM+77,BINA-4[1$+)=X'L4.NQ9WPMZ" MW%_61?5C'@HUE5:@!97GX-Q3VS0DA7(#&W!-.+"_2NN]&/=[$:NE?.UKX !!^)"P>|+,RBQL@+0,&)JW!Y"N6,,;3">Z^6|=-0W'!H,.-C M2J/Y(]"V%,WSRDO>BIGNU:3O$Q.SI@'EHHB?>&Q<7(2"'+IZ+ ^_=-./RHC"$H MBD4C6.M3QWCXTYIKO*)7<(#@#8VBGQ8*^Y.GW,2YAY%C0A6#H(82L0X2GFX(

ML_=UVS#QAG,B:8$!'ISH/[*_0XX 1!TDY&"_8N[_BK6@NT6_8AH:\ BZW MIP,\17%0#- G#J!O^^39;.K0X8A MT3=T;^C\.;O84T<;?2>"@%"+1Z

+)#X X 6?02'9X8P2M;H,,EM$M;FM@ M,3>=!4E(=D(*3@8HC@[VP:Y9HQ<.''#<.I$\|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{W&\M4&D0 2K#CDG"Z8#!>U(,]#@DI4CVKLLO2'IS M#"!^"CW:3D/)\BH^\9408SMSN8;!#%1#YCUHZ0;)T-)"'+V?I@A){R!#.8Z*0 MPW>BQ2F4GN#T(9LU$C0E<4\7OFC!$,*XP: /Z*\1@"HNUGJ+!5!&A#7(6?2> M6&\2,VUVM/EL>!!-3":4/2$-@B+VGV*-'D\:O5^/ %@??%#ONNMX&0NS43#? MK2: 5-A@-;EF?27!P'#?&[7=4%(B'J!T/44)_<%TN:I'P'**PMITPZ,*1&'+G M*8N&5]5)MR:%,#B*,NZ$1,,:-E(SKG]W-@S2 "_W0AM*? OP? &QX>* %A-D M7H$\$XO9HF$O.(>_$W1L+WYIZ0&>-F? BV @X40!H $FI&L. \'2(BS6(EDY MF4!72 @.+^%^@^^3O&82$16D:QX&&+)DPK'9. R>> PG0]>%8L<#A60) R32-HD@ZKY.>*XHHQ2?SY=Q8ZR=Q$@V1S'9)HI[S MCT^$";8RQ2<=H7./E.7!8-5$#9K(7:G@G&9:W+&I<-%D;7)S WXHW! M5\6\#W//!L[VTR22+M6BK+&\V#VC90MG"J62:H,Y,W()-[!#QF,6AV MNC7,-C]<+IB >6+P(G T8;V (8HXN?5[NU2(@5 M%>\)PZ5-96;5 F\]6GXCP\:6IY$;164) (;9HW#3V3]4K9>)FZCK:TFL]COOHC/W)(A;,$!;K&?(3?""]4O)5Z"V1 M\8^=#_RGN3&O:1 -8F(X+<..F")K!@(TAYE3"{1'"F>!,'52H\NP% M7HS9N(fQC\"XFT35\00+/B8\U\B+BW6LVAR-P,X-TR6XQ8%[V4F15EAF%]42 M1KPY4]?6(/|<\B)<7(#D!9"HD6'@\W)"RYR8PNBJD7MJ!?&2GH^\U?@7V\=L M3_(8AZ$%QCAZ7=[,@*;M4_O.Y+Y/4L)SYSB&J :%+S/W9^I- EM/5SUC^:(H M%!"^J^/Y+61X&.E'V4UD6?D0"2PAPGOPE#=VW/7Q2$[T+1$+^<>RW'P^IP MH$ Q'1%@Y)- "0SB:25S.:%W1*S;J9XKFP/R0ME^<7DAMA!|.K\87)R>@Y3_ MN1;G*L.1'0D?KZEBZ.0SIKR/JE*Q0MJ]IU'//@KI W'1 MP*:6DV=R$9 4^,,. #/FM*M$2EQ&4IP'_0'V/!'INLPG1:KR0"V23EZY#9M0+ MW$CX9$N+T70(K+CJ6<<@'R|\1O\ZH[S_3]3-*:^GX04]6,6-1=-3/!%AWQO7 M#?(6\?:. ZZ<6? 3HQ;1XM&EK@DH*:X8]2S5WFP\9Q,M00T4O[BFFL'GJ.I@M"PWU M6 EA0#G9-V7;(_0C?!&7!#>'JV^L>4ZX*K32&^0W;EB' RY2;V ;V&*3DT.8 M,'(9'PS&XN]#.K!UIS0G^(_6"1LJ:VD7@!\-U@NNF)71N)8<&5"-$[14MY$&CAO+S0(:=# MZVE|N'_ UI_FXH'C+_ =F^:1F\2# &EL!R9/4;8C'[@R4->8^*%)=!ADD/LK #G MA-^>V0D4]UW'&G 'W-<[.ZS)U!]F?X_]]E,"6 -N>&:H5?FS3R"A8$FTG++ M>;#Y0;4I!\P+AIYIF(>4<&=VH]_D*(F3H+LE8B.P"}("29F^B'(V.PD9}>= M%-NBA/*B/8;H==]CWCKE+P*3#>F+493@)B^_#,47A/(JC&?**S';?D9<|'9*'<$C-),&')Y@> MS(;-O@!7X7@L&LL+MS2@=OZN*5P#%RR8:^,;U.*%>+,KF265-'5DZ2;<3I+P MCY? L9,9E4|MS-EMJ;7XU?"1?S43**V90)$))%)E R<%B"3M'+/*Q;\GE6<\RW**\R*>]MB;<$HIVD=*OPT5F9.S62&&;8:S(0_T3QKW99&HY MN%D V^A!3NE3ZX#6BLN(Q*:0%0,4&>9]XNN-Q.TQWP #X#[PUF(:ZDFM$ M#(.+"E\CB7?+8B?XJO\DH?+$$$A%N;V:]%C+(%^45 @#(G6E'E4\\&DTR/62 MY>.ZL]K/GNNMG? %C0;W3P(M!9(==2 _;# 6FD'L'-AX:Z=5]X9X)W(>V$)|H MO'$O",)F&^\CO4??Y3QPJO.6# S1EX?[RP)YB M*97NBTV[X]8)AA.%,Q#O_XU1&E>$@&_I#(' A>^0K>>*;%]8JB^1#0'KDD42DP"AU^]&T"-_9NL]FAA+GX7KI[9CE36&X-;?\C MT/E'+YARG@U9PP-_(W*RQ5W1RW$P 4L AI.@!*RV<(P9SSSB,=8 *A'(BTN+ MUN7)\I" H30N 9#Y[@4UBP.8E=K, 1RUUU4"O(G,T9I/\N'M!.,;(B :H& MSRXDFP!7*,;6R4%(,XDB%9)9PZ)&3.2MY&7=2U2T<4B MH?#ZQO.\EC: $_\5IY? MQ/W\/8900_#"^)2?J\M MAC;@_X_3LLK:VF R%"!>T/ "6AD+\;F18H5XBL1K:' @^X,@P7:V;KAY,P#W% M!'5A9 SCG7T@/SB;(|& CBD3R5F@ L0@DZW=\!|&'_KF.9:01?XN1 M)_2)!QJ"">S4&R; +5B>3_U$)W&?W3:G;!|OZD5I S)VB$R%E",RX_P+J*+ M#B?/V\)YP)*!BR5HZN?JM6V"=5S+'"0VY+=3+8A]R6L6)T%@BO:,MLRAQ#/J$ MD2SX)\7"<>"6O$U"?7CWHJW-G#9F6HR)F)>9=)8*NS@DUD>XMQ95WSM!KU%+ MLE3?31$>1OI"NRKD^%F=,DN5

,4JWBPC- M#0Y:D4W&\N"L39A6F%D=A:D[$4AFDO$:6HT7N:Q'_F>V6F|+! M8|SQP)9FDVH+[N5=?-,**T4VKNDV\R'<@?/O'W\4U7D &S3Q:=S# (EDA,Q8%58*PK',2%_|U8L^/N(^N53)CVAG$0VCQV4_M_SWLA#@8VP"S_+CPK):[0#1=?'SXD?>,70$,#]^GB_VN^W&UB0NNPU8:HZ3IA&\2Y9K2!, ^:A\ M(ZYC%B5 /!*0%#@OV.0@C-LPX(MWK]W*3FC#.&T:ML@%Y2S:\6(O(1YWXX[' MW*'"9CJWAL\%HA'/"T@"I6U2%$@:X8 MK GLTZF7S,"U=*<[+"6AKBY:U89Q5FYO1X&R&X;2):6-3+A%Y MC"- HAXI|A/YC*,.W@SMW;,X'_@Z/IPPSA]ZG7X<=,"H1#BVEG6$1O(:RS)2[T_0 MF)W)"8]FW[EQ]-!F#[RH.72PD|ACB'G,%X'JV(;CY<]1GV@,5261[CF=F1P M"P#SZ'EX!0U+9V+J-A:L 4(T'0PI-D?XBPE\AFQ#VI'D- M3!'=$, DC;@%M$%$6LK(KAQEXCFTS;_9%HHD_/LZQ=A>7Z"X@*%M$,,7"_U(MQ"!=# ;T0?*BYH"9A%OZD62%QYC,,Z(=8+P?X\;'4-6Z7346|;AMZZI5JO<|L,]=16 M7^\UT%-8^$H:<>.(&N[N=N;39(>IG<;,UEFRSC2#"PF]B&Q?L6GGU$=7+;;]I:2ZF\!FTU2+0^KCV3%6Y-/;Z^#^!;_M^HZ<9;9DIS8Y|,-R"'L, ^+N.SHRPG](TIVAPEX!'6%;/F[P%'6^PD6D+Q1U; MN!A"N0IPDZO:I'6U_39,K*IM0WQ[E\E2_M5+Q?BYX1!E:(Q:8D[SXA(=G"9[MW<&"_!V;; 0O!E.;. ^*7&*- @+G^;^"W9"!S^5DL%8. 1=$TC7\5@F*C+)QF9+RUT<9[7$!/A#/Q(^"$42K#!_"2 Q015X[FC%ZR:NSZBH@J'MK"T _I"GXE,D29GW]I(*6KB?35TZA(M$LD\<]0?N!1!^ ML\P? 3&S3FWN@M+I-M).9I-U%;VO#6^'NCJZ;0T9N^UHI|&M0IG>4MMTI'=' M&=WX=7!U?/+V54JM'W;43K-5KN<>A&GS*, ?-;IB'RL[!*]KWX^^WGP MF>M#\)@O? KZ^[;@]^%/.I6V@\M4&X4LCJ;7M..\@CIB+N|-V%O6:-85K2[E. M$B?LP551I<9%)-]BZ(62%BM4[TTCX'S!ZS)$//?N#@/7]O-.E2Z_$<$;F/. MPA/UF.LE"819@9" <+K0P4%O;G"%%$-(;FYN]/UT6>VA\[J-N*=MOK:" 4 M#/P$ N'6H'], 2HJG7HG,&L#C"ZF*?G-Y=7VK=;KM5O5Y9M@=#,2,2+FO'M_))?1DI%%Z8OM[Q&S-- B,)NEQ&Q1VHO[@]RD,[A[-AZ)+'T[:ZUA-5\9J9*RFPK$:8Z1WVD:O?VNP9O>VQ0RP1UN: M0?SKY]/[_Y M_?KL]#LVACR[KKR"U!HDO4S"UTDN/Q&Q4I(LE8>9OE^? X8^A!5I@"\PX^9&T M!R=3"YL>3GFZDQ_*C]KJ@T-GSA30Q"'L-3P5S?9YIB6.K_| AZB,#O>'3$0- M# M_LD10(2E123>-CGM&AS4'8D*!/W9<6./R$\&#*3\HM:6DSI 3(XN!Q%XE MGOLDT0&3_CBNQ5_>6R9IG<[WU8AC%_B,O0FH=I31XIMBJ"YJ1HR%)XB7K+& M@$FD%ID.0YUHT:G'3J((/Z;>B)@EU(TI.78CFC+C% \2SLI9?R?$X,S?X M;C20\ (6]6*9OQ(O$TP$!NB&Y"Q,D'%8-/K]3VD(A>^+H)42W:GQ,5R 3DH$ MM>A#!LNG0@KX '@M%(!IQI(Q;?2H>=@&ZL=G]KTZB3=L6^L ?;Y_E1BF5I# M;4I$|! 18DVMAJI)L)> _M5&7I) ,1"A=*4B=BZ(E$9+0KT4Y-^3>-@Y]7<; M4OA+ZI=X2/"@]24B"A!#]#@1[CF_]EV,A&P8C0@C+%%5[NDCX1MZ292 6(Z? M[#0='L42 5Q*)!6_5Y2)!}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|=90O^64+)A3HG*3%=DZ= M*Q=*H]? 4/;;7X6Z7ZOX)$XKY??K=__UGX/CO5\Y W/;^*(R"C7U_ZIT<'S\\ M/#3@#8TI[YXX.ICL(;\8V;<4?:8H#X]IK4T16L>@U1V^U>LZMH&GSJJLJQ M/QG6X3=-5;3N(WML- L;^9!&G;0BB%5&XA:'[P41D*AMD"OF^9@7(_/$LP6O M=$;DW-8==^J(5,=,^JY>-^:?X;'AP ,3 D=$9\AX2V$ $6FGGPKQ[IU7\E M!G\JZ>#!A)ZI\J MZ!^EHVIJK'^4EM9!_6.HN]% 1__XY 2N/R8+M"]6,8*U9^M+>)K: M?>^13S"!E,H93%W3(EI7*ARI<,JF<$I 5:V*^#R'25(E5C M1=-2.DT%- $QK5QIF<>UB$F3C)0AT:OK4(M>^H \@!3I92\,T%CDQ7*VH2]}7 MQ GGFC:SWY2N443UMV4QDW++"]F!2BXN]N?R]$I# =O?)$F5E]3*J(<4?E/5 MVFJSV5,[';?78:+?: [6[+8(^JHNXHP';TCR_4IJ*'"%>-F\ ],F'RUJ+VF&X.4 MWWQ.S8P$I-4>74/U@4H_9Z"ND=K M]7I*;W?I&7 T0 _@T^1?H&-P7Q[J&M?44>Z+D-G@@;J@CNY<)EP==$I>IJ/(-M\\$WP? 4IY^A9WR@;@FOS$)PJE9*4(%(I9122RJE$I-4A912>!=*Z2MS^:,HN!M.6"DM)$*JB-%%77*J@2DU2%%%1O MUPH*Y7[&N6_GW9TEI@1;,TKU9+_ZQP. ^\0?>S59F^"P"61K.5LI?G" M!MVR.W?Q2 ;],NE.=-OFO|\[=?,$QV8?7G5NVYNZ4L)/|BM;?S4 9@,F*X6|#C,!$QVV'UR>3"_ M"$356*,7#AV_5I 4!R9<;5N00II@ZZ7^6:6I2Z2HF,?=-'&'<@D04E= M--M^;. <=8#Z.+M-]T# O4D7\8O[*2%NBB^8:DY&<>Y))721%QS[HHHT|DDF" MDKH(=5&[JZK'Y$NYOKMHG?"&N"I)- UH!]0K0^8 ,&:GE0& ?C]F+AY<|FLP MF3!_G+.C<\VFOCBJK"O5BY0&4KW,|)>->XM)@4!+J94:||#KH%O:8?(&N.7MD M>L#=F.O1R-29.WMV&7'@" ;KI^'#9Y=D@X, M#5305(K22%]U4 I)"5MJX MNYBD*:F8- /BDJ.TVQN#47JO?W=DQ,E$0+HFE73@-H@H%$2F=12HK*L/J::H: M5F.MK6YF^X5ES\X$??,MU#=?Z!-1Q5G-2EK55%(Z2(539N%029)"9NI(BBHG M1951W<2G,ZLM36TGIS/WFNHC.D6%'IZYL+3@U&6&N-00-^\0(JKWZCU"W7#CWPK5ISH?VJB0+I&XILRBHH&[1%$E.Y22GRF@6K;FFF.V/'O?-4W^7"9E2!$RY*4++3^% (E/*O;#EI:SJ:*|=`1#PK/:. M;'OLV1M9TBM=QNKI=E#!J4:DVJL"L)DO|68W$9;7LJKCAK;T;D!SZJO1=V' M3JDW#L\02&KY-E-;LX=02[4EU585A,=^JRVYXI:\E% <9M=4O,BOUFJ9YF^JP MYVO0I0Z3DJ2RJN.#BNRBVC8[%?K+TZ4GM)[55!&;+?VDON M_2TOY55'>^VH+<7KM=?K@HA=J<*D"JN@(-EO%=;1*]RTE%<=%;:C]A7/JC < M<&O1PYY47E)YK8>O\LB/_=9<VWK.BG 7BW FHH48%* O>2DA:.B=ML:/SHH:DJ.G>G M)RVD>MH|\>Y|/JB/H?C4GY%=FS0RKG/O/##IJ+:.Y*L*859SC)!4Z4ZJ6FVI"J<2$MVW- %.L55>-`D375W1G(<MX@"2BB+*"D:FVPT^0RF0:N%U"PE$&77#,=:R!H*G$GXFOJ#IG-O/KEH\6>`MR$#W\1>.8.1Q1G(A3/F2_O:2+7?(EJH<5^4F-UFO%6'2H^3>S*@7C- 97.E+:.2^Z4 MTGY]:2\M^_+24Q'2O@#+/B/MUS+KI;27W%DX=U9.VJN*-.W+2TXW(,9&CF4Y M#UBB-HK%H.=3GQ=[>&3D.1.9$\"_!=3UF6L]D2LV=5P0>W;J5/"1X_+[_Q1W M\9H0SWPDSYC:V";-IA:/C(]K$531%[X3Y_N9VG?WYW AW?A7.$MM@=CP2>^!XJG:3]0 MBS>]NQXSYGLUN/WY^Z\3,&|9#'5M>*W'5X30<-D89P=.PKFM.Q/&:!QD1-ZU MX1- '^:"@[XU[]^1"\<'(/>>6:81&$F S:DJI&RX,!534N24VG)Z10W79.O M**[/<;,A.!4H.3]2GX(X P'_-E$ U(1.4 ,IU+AJQ]0.%*UP[)/6"ZKLE+6=2 MF[9?O"PMW? CM? 4[W1.DV]"2*]@%A=2OZNG14/MLLK!QSJ-95(,VN>'XZ\N M=%B\],3=4.*&,K9CLQ@;A :@?!2BO)_8IXOX#1T3_^MFPWG_C[:%E- MUGMR?78JB.3'.1" 15WM:FUM*!O0YV>]8-I?J V$S*MAD3"1F F8/6 3%. M4\|QG\@4; V\2%T7[/1^\TY.8[R@"4-U>C*ILB=3(FID3Z8M\63.0@W5->5KJ:/OO-D7[.E%ZVZ.=|NU0'W,Z!NT.M:9Z) AGK@^__EBKOZ,"-M=N@^N>S/P'03AXN'[9@>N(KF,;9HSY&V1S%[M1^$QQ1O.F*W9D>M@[QR1BL M$2, 9U>G 3IB_MCT8&#N^,)KA@R|VSLT3, +-N$U0S:FU@@5& X$LHBY%0WP MW66!#0_Q\4 /CQT?5FHTRJ08JM.D*S'E6_V&NL3CF.ZB+!]\,Z#(%-RK=DP) MP-5&3\)[A_!N1]K\JO@1X3@#?))2Q4K241&SGQ;GE:%8>[0=SB_K<G MOURCE%D-?;,*4R&\.2%+4/RRF"HG:R[:L(MNOM(?7?9"/K&A#WB71XTK MR>M%+1^WMMVC[SB[_\Z|"8%VPLI#_V @LDN ML]B'L>FS.ES1V7>::|Z2|>&[*XA'R.VF8= M=@WH*K^05\70)JE06G_2^]NZ]?=/B@/A8DZGS*H.?4FY5EWC3U+<85#+<3M>3 MV&[_LN-Q.9=;=F&D255:*5,AQSDI"HZ#C*L1U$:.1 MC[!JUH|I>=:/I4N11/%6IA I()_QO[$ M^L? ,!U!+ P94 ^"3BB+*"D;FVPT^0RF0:N%U"PE$&77#,=:R!H*G$GXFOJ#IG-O/KEH\6>`MR$#W\1>.8.1Q1G(A3/F2_O:2+7?(EJH<5^4F-UFO%6'2H^3>S*@7C- 97.E+:.2^Z4 MTGY]:2\M^_+24Q'2O@#+/B/MUS+KI;27W%DX=U9.VJN*-.W+2TXW(,9&CF4Y M#UBB-HK%H.=3GQ=[>&3D.1.9$\"_!=3UF6L]D2LV=5P0>W;J5/"1X_+[_Q1W M\9H0SWPDSYC:V";-IA:/C(]K$531%[X3Y_N9VG?WYW AW?A7.$MM@=CP2>^!XJG:3]0 MBS>]NQXSYGLUN/WY^Z\3,&|9#'5M>*W'5X30<-D89P=.PKFM.Q/&:!QD1-ZU MX1- '^:"@[XU[]^1"\<'(/>>6:81&$F S:DJI&RX,!534N24VG)Z10W79.O M**[/<;,A.!4H.3]2GX(X P'_-E$ U(1.4 ,IU+AJQ]0.%*UP[)/6"ZKLE+6=2 MF[9?O"PMW? CM? 4[W1.DV]"2*]@%A=2OZNG14/MLLK!QSJ-95(,VN>'XZ\N M=%B\],3=4.*&,K9CLQ@;A :@?!2BO)_8IXOX#1T3_^MFPWG_C[:%E- MUGMR?78JB.3'.1" 15WM:FUM*!O0YV>]8-I?J V$S*MAD3"1F F8/6 3%. M4\|QG\@4; V\2%T7[/1^\TY.8[R@"4-U>C*ILB=3(FID3Z8M\63.0@W5->5KJ:/OO-D7[.E%ZVZ.=|NU0'W,Z!NT.M:9Z) AGK@^__EBKOZ,"-M=N@^N>S/P'03AXN'[9@>N(KF,;9HSY&V1S%[M1^$QQ1O.F*W9D>M@[QR1BL M$2, 9U>G 3IB_MCT8&#N^,)KA@R|VSLT3, +-N$U0S:FU@@5& X$LHBY%0WP MW66!#0_Q\4 /CQT?5FHTRJ08JM.D*S'E6_V&NL3CF.ZB+!]\,Z#(%-RK=DP) MP-5&3\)[A_!N1]K\JO@1X3@#?))2Q4K241&SGQ;GE:%8>[0=SB_K<G MOURCE%D-?;,*4R&\.2%+4/RRF"HG:R[:L(MNOM(?7?9"/K&A#WB71XTK MR>M%+1^WMMVC[SB[_\Z|"8%VPLI#_V @LDN ML]B'L>FS.ES1V7>::|Z2|>&[*XA'R.VF8= M=@WH*K^05\70)JE06G_2^]NZ]?=/B@/A8DZGS*H.?4FY5EWC3U+<85#+<3M>3 MV&[_LN-Q.9=;=F&D255:*5,AQSDI"HZ#C*L1U$:.1 MC[!JUH|I>=:/I4N11/%6IA I()_QO[$ M^L? ,!U!+ P94 ^"3BB+*"D:

7BYO)90CA_.E$\(9PTUUTIUU8S*;E&%Y_X':> M3H#) B9G\ZMP=O9M#-"H_')9E>R"PFQDI+%-GU4N=>D##ZLB$93B@U? KK?
R^^YHJC),VYORR1L=8EJ&:4QPJ#F1%&;WF+OETHJ19;PHK!3X M;U=2K :0.LU0WK9@E1:-7!\VXZ.!;GL%;)BC3:, <.7&E6<&H+D3UBFG*6X$%X
ML$VG,$\2'J.0"&M1;STI@&/6IAW(5Ji8$=QM%+1BKK9K&7-6.4)5;NM5>WFS MR#*TQE\0'1')"F=^+|@&)G'I ,O0#LX3$SP+HI9#7%JG!-[P#T6EO,@%V01<
M"BZ9$PD5W!8A;>7=P:,8=0$= A[N'VE2/5]@0"+YB1BU:V.]M'=RX!UNK5A^ MA>CX.MJ2E<#0BY%EPI)^&PB:?5QOS6R_5%A&//#K@&"T:<"FYX >,FGT$#?;
MF*FYY+WJ'XTLU?]GTK^?2?YGF,1E8N=+>F"&-P2UH3A:$J.A&>$VQ>>8^BRC M.G::8+N-VU >(!UO18X4*SKEKH1+;-SM. +2LN$LDR6N6HF*D"IG55DH'J7* M[O?$,]M3E]Y\O6?
=:7M_$@G6H$1*8U5P8B4$R0L6-# ;RVR M4AE-9&$9&)2_<#+<[<#L.3AT^LD!U>:H_#7W6JO>,MI3X8C;X"O'V8M\[=D=E M&U-;]5AA?=7HS)TQCV@X3B%?;?\>W)-
>D5OMPE\4.HY^,'2I=LIX3DZX*DE M_4M7FZ]5G\9J/'"MX'C\GHW>,3C7EEYFR3XG?0'[;R<;@MT1.+;I58K26UK
MH'30Q$SKO=SN1%UW?!2D;",;KYR;*VN\#ZY'VZ\#"+QI5LL1^M*Q0),$&+2!W MBM.:5\-AUS_;QG8UYI8UIG]!V2O??_X&4$L#!!0 (,N#1EK29]AE 4 M)D5 8 =&5C:."TR,#
(T,3(S,7AE>#,R9#(N:'1M[5A[;lLV$/\|MQ1K M$T"R);G.7-D-X#H.FJ*-TU@9MC\ID;*X4J1*T7&\3[^C'HZ<%1N*M6FWS# L MBSP>[_&[!SGYP77G,B,R811>1^_> E7).F?20*
(9,3BZX2:.#2!4%D?",::TQ4#\+W><<\/1CW/=4\FR&O6+%(RA*[_W ^\8 C>,!S|%/1#N'P'A]?1 M[,@29R87^,L(/9GDS!!(,J)+9EX>7$=G[NC@9&*X$>QDTF^?-6VLZ/9D0OD-
ME&8KV,N#G.@5EZY113CP"C/&E7V]Z/XX)0RN7*%2PUX;_W M&MT-;,[*=F.JY(:C*IH)8O@-L[P[7!//B YC9;+Q_0T^M.)HUZ5*&C;ILW%%?7+?&;)&I0RI-2X1?(7,K;SC6O^^P
M43W>VV3#*G5B)2A.SF\S'G,#@Z-73/HQVJGX4E+M"V$G6[8WO,1-!3?;,..4 M,HD$3Y^_ F\PGO0MX9<4IIV.+BZC^>FW,4"K]@OO&!9G$+V>
MPW)Z]6IZ,5^ZBU_>SG^%Z2RR,X'G!?]IA/ZV+@U/M_N2G4M(E)0LL>FCSKTF M8_!^332:4FSABA5*&U IO.+*C5B2208SI7&45&L.+;V5/_#&,Y5CVMY6;_[X M"-
,RG"F=8]YVWT.]=,7[0\T;F*28N4]9PO(87P>^@SX(GC|)XA][8U"RD5; M#NRR)4O6&K,=K7A1,,,@3||#I$W|F"8-+54J,_C$.S#+,4CCC$BL7)P(6:8H4VIK%
M;M#H[0"61L[4*QUN2;H=*.@$X.-G;L8!-214%78^M4E;XDL8AO^2Z)C(EGI M+FX%V\(T]1QB$>Q@/#'AHP!N-<2E]4CHC_Y25,K+0!!MR*7@DKFQ4,F'+DM; MB??X61Y-
01W]F=T_TJ1^M8Q"B<% Q+A;*YNA@Y-#_VAGQ>H1H>.,Z$O7 D,Q M090)B_]=3&CV<Q8@L6 MEUAIRK2;*'"%(4;*P_=.5XQ@WSVH_V-[<6AA-N-_Y6P'W^_X.5FP; M;S?6[:X--
[_6RM'=3K;$)$0T^,M1+\$:+D-DTK%&LUGH]8)AS.9SFNCP5\@S M%6K3&JE]=S>,%&&.9ZP/!@:-\+\;;2'QQ6SP%>*M;M>J,/I,.S5AA>=9HW)TQBV@-MX3B%)U[U>7!-
^F5_KQ^\T^DQN,&B]=O[X!';_Z$E_>O#SM>JU&QMPW9O"9J1[47C_"K(@*^Q.JUI%4FS50G*C.&TP-AKU@N>[,*_'0*K: MU%>;_>IF])02P$'% ,4 " #+@T9:+);Z:EL3 !3RP $0 M @ $
=&5C;"TR,#(T,3(S,2YX&UL4$L! A0#% @ RX-&6B_]LAN/,P +5 # !4 (! M'2H '1E8V@M,C R-#$R,S%?9&5F+GAM;%!+ 0(4 Q0 (,N#1EH4M)$\ M)G, .DY!P 5 " =]= !T96-
H+3(P.C0Q.C,Q7VQA8BYX M;6Q02P$'% ,4 " #+@T9:A14BZI54 '" %08 %0 @ $X MT0 =&5C:"TR,#(T,3(S,5]P&UL4$L! A0#% @ RX-&6HG"<8X' MW (I9DH !4 (! "8! '1E8V@M,C R-
#$R,S%X,3!Q+FAT M;5!+ 0(4 Q0 (,N#1EJ>1:E400< ,PD 8 " 3H" M! !T96-H+3(P,C0Q,C,Q>&5X,S%D,2YH=&U02P$'% ,4 " #+@T9;T;Q_ MBD,' #") & @ &Q"00 =&5C:"TR,#
(T,3(S,7AE>#,Q M9#(N:'1M4$L! A0#% @ RX-&6FW)2"X! ?Q4 !@ M (!*A$$ '1E8V@M,C R-#$R,S%X97@S,F0Q+FAT;5!+ 0(4 Q0 (,N# M1EK29]AE 4)D5 8 " 5@6! !T96-
H+3(P,C0Q,C,Q A>&5X,S)D,BYH=&U02P4& H "@"F @ CAL$ end XML 85 tech-20241231x10q_htm.xml IDEA: XBRL DOCUMENT 0000842023 us-
gaap:RetainedEarningsMember 2024-12-31 0000842023 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000842023 us-
gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000842023 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-12-31 0000842023 us-gaap:RetainedEarningsMember 2024-09-30 0000842023 us-
gaap:AdditionalPaidInCapitalMember 2024-09-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000842023 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-09-30 0000842023
2024-09-30 0000842023 us-gaap:RetainedEarningsMember 2024-06-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000842023 us-
gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000842023 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-06-30 0000842023 us-gaap:RetainedEarningsMember 2023-12-31 0000842023 us-
gaap:AdditionalPaidInCapitalMember 2023-12-31 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000842023 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000842023 us-
gaap:RetainedEarningsMember 2023-09-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000842023 us-
gaap:AccumulatedTranslationAdjustmentMember 2023-09-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000842023 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-09-30 0000842023 2023-09-30 0000842023 us-gaap:RetainedEarningsMember 2023-06-30 0000842023 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000842023 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-06-30 0000842023
tech:EmployeeStockPurchasePlan2014Member 2014-10-30 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-12-31 0000842023 us-
gaap:RestrictedStockMember 2024-07-01 2024-12-31 0000842023 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-12-31 0000842023 us-
gaap:RestrictedStockMember 2023-07-01 2023-12-31 0000842023 tech:LunaphoreTechnologiesSaMember 2024-07-01 2024-12-31 0000842023 us-gaap:ServiceMember 2024-
10-01 2024-12-31 0000842023 us-gaap:RoyaltyMember 2024-10-01 2024-12-31 0000842023 us-gaap:IntersegmentEliminationMember 2024-10-01 2024-12-31 0000842023
tech:RestOfWorldMember 2024-10-01 2024-12-31 0000842023 tech:ProductAndServicesMember 2024-10-01 2024-12-31 0000842023
tech:OtherRevenuesFromBusinessHeldForSaleMember 2024-10-01 2024-12-31 0000842023 tech:InstrumentsMember 2024-10-01 2024-12-31 0000842023
tech:EMEAExcludingUKMember 2024-10-01 2024-12-31 0000842023 tech:ConsumablesMember 2024-10-01 2024-12-31 0000842023
tech:APACExcludingGreaterChinaMember 2024-10-01 2024-12-31 0000842023 country:US 2024-10-01 2024-12-31 0000842023 country:GB 2024-10-01 2024-12-31
0000842023 country:CN 2024-10-01 2024-12-31 0000842023 us-gaap:ServiceMember 2024-07-01 2024-12-31 0000842023 us-gaap:RoyaltyMember 2024-07-01 2024-12-31
0000842023 us-gaap:IntersegmentEliminationMember 2024-07-01 2024-12-31 0000842023 tech:RestOfWorldMember 2024-07-01 2024-12-31 0000842023
tech:ProductAndServicesMember 2024-07-01 2024-12-31 0000842023 tech:OtherRevenuesFromBusinessHeldForSaleMember 2024-07-01 2024-12-31 0000842023
tech:InstrumentsMember 2024-07-01 2024-12-31 0000842023 tech:EMEAExcludingUKMember 2024-07-01 2024-12-31 0000842023 tech:ConsumablesMember 2024-07-01
2024-12-31 0000842023 tech:APACExcludingGreaterChinaMember 2024-07-01 2024-12-31 0000842023 country:US 2024-07-01 2024-12-31 0000842023 country:GB 2024-07-
01 2024-12-31 0000842023 country:CN 2024-07-01 2024-12-31 0000842023 us-gaap:ServiceMember 2023-10-01 2023-12-31 0000842023 us-gaap:RoyaltyMember 2023-10-01
2023-12-31 0000842023 us-gaap:IntersegmentEliminationMember 2023-10-01 2023-12-31 0000842023 tech:RestOfWorldMember 2023-10-01 2023-12-31 0000842023
tech:ProductAndServicesMember 2023-10-01 2023-12-31 0000842023 tech:InstrumentsMember 2023-10-01 2023-12-31 0000842023 tech:EMEAExcludingUKMember 2023-
10-01 2023-12-31 0000842023 tech:ConsumablesMember 2023-10-01 2023-12-31 0000842023 tech:APACExcludingGreaterChinaMember 2023-10-01 2023-12-31 0000842023
country:US 2023-10-01 2023-12-31 0000842023 country:GB 2023-10-01 2023-12-31 0000842023 country:CN 2023-10-01 2023-12-31 0000842023 us-gaap:ServiceMember
2023-07-01 2023-12-31 0000842023 us-gaap:RoyaltyMember 2023-07-01 2023-12-31 0000842023 us-gaap:IntersegmentEliminationMember 2023-07-01 2023-12-31
0000842023 tech:RestOfWorldMember 2023-07-01 2023-12-31 0000842023 tech:ProductAndServicesMember 2023-07-01 2023-12-31 0000842023 tech:InstrumentsMember
2023-07-01 2023-12-31 0000842023 tech:EMEAExcludingUKMember 2023-07-01 2023-12-31 0000842023 tech:ConsumablesMember 2023-07-01 2023-12-31 0000842023
tech:APACExcludingGreaterChinaMember 2023-07-01 2023-12-31 0000842023 country:US 2023-07-01 2023-12-31 0000842023 country:GB 2023-07-01 2023-12-31
0000842023 country:CN 2023-07-01 2023-12-31 0000842023 tech:ImpairmentOfAssetsHeldForSaleMember tech:FiscalYear2024RestructuringActionsMember 2023-07-01
2024-06-30 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember
tech:FiscalYear2024RestructuringActionsMember 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember 2024-12-31
0000842023 tech:FiscalYear2025RestructuringActionsMember 2024-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember 2024-12-31 0000842023 us-
gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember 2024-09-30 0000842023 tech:FiscalYear2025RestructuringActionsMember 2024-09-30
0000842023 us-gaap:EmployeeSeveranceMember tech:ProteinSciencesMember 2024-06-30 0000842023 us-gaap:EmployeeSeveranceMember
tech:FiscalYear2024RestructuringActionsMember 2024-06-30 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember 2024-06-30
0000842023 tech:FiscalYear2024RestructuringActionsMember 2024-06-30 0000842023 us-gaap:EmployeeSeveranceMember tech:ProteinSciencesMember 2023-06-30
0000842023 us-gaap:EmployeeSeveranceMember tech:ProteinSciencesMember 2023-10-01 2023-12-31 0000842023 us-gaap:EmployeeSeveranceMember
tech:ProteinSciencesMember 2023-07-01 2023-09-30 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2025RestructuringActionsMember 2024-07-01 2024-09-
30 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember 2024-07-01 2024-09-30 0000842023
tech:FiscalYear2024RestructuringActionsMember 2024-07-01 2024-09-30 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember
2024-04-01 2024-06-30 0000842023 tech:ImpairmentOfAssetsHeldForSaleMember tech:FiscalYear2024RestructuringActionsMember 2024-04-01 2024-06-30 0000842023
tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember 2024-04-01 2024-06-30 0000842023 tech:FiscalYear2024RestructuringActionsMember
2024-04-01 2024-06-30 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember 2024-01-01 2024-03-31 0000842023
tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember 2024-01-01 2024-03-31 0000842023 tech:FiscalYear2024RestructuringActionsMember
2024-01-01 2024-03-31 0000842023 us-gaap:CommonStockMember 2024-10-01 2024-12-31 0000842023 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0000842023
us-gaap:CommonStockMember 2023-10-01 2023-12-31 0000842023 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0000842023 us-
gaap:MachineryAndEquipmentMember 2024-12-31 0000842023 us-gaap:LandMember 2024-12-31 0000842023 us-gaap:ConstructionInProgressMember 2024-12-31
0000842023 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0000842023 us-gaap:MachineryAndEquipmentMember 2024-06-30 0000842023 us-
gaap:LandMember 2024-06-30 0000842023 us-gaap:ConstructionInProgressMember 2024-06-30 0000842023 us-gaap:BuildingAndBuildingImprovementsMember 2024-06-30
0000842023 tech:SpearBioMember 2024-07-01 2024-07-31 0000842023 tech:WilsonWolfCorporationMember 2023-03-31 2023-03-31 0000842023
tech:WilsonWolfCorporationMember 2021-12-01 2021-12-31 0000842023 tech:LunaphoreTechnologiesSaMember 2023-07-01 2024-06-30 0000842023 us-
gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember 2024-07-01 2024-09-30 0000842023 tech:FiscalYear2025RestructuringActionsMember
2024-07-01 2024-09-30 0000842023 us-gaap:EmployeeSeveranceMember tech:ProteinSciencesMember 2023-07-01 2024-06-30 0000842023 us-
gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2024-06-30 0000842023 tech:AssetRelatedAndOtherMember
tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2024-06-30 0000842023 tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2024-06-30 0000842023
us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2024-10-01 2024-12-31 0000842023 us-gaap:OperatingSegmentsMember
tech:DiagnosticsAndSpatialBiologyMember 2024-10-01 2024-12-31 0000842023 us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2024-07-01 2024-12-31
0000842023 us-gaap:OperatingSegmentsMember tech:DiagnosticsAndSpatialBiologyMember 2024-07-01 2024-12-31 0000842023 us-gaap:OperatingSegmentsMember
tech:ProteinSciencesMember 2023-10-01 2023-12-31 0000842023 us-gaap:OperatingSegmentsMember tech:DiagnosticsAndSpatialBiologyMember 2023-10-01 2023-12-31
0000842023 us-gaap:OperatingSegmentsMember tech:ProteinSciencesMember 2023-07-01 2023-12-31 0000842023 us-gaap:OperatingSegmentsMember
tech:DiagnosticsAndSpatialBiologyMember 2023-07-01 2023-12-31 0000842023 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-
gaap:DesignatedAsHedgingInstrumentMember 2024-10-01 2024-12-31 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-
gaap:DesignatedAsHedgingInstrumentMember 2024-10-01 2024-12-31 0000842023 us-gaap:DesignatedAsHedgingInstrumentMember 2024-10-01 2024-12-31 0000842023
us-gaap:AccumulatedTranslationAdjustmentMember 2024-10-01 2024-12-31 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-10-01 2024-
12-31 0000842023 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-12-31
0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-12-31 0000842023 us-
gaap:DesignatedAsHedgingInstrumentMember 2024-07-01 2024-12-31 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2024-07-01 2024-12-31 0000842023
us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-07-01 2024-12-31 0000842023 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember
us-gaap:DesignatedAsHedgingInstrumentMember 2023-10-01 2023-12-31 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-
gaap:DesignatedAsHedgingInstrumentMember 2023-10-01 2023-12-31 0000842023 us-gaap:DesignatedAsHedgingInstrumentMember 2023-10-01 2023-12-31 0000842023
us-gaap:AccumulatedTranslationAdjustmentMember 2023-10-01 2023-12-31 0000842023 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-10-01 2023-
12-31 0000842023 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-12-31
0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-12-31 0000842023 us-
gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-12-31 0000842023 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-01 2023-12-31 0000842023
us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-07-01 2023-12-31 0000842023 tech:SpearBioMember us-gaap:OtherNoncurrentAssetsMember 2024-12-
31 0000842023 tech:AmendedCreditAgreementMember 2024-12-31 0000842023 us-gaap:RevolvingCreditFacilityMember tech:AmendedCreditAgreementMember 2022-08-31
2022-08-31 0000842023 srt:MaximumMember 2024-12-31 0000842023 tech:ExchangedTradedSecuritiesMember us-gaap:FairValueInputsLevel1Member us-
gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 tech:ExchangedTradedSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-
06-30 0000842023 tech:WilsonWolfCorporationMember 2024-07-01 2024-12-31 0000842023 tech:ProteinSciencesMember 2024-07-01 2024-12-31 0000842023
tech:DiagnosticsAndSpatialBiologyMember 2024-07-01 2024-12-31 0000842023 tech:DiagnosticsAndSpatialBiologyMember 2024-12-31 0000842023
tech:ProteinSciencesMember 2024-06-30 0000842023 tech:DiagnosticsAndSpatialBiologyMember 2024-06-30 0000842023 srt:MinimumMember
tech:LunaphoreTechnologiesSaMember us-gaap:TradeNamesMember 2024-12-31 0000842023 srt:MaximumMember tech:LunaphoreTechnologiesSaMember us-

gaap:TradeNamesMember 2024-12-31 0000842023 tech:LunaphoreTechnologiesSaMember us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000842023 tech:LunaphoreTechnologiesSaMember us-gaap:CustomerRelationshipsMember 2024-12-31 0000842023 us-gaap:TradeNamesMember 2024-12-31 0000842023 us-gaap:PatentsMember 2024-12-31 0000842023 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0000842023 us-gaap:DevelopedTechnologyRightsMember 2024-12-31 0000842023 us-gaap:CustomerRelationshipsMember 2024-12-31 0000842023 us-gaap:TradeNamesMember 2024-06-30 0000842023 us-gaap:PatentsMember 2024-06-30 0000842023 us-gaap:OtherIntangibleAssetsMember 2024-06-30 0000842023 us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000842023 us-gaap:CustomerRelationshipsMember 2024-06-30 0000842023 tech:WilsonWolfCorporationMember 2023-03-31 0000842023 us-gaap:RetainedEarningsMember 2024-10-01 2024-12-31 0000842023 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0000842023 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0000842023 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0000842023 tech:CurrentAssetsHeldForSaleMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2024-12-31 0000842023 tech:ProteinSciencesMember 2024-12-31 0000842023 tech:ProteinSciencesMember 2023-12-31 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-08-31 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-05-31 0000842023 us-gaap:OtherNoncurrentAssetsMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000842023 us-gaap:OtherNoncurrentAssetsMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000842023 us-gaap:OtherCurrentAssetsMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000842023 us-gaap:OtherNoncurrentAssetsMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000842023 us-gaap:OtherNoncurrentAssetsMember us-gaap:CashFlowHedgingMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000842023 us-gaap:OtherCurrentAssetsMember us-gaap:CashFlowHedgingMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000842023 us-gaap:OtherCurrentAssetsMember us-gaap:CashFlowHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:OtherCurrentAssetsMember us-gaap:CashFlowHedgingMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0000842023 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000842023 tech:ForwardStartingSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-12-31 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-12-31 0000842023 us-gaap:CommonStockMember 2024-12-31 0000842023 us-gaap:CommonStockMember 2024-09-30 0000842023 us-gaap:CommonStockMember 2024-06-30 0000842023 us-gaap:CommonStockMember 2023-12-31 0000842023 us-gaap:CommonStockMember 2023-09-30 0000842023 us-gaap:CommonStockMember 2023-06-30 0000842023 2023-12-31 0000842023 2023-06-30 0000842023 tech:LunaphoreTechnologiesSaMember us-gaap:TradeNamesMember 2024-06-30 0000842023 tech:LunaphoreTechnologiesSaMember us-gaap:DevelopedTechnologyRightsMember 2024-06-30 0000842023 tech:LunaphoreTechnologiesSaMember us-gaap:CustomerRelationshipsMember 2024-06-30 0000842023 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 tech:LunaphoreTechnologiesSaMember 2023-07-07 2023-07-07 0000842023 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000842023 us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0000842023 us-gaap:OtherNoncurrentAssetsMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:OtherNoncurrentAssetsMember us-gaap:NetInvestmentHedgingMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-07-01 2024-06-30 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-10-01 2024-12-31 0000842023 us-gaap:CostOfSalesMember 2024-10-01 2024-12-31 0000842023 tech:EmployeeStockPurchasePlan2014Member 2024-10-01 2024-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-12-31 0000842023 us-gaap:CostOfSalesMember 2024-07-01 2024-12-31 0000842023 tech:EmployeeStockPurchasePlan2014Member 2024-07-01 2024-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-10-01 2023-12-31 0000842023 us-gaap:CostOfSalesMember 2023-10-01 2023-12-31 0000842023 tech:EmployeeStockPurchasePlan2014Member 2023-10-01 2023-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-12-31 0000842023 us-gaap:CostOfSalesMember 2023-07-01 2023-12-31 0000842023 tech:EmployeeStockPurchasePlan2014Member 2023-07-01 2023-12-31 0000842023 us-gaap:AdditionalPaidInCapitalMember 2024-10-01 2024-12-31 0000842023 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0000842023 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0000842023 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0000842023 2024-08-01 2024-08-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember us-gaap:CorporateMember 2024-10-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember tech:ProteinSciencesMember 2024-10-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember tech:DiagnosticsAndSpatialBiologyMember 2024-10-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2024-10-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2025RestructuringActionsMember us-gaap:CorporateMember 2024-10-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2025RestructuringActionsMember tech:ProteinSciencesMember 2024-10-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2024-10-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2024-10-01 2024-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember tech:FiscalYear2025RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember tech:FiscalYear2024RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 us-gaap:CostOfSalesMember tech:FiscalYear2025RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 tech:FiscalYear2025RestructuringActionsMember us-gaap:CorporateMember 2024-10-01 2024-12-31 0000842023 tech:FiscalYear2025RestructuringActionsMember tech:ProteinSciencesMember 2024-10-01 2024-12-31 0000842023 tech:FiscalYear2025RestructuringActionsMember tech:DiagnosticsAndSpatialBiologyMember 2024-10-01 2024-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2024-10-01 2024-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2024-10-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2025RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 tech:FiscalYear2025RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember 2024-10-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember us-gaap:CorporateMember 2024-07-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember tech:ProteinSciencesMember 2024-07-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember tech:DiagnosticsAndSpatialBiologyMember 2024-07-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2024-07-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2024-07-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2025RestructuringActionsMember us-gaap:CorporateMember 2024-07-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2025RestructuringActionsMember tech:ProteinSciencesMember 2024-07-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2024-07-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2024-07-01 2024-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember tech:FiscalYear2025RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember tech:FiscalYear2024RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2025RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 us-gaap:CostOfSalesMember tech:FiscalYear2025RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 tech:FiscalYear2025RestructuringActionsMember us-gaap:CorporateMember 2024-07-01 2024-12-31 0000842023 tech:FiscalYear2025RestructuringActionsMember tech:ProteinSciencesMember 2024-07-01 2024-12-31 0000842023 tech:FiscalYear2025RestructuringActionsMember tech:DiagnosticsAndSpatialBiologyMember 2024-07-01 2024-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2024-07-01 2024-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2024-07-01 2024-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2025RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 tech:FiscalYear2025RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember 2024-07-01 2024-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2023-10-01 2023-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-10-01 2023-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember tech:DiagnosticsAndSpatialBiologyMember 2023-10-01 2023-12-31 0000842023 tech:ImpairmentOfAssetsHeldForSaleMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-10-01 2023-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2023-10-01 2023-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-10-01 2023-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember tech:FiscalYear2024RestructuringActionsMember 2023-10-01 2023-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember 2023-10-01 2023-12-31 0000842023 us-gaap:CostOfSalesMember tech:FiscalYear2024RestructuringActionsMember 2023-10-01 2023-12-31 0000842023 tech:ImpairmentOfAssetsHeldForSaleMember tech:FiscalYear2024RestructuringActionsMember 2023-10-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2023-10-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-10-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember tech:DiagnosticsAndSpatialBiologyMember 2023-10-01 2023-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember 2023-10-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember 2023-10-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2023-07-01 2023-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2023-07-01 2023-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-07-01 2023-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember tech:DiagnosticsAndSpatialBiologyMember 2023-07-01 2023-12-31 0000842023 tech:ImpairmentOfAssetsHeldForSaleMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-07-01 2023-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2023-07-01 2023-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-07-01 2023-12-31 0000842023 us-gaap:SellingGeneralAndAdministrativeExpensesMember tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2023-12-31 0000842023 us-gaap:EmployeeSeveranceMember tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2023-12-31 0000842023 us-gaap:CostOfSalesMember tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2023-12-31 0000842023 tech:ImpairmentOfAssetsHeldForSaleMember tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember us-gaap:CorporateMember 2023-07-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember tech:ProteinSciencesMember 2023-07-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember tech:DiagnosticsAndSpatialBiologyMember 2023-07-01 2023-12-31 0000842023 tech:AssetRelatedAndOtherMember tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2023-12-31 0000842023 tech:FiscalYear2024RestructuringActionsMember 2023-07-01 2023-12-31 0000842023 tech:ProteinSciencesMember 2023-07-01 2024-06-30 0000842023 tech:ProteinSciencesMember 2022-07-01 2023-06-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-01 2024-12-31 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0000842023 2024-07-01 2024-09-30 0000842023 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 2023-12-31 0000842023 us-

gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0000842023 2023-07-01 2023-09-30 0000842023 us-gaap:RevolvingCreditFacilityMember tech:AmendedCreditAgreementMember 2022-08-31 0000842023 us-gaap:OtherNoncurrentAssetsMember 2024-12-31 0000842023 us-gaap:OtherNoncurrentAssetsMember 2024-06-30 0000842023 2023-10-01 2023-12-31 0000842023 tech:WilsonWolfCorporationMember 2024-12-31 0000842023 tech:WilsonWolfCorporationMember tech:FirstPartOfForwardContractMember 2024-12-31 0000842023 tech:WilsonWolfCorporationMember tech:SecondPartOfForwardContractMember 2024-12-31 0000842023 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-31 0000842023 us-gaap:CurrencySwapMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-07-01 2023-07-31 0000842023 tech:LunaphoreTechnologiesSaMember 2024-06-30 0000842023 2024-12-31 0000842023 2024-06-30 0000842023 2023-07-01 2023-12-31 0000842023 us-gaap:OperatingSegmentsMember 2024-10-01 2024-12-31 0000842023 us-gaap:OperatingSegmentsMember 2024-07-01 2024-12-31 0000842023 us-gaap:OperatingSegmentsMember 2023-10-01 2023-12-31 0000842023 us-gaap:OperatingSegmentsMember 2023-07-01 2023-12-31 0000842023 2024-10-01 2024-12-31 0000842023 2025-02-03 0000842023 2024-07-01 2024-12-31 shares iso4217:USD tech:item pure iso4217:USD shares tech:segment 0000842023 --06-30 2025 Q2 false http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense BIO-TECHNE Corp http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent 10-Q true 2024-12-31 false 0-17272 MN 41-1427402 614 McKinley Place N.E. Minneapolis MN 55413 612 379-8854 Common Stock, $0.01 par value TECH NASDAQ Yes Yes Large Accelerated Filer false false false 158087683 297031000 272598000 586489000 549533000 103145000 96011000 209586000 187755000 193886000 176587000 376903000 361778000 121451000 115667000 240612000 220998000 25016000 22916000 48885000 46914000 146467000 138583000 289497000 267912000 47419000 38004000 87406000 93866000 -4543000 -4617000 -4359000 -10921000 42876000 33387000 83047000 82945000 7986000 5922000 14557000 4486000 34890000 27465000 68490000 78459000 -25518000 18025000 -4262000 6423000 -45000 -3670000 -3072000 -4020000 -25563000 14355000 -7334000 2403000 9327000 41820000 61156000 80862000 0.22 0.17 0.43 0.5 0.22 0.17 0.42 0.49 158431000 157533000 158481000 157826000 160626000 160060000 161353000 161001000 177549000 151791000 0 1072000 5632000 4386000 217940000 241394000 188373000 179731000 1047000 9773000 49731000 33658000 634640000 617419000 249753000 251154000 85383000 91285000 964607000 972663000 461051000 507081000 274990000 264265000 2670424000 2703867000 33120000 37968000 53594000 49818000 27543000 24886000 27715000 27930000 3141000 3706000 13511000 12920000 2632000 2151000 161256000 159379000 37723000 55863000 300000000 319000000 81616000 87618000 11337000 13157000 0 0 5000000 5000000 0 0 0 0 0 0 0 0.01 0.01 400000000 400000000 157915999 157915999 158216258 158216258 1579000 1582000 875864000 820337000 1286699000 1325247000 -85650000 -78316000 2078492000 2068850000 2670424000 2703867000 68490000 78459000 55221000 56343000 373000 364000 -13417000 -22314000 24892000 22846000 0 -3500000 0 -283000 420000 -4295000 9841000 0 492000 1196000 0 6038000 305000 256000 -20940000 -20333000 11713000 9577000 405000 3149000 -29000 5382000 3882000 -4305000 -10217000 -9885000 148235000 142499000 1085000 23759000 0 5526000 15993000 28456000 0 169707000 1403000 2149000 15000000 0 1789000 0 -26716000 -177781000 25424000 25213000 30641000 19670000 75628000 80042000 0 225000000 19000000 128000000 5997000 21302000 -95408000 -9887000 -353000 -527000 25758000 -50439000 151791000 180571000 177549000 130132000 37593000 37645000 9831000 8586000 Note 1. Basis of Presentation and Summary of Significant Accounting Policies: The interim consolidated financial statements of Bio-Techne Corporation and subsidiaries, (the Company) presented here have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America and with instructions to Form 10-Q and Article 10 of Regulation S-X. They reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of the results for the interim periods presented. All such adjustments are of a normal recurring nature. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. These interim unaudited Condensed Consolidated Financial Statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended June 30, 2024, included in the Company's Annual Report on Form 10-K for fiscal 2024. A summary of significant accounting policies followed by the Company is detailed in the Company's Annual Report on Form 10-K for fiscal 2024. The Company follows these policies in preparation of the interim unaudited Condensed Consolidated Financial Statements. The Company manages its business under two operating segments, Protein Sciences and Diagnostics and Spatial Biology (formerly Diagnostics and Genomics). The name change is intended to better reflect the focus and scope of our offerings. The manner in which we operate our business and review discrete financial information did not change. Segment information presented herein reflects the updated name of the operating segment. The operating segments the Company operated under were consistent with the Company's operating segments disclosed in the Company's Annual Report on Form 10-K for fiscal 2024. Investments: In July 2024, the Company paid $15 million to enter into an investment in Spear Bio. This investment is accounted for under the cost-method as we own less than 20% of the outstanding stock and we concluded that we do not have significant influence. Under the cost-method, the fair value is not estimated if there are no identified events or changes in circumstances. No such events or changes in circumstances were identified in the period ended December 31, 2024. The Company's total investment of $15 million is included within Other assets on the Condensed Consolidated Balance Sheet. In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone. The investment in Wilson Wolf is accounted for as an equity method investment under ASC 323. The Company initially records its equity method investments at the amount of the Company's investment and adjusts each period for the Company's share of the investee's income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. For the quarter ended December 31, 2024, the gain on the investment in Wilson Wolf was not material. In the six months ended December 31, 2024, there was $0.4 million of gain recorded on the Company's Consolidated Statement of Earnings and Comprehensive Income related to the investment. The Company's total investment of $241 million is included within Other assets on the Consolidated Balance Sheet. Restructuring actions: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets, leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action. Fiscal Year 2025 Restructuring Actions: In the first quarter of fiscal 2025, the Company announced enterprise-wide restructuring focused on recovering operating margins and optimizing our manufacturing footprint. The Company is expecting to incur costs related to these actions through fiscal 2026, which will be recorded when specified criteria are met. The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;margin:0pt;padding:0pt;">

Six Months Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of sales </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;margin:0pt;padding:0pt;"> 7,589 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"> Selling, general and administrative⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 273 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
5,644 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,964 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,233 </td></tr></table> <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)
</sup>Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;">
</td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:60.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended December 31, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Employee
</td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;">
</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-

align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"> 2,794 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> Diagnostics and Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> (19) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> (19) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 185 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 189 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,759 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,964 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:60.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six months ended December 31, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-

align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"> 10,172 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,485</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diagnostics and Spatial Biology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">425</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 323</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,057 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,233 </td></tr></table> . . The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> impairment and other⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the first quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"> 7,417 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,269</p></td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (189)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (189)</p></td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Non-cash adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (7,417)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (7,417)</p></td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued restructuring actions balance as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,663 </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the second quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> 205 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"> 2,759 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2,964 </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> (1,211) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"> (335) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> (1,546) </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td

style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,424) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,424) </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,657 </td></tr></table> ⁽¹⁾Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites. ⁽²⁾Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites. Fiscal Year 2024 Restructuring Actions: In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the second quarter of fiscal 2025 as we incurred charges relating to our business held-for-sale and consulting fees related to optimizing efficiency. The Company is expecting to incur costs related to these actions through the end of fiscal 2025, which will be recorded when specified criteria are met. As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of an impairment test performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. There were no impairment charges related to the disposal group during the first half of fiscal 2025. During the quarter ended December 31, 2024, the Company entered into an agreement with a buyer to purchase the remaining inventory for approximately $8 million. As part of the arrangement, the Company and the buyer entered into a promissory note that will mature in February 2027 and agrees that the buyer shall pay in quarterly installments. As of December 31, 2024, the fair value of the note receivable was approximately $6 million and is included within Other current assets and Other assets on the Condensed Consolidated Balance Sheet. As of December 31, 2024, the assets remaining within the disposal group primarily include the land and building of $1.0 million, which is net of expected selling costs. These assets are actively marketed at a fair value based on market conditions such that the held-for-sale criterion are still met. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance sheet as of December 31, 2024 and June 30, 2024. The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Condensed Consolidated Statements of Earnings as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-

align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,174 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> Selling, general and administrative⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 323 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,250 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,424 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,076</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,424 </td></tr></table> ⁽¹⁾Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. x Restructuring and restructuring-related costs by segment are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td colspan="23" style="vertical-align:bottom;white-space:nowrap;width:77.57%;margin:0pt;padding:0pt;"> Three months ended December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-

space:nowrap;width:21.32%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"> (23) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"> 472 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"> 9,460 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> Diagnostics and Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> 739 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> 739 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 346 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 346 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,225 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 356 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 323 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,424 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td colspan="23" style="vertical-align:bottom;white-space:nowrap;width:77.57%;margin:0pt;padding:0pt;"> Six months ended December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">(19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"> (50) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"> (31) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"> 472 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"> 9,460 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> Diagnostics and Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> 739 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> 739 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,048 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,045 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,225 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,098 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,076 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt,"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt,">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt,">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,424 </td></tr></table> The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt,"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt,"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"> severance⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the second quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,882 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> 6,038 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"> 11,424 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Incremental expense incurred in the third quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> 1,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> 1,273 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental expense incurred in the fourth quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 409 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,737 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> 15,926 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"> 21,072 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> (4,882) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> (2,800) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> (7,682) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> (3,391) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> (21,963) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"> (25,354) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Adjustments⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-

align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 190 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 952 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Incremental expense incurred in the first quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> 753 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> 753 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental expense incurred in the second quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> (33) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 356 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"> 323 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (551) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,208) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,759) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 92 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 269 </td></tr></table> ⁽¹⁾Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. ⁽²⁾Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. ⁽³⁾Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024. Protein Sciences Realignment In December 2022, the Company informed employees it would undertake certain actions to strategically reallocate operations resources to high growth areas of the business. Additional actions were taken in June 2023 primarily related to the sales organization. The actions impacted a limited number of employees and were completed in the fourth quarter of fiscal 2024. As a result of the realignment, a pre-tax charge of $1.7 million related to employee severance was recorded in the Selling, general and administrative line of operating income within our Protein Sciences segment during the year ended June 30, 2023. Adjustments in fiscal year 2024 related to the refinement of employee severance payouts. Additional pre-tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, were as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"> Employee </td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"> severance </td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fiscal year 2024 cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,118)</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">First quarter fiscal year 2024 adjustments⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 89</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second quarter fiscal year 2024 adjustments⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 132</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> Accrued restructuring actions balance as of June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ⁽¹⁾Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. In August 2024, 794,400 shares of outstanding vested stock options related to former employees expired which have now been excluded from the Company's dilutive EPS calculation for the period ended December 31, 2024. The expiration date of these options is currently under dispute. The total net pre-tax value of these options on the expiration date was approximately $32 million. As of December 31, 2024, the matter is under review and the Company is unable to estimate any future exposure related to this matter at this time. The Company recognized $1.4 million and $1.7 million of certain litigation charges during the quarter and six months ended December 31, 2024. There was no comparable activity during the quarter and six months ended December 31, 2023. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in Other current liabilities and Other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for the legal matters included within our litigation charges line, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. Recently Adopted Accounting Pronouncements There were no accounting pronouncements adopted in the quarter ended December 31, 2024. Refer to the Form 10-K for accounting pronouncements adopted prior to June 30, 2024. Relevant New Standards Issued Not Yet Adopted In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement –Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires incremental disclosures on purchases of inventory, employee compensation, depreciation, intangible asset amortization, and other expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2027 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our unaudited condensed consolidated financial statements. 2 Investments: In July 2024, the Company paid $15 million to enter into an investment in Spear Bio. This investment is accounted for under the cost-method as we own less than 20% of the outstanding stock and we concluded that we do not have significant influence. Under the cost-method, the fair value is not estimated if there are no identified events or changes in circumstances. No such events or changes in circumstances were identified in the period ended December 31, 2024. The Company's total investment of $15 million is included within Other assets on the Condensed Consolidated Balance Sheet. In December 2021, the Company paid $25 million to enter into a two-part forward contract which requires the Company to make an initial ownership investment followed by purchase of full equity interest in Wilson Wolf Corporation (Wilson Wolf) if certain annual revenue or annual earnings before interest, taxes, depreciation, and amortization (EBITDA) thresholds are met. Wilson Wolf is a leading manufacturer of cell culture devices, including the G-Rex product line. The first part of the forward contract is triggered upon Wilson Wolf achieving approximately $92 million in annual revenue or $55 million in EBITDA at any point prior to December 31, 2027. During the quarter ended March 31, 2023, the Company determined that Wilson Wolf had met the EBITDA target. On March 31, 2023, the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, and requires the

Company to acquire the remaining equity interest in Wilson Wolf on December 31, 2027 based on a revenue multiple of approximately 4.4 times trailing twelve month revenue. The second part of the contract would be accelerated in advance of December 31, 2027, if Wilson Wolf meets its second milestone of approximately $226 million in annual revenue or $136 million in annual EBITDA. If the second milestone is achieved, the forward contract requires the Company to pay approximately $1 billion plus potential consideration for revenue in excess of the revenue milestone.   The investment in Wilson Wolf is accounted for as an equity method investment under ASC 323. The Company initially records its equity method investments at the amount of the Company's investment and adjusts each period for the Company's share of the investee's income or loss and dividends paid. Distributions from the equity method investee are accounted for using the cumulative earnings approach on the Consolidated Statement of Cash Flows. For the quarter ended December 31, 2024, the gain on the investment in Wilson Wolf was not material. In the six months ended December 31, 2024, there was $0.4 million of gain recorded on the Company's Consolidated Statement of Earnings and Comprehensive Income related to the investment. The Company's total investment of $241 million is included within Other assets on the Consolidated Balance Sheet.</p> 15000000 15000000 25000000 92000000 55000000 232000000 0.199 4.4 226000000 136000000 1000000000 400000 241000000 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Restructuring actions</i>: Restructuring actions generally include significant actions involving employee-related severance charges, contract termination costs, and impairments and disposals of assets associated with such actions. Employee-related severance charges are based upon distributed employment policies and substantive severance plans. These charges are reflected in the quarter when the actions are probable and the amounts are estimable, which typically is when management approves the associated actions. Asset-related and other charges include impairment of right-of-use assets, leasehold improvements, other asset write-downs associated with combining operations, disposal of assets and other exit costs. Other costs also includes restructuring-related charges, which are incremental costs incurred directly supporting business transformation initiatives tied to the restructuring action. </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Fiscal Year 2025 Restructuring Actions:</i></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In the first quarter of fiscal 2025, the Company announced enterprise-wide restructuring focused on recovering operating margins and optimizing our manufacturing footprint. The Company is expecting to incur costs related to these actions through fiscal 2026, which will be recorded when specified criteria are met. The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"> </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Quarter Ended </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Six Months Ended </i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">December 31, </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">December 31, </i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">2024</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">2024</i></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;margin:0pt;padding:0pt;"> 2,691 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,589</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Selling, general and administrative⁽¹⁾</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,644</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,964 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,233 </td></tr></table> ⁽¹⁾Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:60.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended December 31, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Employee </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"> 2,755 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,794</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Diagnostics and Spatial Biology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 189</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 205 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,964 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-

space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:60.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six months ended December 31, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"> 10,172 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,485</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diagnostics and Spatial Biology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 425</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 323</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,057 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,233 </td></tr></table> The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> impairment and other⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> — </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the first quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"> 7,417 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 10,269 </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> (189) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> (189) </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,417) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:solid #000000;margin:0pt;padding:0pt;"> (7,417) </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,663 </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the second quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> 205 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"> 2,759 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2,964 </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> (1,211) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"> (335) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> (1,546) </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,424) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,424) </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,657 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,657 </td></tr>
</table> ⁽¹⁾Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites. ⁽²⁾Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites. Fiscal Year 2024 Restructuring Actions: In the second quarter of fiscal 2024, the Company announced enterprise-wide restructuring focused on recovering operating margins, optimizing our distribution footprint, and enhancing our organization efficiency. These actions impacted approximately 4% of our global workforce. These actions continued through the second quarter of fiscal 2025 as we incurred charges relating to our business held-for-sale and consulting fees related to optimizing efficiency. The Company is expecting to incur costs related to these actions through the end of fiscal 2025, which will be recorded when specified criteria are met. As part of these actions, certain assets and liabilities associated with a disposal group in our Protein Sciences segment were classified as held-for-sale as of December 31, 2023, including $1.4 million of goodwill allocated to the disposal group on a relative fair value basis. As a result of an impairment test performed over the disposal group during fiscal 2024, a cumulative impairment charge of $22.0 million which includes the allocated goodwill, was recorded in the Selling, general and administrative line in the Consolidated Statements of Earnings for the year ended June 30, 2024. There were no impairment charges related to the disposal group during the first half of fiscal 2025. During the quarter ended December 31, 2024, the Company entered into an agreement with a buyer to purchase the remaining inventory for approximately $8 million. As part of the arrangement, the Company and the buyer entered into a promissory note that will mature in February 2027 and agrees that the buyer shall pay in quarterly installments. As of December 31, 2024, the fair value of the note receivable was approximately $6 million and is included within Other current assets and Other assets on the Condensed Consolidated Balance Sheet. As of December 31, 2024, the assets remaining within the disposal group primarily include the land and building of $1.0 million, which is net of expected selling costs. These assets are actively marketed at a fair value based on market conditions such that the held-for-sale criterion are still met. The held-for-sale assets are recorded in Current assets held-for-sale in our Consolidated Balance sheet as of December 31, 2024 and June 30, 2024.
The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Condensed Consolidated Statements of Earnings as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:2.5

space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of sales </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,174 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;margin:0pt;padding:0pt;"> 1,174 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;margin:0pt;padding:0pt;"> Selling, general and administrative⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 323 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,250 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,250 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:35.69%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 323</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,424 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:11.74%;background:#ccceff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,424 </td></tr></table> ⁽¹⁾Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td colspan="23" style="vertical-align:bottom;white-space:nowrap;width:77.57%;margin:0pt;padding:0pt;"> Three months ended December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> <span style="font-

size:8pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">(33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"> 10 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"> (23) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"> 472 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"> 9,460 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> Diagnostics and Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> 739 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> 739 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 346 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 346 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,225 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (33)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 356 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 323 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,424 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td colspan="23" style="vertical-align:bottom;white-space:nowrap;width:77.57%;margin:0pt;padding:0pt;"> Six months ended December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:38.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"> 50 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;margin:0pt;padding:0pt;"> 31 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,950</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"> 472 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;margin:0pt;padding:0pt;"> 9,460 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> Diagnostics and Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> 739 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;margin:0pt;padding:0pt;"> 739 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,048 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,045 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,225 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.32%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (22)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,098 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,076 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,038</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 11,424 </td></tr></table> The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> Impairment of </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the second quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,882 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 504 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> 6,038 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"> 11,424 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Incremental expense incurred in the third quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> 133 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> 1,140 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> 1,273 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental expense incurred in the fourth quarter of 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 409 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 4,737 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> 15,926 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"> 21,072 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> (4,882) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> (2,800) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> (7,682) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash

adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> (3,391) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> (21,963) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"> (25,354) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Adjustments⁽³⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 219 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 190 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 952 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Incremental expense incurred in the first quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;margin:0pt;padding:0pt;"> 753 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;margin:0pt;padding:0pt;"> 753 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Incremental expense incurred in the second quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> (33) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;margin:0pt;padding:0pt;"> 356 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;margin:0pt;padding:0pt;"> 323 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (551) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,208) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td

style="vertical-align:bottom;white-space:nowrap;width:0.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,759) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:48.16%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 92 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 269 </td></tr></table> ⁽¹⁾Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or sale of certain distribution and manufacturing sites. ⁽²⁾Primarily relates to impairment of right-of-use assets, lease termination fees, consulting fees, and expenses for changes to supporting IT systems that are enabling the Company to complete the restructuring initiatives. ⁽³⁾Relates to the refinement of the accrual recorded in the second quarter of fiscal 2024. Protein Sciences Realignment In December 2022, the Company informed employees it would undertake certain actions to strategically reallocate operations resources to high growth areas of the business. Additional actions were taken in June 2023 primarily related to the sales organization. The actions impacted a limited number of employees and were completed in the fourth quarter of fiscal 2024. As a result of the realignment, a pre-tax charge of $1.7 million related to employee severance was recorded in the Selling, general and administrative line of operating income within our Protein Sciences segment during the year ended June 30, 2023. Adjustments in fiscal year 2024 related to the refinement of employee severance payouts. Additional pre-tax charges for the year ended June 30, 2024 were $0.2 million. Restructuring actions, including cash and non-cash impacts, were as follows (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">Employee</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">severance</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued restructuring actions balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;margin:0pt;padding:0pt;"> 897 </td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"> Fiscal year 2024 cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"> (1,118) </td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"> First quarter fiscal year 2024 adjustments⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;margin:0pt;padding:0pt;"> 89 </td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"> Second quarter fiscal year 2024 adjustments⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 132 </td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ⁽¹⁾Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. The restructuring and restructuring-related charges for periods presented were recorded in the Consolidated Statements of Earnings as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of sales </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,691</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;margin:0pt;padding:0pt;"> 7,589 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;margin:0pt;padding:0pt;"> Selling, general and administrative⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 273 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,644 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.2%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,964</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:18.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,233 </td></tr></table> ⁽¹⁾Restructuring actions impacting research and development are not material to separately disclose and have been included within Selling, general and administrative costs. Restructuring and restructuring-related costs by segment are as follows (in thousands): <table text="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:60.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended December 31, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td

style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"> 2,755 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,794</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diagnostics and Spatial Biology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 185</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 189</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 205 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,964 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:60.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Six months ended December 31, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> Asset-related </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:center;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> and other </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"> 10,172 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,485</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Diagnostics and Spatial Biology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 425</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">425</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 319</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 323</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:29.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,057 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,233 </td></tr></table> The following table summarizes the changes in the Company's accrued restructuring balance, which is included within Other current liabilities in the accompanying balance sheet. Other amounts reported as restructuring and restructuring-related costs in the accompanying statements of income have been summarized in the notes to the table (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;text-align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"> Employee </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.35%;margin:0pt;padding:0pt;"> Asset </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> severance⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> impairment and other⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the first quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"> 7,417 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,269</p></td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Cash payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (189)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (189)</p></td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Non-cash adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(7,417)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;">(7,417)</p></td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued restructuring actions balance as of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,663 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,663 </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Expense incurred in the second quarter of 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;margin:0pt;padding:0pt;"> 205 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"> 2,759 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"> 2,964 </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> Cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;margin:0pt;padding:0pt;"> (1,211) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"> (335) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-

align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"> (1,546) </td></tr><tr><td style="vertical-align:bottom;width:41.6%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,424) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,424) </td></tr><tr><td style="vertical-align:bottom;width:41.6%;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:6.52%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1,657</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">1,657</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">⁽¹⁾Relates to impacted employees' final paycheck, separation payments, outplacement services, legal fees, and retention packages related to the closure or relocation of certain manufacturing sites. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">⁽²⁾Primarily relates to impairment of intangibles and inventory as a result of the closure and relocation of certain manufacturing sites.</p>The restructuring and restructuring-related charges, including the impairment of assets held-for-sale, for periods presented were recorded in the Condensed Consolidated Statements of Earnings as follows (in thousands): 2691000 7589000 273000 5644000 2964000 13233000 39000 2755000 2794000 -19000 -19000 185000 4000 189000 205000 2759000 2964000 2313000 10172000 12485000 425000 425000 319000 4000 323000 3057000 10176000 13233000 2852000 7417000 10269000 189000 189000 7417000 7417000 2663000 2663000 205000 2759000 2964000 1211000 335000 1546000 2424000 2424000 1657000 1657000 0.04 1400000 22000000 0 8000000 6000000 1000000 1174000 1174000 323000 10250000 1076000 10250000 323000 11424000 1076000 11424000 -33000 10000 -23000 2950000 472000 6038000 9460000 739000 739000 346000 346000 1193000 32000 1225000 -33000 356000 323000 4882000 504000 6038000 11424000 -19000 50000 31000 2950000 472000 6038000 9460000 739000 739000 -3000 1048000 1045000 1193000 32000 1225000 -22000 1098000 1076000 4882000 504000 6038000 11424000 4882000 504000 6038000 11424000 133000 1140000 1273000 409000 4737000 15926000 21072000 4882000 2800000 7682000 3391000 21963000 25354000 219000 219000 761000 190000 952000 753000 753000 -33000 356000 323000 551000 1208000 1759000 177000 92000 269000 1700000 200000 Restructuring actions, including cash and non-cash impacts, were as follows (in thousands):<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Employee</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">severance</p></td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued restructuring actions balance as of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;margin:0pt;padding:0pt;"> 897 </td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"> Fiscal year 2024 cash payments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"> (1,118) </td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"> First quarter fiscal year 2024 adjustments⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;margin:0pt;padding:0pt;"> 89 </td></tr><tr><td style="vertical-align:bottom;width:81.53%;margin:0pt;padding:0pt;"> Second quarter fiscal year 2024 adjustments⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 132 </td></tr><tr><td style="vertical-align:bottom;width:81.53%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued restructuring actions balance as of June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table> ⁽¹⁾Fiscal year 2024 adjustments relate to the refinement of the accrual recorded in fiscal year 2023. 897000 1118000 89000 132000 0 Legal Matters: The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. . The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of

probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges in the consolidated statements of income. ‌ In August 2024, 794,400 shares of outstanding vested stock options related to former employees expired which have now been excluded from the Company's dilutive EPS calculation for the period ended December 31, 2024. The expiration date of these options is currently under dispute. The total net pre-tax value of these options on the expiration date was approximately $32 million. As of December 31, 2024, the matter is under review and the Company is unable to estimate any future exposure related to this matter at this time. ‌ The Company recognized $1.4 million and $1.7 million of certain litigation charges during the quarter and six months ended December 31, 2024. There was no comparable activity during the quarter and six months ended December 31, 2023. As of each of the balance sheet dates presented, there was no accrued litigation. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in Other current liabilities and Other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for the legal matters included within our litigation charges line, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. 794400 32000000 1400000 1700000 0 0 0 0 Recently Adopted Accounting Pronouncements There were no accounting pronouncements adopted in the quarter ended December 31, 2024. Refer to the Form 10-K for accounting pronouncements adopted prior to June 30, 2024. ‌ Relevant New Standards Issued Not Yet Adopted ‌ In November 2023, the FASB issued ASU 2023-07, Improvements to Reportable Segment Disclosures (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. ‌ In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. ‌ In November 2024, the FASB issued ASU 2024-03, Income Statement –Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires incremental disclosures on purchases of inventory, employee compensation, depreciation, intangible asset amortization, and other expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2027 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. ‌ Other than the items noted above, there have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, on our unaudited condensed consolidated financial statements. Note 2. Revenue Recognition: Consumables revenues consist of specialized proteins, immunoassays, antibodies, reagents, blood chemistry and blood gas quality controls, and hematology instrument controls that are typically single-use products recognized at a point in time following the transfer of control of such products to the customer, which generally occurs upon shipment. Instruments revenues typically consist of longer-lived assets that, for the substantial majority of sales, are recognized at a point in time in a manner similar to consumables. Service revenues consist of extended warranty contracts, post contract support, and custom development projects that are recognized over time as either the customers receive and consume the benefits of such services simultaneously or the underlying asset being developed has no alternative use for the Company at contract inception and the Company has an enforceable right to payment for the portion of the performance completed. Service revenues also include laboratory services recognized at point in time. We recognize royalty revenues in the period the sales occur using third party evidence. The Company elected the "right to invoice" practical expedient based on the Company's right to invoice a customer at an amount that approximates the value to the customer and the performance completed to date. The Company elected the exemption to not disclose the unfulfilled performance obligations for contracts with an original length of one year or less and the exemption to exclude future performance obligations that are accounted under the sales-based or usage-based royalty guidance. The Company's unfulfilled performance obligations for contracts with an original length greater than one year were not material as of December 31, 2024. Contracts with customers that contain instruments may include multiple performance obligations. For these contracts, the Company allocates the contract's transaction price to each performance obligation on a relative standalone selling price basis. Allocation of the transaction price is determined at the contracts' inception. ‌ Payment terms for shipments to end-users are generally net 30 days. Payment terms for distributor shipments may range from 30 to 90 days. Service arrangements commonly call for payments in advance of performing the work (e.g. extended warranty and service contracts), upon completion of the service (e.g. custom development manufacturing) or a mix of both. Contract assets include revenues recognized in advance of billings. Contract assets are included within Other current assets in the accompanying balance sheet as the amount of time expected to lapse until the Company's right to consideration becomes unconditional is less than one year. We elected the practical expedient allowing us to expense contract costs that would otherwise be capitalized and amortized over a period of less than one year. Contract assets as of December 31, 2024 are not material. Contract liabilities include billings in excess of revenues recognized, such as those resulting from customer advances and deposits and unearned revenue on warranty contracts. Contract liabilities as of December 31, 2024 and June 30, 2024 were approximately $30.4 million and $30.2 million, respectively. Contract liabilities as of June 30, 2024 subsequently recognized as revenue during the quarter and six month period ended December 31, 2024 were approximately $8.0 million and $19.9 million, respectively. Contract liabilities as of June 30, 2023 subsequently recognized as revenue during the quarter and six months ended December 31, 2023 were approximately $7.1 million and $18.8 million, respectively. Contract liabilities in excess of one year are included in Other long-term liabilities on the Consolidated Balance Sheet. Any claims for credit or return of goods must be made within 10 days of receipt. Revenues are reduced to reflect estimated credits and returns. Although the amounts recorded for these revenue deductions are dependent on estimates and assumptions, historically our adjustments to actual results have not been material. Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from revenue. Amounts billed to customers for shipping and handling are included in revenue, while the related shipping and handling costs are reflected in cost of products. We elected the practical expedient that allows us to account for shipping and handling activities that occur after the customer has obtained control of a good as a fulfillment cost, and we accrue costs of shipping and handling when the related revenue is recognized. The following tables present our disaggregated revenue for the periods presented. Revenue by type is as follows (in thousands): ‌ <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> ‌ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.53%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;background:#cceeff;margin:0pt;padding:0pt;"> Consumables </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 230,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> 211,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 461,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"> 435,673 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 30,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 29,825 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 57,074 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> 54,685 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;background:#cceeff;margin:0pt;padding:0pt;"> Services </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 27,350 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,129 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 54,707 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45,583 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> Total product and services revenue, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 288,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 265,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 573,341 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 535,941</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:57.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalty revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,148</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,592</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt;">Total revenues, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 297,031 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 272,598</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 586,489 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 549,533 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td></tr></table> . . Revenue by geography is as follows (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.81%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 147,793 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 324,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"> 306,898 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> EMEA, excluding United Kingdom </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 70,392 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 62,538 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 129,455 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> 117,334 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"> United Kingdom </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 13,243 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 10,675 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 27,187 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"> 23,126 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> APAC, excluding Greater China </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 19,010 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 19,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 37,131 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> 36,392 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"> Greater China </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 24,754 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 24,459 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 49,074 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"> 49,944 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">Rest of World </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,726 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,721 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,839 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"> Net sales </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 272,598 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 549,533 </td></tr></table> 30400000 30200000 8000000 19900000 7100000 18800000 Revenue by type is as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.53%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.47%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;">Consumables </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 230,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"> 211,126 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 461,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"> 435,673 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 30,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 29,825 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 57,074 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> 54,685 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.52%;background:#cceeff;margin:0pt;padding:0pt;"> Services </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 27,350 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 24,129 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 54,707 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 45,583 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> Total product and services revenue, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 288,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"> 265,080 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 573,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"> 535,941 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.52%;background:#cceeff;margin:0pt;padding:0pt;"> Royalty revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,098 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,518 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,148 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 13,592 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:57.52%;margin:0pt;padding:0pt;"> Total revenues, net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 297,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 272,598 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 586,489 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 549,533 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"> </td></tr></table>
Revenue by geography is as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.86%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.81%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 159,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 147,793 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 324,921</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"> 306,898 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;">EMEA, excluding United Kingdom </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 70,392 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 62,538 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 129,455 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> 117,334 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"> United Kingdom </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 13,243 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 10,675 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 27,187 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"> 23,126 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> APAC, excluding Greater China </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 19,010 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 19,042 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;margin:0pt;padding:0pt;"> 37,131 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;margin:0pt;padding:0pt;"> 36,392 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"> Greater China </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 24,754 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 24,459 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;margin:0pt;padding:0pt;"> 49,074 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;margin:0pt;padding:0pt;"> 49,944 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;margin:0pt;padding:0pt;"> Rest of World </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,726 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 8,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,721 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 15,839 </td></tr><tr><td style="vertical-align:bottom;width:58.6%;background:#cceeff;margin:0pt;padding:0pt;"> Net sales </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 272,598 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 549,533 </td></tr></table>
 230715000 211126000 461560000 435673000 30868000 29825000 57074000 54685000 27350000 24129000

54707000 45583000 288933000 265080000 573341000 535941000 8098000 7518000 13148000 13592000 297031000 272598000 586489000 549533000 159906000 147793000 324921000 306898000 70392000 62538000 129455000 117334000 13243000 10675000 27187000 23126000 19010000 19042000 37131000 36392000 24754000 24459000 49074000 49944000 9726000 8091000 18721000 15839000 297031000 272598000 586489000 549533000 Note 3. Selected Balance Sheet Data: Inventories: Inventories consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 79,377 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> Finished goods⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 110,153 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 106,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"> Inventories, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 194,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 185,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> ⁽¹⁾Finished goods inventory of $5,740 and $5,718 included within Other long-term assets in the respective December 31, 2024 and June 30, 2024, Consolidated Balance Sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the Consolidated Balance Sheet date. Property and Equipment: Property and equipment consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;background:#cceeff;margin:0pt;padding:0pt;"> Land </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 8,150 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> Buildings and improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 249,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> 243,863 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;background:#cceeff;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 235,984 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 215,948 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 26,785 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39,749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 520,066 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 507,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> Accumulated depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (270,313) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (256,556) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 249,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 251,154 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> Intangible Assets: Intangible assets consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 675,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"> 675,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> 151,066 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> 151,561 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;background:#cceeff;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"> 210,881 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt;"> 211,276 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> 4,736 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> 4,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;background:#cceeff;margin:0pt;padding:0pt;"> Other intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,161 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 12,006 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> Definite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> 1,048,916 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> 1,054,860 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (587,865) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (547,779) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> Total intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 507,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td></tr></table> Changes to the carrying amount of net intangible assets for the period ended December 31, 2024 consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.82%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 507,081</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Other additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 249</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"> (38,911)</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Restructuring impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"> (7,050)</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"> (318)</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 461,051 </td></tr></table> The estimated future amortization expense for intangible assets as of December 31, 2024 is as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:76.89%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 37,819 </td></tr><tr><td style="vertical-align:bottom;width:76.89%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> 72,318 </td></tr><tr><td style="vertical-

align:bottom;width:76.89%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 62,182 </td></tr><tr><td style="vertical-align:bottom;width:76.89%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> 58,478 </td></tr><tr><td style="vertical-align:bottom;width:76.89%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"> 45,912 </td></tr><tr><td style="vertical-align:bottom;width:76.89%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 184,342 </td></tr><tr><td style="vertical-align:bottom;width:76.89%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 461,051</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"><i style="font-style:italic;">Goodwill:</i></p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Changes to the carrying amount of goodwill for the period ended December 31, 2024 consist of (in thousands):</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">)</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Diagnostics and</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">)</p></td></tr><tr><td style="vertical-align:bottom;width:45.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Protein Sciences</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Spatial Biology</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;">)</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Total</i></p></td></tr><tr><td style="vertical-align:bottom;width:45.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 423,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 549,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 972,663 </td></tr><tr><td style="vertical-align:bottom;width:45.63%;margin:0pt;padding:0pt;"> Currency translation </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,642) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,414) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,056) </td></tr><tr><td style="vertical-align:bottom;width:45.63%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 419,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 544,800 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 964,607</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We evaluate the carrying value of goodwill in the fourth quarter of each fiscal year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. The Company performed a qualitative goodwill impairment assessment for all of its reporting units during the fourth quarter of fiscal 2024. No indicators of impairment were identified as part of our assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;background:#ffffff;">Other Assets: </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Other assets consist of (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">June 30, </p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity method investment in Wilson Wolf</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"> 241,354 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> 242,337 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Derivative instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> 3,227 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> 9,813 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"> 5,740 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> 5,718 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Investment in Spear Bio </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> 15,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,669 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,397 </td><td></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 274,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 264,265 </td></tr></table> Inventories consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"> Raw materials </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;margin:0pt;padding:0pt;"> 79,377 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;width:72.45%;margin:0pt;padding:0pt;"> Finished goods⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 110,153 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 106,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"> x </td></tr><tr><td style="vertical-align:bottom;width:72.45%;background:#cceeff;margin:0pt;padding:0pt;"> Inventories, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 194,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">x</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 185,449 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"> x </td></tr></table> ⁽¹⁾Finished goods inventory of $5,740 and $5,718 included within Other long-term assets in the respective December 31, 2024 and June 30, 2024, Consolidated Balance Sheet. The inventory is included in long-term assets as it is forecasted to be sold after the 12 months subsequent to the Consolidated Balance Sheet date. 83960000 79377000 11015300 0 106072000 194113000 185449000 5740000 5718000 Property and equipment consist of (in thousands): x <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> x </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:71.98%;background:#cceeff;margin:0pt;padding:0pt;"> Land </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 8,150 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> Buildings and improvements </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"> 249,193 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"> 243,863 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.98%;background:#cceeff;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 235,984 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 215,948 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt;padding:0pt;"> Construction in progress </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 26,785 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 39,749 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.98%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"> 520,066 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"> 507,710 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.98%;margin:0pt 0pt 0pt 6pt;">Accumulated depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (270,313) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (256,556) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:71.98%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 249,753</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-

align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 251,154 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 8104000 8150000 249193000 243863000 235984000 215948000 26785000 39749000 520066000 507710000 270313000 256556000 249753000 251154000 Intangible assets consist of (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt,"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt,"> . </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt,"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"> . </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt,"> . </td></tr><tr><td style="vertical-align:bottom;width:72.66%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technology </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt,"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 675,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt,">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt,"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt,">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt,"> 675,674 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt,"> . </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt,"> 151,066 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt,"> 151,561 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt,"> . </td></tr><tr><td style="vertical-align:bottom;width:72.66%;background:#cceeff;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"> 210,881 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;margin:0pt;padding:0pt,"> 211,276 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt,"> . </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> Patents </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt,"> 4,736 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt,"> 4,343 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt,"> . </td></tr><tr><td style="vertical-align:bottom;width:72.66%;background:#cceeff;margin:0pt;padding:0pt;"> Other intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"> 7,161 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt,"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt,"> 12,006 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px

solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> Definite-lived intangible assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,048,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;margin:0pt;padding:0pt;"> 1,054,860 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;background:#cceeff;margin:0pt;padding:0pt;"> Accumulated amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (587,865) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (547,779) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:72.66%;margin:0pt;padding:0pt;"> Total intangible assets, net </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">461,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 507,081 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td></tr></table> 675072000 675674000 151066000 151561000 210881000 211276000 4736000 4343000 7161000 12006000 1048916000 1054860000 587865000 547779000 461051000 507081000 Changes to the carrying amount of net intangible assets for the period ended December 31, 2024 consist of (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.65%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.82%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">507,081</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">249</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(38,911)</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restructuring impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(7,050)</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currency translation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(318)</p></td></tr><tr><td style="vertical-align:bottom;width:74.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:17.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 461,051 </td></tr></table> 507081000 249000 38911000 7050000 318000 461051000 The estimated future amortization expense for intangible assets as of December 31, 2024 is as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:76.89%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td>

<td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,819</p></td></tr><tr><td style="vertical-align:bottom;width:76.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 72,318</p></td></tr><tr><td style="vertical-align:bottom;width:76.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 62,182</p></td></tr><tr><td style="vertical-align:bottom;width:76.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,478</p></td></tr><tr><td style="vertical-align:bottom;width:76.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45,912</p></td></tr><tr><td style="vertical-align:bottom;width:76.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,342</p></td></tr><tr><td style="vertical-align:bottom;width:76.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 461,051 </td></tr></table> 37819000 72318000 62182000 58478000 45912000 184342000 461051000 Changes to the carrying amount of goodwill for the period ended December 31, 2024 consist of (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> Diagnostics and </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:45.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:45.63%;background:#cceeff;margin:0pt;padding:0pt;"> June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 423,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 549,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"> 972,663 </td></tr><tr><td style="vertical-align:bottom;width:45.63%;margin:0pt;padding:0pt;"> Currency translation </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,642) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,414) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,056) </td></tr><tr><td style="vertical-align:bottom;width:45.63%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 419,807</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 544,800 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 964,607</p></td></tr></table> 423449000 549214000 972663000 -3642000 -4414000 -8056000 419807000 544800000 964607000 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:justify;margin:0pt;">Other assets consist of (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;">December 31, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;">June 30,</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;text-align:center;margin:0pt;">2024</p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">Equity method investment in Wilson Wolf</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"> 241,354 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> 242,337 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Derivative instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> 3,227 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> 9,813 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"> 5,740 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;margin:0pt;padding:0pt;"> 5,718 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Investment in Spear Bio </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"> 15,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:73.87%;background:#cceeff;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,669 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-

align:bottom;white-space:nowrap;width:9.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,397 </td></tr><tr><td style="vertical-align:bottom;width:73.87%;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 274,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 264,265 </td></tr></table> . 241354000 242337000 3227000 9813000 5740000 5718000 15000000 9669000 6397000 274990000 264265000 Note 4. Acquisitions: We periodically complete business combinations that align with our business strategy. Acquisitions are accounted for using the acquisition method of accounting, which requires, among other things, that assets acquired and liabilities assumed be recognized at fair value as of the acquisition date and that the results of operations of each acquired business be included in our Consolidated Statements of Earnings and Comprehensive Income from their respective dates of acquisitions. Acquisition costs are recorded in selling, general and administrative expenses as incurred. There were no acquisitions in the first half of fiscal 2025. . Fiscal year 2024 Acquisitions Lunaphore Technologies SA. On July 7, 2023, the Company acquired all of the ownership interests of Lunaphore Technologies SA ("Lunaphore") for $169.7 million, in a cash-free, debt-free acquisition. Lunaphore is a leading developer of fully automated spatial biology solutions. The Lunaphore acquisition adds spatial biology instruments to Bio-Techne's portfolio to accelerate our leadership position in translational and clinical research markets. The transaction was accounted for in accordance with ASC <i style="font-style:italic;">805,</i> <i style="font-style:italic;">Business Combinations</i>. The goodwill recorded as a result of the acquisition represents the strategic benefits of growing the Company's product portfolio and the expected revenue growth from increased market penetration. The goodwill is not deductible for income tax purposes. The business became part of the Diagnostics and Spatial Biology operating segment in the first<i style="font-style:italic;"> </i>quarter of fiscal year 2024<i style="font-style:italic;">.</i><i style="font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The allocation of purchase price consideration related to Lunaphore was completed in the fourth quarter of fiscal 2024. The fair values of the assets acquired and liabilities assumed as of June 30, 2024 are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Final allocation at June 30, 2024</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"> 12,155 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> Equipment and other long-term assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> 1,470 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"> Goodwill </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"> 104,650 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> Intangible assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"> Developed technologies </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"> 60,300 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> Tradenames </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> 4,900 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"> Customer relationships </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,200 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> Total assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> 184,675 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> 7,096 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred income taxes, net </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,872 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> Net assets acquired </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 169,707 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> Cash paid </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> 169,707 </td></tr></table> . . Tangible assets and liabilities acquired were recorded at fair value on the date of close based on management's assessment. The purchase price allocated to developed technology and customer relationships was based on management's forecasted cash inflows and outflows and using a multiperiod excess earnings method to calculate the fair value of assets purchased. The purchase price allocated to trade names was based on management's forecasted cash inflows and outflows and using a relief from royalty method. The amount recorded for developed technology is being amortized with the expense reflected in cost of goods sold in the Condensed Consolidated Statement of Earnings and

Comprehensive Income. The amortization period for developed technology is 14 years. Amortization expense related to customer relationships is reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for customer relationships is 8 years. The amount recorded for trade names is being amortized with the expense reflected in selling, general and administrative expenses in the Condensed Consolidated Statement of Earnings and Comprehensive Income. The amortization period for trade names ranges from 4 years to 8 years. The net deferred income tax liability represents the net amount of the estimated future impact of adjustments for costs to be recognized as intangible asset amortization, which is not deductible for income tax purposes, offset by the deferred tax asset for the calculation of acquired net operating losses. 169700000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.54%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:26.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Final allocation at June 30, 2024 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"> Current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,155</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment and other long-term assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,470</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,650</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Developed technologies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 60,300</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Tradenames</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,900</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Customer relationships</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,200</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 184,675</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,096</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred income taxes, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,707</p></td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net assets acquired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 169,707 </td></tr><tr><td style="vertical-align:bottom;width:73.45%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:73.45%;margin:0pt;padding:0pt;"> Cash paid </td><td style="vertical-align:bottom;white-space:nowrap;width:3.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:22.84%;margin:0pt;padding:0pt;"> 169,707 </td></tr></table> 12155000 1470000 104650000 60300000 4900000 1200000 184675000 7096000 7872000 169707000 169707000 P14Y P8Y P4Y P8Y Note 5. Fair Value Measurements: The Company's financial instruments include cash and cash equivalents, available-for-sale investments, derivative instruments, accounts receivable, accounts payable, contingent consideration obligations, and long-term debt. Fair value is defined as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. This standard also establishes a hierarchy for inputs used in measuring fair value. This standard maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability based on market data obtained from independent sources. Unobservable inputs are inputs that reflect our assumptions about the factors market participants would use in valuing the asset or liability based upon the best information available in the circumstances. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels. Level 1 inputs are quoted prices in active markets for identical assets or liabilities. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs (other than quoted prices) that are observable for the asset or liability, either directly or indirectly. Level 3 inputs are unobservable for the asset or liability and their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. Level 3 may also include certain investment securities for which there is limited market activity or a decrease in the observability of market pricing for the investments, such that the determination of fair value requires significant judgment or estimation. The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands). <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> value as of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"> Fair Value Measurements Using </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> Balance Sheet Location </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs Considered as </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> Other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 528 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"> 528 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - net investment hedge </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,699 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,699 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> value as of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.11%;margin:0pt;padding:0pt;"> Fair Value Measurements Using </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> Balance Sheet Location </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs Considered as </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> Certificates of deposit⁽¹⁾ </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> Short-term available-for-sale investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> 1,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;"> Other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"> 805 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> 805 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,813 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,813 </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - net investment hedge </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> Other long-term liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">The certificates of deposit have contractual maturity dates within one year. </td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;margin:0pt;"> Fair value measurements of derivative instruments The Company utilizes forward starting swaps designated as a cash flow hedge on forecasted debt. The forward starting swaps reduce the variability of cash flow payments for the Company by converting the variable interest rate on the Company's forecasted variable interest long-term debt to that of a fixed interest rate. Accordingly, as part of the forward starting swaps, the Company exchanges, at specified intervals, the difference between floating and fixed interest amounts based on a notional principal amount. The Company also uses a cross-currency swap contract to manage its exposure to foreign currency risk associated with the Company's net investment in its Swiss subsidiary. The following table presents the contractual amounts of the Company's outstanding instruments (in millions): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> Designation </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"> Forward starting swaps⁽¹⁾ </td><td style="vertical-align:bottom;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"> Cash flow hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td></tr><tr><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> Cross-currency swap⁽²⁾ </td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> Net investment hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> 140 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> 150 </td></tr></table> ⁽¹⁾ In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $200 million of notional principal. The effective date of the swap was November 2022 with the full swap maturing in November 2025. In March 2023, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $100 million of notional principal. The effective date of the swap was April 2023 with the full swap maturing in April 2025. In August 2024, the Company entered into a new forward starting swap designated as a cash flow hedge on forecasted debt based on $100 million of notional principal that will go into effect in April 2025 to replace a swap that matures in April 2025. The effective date of the new swap is April 2025 with the full swap maturing in April 2026. ⁽²⁾ In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has three interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity. The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our Consolidated Financial Statements for the three and six months ended December 31, 2024 and 2023 were as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:69.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Gain) Loss Recognized in Accumulated Other Comprehensive Loss </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.96%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:24.5%;background:#cceeff;margin:0pt;padding:0pt;"> Cash flow hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> Forward starting swaps </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;width:12.44%;margin:0pt;padding:0pt;"> 5,669 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,699</p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;width:12.41%;margin:0pt;padding:0pt;"> 7,956 </td></tr><tr><td style="vertical-align:bottom;width:24.5%;background:#cceeff;margin:0pt;padding:0pt;"> Net investment hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:middle;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> Cross-currency swap </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,690) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,545 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,525) </td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,243 </td></tr><tr><td style="vertical-align:bottom;width:24.5%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (6,001)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,199 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:56.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Gain) Loss Reclassified into Income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.13%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.91%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:15.66%;margin:0pt;padding:0pt;"> Location of (Gain) Loss </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> In Income Statement </td></tr><tr><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt;"> Cash flow hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> Forward starting swaps </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"> (2,620) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,754)</p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"> (5,159) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"> Interest expense </td></tr><tr><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt;"> Net investment hedges </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> Cross-currency swap </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ (660) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ (837) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ (1,442) </td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ (1,535) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"> Interest expense </td></tr><tr><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (2,815)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (3,457) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (6,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (6,694) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> Gains or losses related to the net investment hedges are classified as foreign currency translation adjustments in the schedule of changes in Accumulated Other Comprehensive Income (“AOCI”) in Note 8, as these items are attributable to the Company’s hedges of its net investment in foreign operations. Gains or losses related to the cash flow hedges are classified as Unrealized gains (losses) on cash flow hedges in the schedule of changes in AOCI in Note 8. Fair value measurements of other financial instruments – The following methods and assumptions were used to estimate the fair value of each class of financial instrument for which it is practicable to estimate fair value. Cash and cash equivalents, certificates of deposit, accounts receivable, and accounts payable – The carrying amounts reported in the Consolidated Balance Sheets approximate fair value because of the short-term nature of these items. Long-term debt – The carrying amounts reported in the Consolidated Balance Sheets for the amount drawn on our line-of-credit facility and long-term debt approximates fair value because our interest rate is variable and reflects current market rates. The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands). <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> value as of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"> Fair Value Measurements Using </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> Balance Sheet Location </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs Considered as </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> Other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"> 528 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;margin:0pt;padding:0pt;"> 528 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - net investment hedge </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,699 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,699 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.21%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;width:34.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,290</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.33%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> carrying </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> value as of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.11%;margin:0pt;padding:0pt;"> Fair Value Measurements Using </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> Balance Sheet Location </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> June 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:28.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Inputs Considered as </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;">

) </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 2 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level 3 </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;">) </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Assets </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Certificates of deposit⁽¹⁾ </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> Short-term available-for-sale investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,072</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> 1,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;"> Other current assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"> 805 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> 805 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - cash flow hedges </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> Other assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,813 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 9,813 </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total assets </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,690</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,072 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;margin:0pt;padding:0pt;"> - </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;margin:0pt;padding:0pt;"> Derivatives designated as hedging instruments - net investment hedge </td><td style="vertical-align:bottom;width:34.59%;margin:0pt;padding:0pt;"> Other long-term liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:25.47%;background:#cceeff;margin:0pt;padding:0pt;"> Total liabilities </td><td style="vertical-align:bottom;width:34.59%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times',serif;font-size:7.5pt;vertical-align:top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">The certificates of deposit have contractual maturity dates within one year. </td></tr></table> 6063000 6063000 528000 528000 2699000 2699000 9290000

9290000 1072000 1072000 805000 805000 9813000 9813000 11690000 1072000 10618000 2051000 2051000 2051000 2051000 The following table presents the contractual amounts of the Company's outstanding instruments (in millions): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.53%;margin:0pt;padding:0pt;"> June 30, </td></tr><tr><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> Designation </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"> Forward starting swaps⁽¹⁾ </td><td style="vertical-align:bottom;width:2.66%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;background:#cceeff;margin:0pt;padding:0pt;"> Cash flow hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"> 300 </td></tr><tr><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> Cross-currency swap⁽²⁾ </td><td style="vertical-align:bottom;width:2.66%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:25.37%;margin:0pt;padding:0pt;"> Net investment hedge </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> 140 </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"> 150 </td></tr></table> ⁽¹⁾ In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $200 million of notional principal. The effective date of the swap was November 2022 with the full swap maturing in November 2025. In March 2023, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $100 million of notional principal. The effective date of the swap was April 2023 with the full swap maturing in April 2025. In August 2024, the Company entered into a new forward starting swap designated as a cash flow hedge on forecasted debt based on $100 million of notional principal that will go into effect in April 2025 to replace a swap that matures in April 2025. The effective date of the new swap is April 2025 with the full swap maturing in April 2026. ⁽²⁾ In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has three interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity. 300000000 300000000 140000000 150000000 200000000 100000000 100000000 150000000 3 10000000 110000000 The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our Consolidated Financial Statements for the three and six months ended December 31, 2024 and 2023 were as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:69.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Gain) Loss Recognized in Accumulated Other Comprehensive Loss </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.96%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.95%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:24.5%;background:#cceeff;margin:0pt;padding:0pt;"> Cash flow hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> Forward starting swaps </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,689</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;width:12.44%;margin:0pt;padding:0pt;"> 5,669 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,699</p></td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;width:12.41%;margin:0pt;padding:0pt;"> 7,956 </td></tr><tr><td style="vertical-align:bottom;width:24.5%;background:#cceeff;margin:0pt;padding:0pt;"> Net investment hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:24.5%;margin:0pt;padding:0pt;"> Cross-currency swap </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,690) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,545 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,525) </td><td style="vertical-align:bottom;width:3.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,243 </td></tr><tr><td style="vertical-align:bottom;width:24.5%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,001)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 13,214 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 15,199 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:56.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (Gain) Loss Reclassified into Income </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> <span style="font-

family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"> </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.13%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.91%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:15.66%;margin:0pt;padding:0pt;"> Location of (Gain) Loss </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:15.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> in Income Statement </td></tr><tr><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt;"> Cash flow hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> Forward starting swaps </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (2,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;width:10.15%;margin:0pt;padding:0pt;"> (2,620) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (4,754)</p></td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"> (5,159) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"> Interest expense </td></tr><tr><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt;"> Net investment hedges </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:20%;margin:0pt;padding:0pt;"> Cross-currency swap </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (660) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (837) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,442) </td><td style="vertical-align:bottom;width:2.58%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,535) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.66%;margin:0pt;padding:0pt;"> Interest expense </td></tr><tr><td style="vertical-align:bottom;width:20%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(2,815)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (3,457) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(6,196)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (6,694) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 1689000 5669000 6699000 7956000 -7690000 7545000 -2525000 7243000 -6001000 13214000 4174000 15199000 -2155000 -2620000 -4754000 -5159000 -660000 -837000 -1442000 -1535000 -2815000 -3457000 -6196000 -6694000 Note 6. Debt and Other Financing Arrangements: On August 31, 2022, the Company entered into a revolving line-of-credit and term loan by a Credit Agreement (the Credit Agreement). The Credit Agreement provides for a revolving credit facility of $1 billion, which can be increased by an additional $400 million subject to certain conditions. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions. Borrowings under the Credit Agreement bear interest at a variable rate. The current outstanding debt is based on the one-month Secured Overnight Financing Rate (SOFR) plus an applicable margin. The applicable margin is determined from the total leverage ratio of the Company and updated on a quarterly basis. The annualized fee for any unused portion of the credit facility is currently 10 basis points. The Credit Agreement matures on August 31, 2027 and contains customary restrictive and financial covenants and customary events of default. As of December 31, 2024, the outstanding balance under the Credit Agreement was $300.0 million. 1000000000 400000000 0.0010 300000000 Note 7. Leases: As a lessee, the Company leases offices, labs, and manufacturing facilities, as well as vehicles, copiers, and other equipment. The Company recognizes operating lease expense on a straight-line basis over the lease term. Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is Bio-Techne's incremental borrowing rate or, if available, the rate implicit in the lease. Bio-Techne determines the incremental borrowing rate for each lease based primarily on its lease term and the economic environment of the applicable country or region. During the six months ended December 31, 2024, the Company recognized $2.6 million in variable lease expense and $8.7 million relating to fixed lease expense in the Condensed Consolidated Statements of Earnings and Comprehensive Income. The following table summarizes the balance sheet classification of the Company's operating leases and amounts of right-of-use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company's operating leases (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance Sheet Classification </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> Operating lease right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> Right-of-use asset </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,383</p></td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Current operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> 13,511 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> Noncurrent operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 81,616 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> Total operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 95,127 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;width:59.26%;margin:0pt;padding:0pt;"> Weighted average remaining lease term (in years): </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> 8.09 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> Weighted average discount rate (%): </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> 4.26 </td></tr></table> . The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for new operating lease liabilities for the six months ended December 31, 2024 (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt;"> Six months ended </td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:79.77%;background:#cceeff;margin:0pt;padding:0pt;"> Cash amounts paid on operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,068</p></td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:79.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> 1,321 </td></tr></table> . The following table summarizes the fair value of the lease liability by payment date for the Company's operating leases by fiscal year (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 8,399 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 16,568 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 13,732 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> 13,569 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"> 13,115 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> Thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 48,159 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,542</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Less: Amounts representing interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,415</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Total lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 95,127 </td></tr></table> . Certain leases include one or more options to renew, with terms that extend the lease term up to five years. Bio-Techne includes the option to renew the lease as part of the right-of-use lease asset and liability when it is reasonably certain the Company will exercise the option. In addition, certain leases contain fair value purchase and termination options with an associated penalty. In general, Bio-Techne is not reasonably certain to exercise such options. 2600000 8700000 The following table summarizes the balance sheet classification of the Company's operating leases and amounts of right-of-use assets and lease liabilities and the weighted average remaining lease term and weighted average discount rate for the Company's operating leases (in thousands): . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> As of </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.85%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Balance Sheet Classification </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:10.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> Operating leases: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> Operating lease right-of-use assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> Right-of-use asset </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,383</p></td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Current operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> 13,511 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> Noncurrent operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 81,616 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> Total operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> $ </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 95,127 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted average remaining lease term (in years): </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> 8.09 </td></tr><tr><td style="vertical-align:bottom;width:59.26%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:59.26%;margin:0pt;padding:0pt;"> Weighted average discount rate (%): </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> 4.26 </td></tr></table> 85383000 13511000 81616000 95127000 P8Y1M2D 0.0426 The following table summarizes the cash paid for amounts included in the measurement of operating lease liabilities and right-of-use assets obtained in exchange for new operating lease liabilities for the six months ended December 31, 2024 (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt;"> Six months ended </td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">December 31, </td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:79.77%;background:#cceeff;margin:0pt;padding:0pt;"> Cash amounts paid on operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,068</p></td></tr><tr><td style="vertical-align:bottom;width:79.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:79.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.1%;background:#cceeff;margin:0pt;padding:0pt;"> 1,321 </td></tr></table> 8068000 1321000 The following table summarizes the fair value of the lease liability by payment date for the Company's operating leases by fiscal year (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> Remainder 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,399</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,568</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,732</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,569</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,115</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 48,159</p></td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 113,542 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;margin:0pt;padding:0pt;"> Less: Amounts representing interest </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,415 </td></tr><tr><td style="vertical-align:bottom;width:83.34%;background:#cceeff;margin:0pt;padding:0pt;"> Total lease obligations </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 95,127 </td></tr></table> 8399000 16568000 13732000 13569000 13115000 48159000 113542000 18415000 95127000 P5Y Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (Loss): Supplemental Equity The Company has declared cash dividends per share of $0.08 and $0.16 in the three and six months ended December 31, 2024 and 2023, respectively. Consolidated Changes in Equity (amounts in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> <span

style="font-size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:48.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Bio-Techne Shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"> Additional </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"> Paid-in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> Retained </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Comprehensive </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Capital </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Income(Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 158,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 820,337 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,325,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (78,316) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,068,850 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 33,600 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 33,600 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Other comprehensive income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> 18,229 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 18,229 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Common stock issued for exercise of options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 577 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> 6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> 23,224 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (2,338) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 20,892 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock issued for restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 50 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (2,646) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (2,644) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Cash dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,688) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,688) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> 10,146 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 10,146 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Common stock issued to employee stock purchase plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 35 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> 2,227 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 2,227 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Employee stock purchase plan expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,890 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 34,890 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Other comprehensive income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> (25,563) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (25,563) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Share repurchases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> (1,118) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> (11) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (75,617) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (75,628) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Common stock issued for exercise of options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 132 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> 5,183 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (20) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 5,164 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock issued for restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (993) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (993) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Cash dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,736) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.07%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,736) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> 14,335 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 14,335 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Employee stock purchase plan expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 373 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 373 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 157,916 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 875,864 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,286,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (85,650) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,078,492 </td></tr></table>   <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:51.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Bio-Techne Shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> Additional </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> Paid-in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> Retained </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Comprehensive </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt;">Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Capital </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Income(Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 157,642 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 721,543 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,309,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (66,064) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,966,516 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 50,993 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 50,993 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Other comprehensive income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> (11,952) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (11,952) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Common stock issued for exercise of options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> 633 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 12,877 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (15,460) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (2,577) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock issued for restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> 47 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (4,768) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (4,767) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Cash dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,654) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,654) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> 9,981 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 9,981 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Common stock issued to employee stock purchase plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> 33 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 2,093 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 2,094 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Employee stock purchase plan expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 112 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 112 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Balances at September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 158,355 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 746,606 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,327,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (78,016) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,997,746 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 27,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 27,465 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Other comprehensive income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> 14,355 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 14,355 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Share repurchases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> (1,397) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> (14) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (80,028) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (80,042) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Common stock issued for exercise of options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> 157 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 4,914 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (1,074) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 3,841 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock issued for restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> 27 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Cash dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,559) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,559) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> 12,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 12,413 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Employee stock purchase plan expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 340 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 340 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 157,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,571</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 764,273 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,261,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (63,661) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,963,559 </td></tr></table> Accumulated Other Comprehensive Income The components of Other comprehensive income (loss) consist of changes in foreign currency translation adjustments and changes in net unrealized gains (losses) on derivative instruments designated as cash flow hedges. The accumulated balances related to each component of Other comprehensive income (loss) are summarized as follows: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Three months ended December 31, 2024 (in thousands): </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> <span style="font-

style:italic;visibility:hidden;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> (Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;">   </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of September 30, 2024, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (65,162) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (60,087) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (1,689) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (26,021) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (27,710) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 660 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,815 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 466 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (25,361) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (24,895) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Tax (expense)/benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (511) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (157) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (668) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (45) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (25,518) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (25,563) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Balance as of December 31, 2024, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (90,680) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (85,650) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Three months ended December 31, 2023 (in thousands): </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt;">Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> (Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of September 30, 2023 net of tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,512</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (90,528) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (78,016) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (5,669) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 17,387 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 11,718 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,620 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 837 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,457 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (3,049) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 18,224 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 15,175 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Tax (expense)/benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (621) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (199) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (820) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,670) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,355 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Balance as of December 31, 2023, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (72,503) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (63,661) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Six months ended December 31, 2024 (in thousands): </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> (Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of June 30, 2024, net of tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (86,418) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (78,316) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (6,699) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (5,362) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (12,061) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,754 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,442 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,196 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (1,945) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (3,920) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (5,865) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Tax (expense)/benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,127) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (342) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,469) </td></tr><tr><td

style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,072) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,262) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,334) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Balance as of December 31, 2024, net of tax⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (90,680) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (85,650) </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Six months ended December 31, 2023 (in thousands): </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> (Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-

align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of June 30, 2023, net of tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 12,862 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (78,926) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (66,064) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (7,956) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 5,252 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (2,704) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,535 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,694 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (2,797) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 6,787 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 3,990 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Tax (expense)/benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,223) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (364) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,587) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,020) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,423 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,403 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Balance as of December 31, 2023, net of tax⁽¹⁾ </td><td

style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (72,503) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (63,661) </td></tr></table> ⁽¹⁾ The Company had a net deferred tax liability for its cash flow hedge of $1.6 million and $2.7 million as of December 31, 2024 and 2023, respectively. Income taxes are not provided for foreign translation relating to permanent investments in international subsidiaries, but tax effects within foreign currency translation adjustments do include impacts from the net investment hedge. 0.08 0.08 0.16 0.16 Consolidated Changes in Equity (amounts in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:48.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Bio-Techne Shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr></table>

style:italic;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"> Additional </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"> Paid-in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> Retained </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Comprehensive </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Capital </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Income(Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at June 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 158,216 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,582</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 820,337 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,325,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (78,316) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,068,850 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 33,600 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 33,600 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Other comprehensive income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> 18,229 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 18,229 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Common stock issued for exercise of options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 577 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> 6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> 23,224 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (2,338) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 20,892 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock issued for restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 50 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (2,646) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (2,644) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Cash dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,688) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,688) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;">) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> 10,146 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 10,146 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Common stock issued to employee stock purchase plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 35 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> 2,227 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 2,227 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Employee stock purchase plan expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Balances at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 158,878 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,589</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 855,973 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,341,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (60,087) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,138,650 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 34,890 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 34,890 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Other comprehensive income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (25,563) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> (25,563) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (25,563) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Share repurchases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> (1,118) </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> (11) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (75,617) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (75,628) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Common stock issued for exercise of options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 132 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> 5,183 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (20) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 5,164 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock issued for restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 24 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (993) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (993) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Cash dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,736) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,736) </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;margin:0pt;padding:0pt;"> 14,335 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 14,335 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;margin:0pt;padding:0pt;"> Employee stock purchase plan expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 373 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 373 </td></tr><tr><td style="vertical-align:bottom;width:37.82%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at December 31, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 157,916 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,579</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 875,864 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,286,699</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (85,650) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.07%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#ccceff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,078,492 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:51.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Bio-Techne Shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Accumulated </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> Additional </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Common Stock </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> Paid-in </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"> Retained </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"> Comprehensive </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amount </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Capital </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Income(Loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at June 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 157,642 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,576</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 721,543 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,309,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (66,064) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,966,516 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 50,993 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 50,993 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Other comprehensive income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> (11,952) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (11,952) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Common stock issued for exercise of options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> 633 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 6 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 12,877 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (15,460) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (2,577) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock issued for restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> 47 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (4,768) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (4,767) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Cash dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,654) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,654) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> 9,981 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 9,981 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Common stock issued to employee stock purchase plan </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> 33 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 2,093 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 2,094 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Employee stock purchase plan expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 112 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 112 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Balances at September 30, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 158,355 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,584</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 746,606 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,327,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (78,016) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,997,746 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 27,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 27,465 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Other comprehensive income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> 14,355 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 14,355 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Share repurchases </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> (1,397) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> (14) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (80,028) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> (80,042) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Common stock issued for exercise of options </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> 157 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> 4,914 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (1,074) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> 3,841 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Common stock issued for restricted stock awards </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> 27 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 0 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Cash dividends </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:8.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,559) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"> (12,559) </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Stock-based compensation expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"> 12,413 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"> 12,413 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;margin:0pt;padding:0pt;"> Employee stock purchase plan expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 340 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 340 </td></tr><tr><td style="vertical-align:bottom;width:35.04%;background:#cceeff;margin:0pt;padding:0pt;"> Balances at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 157,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 764,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,261,376 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (63,661)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,963,559 </td></tr></table> 158216000 1582000 820337000 1325247000 -78316000 2068850000 33600000 33600000 18229000 18229000 577000 6000 23224000 -2338000 20892000 50000 1000 1000 -2646000 -2644000 12688000 12688000 10146000 10146000 35000 0 2227000 2227000 38000 38000 158878000 1589000 855973000 1341175000 -60087000 2138650000 34890000 34890000 -25563000 -25563000 1118000 11000 75617000 75628000 132000 1000 5183000 -20000 5164000 24000 0 0 -993000 -993000 12736000 12736000 14335000 14335000 373000 373000 157916000 1579000 875864000 1286699000 -85650000 2078492000 157642000 1576000 721543000 1309461000 -66064000 1966516000 50993000 50993000 -11952000 -11952000 633000 6000 12877000 -15460000 -2577000 47000 1000 0 -4768000 -4767000 12654000 12654000 9981000 9981000 33000 1000 2093000 2094000 112000 112000 158355000 1584000 746606000 1327572000 -78016000 1997746000 27465000 27465000 14355000 14355000 1397000 14000 80028000 80042000 157000 1000 4914000 -1074000 3841000 27000 0 0 0 12559000 12559000 12413000 12413000 340000 340000 157142000 1571000 764273000 1261376000 -63661000 1963559000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Three months ended December 31, 2024 (in thousands): </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> (Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of September 30, 2024, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (65,162) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (60,087) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax, </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (1,689) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (26,021) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (27,710) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,155 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 660 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,815 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 466 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (25,361) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (24,895) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Tax (expense)/benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (511) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (157) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (668) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (45) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (25,518) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (25,563) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Balance as of December 31, 2024, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (90,680) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (85,650) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36

space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Three months ended December 31, 2023 (in thousands): </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Net income (loss) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,512</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (90,528) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (78,016) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax, </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (5,669) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 17,387 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 11,718 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,620 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 837 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,457 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (3,049) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 18,224 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 15,175 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Tax (expense)/benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (621) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (199) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (820) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,670) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 18,025 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 14,355 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Balance as of December 31, 2023, net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (72,503) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (63,661) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Six months ended December 31, 2024 (in thousands): </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> (Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of June 30, 2024, net of tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (86,418) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (78,316) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (6,699) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (5,362) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (12,061) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,754 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,442 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,196 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (1,945) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (3,920) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (5,865) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Tax (expense)/benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,127) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (342) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,469) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,072) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,262) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (7,334) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Balance as of December 31, 2024, net of tax⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,030</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (90,680) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (85,650) </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Six months ended December 31, 2023 (in thousands): </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Unrealized </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Gains </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Foreign </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Losses) on </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Currency </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Derivative </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"> Translation </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Instruments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Adjustments </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Balance as of June 30, 2023, net of tax: </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,862</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (78,926) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (66,064) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Other comprehensive income (loss), before tax, </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Amounts before reclassifications </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (7,956) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 5,252 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (2,704) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Amounts reclassified out </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,159 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,535 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,694 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), before tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> (2,797) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 6,787 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"> 3,990 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Tax (expense)/benefit </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,223) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (364) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,587) </td></tr><tr><td style="vertical-align:bottom;width:62.13%;background:#cceeff;margin:0pt;padding:0pt;"> Total other comprehensive income (loss), net of tax </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,020) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,423 </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,403 </td></tr><tr><td style="vertical-align:bottom;width:62.13%;margin:0pt;padding:0pt;"> Balance as of December 31, 2023, net of tax⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (72,503) </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (63,661) </td></tr></table> ⁽¹⁾ The Company had a net deferred tax liability for its cash flow hedge of $1.6 million and $2.7 million as of December 31, 2024 and 2023, respectively. 5075000 -65162000 -60087000 -1689000 -26021000 -27710000 -2155000 -660000 -2815000 466000 -25361000 -24895000 511000 157000 668000 -45000 -25518000 -25563000 5030000 -90680000 -85650000 12512000 -90528000 -78016000 -5669000 17387000 11718000 -2620000 -837000 -3457000 -3049000 18224000 15175000 621000 199000 820000 -3670000 18025000 14355000 8842000 -72503000 -63661000 8102000 -86418000 -78316000 -6699000 -5362000 -12061000 -4754000 -1442000 -6196000 -1945000 -3920000 -5865000 1127000 342000 1469000 -3072000 -4262000 -7334000 5030000 -90680000 -85650000 12862000 -78926000 -66064000 -7956000 5252000 -2704000 -5159000 -1535000 -6694000 -2797000 6787000 3990000 1223000 364000 1587000 -4020000 6423000 2403000 8842000 -72503000 -63661000 1600000 2700000 Note 9. Earnings Per Share: The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.04%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Earnings per share – basic: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 27,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 78,459 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Income allocated to participating securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (13) </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Income available to common shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,462 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,478</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 78,446 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average shares outstanding – basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> 158,431 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 157,533 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 158,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 157,826 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Earnings per share – basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 0.22 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 0.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 0.43 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 0.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Earnings per share - diluted: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 27,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 78,459 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Income allocated to participating securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (13) </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Income available to common shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,462 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 68,478 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Weighted-average shares outstanding – basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 157,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,481</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 157,826</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Dilutive effect of stock options and restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Weighted-average common shares outstanding – diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,060</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161,001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Earnings per share – diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> 0.22 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 0.42 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 0.49 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> The dilutive effect of stock options and restricted stock units in the above table excludes all options for which the aggregate exercise proceeds exceeded the average market price for the period. The number of potentially dilutive option shares excluded from the calculation was 4.1 million and 6.2 million for the quarter ended December 31, 2024 and 2023, respectively, and 3.6 million and 4.1 million for the six months ended December 31, 2024 and 2023, respectively. The following table reflects the calculation of basic and diluted earnings per share (in thousands, except per share amounts): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.04%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Earnings per share – basic: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 27,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 68,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 78,459 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Income allocated to participating securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (13) </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

</td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Income available to common shareholders </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 27,462 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 68,478 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 78,446 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Weighted-average shares outstanding – basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> 158,431 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 157,533 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 158,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 157,826 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Earnings per share – basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 0.22 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 0.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 0.43 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 0.50 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Earnings per share – diluted: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Net earnings </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,890</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 27,465 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td

style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 68,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Income allocated to participating securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">Income available to common shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 34,887 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,462</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 68,478 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 78,446 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;margin:0pt;padding:0pt;"> Weighted-average shares outstanding – basic </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 158,431 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 157,533 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"> 158,481 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"> 157,826 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Dilutive effect of stock options and restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,195 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,527 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,872 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,175 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.37%;margin:0pt;padding:0pt;"> Weighted-average common shares outstanding – diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 160,626 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 160,060 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 161,353 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 161,001 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;width:56.37%;background:#cceeff;margin:0pt;padding:0pt;"> Earnings per share – diluted </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> 0.22 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 0.17 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"> 0.42 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"> 0.49 </td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td></tr></table> 34890000 27465000 68490000 78459000 3000 3000 12000 13000 34887000 27462000 68478000 78446000 158431000 157533000 158481000 157826000 0.22 0.17 0.43 0.5 34890000 27465000 68490000 78459000 3000 3000 12000 13000 34887000 27462000 68478000 78446000 158431000 157533000 158481000 157826000 2195000 2527000 2872000 3175000 160626000 160060000 161353000 161001000 0.22 0.17 0.42 0.49 4100000 6200000 3600000 4100000 Note 10. Share-based Compensation: During the six months ended December 31, 2024 and 2023, the Company granted 0.8 million and 0.9 million stock options at weighted average grant prices of $74.65 and $81.49 and weighted average fair values of $25.43 and $27.83, respectively. During the six months ended December 31, 2024 and 2023, the Company granted 0.5 million and 0.3 million restricted stock units at a weighted average fair value of $74.96 and $79.26, respectively. During the six months ended December 31, 2024 and 2023, the Company granted 11,696 and 27,196 shares of restricted common stock shares at a weighted average fair value of $68.37 and $56.98. Stock options for 0.8 million and 1.2 million shares of common stock with total intrinsic values of $28.3 million and $61.6 million were exercised during the six months ended December 31, 2024 and 2023, respectively. Stock-based compensation expense, inclusive of payroll taxes, of $14.5 million and $12.4 million was included in selling, general and administrative expenses for the quarter ended December 31, 2024 and 2023, respectively. Stock-based compensation expenses, inclusive of payroll taxes, of $24.8 million and $23.5 million was included in selling, general, and administrative expenses for the six months ended December 31, 2024 and 2023, respectively. Additionally, the Company recognized $0.4 million and $0.7 million of stock-based compensation costs in cost of goods sold in the quarter and six months ended December 31, 2024, respectively, compared to $0.3 million and $0.5 million in cost of goods sold in the comparative prior year periods. As of December 31, 2024, there was $62.6 million of unrecognized compensation cost related to non-vested stock options, non-vested restricted stock units and non-vested restricted stock. The weighted average period over which the compensation cost is expected to be recognized is 2.1 years. In fiscal 2015, the Company established the Bio-Techne Corporation 2014 Employee Stock Purchase Plan (ESPP), which was approved by the Company's shareholders on October 30, 2014, and which is designed to comply with IRS provisions governing employee stock purchase plans. 800,000 shares were allocated to the ESPP. The Company recorded expense of $0.4 million for the quarter ended December 31, 2024 and $0.3 million for the quarter ended December 31, 2023. The Company recorded expense of $0.4 million and $0.5 million for the six months ended December 31, 2024 and 2023, respectively. 800000 900000 74.65 81.49 25.43 27.83 500000 300000 74.96 79.26 11696 27196 68.37 56.98 800000 1200000 28300000 61600000 14500000 12400000 24800000 23500000 400000 700000 300000 500000 62600000 P2Y1M6D 800000 400000 300000 400000 500000 Note 11. Other Income / (Expense): The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-

align:center;margin:0pt;">2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;background:#cceeff;margin:0pt;padding:0pt;"> Interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,148)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> (4,329) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,324)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> (9,222) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> Interest income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 1,348 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 816 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 2,274 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 1,706 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;background:#cceeff;margin:0pt;padding:0pt;"> Gain (loss) on investment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> 283 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> Gain (loss) on equity method investment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 46 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> (1,914) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 420 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> (4,204) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;background:#cceeff;margin:0pt;padding:0pt;"> Other non-operating income (expense), net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,789) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 810 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,729) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 516 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> Total other income (expense) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (4,617) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,359)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (10,921) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr></table> The components of other income (expense) in the accompanying Statement of Earnings and Comprehensive Income are as follows (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.24%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.18%;margin:0pt;padding:0pt;"> Six Months Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;background:#cceeff;margin:0pt;padding:0pt;"> Interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,148)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> (4,329) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,324)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> (9,222) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> Interest income </td><td

style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 1,348 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 816 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 2,274 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 1,706 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;background:#cceeff;margin:0pt;padding:0pt;"> Gain (loss) on investment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;margin:0pt;padding:0pt;"> 283 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> Gain (loss) on equity method investment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 46 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> (1,914) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> 420 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;margin:0pt;padding:0pt;"> (4,204) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;background:#cceeff;margin:0pt;padding:0pt;"> Other non-operating income (expense), net </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,789) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 810 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,729) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 516 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:54.9%;margin:0pt;padding:0pt;"> Total other income (expense) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (4,543)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (4,617) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt;"> (4,359)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (10,921) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"> . </td></tr></table> . 2148000 4329000 4324000 9222000 1348000 816000 2274000 1706000 283000 46000 -1914000 420000 -4204000 -3789000 810000 -2729000 516000 -4543000 -4617000 -4359000 -10921000 Note 12. Income Taxes: The Company's effective income tax rate for the second quarter of fiscal 2025 and 2024 was 18.6% and 17.7%, respectively, of consolidated earnings before income taxes, inclusive of discrete items, and 17.5% and 5.4% for the first six months of fiscal 2025 and 2024, respectively. The change in the Company's tax rate for the quarter and six months ended December 31, 2024 compared to the quarter and six months ended December 31, 2023 was driven by discrete tax items. The Company recognized total net benefits related to discrete tax items of $2.2 million and $5.2 million during the quarter and six months ended December 31, 2024, respectively, compared to total net benefits of $2.8 million and $16.3 million during the quarter and six months ended December 31, 2023, respectively. Share-based compensation excess tax benefit contributed $1.0 million and $4.3 million in the quarter and six months ended December 31, 2024, respectively, compared to $1.3 million and $11.7 million in the quarter and six months, ended December 31, 2023, respectively. During the quarter and six months ended December 31, 2024, the Company had total other immaterial discrete tax benefits of $1.2 million and $0.9 million, respectively. The Company recognized total other immaterial net discrete tax benefits of $1.5 million and $4.6 million in the quarter and six months ended December 31,

2023, respectively. 0.186 0.177 0.175 0.054 -2200000 -5200000 -2800000 -16300000 1000000 4300000 1300000 11700000 -1200000 -900000 -1500000 -4600000 Note 13. Segment Information: The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with the impact of partially-owned consolidated subsidiaries as well as acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Spatial Biology segments both include consumables, instruments, services and royalty revenue. The following is financial information relating to the Company's reportable segments (in thousands): <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"> Quarter Ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;"> Six Months Ended </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Net sales: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 211,551</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 197,670 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 416,086</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> 402,325 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Diagnostics and Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt

3pt 0pt 0pt;"> 84,135 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 75,408 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 167,327 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 148,204 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Other revenue⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 1,849 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 4,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Intersegment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (504) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (480) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,076) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (996) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Consolidated net sales </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 272,598 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 549,533 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Operating income; </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td

style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 79,586 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 167,653</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 167,947 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Diagnostics and Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,240 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,556 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,517 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,082 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Segment operating income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90,352</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 84,142 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 175,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 173,029 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Costs recognized on sale of acquired inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (185) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (183) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (373) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> (364) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Amortization of intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (18,559) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (19,769) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (38,300) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> (39,620) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Acquisition related expenses and other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (2,010) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 525 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (3,523) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> 1,114 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Certain litigation charges </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,386) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,678) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Impairment of assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (6,038) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> (6,038) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Stock based compensation, inclusive of employer taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (15,238) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (12,958) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (25,875) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> (24,453) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Restructuring and restructuring-related costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (3,287) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (5,518) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (14,309) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> (5,607) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate general, selling, and administrative expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,641) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (2,197) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (3,227) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> (4,195) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Impact of business held-for-sale⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (627) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (479) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Consolidated operating income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> - </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-

align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 87,406 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93,866</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">⁽¹⁾ Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following is financial information relating to the Company's reportable segments (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Quarter Ended </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">Six Months Ended </i></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">December 31, </i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">December 31, </i></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">2024</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">2023</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">2024</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;"> </i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">2023</i></p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">Net sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Protein Sciences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 211,551 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 197,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 416,086 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> 402,325 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Diagnostics and Spatial Biology </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 84,135 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 75,408 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 167,327 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 148,204 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Other revenue⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 1,849 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 4,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Intersegment </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (504) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (480) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,076) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (996) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Consolidated net sales </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 297,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 272,598 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586,489</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 549,533 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Operating income: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Protein Sciences </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 87,112 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 167,653 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 167,947</p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Diagnostics and Spatial Biology</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,240</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,082</p></td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Segment operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 90,352 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,142</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> 175,170 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> 173,029 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Costs recognized on sale of acquired inventory </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (185) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (183) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (373) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> (364) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Amortization of intangibles </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (18,559) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (19,769) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (38,300) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> (39,620) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Acquisition related expenses and other </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (2,010) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> 525 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (3,523) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> 1,114 </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Certain litigation charges </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,386) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt

3pt 0pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,678) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Impairment of assets held-for-sale </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> (6,038) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Stock based compensation, inclusive of employer taxes </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (15,238) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (12,958) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (25,875) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> (24,453) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Restructuring and restructuring-related costs </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (3,287) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (5,518) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;margin:0pt;padding:0pt;"> (14,309) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;margin:0pt;padding:0pt;"> (5,607) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Corporate general, selling, and administrative expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,641) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (2,197) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;margin:0pt;padding:0pt;"> (3,227) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;margin:0pt;padding:0pt;"> (4,195) </td></tr><tr><td style="vertical-align:bottom;width:55.53%;margin:0pt;padding:0pt;"> Impact of business held-for-sale⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (627) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (479) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:55.53%;background:#cceeff;margin:0pt;padding:0pt;"> Consolidated operating income </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 38,004 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 93,866 </td></tr></table> ⁽¹⁾ Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023. 211551000 197670000 416086000 402325000 84135000 75408000 167327000 148204000 1849000 4152000 -504000 -480000 -1076000 -996000 297031000 272598000 586489000 549533000 87112000 79586000 167653000 167947000 3240000 4556000 7517000 5082000 90352000 84142000 175170000 173029000 185000 183000 373000 364000 18559000 19769000 38300000 39620000 2010000 -525000 3523000 -1114000 -1386000 -1678000 -6038000 -6038000 15238000 12958000 25875000 24453000 3287000 5518000 14309000 5607000 1641000 2197000 3227000 4195000 -627000 -479000 47419000 38004000 87406000 93866000 Note 14. Subsequent Events: None. false false false false